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AIM OF PRESENT INVESTIGATION 
A nation with a good social health is the happiest situation and the pharmacist’s role 
is to contribute a lot towards healthcare management in the society through his 
community service and  research apt  to the country’s needs. Today’s pharmaceutical 
research is the mother of all the expertise including technology required to 
manufacture, simple as well as sophisticated remedies in the country. 
The cost involved both in the terms of money and time in the development of a single 
new molecule has mandatory for pharmaceuticals companies to reconsider research 
focus. Great strides have been made in the management of disease through the 
invention of drugs over the past 50 years, clearly, unless a drug can be delivered to its 
target area at a rate and concentration that both minimize side effects and maximize 
therapeutic effect, the drug will not be maximally beneficial to the patient and in the 
extreme, an otherwise useful drug must be discarded. 
Pharmaceutical field is the research and development intensive field. The search for 
safe and effective drugs continues to be major effort involving the pharmaceutical 
industries, universities and government. The complexities of discovering and testing 
new drugs have become enormous as a result of the many aspects of safety, efficacy 
and economics that determine acceptability of a drug. Indeed the situation as a whole 
has become almost a Gordian knot. The concept of controlled drug delivery has been 
embraced with great enthusiasm by many as the sword that will slice through Gordian 
knot. 
Current state of drug delivery approaches are humble steps in the direction of creating 
ZION on earth by attaining Zenith of health and cure for everyone. Last century had 
witnessed spectacular developments on the diverse kind of oral delivery systems. 
Nevertheless there is continuous need for developing delivery systems that can 
regulate drugs levels in a more efficacious, elegant and economic manner. 
In an attempt to reduce the cost of drug development process and advantageously reap 
the benefits of patient’s regime, companies are now investing strategically in the 
development of controlled drug delivery system [CDDS]. Evolution of an existing 
drug molecule from a conventional form to CDDS can significantly improves its 
performance in terms of patient compliance, safety and efficacy. CDDS that can 
precisely control the release rate or target drugs to a specific body site have had an 
enormous impact on the healthcare system. Drug delivery companies are engaged in 
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the development of multiple platform technologies to get competitive advantage, 
extended patent life and increase in market share of their products. The last two 
decade in the pharmaceutical industry have witnessed an avant-garde interaction 
among the field of polymer and material science, resulting in the development of 
CDDS. 
There are high hopes in achieving satisfactory results in developing newer 
formulations and remedies for cardiovascular diseases, coronary heart diseases, 
bronchial asthma, diabetes, rheumatoid arthritis, hepatitis, cancer, AIDS etc. from 
indigenous and natural resources under WHO guidelines. 
Cardiovascular diseases rank first amongst dreaded diseases, second is the cancer. 
Coronary cardiac problems and ischemic heart diseases (IHD) are major causes for 
death among other diseases.  
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As per WHO report for the cause of death, cardiovascular diseases contributing to 
about 30% of total deaths. In US about 23 to 30% deaths are due to IHD. Every year, 
out of 5 million patients presented to emergency room with chest discomfort 
approximately 1.5 million are hospitalized for acute coronary syndromes. Each year 
in US more then 1 million patient suffer an acute myocardial infraction. In India the 
situation is quite gloomy about 35%  to 40%  deaths are due to IHD, out of 5 millions 
are hospitalized for acute coronary syndrome. 
Every CVD does not lead itself to deaths but it is responsible to economic loss to the 
nation also. The top ten therapeutic segments accounting nearly 30% of total world 
market, the leading out of 10% is CVD; which is growing at the rate of 20% per 
annum. The economic implication of preventive and therapeutic interventions directed 
against heart diseases along with medical care and medical interventions had become 
a subject if considerable and intensive research of CVD. 
Globally the situation is very poor, as per WHO press release titled “Stop the global 
epidemic of chronic diseases” mentioned the following facts. 
i) In 1999 CVD contributed to a third of global deaths. 
ii) In 1999 low and middle income countries constituted to 78% of CVD 
deaths. 
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iii) By 2010 CVD is estimated to be leading cause of death in developing 
countries. 
iv) Heart disease has no geographic, gender, socio-economic boundaries. 
v) Majority of CVD are presentable and controllable. 
vi) By 2015 almost 20 million people will die from CVD, every year. 
 
WHO press release mentions an estimated economic loss of US $ 558 billion due to 
chronic diseases. 
The drugs used in the treatment of cardiovascular disease like Diltiazem, Nifedipin, 
Verapamil, Atenolol etc. are not free from biopharmaceutics and pharmacokinetic 
problems of absorption, hepatic metabolism and poor bioavailability. Despite the 
tremendous advancement in drug delivery, the transdermal route remains the 
preferred route for the administration of therapeutic agents because the cost of therapy 
and ease of administration lead to high level of patient compliance. 
Transdermal drug delivery system [TDDS] are the novel drug delivery system in 
which a constant, prolonged and therapeutically effective drug levels are maintained 
by using intact skin as a port of drug administration. Modern transdermal technology 
is entering its fourth decade after 2000. The 1970’s was the era of experimentation. 
Since then this new mode of drug delivery not made journey to deliver simple bases 
clonidine, scopolamine, nicotine, to complicated molecules like insulin, acyclovir, 
nitroglycerin but it has also developed fabrication techniques, exploited  pressure 
sensitive adhesive  as matrix moderated delivery component,  penetration 
enhancement concept, exploited ultrasonic waves sonophoresis, microelectronics,  
liposomes, microneedles, transfersomes etc. as strategic means for skin penetration to 
meet required steady state plasma concentration of drug.  
Over the past 10 years there have been 8000 transdermal related presentation at the 
annual conventions of controlled release society and American Association of 
Pharmaceuticals Science. 
Nitroglycerine, scopolamine, clonidine, fentanyl, estradiol are the drugs that have 
sizable transdermal market in US. The global drug delivery market of transdermal 
formulation is expected to increase from $ 6.7 billions in 2000 to $ 26.7 billion in 
2010. Transdermal drug delivery system offers a solution to bioavailability problems. 
Also economically T.D.D.S. market is growing at the rate of 15 % per annum; offers a 
good economical gain along with some distinct advantages over other controlled drug 
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delivery system which are, 
• No pricking with needle required. 
• External mode of administration. 
• Easy to discontinue therapy in case of side effect. 
• No sterilization processing involved compared to parentaral manufacturing. 
• Bioavailability problem are minimized. 
Drugs that have a short biological half life need to be administered two or three times 
in a day. For the drugs which are susceptible to hepatic metabolism need to  be 
administered in a higher doses to meet the requirement of steady state plasma 
concentration for therapeutic effect. 
Diltiazem is classified as calcium channel blocker, is used in cardiovascular disease. It 
has a mean plasma half-life of 3.5 hrs and only 40% of the orally administered drug 
reaches the circulation due to hepatic metabolism.  
Atenolol (TENORMIN) is a β1–selective antagonist, used in hypertention. Atenolol is 
very hydrophilic and appears to penetrate the brain only to a limited extent. Its half-
life is somewhat about 5 to 8 hours. Only 50% orally absorbed dose reaches the 
systematic circulation. 
To obviate the problems of bioavaibility and to enhance patient’s compliance to the 
therapy transdermal drug delivery system of the above drugs shall be a proper 
solution. 
The present search was directed to examine the biopharmaceutics aspect of selected 
drugs, prior to incorporate into delivery devices. The permeability of Diltiazem and 
Atenolol was evaluated using membrane, matrices and human skin. 
In recent years the value of hydrophilic and hydrophobic polymers based drug 
delivery system as vehicles for controlled release delivery has been increasingly 
demonstrated as vehicle of numerous patents and research papers and their utilization 
n new product in the market place. The use of biopolymeric devices to control the 
release of a variety of drugs has become important in the development of modified 
release dosage form. In part the widespread and successful use of such polymeric 
systems can be attributed to their ease of manufacturing, relatively low cost, their 
favorable in vivo performance and their versatility in controlling the rate of drugs 
with a wide range of physiochemical properties. 
The aim of present investigation was to develop transdermal drug delivery system of 
Diltiazem base and Atenolol using various hydrophilic and hydrophobic polymers. 
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Optimization techniques shall be applied in the present study to systematically study 
the influence of formulation variables on the development of dosage forms. Matrix 
diffusion and membrane moderated T.D.D.S., shall be deviced using various 
polymers. Specific strategies like use of drug penetration enhancers shall be employed 
to meet systemic requirement of drug. Different formulations variables shall be 
studied and optimized to achieve the desired release profile. Finally selected devices 
shall be evaluated for in vitro studies using human skin. 
The present study was aimed at the development of membrane moderated and matrix 
moderated transdermal drug delivery system of Diltiazem and Atenolol using various 
polymers. Specific strategies like use of penetration enhancers shall be employed to 
meet systematic requirement of drug. Different formulation variable shall be studied 
and optimized to achieve the desired release profile. 
Finally selected devices shall be evaluated for in vitro study using human live skin. 
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1.1 CONTROLLED DRUG DELIVERY SYSTEM 
1.1.1 Introduction 
The administration of conventional oral dosage forms like tablets, capsules, liquids 
orals of drugs suffers a set back due to problem of gastro intestinal tract absorption, 
local irritation, dilution of drug strength ,  Liver first  pass metabolism, degradation of 
drug by gastro intestinal tract enzymes, the protein binding of drug at an absorption 
surface and local toxicity. The bioavailability as well as duration of action is reduced 
which requires frequent administration, which in turn is associated with the problem 
of patients compliance to therapy and the economy of the treatment. 
Parenteral route is the preferred route of administration for moderate to severe 
complication, even though patients compliance are rather low for this mode of drug 
delivery as it is invasive drug delivery technique, requiring frequent pricking with 
needle.  
All conventional dosage form except intravenous infusion, follow second-order 
kinetic.1 Dosage form releases drug initially at faster rate, leading to quick rise in 
blood level of drug and then falls exponentially until a further dose is administered. 
This results in peak and valleys pattern of drug concentration in blood and tissues. 
Thus, for most of the time the concentration of drugs either above the required 
therapeutic level or below it. The time course of various modes of administration2   is 
represented in figure 1.1.1. 
It is evident that the quality of the rate of absorption and the rates of metabolic 
elimination would result on the equilibrium distribution of the drug in tissues and 
blood, but however missing in the case of conventional dosage forms. This factor as 
well as some other factors such as repetitive dosing and unpredictable absorption, led 
to the concept of drug delivery system or the therapeutic system. 
Drug delivery system may be a controlled release drug delivery system where there is 
predictive control over the release pattern, and subsequent tissue or blood levels can 
be achieved. From figure 1.1.1, it is observed that the equality of the rate of 
absorption and the rate of metabolism is only in the case of controlled drug delivery 
system. 
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Figure 1.1.1: Time course of various modes of administration 
 
 
                                  
 
 
 
 
 
 
                      
 
 
 
 
 
 
(1)      Conventional single administration 
                                    (2)      Multiple administrations 
                                    (3)      Sustained release administration 
                                    (4)      Controlled drug delivery administration 
 
Administration of drug in conventional dosage form requires- large dose, frequent 
administration and lacks extended duration, with chances of toxicity. While in 
controlled drug delivery devices there is efficient utilization of drug, desired extended 
duration, with very low chances of toxicity, facilitating enhanced complication of 
patient, leading to better management of therapeutics. The efficacious use of drug 
influences cost factor and economy of therapy too. 
It seems that the controlled delivery should be the goal for all products and now a 
day’s drug firms have been allocating large resources on the reformulation of older, 
existing drugs, in sustained and controlled drug delivery often resulting in special 
economic gains. 
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1.1.2 Types of controlled release preparation 3-13 
On the basis of technical sophistication, controlled drug delivery system can be 
categorized into 3 major classes. 
A. Rate programmed controlled drug delivery system 
These drug delivery system are those from which the drug release has been 
programmed at specific rate profiles. They are further subdivided into following 
subclasses. 
1. Dissolution controlled drug delivery system 
     Slow dissolution rate of the drug 
     Slow dissolution rate of the reservoir membrane or matrix  
2. Diffusion controlled drug delivery system 
     Porous matrix controlled system             
     Porous membrane controlled systems                       
3. Erosion controlled drug delivery system 
    Surface erosion  
    Bulk erosion 
4. Dissolution, Diffusion and/or Erosion controlled drug delivery system 
     Reservoir system (membrane controlled drug delivery system) 
     Matrix system (monolithic drug delivery system) 
     Hybrid systems (membrane cum matrix drug delivery system) 
 
B. Stimuli activated drug delivery system 
1. Activation by physical process 
    Osmotic pressure activated drug delivery system 
    Hydrodynamic pressure activated drug delivery system 
    Vapor pressure activated drug delivery system 
    Mechanical force activated drug delivery system 
    Magnetically activated drug delivery system 
    Thermally activated drug delivery system 
     Photo activated drug delivery system 
     Photo mechanically waves (laser) activated drug delivery system 
     Ultrasound activated drug delivery system 
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     Electrically activated (Iontophoresis) drug delivery system 
2. Activation by chemical process 
    pH activated drug delivery system 
    Ion activated drug delivery system 
    Hydrolysis activated drug delivery system 
    Chelation activated drug delivery system 
3. Activation by biological system 
    Enzyme activated drug delivery system 
    Antibody interaction drug delivery system 
    Antigen activated drug delivery system 
    Inflammation activated drug delivery system 
 
C. Site targeted drug delivery system 
1. Polymeric carriers for drug targeting 
2. Albumin as carrier for drug targeting 
3. Lipoprotein as carrier for drug targeting 
4. Liposomes as carrier for drug targeting 
  
1.1.3 Drug release mechanisms for controlled drug delivery system 
Most of the design of controlled release dosage form employs polymers for 
controlling the drug release. There are three fundamental mechanisms by which 
polymers release drugs.14 
(1)  Diffusion e.g.              Reservoir type systems  
• Microcapsules 
• Matrix/laminates 
(2)  Chemical reaction        Water or enzyme causes degradation of a polymer which        
                                             is used  to encapsulate a drug. 
• Erodible 
• Degradable systems 
• Pendant chain systems 
(3)  Solvent activated             In this case drug is entrapped in the polymer until either     
                                               external systems  solvent swells the polymer or water     
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                                               imbibement creates osmotic pressure.                                                    
(4) Other general mechanism includes 
Magnetic signal        Placement of drug into magnetic beads in matrix 
systems, Applying an external magnetic field, the beads 
can be made to Squeeze drug through the polymer. 
Chemical signal        This can also be utilized to create self regulated 
systems. In such cases an external molecule such as 
glucose can diffuse into a polymer membrane and react 
with an enzyme that is immobilized. Enzymatic reaction 
causes pH sifts which alters membrane permeability or 
drug solubility and there by changes the release rate. 
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1.2 TRANSDERMAL DRUG DELIVERY SYSTEM                  
                         
 
1.2.1 Introduction 
Conventional systems of medication that require multi dose therapy are having many 
problems. The controlled drug delivery is a newer approach is to deliver drug in to 
systemic circulation at a predetermined rate. Our system should duplicate continuous 
intravenous infusion, which not only by passes hepatic ‘first pass’ elimination but also 
maintains a constant, prolonged and therapeutically effective drug level in the body. 
This is made possible by using intact skin as a port of drug administration to provide 
continuous delivery of drug in to systemic circulation. Following skin permeation, the 
drugs first reach the systemic circulation. The drug molecules are then transported to 
the target site, which could be relatively remote from the site of administration, to 
produce therapeutic action. 
 
Transdermal drug delivery offers the following potential advantages 1, 2, 3 
1. Avoid the risks and inconveniences of intravenous therapy and of varied 
conditions of absorption and metabolism associated with the oral therapy. 
2. Continuity of drug administration in TDDS permits the use of a drug with 
short biological half-life. 
3. Transdermal drug delivery improves the bioavailability that reduces the total 
daily dose. 
4. Avoids first-pass hepatic metabolism. 
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5. Less chances of over or under dosing as the result of prolonged pre 
programmed delivery of drug at the required therapeutic rate. 
6. Decrease gastrointestinal side effects. 
7. Elimination drug food interactions. 
8.   Increased patient compliance in following manner 
• Provisions of simplified therapeutic regimen. 
• Painless delivery of drug. 
• Eliminates swallowing. 
• No chances of forgetting the dose once the device is applied on skin. 
• Easy to carry a patch in wallet or ladies purse. 
9. Patches offer less friability problems of wear and tear than the tablets. 
10. In a multi drug regimen TDDS avoids drug interaction in GIT. 
11. It is easy to terminate the medication simply by removing the dug delivery 
device from the skin surface. 
12. TDDS system can be taken without any aid, which makes it most suitable 
formulation; for instance, tablet and capsule need little water. Liquid oral 
preparation needs teaspoon and parentaral delivery needs specialized person 
whereas if a patient is told to apply TDDS patch, he/she can do it any where 
e.g. in office, in theatre, in club, in house without any aid. 
13. Chance of toxicity due to additives e.g. preservatives, stabilizing agent 
antioxidants etc. are less as compared to other dosage forms. 
14. Problem of dose dumping is least in TDDS, because stratum corneum is more 
resistant than the inner membranes (i.e. mucous membrane in case of oral 
controlled release delivery systems) and stratum corneum itself is a rate 
limiting factor. 
15. Need not to be sterile, obviates processing problem. 
 
Disadvantages of transdermal drug delivery system4 
1. The limitation of transdermal drug delivery is principally associated with skins 
barrier function, which severely constrains the absolute amount of drug that 
can be absorbed across reasonable area of skin during the dosing period. Thus, 
the major disadvantage of the method is that it is limited to potent drug 
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molecule typically those requiring a daily dose on the order of 20 mg or less.  
2. Even if the drug is sufficiently potent, it must yet satisfy other criteria to be 
considered a viable candidate for transdermal drug delivery. For example its 
physiochemical properties must allow to be absorbed percutaneously. This 
mean that its molecular weight should ideally be less than 500 Daltons and it 
should have adequate solubility in both lipophillic and aqueous environments 
since, to reach dermal micro circulation and gain access to systemic 
circulation, the molecule must cross that stratum corneum (a lipid barrier) and 
then transfer through the much-more-aqueous-in-nature viable epidermis and 
upper dermis. Absence of either oil or water solubility altogether, will 
preclude permeation at a useful rate. 
3. The pharmacokinetic and pharmacodynamic characteristic of the drug must be 
such that relatively sustained and slow input provided by transdermal delivery 
makes sense. Tolerance inducing compounds are not intelligent choice for this 
mode of administration unless until an appropriate “wash out” period is 
programmed into the dosing regimen. 
4. Drugs that can be given once a day orally, with reproducible bioavailability 
and which are well tolerated by patient do not really need a patch formulation. 
Drugs must not be locally irritating or sensitizing since provocation of significant skin 
reactions beneath a transdermal delivery system will most likely prevent its regulatory 
approval. 
 
1.2.2 Physiology of human skin2 
The skin is the largest single organ in the body. An average human skin is known to 
contain, on an average 40-70 hair follicles and 200-250 sweat ducts per every square 
centimeter of the skin. These skin appendages, however actually occupy grossly only 
0.1% of total stratum corneum surface henceforth the transappendageal route of 
percutaneous absorption has provided only a very limited contribution to the overall 
kinetic profile of transdermal permeation. Therefore, the transdermal permeation of 
most neutral molecule at steady can thus be considered as primarily diffusion through 
the intact stratum corneum in the interfollicular region. So, for fundamental 
understanding of TDD (Transdermal drug delivery), the structure should be 
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understood.3 Figure 1.2.1 is transeverse section of the human skin. The skin can be 
divided in to two layers. 
I Epidermis - It is superficial layer of stratified epithelium which is of 
ectodermal origin. 
II Dermis or Corium - It is foundation of firm connective tissue upon which 
epidermis is laid and is of mesoderm origin. 
The total thickness of skin has got considerable regional variation, ranging in human 
body from less than 1/10 of millimeter tip to 3 or even 4 millimeters. 
 
I. Epidermis 5,6 
In a typical part of the epidermis there are number of different strata in which the cells 
have distinct anatomical features. From below, the first stratum is the basal layer or 
layer of Malpighi. Its cells are mostly polygonal in shape, the deepest tending to a 
cylindrical columner form, and the most superficial becoming somewhat flattened. 
 
Active mitotic proliferation takes place in the deeper layers, the development of new 
cells leading to a gradual displacement of the older cells towards the surface. 
 
Hence, this stratum is also called stratum germinatum. The epidermis is quiet 
avascular, and between the cells of stratum germinatum there are fine intercellular 
channels which probably allow the transmission of nutrient fluids derived from 
capillary blood vessels in the adjacent dermis. These channels are bridged across by 
delicate protoplasmic threads connecting one cell with another. The stratum 
germinatum, therefore, appears to be syncytium of cells. 
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Figure 1.2.1: Transverse section of human skin 
 
 
 
 
 
Covering the stratum of Malpighi is a layer two or three cells deep called the stratum 
granulosam. These cells are flattened and contain abundance of granules in their 
cytoplasm.  
Above stratum granulosam is stratum lucidam - it called so, because it has a clear 
translucent appearance in stained sections. At this level of their growth towards the 
surface, the cells have lost their clear-cut outline, the nuclei are becoming indistinct, 
and the granules of the subjacent stratum have become converted in to larger masses 
of an achromatic substance. 
The surface stratum forms the greater part of’ the whole thickness of the epidermis in 
many parts of the skin. Because of’ horny character of the cellular elements that 
composes this layer; henceforth it is called the stratum corneum. In stratum corneum 
the cell structure has become completely obscured and nuclei are no longer evident.6 
The cells are now known as corneocytes. Corneocytes are dead, flattened and rich in 
keratin. Corneocytes are densely arranged and are surrounded by a complex mixture 
of intercellular lipids. The complex mixture of intercellular lipids comprises 
ceramides, free fatty aids, cholesterol and cholesterol sulphate. Their most important 
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feature is that they are structured into ordered bilayer arrays. The predominant 
diffusional path for a molecule crossing the stratum corneum appears to be 
intercellular.7 The stratum corneum is traversed by the ducts of sweat glands and hair 
where these are present. Table 1.2.1 and Table 1.2.2 show the composition of the 
human stratum corneum and composition of stratum corneum lipids respectively.8, 9, 10 
 
Table 1.2.1:  Composition of human stratum corneum 
Sr. No. Components Percentage Gross Biochemical composition 
1 Cell membrane 5 lipid and non-fibrous protein 
2 Cell contents 85 
Lipids (20 %) 
α-Protein (50 %) 
β- Protein (20 %) 
Non-fibrous protein (10 %) 
3 Intercellular proteins 10 lipid and non fibrous proteins 
 
Table 1.2.2:  Composition of stratum corneum lipids 
SR. NO. COMPONENTS PIG HUMAN 
1 Cholesteryl esters 1.7 10.0 
2 Triglyceride 2.8 0.0 
3 Fatty acids 13.1 9.1 
4 Cholesterol 26.0 26.9 
5 Ceramide 1 4.1 3.2 
6 Ceramide 2 16.7 8.9 
7 Ceramide 3 6.9 4.9 
8 Ceramide 4 4.4 6.1 
9 Ceramide 5 4.5 5.7 
10 Ceramide 6 7.6 12.3 
11 Glucosyl Ceramides 1.0 0.0 
12 Cholesteryl Sulphate 3.9 1.9 
13 Others 5.7 11.1 
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II. Dermis 
The dermis or corium consists of a dense felt work of connective tissue in which 
bundles of collagenous fibres predominate, mingled with a certain proportion of elastic 
tissue in superficial levels. Dermis contains fine plexuses of blood vessels, lymphatics 
and nerves, hair follicles, sweat glands and sebaceous glands.2,3 The thicker the 
epidermis, therefore, the more prominent are the papillae.11 
 
1.2.3 Drug penetration pathways 12-24 
There are critically three ways in which a drug molecule can cross the intact stratum 
corneum: via skin appendages (shunt routes); through the intercellular lipid domains; 
or by a transcellular route (Figure 1.2.2) A particular drug is likely to permeate by a 
combination of these routes, with the relative contributions of these pathways to the 
gross flux governed by the physicochemical properties of the molecule. 
 
Figure 1.2.2: Drug penetration pathways across skin. 
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THE APPENDGEAL ROUTE 
Skin appendages provide a continuous channel directly across the stratum corneum 
barrier. However, their influence on drug penetration is hindered by a number of 
factors. The surface area occupied by hair follicles and sweat ducts are small (typically 
0.1% of skins surface area), therefore limiting the area available for direct contact of 
the applied drug formulation.  
 
TRANSCELLULAR ROUTE 
Drugs entering the skin via the transcellular route pass through corneocytes. 
Corneocytes, containing highly hydrate keratin, provide an aqueous environment for 
which hydrophilic drugs can pass. The cells are surrounded by a lipid envelope which 
connects the cells to the interstitial lipids. Separating keratinised skin cells are multiple 
lipid bilayers; there are estimated to be up to 20 such lamellae between each 
corneocyte. Therefore, the diffusion pathway for a drug via the transcellular route 
requires a number of partitioning and diffusion steps.  
 
INTERCELLULAR ROUTE 
The intercellular pathway involves drug diffusing through the continuous lipid matrix. 
This route is a significant obstacle for 2 reasons. Firstly, recalling the ‘bricks and 
mortar’ model of the stratum corneum, the interdigitating nature of the corneocytes 
yields a tortuous pathway for intercellular drug permeation, which is in contrast to the 
relatively direct path of the transcellular route. It has been estimated that water has 50 
times further to travel by the intercellular pathway, than the direct thickness of the 
horny layer. Secondly, the intercellular domain is a region of alternating structured 
bilayers. Consequently, a drug must sequentially partition into, and diffuse through 
repeated aqueous and lipid domains. This route is generally accepted as the most 
common path for small uncharged molecules penetrating the skin. 
 
1.2.4 Stratum corneum the rate limiting barrier to percutaneous 
absorption 
The skin contains a dead layer stratum corneum and viable layers, the viable tissue 
contains catechol-o-methyl transferase which metabolizes the drugs, the papillary 
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layer of Dermis contains so many capillaries and it is highly probable that most 
molecules enter the micro circulation soon after leaving the epidermis. Thus the 
average total resistance time of a drug species in the dermal aqueous phase may be 
only a fraction of minute.25 
A simplified model of the human skin for mechanistic analysis26 is shown in figure 
1.2.3 
Figure 1.2.3: Human skin model 
Stratum 
corneum
Epidermis Dermis
Capillary networkPapillary layer
 
For abdominal skin the thickness of Stratum corneum is 10µm, Viable epidermis 100 
µm and for Upper portion of dermis is 100µm.  
The diffusional resistant total. 
 
DD
D
EE
E
KD
h
KD
h
KscDsc
hscR
⋅
+
⋅
+
⋅
=∑ 1  
      h    = Thickness    
      D   = Diffusion coefficient  
      K   = Partition coefficient 
      Sc  = Stratum corneum 
      E    = Epidermis 
The sum of tissue resistance Rs of skin calculated for water permeation 27 by using 
appropriate parameters for above equation. 
 
RS =   RSC + RE +RD 
=   9.1 x 106 + 6.3 x 103 + 6.3 x 103  
=   9.1 X 106 cm/sec. 
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The dermis and epidermis are extensively hydrated and diffusion coefficients are 
typical of liquid-state diffusion. In dermis molecules probably moves within water 
filled interstices. In contrast, the stratum corneum is semi fibrous structure which is 
characterized by semisolid diffusivity. According to these calculations the diffusional 
resistance of the stratum corneum to water is approximately 1000 times that of the 
either the viable epidermis or the superficial regions of dermis. 
Polar Solutes (other than water) and larger molecules usually have smaller diffusion 
coefficients than that of the water, and stratum corneum becomes even more dominant 
in permeation process. In general conclusion, the stratum corneum (Horny layer) 
provides the rate limiting barrier for diffusion is true for the entire class of the water 
soluble substances. 
Lipid Soluble Molecules, Octanol applied to cadaver skin as an aqueous solution.28 
Comparing the result with that for water, it was observed that the resistance of the 
skin has decreased dramatically and that this reduction arose from the more favorable 
distribution of the octanol into the stratum corneum (as measured by Ksc). Thus for 
non polar molecules also stratum corneum provides rate limiting barrier to 
percutaneous absorption. 
Probably the intercellular keratin structure, rather than cell wall of stratum corneum is 
the main site for membrane diffusional resistance,27,28 although thickened plasma 
membrane has, been reported 29 to be the main diffusional barrier in stratum corneum. 
The dependency of permeation on the partition coefficient it appears that the lipid-
soluble molecules segregate and diffuse through lipid region in stratum corneum. A 
mathematical model for stratum corneum30 does assume that there is strict separation 
of protein and lipid in stratum corneum. 
Percutaneous absorption of drugs for localized therapeutic actions in the skin tissues 
or for systemic medication in the tissues remote from the site of topical drug 
application 26 is shown in figure 1.2.4. 
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Figure 1.2.4: Percutaneous absorption of drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.5 Pharmacokinetic model for percutaneous absorption 
In figure 1.2.5, it is shown that how a drug molecule is partitioned and diffused to 
various layers of skin and reaches to systemic circulation. In this model, the rate 
constants are assigned true physicochemical significance and may be predicted from 
basic physical properties.31  In figure 1.2.6 events during percutaneous absorption are 
shown.32 
The kinetic parameters (Figure 1.2.5) are associated with the following significance.33 
f(K1) describes the input kinetics From the transdermal device for a “membrane 
controlled” system, f(K1) consists of both First-order (K1) and zero-order (K0) 
components. The former represents drug release from the contact adhesive; the latter 
signifies the membrane limited leaching of drug from reservoir. 
Kr reflects the fact that there will be competition for the drug between the patch and 
the stratum corneum, if the system is well designed, then Kr will be small. 
K1 and K2 are first order rate constants describing drug transport across the stratum 
corneum and viable tissue, respectively K1 and K2 are therefore proportional to the 
corresponding diffusion coefficients through these layers of skin and may be 
simplistically related to the penetrant molecular weight (M) by equation. 
D=C.M1/3     (1) 
 
 
Drug in delivery 
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Figure 1.2.5: Pharmacokinetic model for transdermal drug delivery system 
 
 
 
 
 
 
 
 
 
Chapter – 1                                                                                                    Introduction 
 
 
 
Shital D Faldu  Ph.D. Thesis 19
  
Figure1.2.6: Events governing percutaneous absorption 
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1.2.6 Pharmacokinetic Aspects for Transdermal Drug Delivery  
         System  
The development of drug delivery is extremely complex and requires the 
understanding of basic pharmacokinetic and bio-pharmaceutics. 
For transdermal controlled drug delivery device the general diffusivity of drug across 
skin is the must. All the controlled release delivery devices are multiple dose devices 
designed to result in steady state concentration Css. The magnitude of Css depends on 
the dose rate R (amount of drug per unit of time), and total clearance CL (loss of drug 
from the volume of distribution per unit of time) of the drug. 
Following are basic principles to understand design and evaluation. 
 
(A) Compartment model  
 Single compartment model for transdermal delivery device is given below 
 
(B) Terminal half life ( t1/2) 
The terminal half life or biological half life is the time required to reduce the 
concentration in blood, plasma, or serum to one half, after equilibrium has been 
reached. It is an important parameter in selecting the drug candidate. The shorter the 
t1/2, the greater will be the amount of drug to be incorporated into the device. Only the 
drugs whose t1/2 can be correlated with the pharmacological response are candidates 
for controlled release drug delivery devices. 
 
(C) The area under curve (AUC) 
AUC is the measure of quantity of drug in the body. It is a "robust" pharmacokinetic 
parameter. It is the key parameter in determining absolute and relative bio-
availability. It is determined by a compartment model- independent approach, using a 
trapezoidal rule. 
It permits estimation of total clearance (CL) and apparent volume of distribution (Vd). 
 
(D) Total clearance (CL) 
SKIN Stratum corneum Blood Elimination Urine 
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The total clearance is that hypothetical volume of distribution of un-metabolized drug 
that is cleared per unit of time by any pathway of drug removal. 
CL can be determined from the dose administered D, the absolute bio-availability F, 
and AUC 
AUC
DFCL =  
CL, Vd and t1/2   interrelated as follow 
 
2/1
693.0
t
vdCL =  
Upon multiple dosing, once steady state is reached CL is  
                                  ( )1+→
=
nn TTAUC
DCL  
 
Where,  AUC (Tn→T n+1) is the AUC during any dosing interval  
The total clearance is the key to estimate the dose rate R0 (=D/T) for controlled release 
delivery device is related to the mean steady – state concentration Css.  
 
(E) Apparent volume of Distribution (Vd) 
It is a hypothetical volume, indicating the volume of fluid, which is required to 
dissolve the amount of drug at the concentration that is found in blood. It is a 
proportionality constant relating the amount of drug in the body to the measured 
concentration in blood. 
                                       
KelAUC
DFVd ⋅
=  
 
(F) Mean Steady State Concentration (CSS) 
The mean steady state concentration Css is not the numeric mean between peak (Css 
max) and through (Css min) at steady state but an integrated concentration. With 
constant rate infusion and in ideal controlled release device, no fluctuations occur at 
steady state hence,  
   Css = Css max = Css min 
The value of Css can be estimated from the dose rate 
Css = R0/CL    or       Css = AUC (Tn→Tn+1)/T 
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The means steady-state concentration is usually the target concentration to be reached 
and maintained using controlled release delivery. 
Incase of transdermal controlled delivery device the input rate R° is corrected for the 
surface area A of the delivery device. 
R° = (CSS CL)/ A 
 
1.2.7 Mathematical model for transdermal diffusion and in vitro permeation  
         study 
 
Figure 1.2.7: Diffusant flowing through into and out of region separated by a 
                           membrane 
 
1.2.7.1 Diffusion equation35 
  
For understanding drug permeation through skin let us revise Fick’s laws regarding 
diffusion 
Ficks First Law (Steady—state diffusion) 
It states that amount M of material flowing through a unit cross section. s, of barrier in 
unit time t, is known as flux J. 
                                           S
dt
dMJ =                                   (I) 
This flux is in turn proportional to concentration gradient, dc/dx 
  
                                         
dx
dCDJ −=                         (II) 
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The negative sign of equation (II) signifies that the diffusion occurs in a direction 
opposite to that of increasing concentration. That is to say, diffusion occurs in the 
direction of decreasing concentration of diffusion, thus the flux is always a positive 
quantity. D is   the   diffusion  coefficient  of  penetrant (diffusant)  in  cm 2/sec,  C is 
concentration in g/cm3, and x the distance in cm of movement perpendicular to the 
surface of barrier. In equation (I), mass M is usually given in grams, the barrier 
surface S in cm2 and the time t, in seconds. 
 
Fick’s second law: 
This law includes the study of mass transport with the rate of change diffusant 
concentration rather then the mass diffusing across a unit area of barrier in unit time. 
This equation is derived as follows: 
In figure 1.2.7 it is shown that a diftusant is flowing into and out of region. A 
difference in concentration results from a difference in input and output. A barrier in a 
membrane form separates the donor and receptor compartments. The concentration of 
diffusant in volume element changes with time, i.e. ΔC/∆t, as the flux or amount of 
diffusant changes with distance, ∆J /∆ x in the x direction. 
 
dx
dJ
dx
dC
=                                   (Ill) 
             
Differentiating the equation (II) of first law, with respect to x, one obtains 
2
2
dx
cdD
dx
dJ
=−                           (IV) 
          
Substituting dc/dt form equation (Ill) in to equation (IV) results in Fick’s second law, 
namely,                                                       
2
2
dx
cdD
dx
dc
=−                            (V) 
Equation (V) represents diffusion only in the x direction and this expression is 
sufficient to describe transdermal drug permeation. 
Ficks adapted the two diffusion equation I and V to the transport of matter from the 
laws of heat conduction.36 
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1.2.7.2 Mechanisms and kinetics of transdermal drug delivery system 
The rate of permeation,  dq/dt, across various layers of skin tissues in the course of 
transdermal permeation can be expressed mathematically as:37 
  
( )rss CCPdt
dQ
−=                   (1) 
 
Where Cd and Cr are, respectively, the concentration of pharmacologically active 
molecule in the donor phase. e.g. concentration on the stratum corneum surface, and 
in the receptor phase e.g. concentration in the systematic circulation; and Ps is the 
over all permeability coefficient of the skin tissues to the penetration 
pharmacologically active molecule, which is called the penetrant, and is defined by 
 
  Ps = Ks Ds/hs                   (2) 
   
Where Ks, is the partition coefficient for the interfacial partitioning of the penetrant 
molecule from the TDDS on to stratum corneum; Ds is the apparent diffusivity for the 
steady state diffusion of the penetrant molecule through the skin tissues; and hs is the 
overall thickness of skin tissues. The overall permeability coefficient P for a skin 
penetrant can be considered as an invariant value if Ks, Ds and hs in equation (2) are 
maintained at constant values under a given set of conditions. 
Analysis of equation (1) suggest that, to achieve a constant rate of transdermal 
permeation, one needs to maintain a condition in which the drug concentration on the 
surface of’ stratum corneum Cd is consistently and/or substantially greater than the 
dug concentration in the body 
(Cr), i.e., Cd > Cr; under such condition equation 1 can be reduced to: 
 
dQ/dt = Ps Cd                            (3) 
 
The rate of transdermal permeation (dQ/dt) should be constant, as the magnitude of Cd 
remains fairly constant through out the course of skin permeation. To maintain the Cd 
at a constant value, it is necessary to deliver the drug in to the skin surface at a greater 
rate Rd, that is either a constant or always greater than the rate of skin absorption Ra, 
i.e., Rd> Ra. 
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By making Rd greater than Ra the drug concentration on the skin surface Cd will soon 
achieve a drug level which is equal to or greater than the equilibrium (or saturation) 
solubility of the drug in stratum corneum (Cs), i.e., Cd ≥ Cs, and the maximum rate of 
transdermal permeation (Dq/dt)m is expressed by the following equation 
 
{Dq/dt}m = Ps Cs e                   (4) 
 
In such a case, the magnitude of (dq/dt)m is determined by inherent permeability 
coefficient Ps of the skin to the drug and the equilibrium solubility of the drug in the 
stratum corneum Cse. Analysis of urinary recovery data suggested that the rate of 
transdermal permeation dq/dt increased as the nitroglycerine dose Cd, applied on a 
unit surface area increases. It appeared that the maximum rate of transdermal 
permeation (1.585 mg/cm2/day) was achieved for nitroglycerine in rhesus monkeys38 
when the applied dose reached the level of 4.786 m/cm2 or higher. 
 
1.2.8 Computation of desired release rate and maintenance dose 
Controlled release drug delivery devices are in fact multiple - dose products and 
usually are comparable to intravenous constant rate infusion, Infusions delivers 
specific amounts of drug in extremely short dosing interval t , In drip infusion rate 20 
drops per minute X mg of drug is delivered every 0.05 hour. Using an infusion pump 
of constant delivery t becomes infinitely small. 
The delivery rate R° is 
Ro = D/t     (1) 
If the drug elimination follows first order process and drug release from the delivery 
device follows a zero order process, the rate of drug release or drug input Ro must 
equal to the rate of elimination or rate of drug output  
Ro = R output           (2) 
   Routput = DM * Kel    (3) 
 
The rate of drug output is the product of the maintenance dose DM and the 
elimination rate constant Kel. 
2/1
693.0
t
Kel =                                (4) 
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Equation (3) becomes 
   
2/1
693.0
t
DMRoutput =                            (5) 
 
Now, Amount = gms / CC = Concentration x Volume and DM i.e. maintenance dose 
is an amount of drug 
DM = Concentration x Volume. 
Now concentration is steady-state i.e. Css and Volume is Vd  
      
DM = Css  *  Vd     (6)        
                                                                                                                                                                            
Substituting equation (6) in equation (3) 
Routput = Css Vd  Kel                     (7)      
                                                                 
                        Kel  Vd  = CL      (8) 
 
                        Routput =  CSS   *    CL       (9) 
 
                        RO = R output = Css * CL 
 
Input Rate for transdermal delivery device is dependant on area of device. 
                        R° = Routput = (Css   *    CL) /A     (10) 
 
1.2.9 Factors affecting Transdermal Permeation 
(A)  Physicochemical properties of the diffusant  
Partition Coefficient: 
Partition coefficient plays an important role in establishing flux from a membrane and 
skin to receiver fluid. For drugs the passage through skin, startum corneum is rate 
limiting. The stratum corneum to vehicle partition coefficient is then crucially 
important in establishing a high initial concentration of diffusant in first layer of 
tissue. Drugs possessing both water and lipid solubility is favorably absorbed through 
skin. Transdermal permeability coefficient shows a linear dependency on partition 
coefficient. 
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A lipid water partition coefficient of 1 or greater is required for optimum transdermal 
permeability.39-42 The partition coefficient of a drug molecule may be altered by 
chemical modification of its functional groups,43 by varying the vehicle, or by 
incorporating lipophillic agent with drug e.g. pentanol, which effect skin vehicle 
partition coefficient. 
Diffusant solubility: 
Flux of a solute is proportional to the concentration gradient across the entire barrier 
phase. Therefore for maximal flux, solute should be in saturated solution in donor 
phase. The solubility of a solute can be controlled by controlling solvent composition 
of the vehicle. 
Effective Concentrations: 
The concentration differential is considered as driving force for diffusion, in actual it 
is the chemical potential gradient or activity gradient which is the fundamental 
parameter. The thermodynamic activity of penetrant in either the donor phase or the 
membrane may be radically altered by such phenomena as (1) pH changes (ii) 
complex formation (iii) co-solvents, (iv) presence of surfactants, micelle etc. 
pH variation : 
According to pH partition hypothesis, only unionized molecules pass across lipid 
membranes in significant amount.45 Ionized species do not have favorable free 
energies for transfer to lipid phase. Weak acids and the weak basis dissociated to 
different degrees, depending on the pH and the pKa and pKb of diffusant. Thus the 
fraction of unionized drug in the applied phase determines the effective membrane 
gradients, and this fraction is function of pH.46 Usually transdermal flux of drug 
increases with increasing pH up to approximately 1 to 2 pH units higher than the pKa 
value or decreasing 1 to 2 pH lower than pKb values, at which point the drug 
molecule exist totally as the non protonated form. 
Co-solvents: 
Co-solvents are used to increase solubility of solute in vehicle, so as to maximize the 
concentration gradient across stratum corneum, membrane. In general partition 
coefficient of a drug between a membrane and a solvent mixture falls as the drug 
solubility in the solvent system rises47 as shown figure 1.2.8. Hence it is important not 
to over solubilize a drug in a vehicle if the aim is to promote penetration through 
stratum corneum. 
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Figure 1.2.8: Relationship between partition coefficient, Solubility and 
                                concentration of solubilizer in vehicle 
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Surface Activity and Micellization: 
When surface active agent forms micelle, the total apparent solubility of agent in the 
aqueous phase increases dramatically, with a consequent decrease, in the apparent 
partition coefficient Figure 1.2.8. When drug and surfactant are different, the part 
played by surfactant is more complicated. Sometimes surfactant decreases 
permeation, reflecting reduced biological activity e.g. retarded rectal absorption of 
triiodophenol.48 
Complexation: 
Complex formation influences apparent solubility and apparent partition coefficient of 
a drug. When complex is formed in donor solution, flux of diffusant across skin or 
membrane decreases, because concentration of free drug falls. It is reported that 
complexes have lowered partition Coefficient than respective free drugs.49  
Molecular Weight:  
(a)   Convection  
Usually the lower the molecular weight the faster and more complete is the transport. 
Small molecules may pass through pores of the membrane by convective transport. 
Spherical compounds up to MW of 150 and thread like compounds up to MW 400 are 
considered of being permeable by convective transports. 
(b)   Diffusion: 
Most drugs are transported across membrane by passive diffusion, since in passive 
diffusion the drug outside and inside the aqueous compartment is in true solution, but 
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dissolves in the lipid material of the membrane during the transport across the barrier. 
The compound must possess minimal lipid solubility. 
The transport stream Q depends on the diffusion constant of drug in lipid material D, 
the surface area A, the partition coefficient K, the membrane thickness "h" and the 
concentration C0 and Ci on both sides of the membrane. 
Q = DAK (C0 – Ci) / h 
Under sink condition, where the drug is immediately carried away by the blood after 
crossing the membrane and diluted within the volume of distribution, according to 
Ficks first law. The flux and diffusion coefficient D decreases with increasing MW. 
The flux of some drugs and their molecular weights 50 are listed below. 
The majority of drugs have low molecular weights (MW 200-250). In recent years 
increasing interest is being devoted to drugs of large molecular weights i.e. (MW 
1000-30000) the peptides such as insulin (MW 6000) growth hormone (22600), 
oxytocin (1007), vasopressin (1200) and antibodies (> 150,000). 
Table 1.2.3: Molecular weights (MW) and total flux across skin of some selected        
                     drugs 
Drug 
 
MW 
 
Flux 
(µg/ cm2 hr) 
Ephedrine 165 300 
Diethyl carbamazine 199 100 
Octanol 130 23 
Nitroglycerin 227 13 
Scopolamine 303 3 
Ethanol 48 3 
Chlorpheniramine 275 3 
Fentanyl 337 2 
Estradiol 272 0.016 
Testosterone 288 0.014 
Progesterone 315 0.011 
Quabain 585 0.008 
Cortisone 402 0.0015 
Hydrocortisone 362 0.00091 
Digitoxin 765 0.00013 
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pKa: lonization at Physiological pH. 
The nonionized moiety is usually lipid soluble hence may dissolve in the lipid 
material of a membrane and may be transported by passive diffusion, whereas the 
ionized moiety usually is not lipid soluble enough to permit permeation. The percent 
of ionization can be calculated from Henderson -Hasselbalch equation. 
To cross or to reach membrane or regions by passive diffusion within the body the 
percentage of drug nonionized at that site should be between at least 0.1 and 0.5%. 
Table 1.2.4 gives a serve of pH values of body fluids and anatomical units.51 
 
Table 1.2.4: Body pH values 
 pH Range 
Blood arterial 7.40 7.35-7.45 
Blood  venous 7.37 7.32-7.42 
Plasma 7.40 7.38-7.42 
Urine 5.70 4.80-7.50 
 
Isoelectric Point 
Isoelectric point is the pH at which the zwitterion concentration of protein or peptide 
is at a maximum and the net movement of molecule is negligible. The permeation 
across the membrane is at its minimum at the isoelectric point. The permeation across 
skin upon topical administration of vasopressin was minimum at isoelectric point. 52 
 
(B)  Physicochemical properties of drug delivery system 
 
Release characteristics: 
The affinity of the vehicle for the drug molecule can influence the release of drug 
molecule from the vehicle.53 The solubility in the vehicle will determine the release 
rate of drug. Generally more easily the drug is released from the drug delivery system; 
higher will be the rate of transdermal permeation. A linear relationship is observed 
between the median effective dose of a corticosteroid against product of partition 
coefficient and square-root of their solubility in vehicle,54 pH of the vehicle can also 
influence the rate of release of drug from the drug delivery system. 
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Composition of drug delivery system: 
The vehicle used in drug delivery system usually assumed to be "inert" but it is not so. 
The composition of the vehicle and drug delivery system influences greatly on 
percutaneous absorption of drug particles. It may affect not only the rate of drug 
release but also the permeability of stratum corneum by means of hydration, mixing 
with skin lipids, or other sorption promoting effects.  
Enhancers / sorption promoters: 
Sorption promoters or sorption enhancers are not drugs but they are molecules which 
reversibly decrease the barrier nature of the stratum corneum.55,56,57,58 Sorption 
promoters allow the drugs to penetrate into skin and the permeate across more readily 
and thus increase systemic availability.59,60 
Sorption promotes act by interaction with intracellular lipids leading to disrtruption of 
their organization and increasing their fluidity.61 Some of them also interact with 
intercellular protein, keratin denaturation (azone and oleic acid) 62,63 while others act 
by both mechanism (DMSO and propylene glycol).64 Another possible mechanism is 
by altering the skin hydration.65,66  
The mechanism of these sorption promoters to some extent is also related to 
octanol/water partition co-efficient.67 Recently, lipid-protein partition theory has been 
formulated to describe the potential mechanism of action of sorption promoters.55,64,68 
Mechanism of penetration enhancers on skin 69,70 
Most of the enhancer especially chemical enhancer works on the either lipophilic part 
or hydrophilic part of the bilayer of SC and alter its property and ultimately increases 
the delivery of the drug through the skin. Chemical enhancers may either work of 
lipid portion of the lipid bilayer (intracellular mechanism) or they may work on the 
protein part of the cell (cellular mechanism).  
They may act as lipid enhancer and so here total lipidic portion increases and 
ultimately lipophilic drug can penetrate easily, some chemical enhancer are increases 
the total hydrophilic portion and so they increases flux of hydrophilic drug, some drug 
may able to change the polarity of bilayer and as rule of thumb like dissolve like drug 
of nearly similar polarity may penetrate through skin easily. 
Some enhancer work of cellular part of SC. Enhancers (chemical or other) may 
increase the distance between the two cell and so large molecule can penetrate 
through skin or they may change the arrangement of cellular keratin fibers and 
generate vacuoles in it so it become more permeable to drug. 
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Figure 1.2.9: Action of chemical enhancer on Intercellular lipids 
 
Some enhancer causes the phase separation of bilayer and so drug can penetrate 
through skin. Some enhancer develop pool of increases the flux of hydrophilic drug. 
Solvent like ethanol have tendency to dissolve lipid and it extract out lipid of SC and 
so obstruction for hydrophilic molecule decreases. Estraderm®, containing estradiol 
was the first commercial transdermal system to use ethanol as a permeation enhancer. 
  
Figure 1.2.10:  Action of penetration enhancer on the integrity of stratum    
                          corneum adhesion. 
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Table 1.2.5: Different classes of sorption promoters 
Sr. No. Sorption Promoters Example Refrences 
1. 
Sulfoxides and similar 
Compounds 
Dimethyl sulfoxide 
Dimethyl acetamide 
Dimethyl formamide 
N- methyl formamide 
57,60,71,72 
2. Pyrrolidone 
2-pyrrolidone 
1-methyl 2-pyrrolidone 
5-methyl 2-pyrrolidone 
1,5-methyl 2-pyrrolidone 
1-ethyl 2-pyrrolidone` 
57,60 
3. Fatty acids 
Oleic acid, lauric acid, 
linolic acid, myristic acid 57,60,61,63,73 
4. Azone 
Laurocapram and its 
derivatives 57,60,73,74,75,76 
5. Urea Urea 57,58,60 
6. Surfactant 
Sodium lauryl sulfate 
Triethyl ammonium bromide 
Synperonic NP series 
57,60 
7. Alcohols 
Ethanol 
Lauryl alcohol 
Linolenyl alcohol 
Octanol 
57,60,77 
8. Glycols 
Propylene glycol 
PEG 400 57,64,60,73 
9. Terpenes and terpenoids 
Menthol 
Camphor 57,68,78,79 
10. 
N-pentyl N-acetyl 
prolinate - 80 
11. 
Latam N-acetic acid 
esters 
- 81 
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(C)  Physiological and pathological conditions of the skin 
Reservior Effect of Horny Layer: 
A reservoir for potent fluorinated steroid was demonstrated to be associated with 
stratum corneum.82 A depot for steroid resides in normal horny layer. Depot usually 
occurs for substances having small diffusivity and low solubility in stratum corneum.  
 
Skin Hydration: 
Hydration of stratum corneum facilitates the penetration of most materials through the 
skin. Hydration swells the cells of stratum corneum, wrinkles and its permeability 
dramatically increases. 
 
Skin Temperature: 
Thermal energy is necessary for the diffusivity and solubility of drug in skin tissues. 
Rise of temperature may increase vasodilation of skin vessels leading to an increased 
percutaneous absorption. 
 
Regional Skin Sites: 
Variation on cutaneous permeability will depend on the thickness of the stratum 
corneum, its nature and the density of skin appendages. Compounds like salicylic 
acid, hydrogen sulfide gas and lidocain base penetrates the different skin as follow; in 
decreasing order. 
Scrotum > forehead > Scalp > back > Forearms > Palms > foot arch. 
 
Injuries to skin: 
Injury that disrupts the continuity of stratum corneum increases skin permeability. 
Chemical injury to the skin, erythema, hyperemia, etc increases transderrnal 
permeability. 
 
Skin Metabolism: 
Skin plays as a site of drug and chemical metabolism. Skin actively metabolizes 
steroids, hormones, chemical carcinogens, and drugs and that such metabolism may 
ultimately prove to be a critical determinant of therapeutic-efficacy of topically 
applied drugs and of the carcinogenic response in the skin. 
 
Chapter – 1       Introduction 
 
 
Shital D. Faldu  Ph.D. Thesis 35 
Circulatory Effects: 
Increases blood flow raises the concentration gradient across the skin. 
Vasoconstriction agent such as topical steroids could reduce their own rate of 
clearance from the skin. 
 
Species difference: 
Mammalian skin from different species display wide difference in anatomy, e.g. 
thickness of skin, numbers of sweat glands, and hair follicles per unit surface area, 
distribution of blood supply etc... And such factors affect both, the routes of 
penetration and the resistance to penetration. 
 
(D) Biopharmaceutical aspect of drug. 
Extent of Protein Binding: 
Extent of drug binding the plasma protein and tissue proteins is not constant and may 
change due to physiological and pathological factors, or displacement. Proteins also 
work to carry drugs which may be utilized for drug transport. 
 
Erythrocyte Uptake: 
Erythrocyte may take up drugs. Uptake occur by several mechanisms, (a) Lipophillic 
drugs dissolves in erythrocyte membrane (b) Anions attracted by positively charged 
pores of RBC (c) Adsorption to erythrocyte membrane (d) Binding with erythrocytes 
to carbonic anhydrous drugs. 
 
General absorbability: 
The parameters molecular weight, PKa, solubility and partition coefficient gives 
reasonable information on the potential for absorption from a given site. To verify the 
absorbability weather by passive diffusion or active diffusion can be tested by guinea 
pig ileum.83 
 
1.2.10 Types of Transdermal Delivery Systems 
There are mainly four types of basic transdermal patches in the market.84 
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(1) Drug in adhesive type 
In this type drug is loaded in adhesive itself and stratum corneum acts as rate 
controlling barrier. This is most old type of transdermal patch design. This type of 
transdermal drug delivery system is best illustrated by the development and marketing 
of a nitro glycerin releasing system named as deponit by PharmaSchwartz/Lohmann 
in Europe. Basic construction includes backing membrane, adhesive loaded with drug 
and release liner. 
 
(2) Multi laminate type 
This is most complicated type of design for transdermal patches. Basic construction 
includes backing membrane, drug in adhesive, rate controlling membrane, then again 
adhesive (loaded with drug) on to it. This shows that there are two adhesive layers. 
First layer that is in contact with the release liner is actually delivering drug and 
second layer of adhesive (after membrane) acts as depot of drug. The example is 
scopolamine releasing TDDS named as Transderm-scop by Ciba and clonidine 
releasing TDDS named as CataPress-TTS by Boehringer Ingelheim.   
 
(3) Reservoir type 
 In this type the drug is incorporated in reservoir which is lined with membrane. The 
adhesive is coated on to this membrane. This membrane can be rate controlling. Basic 
construction includes backing membrane, drug in reservoir, membrane, adhesive and 
release liner. Example of this type of TDDS is nitro-glycerine releasing system named 
ass Nitrodisc by Searle. 
 
(4) Matrix type 
In this type, the drug is incorporated in the matrix of polymer which itself releases 
drug in zero order. The adhesive layer is just at the periphery and little inside the 
periphery of the patch. Basic construction includes backing membrane, adhesive, and 
drug in matrix and release liner. The example of matrix type transdermal patch in 
nitroglycerine releasing TDDS named as Nitro-dur by Key. 
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Figure 1.2.11 Basic patch construction 
Single-layer Drug-in-Adhesive 
 
Multi-layer Drug-in-Adhesive 
 
Drug Reservoir-in-Adhesive 
 
Drug Matrix-in-Adhesive 
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1.2.11 Drugs Studied For Transdemal Drug Delivery System 
Table-1.2.6 indicates about the drugs studied for TDDS development. The 
information was collected after extensive literature survey from various journals. 
Table- 1.2.6: Drugs studied for skin permeation and TDDS Development. 
Drug Therapeutic use Skin model used References 
LNG- Estradiol Contraceptive In-vivo (Human) 85 
Fentanyl Post operative analgesic In-vivo (Human) 
 
86 
Estradiol To reduce hot flushes in post menopausal woman 
In-vivo (Human) 87 
Estrogen Estrogen replacement 
therapy 
In-vivo (Human) 88 
Vipocetine Cerebral diseases In-vitro(male Wistar rats) 89 
Acyclovir Antiviral Nude mouse skin 90 
Physostigmine Organophosphorus 
poisoning 
Isolated human skin 91 
Proparanol Anthypertensive Excised hair free rat skin and 
in vivo in male albino rabbits 
92 
Methotrexate Recalcitrant Rheumatoid 
arthritis 
Hairless mouse skin for In-
vitro and Hairless mice for 
In-vivo 
93 
Diazepam Anxiolytic In-vivo mice 94 
Zalcitabine Anti-HIV Hairless rat skin 95 
Terbutaline Antiasthmatic Rat, guinea pig and human 
skin 
96 
Atenolol Antihypertensive Guinea pig and rat skin 97 
Alizapride,  
Bromopride 
metoclopramide 
Antiemetics Rat skin 98 
Nitroglycerine Prophylaxis against angina-pectoris In-vivo (human) 99 
Glutathion Endogenous  100 
Chapter – 1       Introduction 
 
 
Shital D. Faldu  Ph.D. Thesis 39 
Peroxidase 
Catalase 
Anti oxidant for 
photoprotection of skins 
In-vivo (human) 
 
Tranilast Keloids and hypertropic scars In vivo (humans) 101 
Elcatonin Paget's disease in-vivo (humans) 102 
Nicotine Adjunct to smoking cessation therapy In-vivo (humans) 103 
Flubriprofen 
Indomethacin 
Anti-inflammatory Full thickness rat skin 104 
Clonidine Antihypertensive In-vivo (humans) 105 
Testosterone Hypogonadism In-vivo (rhesus monkeys) 106 
Nicardiapine Antihypertensive Hairless guinea pig 107 
Tripolidine        --------------- Hairless mouse skin 108 
Insuline Hypoglycemic ------------- 109 
Melatonine        --------------- Porcine skin 110 
Anti- estrogen        --------------- Hair less mice skin 111 
Tolbuterol Antiasthmatic In vivo, humans 112 
Progesterone Hormone replacement therapy In-vitro porcine skin 113 
Interlukin-2 and 
interferone alpha For passive immunity 
Murine RENCA cell line 
model 114 
Haloperidol Antipsychotic In-vivo, Rat and Rabbit 115 
Prednisolone Antiinflammatory for eye In-vivo rates 116 
Pinacidil 
monohydrate Vasodialator In-vitro albino rat skin 117 
Ketoprofen Anti inflammatory In-vitro rat 119 
Gestodene Prodrug of active progestine In-vitro mice skin 120 
7-Hydroxy 
coumarine Anticoagulants In-vitro human, snake 121 
Chlorphenaramine 
maleate Antiallergic 
TESTSKIN® living skin 
equivalent 122 
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Diclofenac  Anti-inflammatory In-vitro , cadaver skin 123 
Nimesulide Antiinflammatory In-vitro porcine and human skin 124 
Testosterone Hypogonadism In-vitro (rat skin) 125 
 
1.2.12 Commercially available Transdermal therapeutic system 126,127 
 
Table 1.2.7: Commercially available transdermal therapeutic system 
 
Drug/ Manufacturer Trade Name Duration 
Type of 
system 
Therapeutic Use 
Scopolamine 
Alza/Ciba 
Transderm® Scop 2 days Reservoir 
Alleviate motion 
sickness 
Nitroglycerine 
Alza/Ciba 
Transderm ®-Nitro 
 
1 day 
 
Reservoir 
 
Treatment and 
prophylaxis of 
angina pectoris 
Hercom NTS®   
Matrix 
 
 
 
Searle Nitrodisc®   
Matrix 
 
 
 
Key 
 Nitro-dur ® 
 
 
Matrix 
 
 
 
Wayth 
 Deponite ® 
 
 
Sand witch 
 
 
 
Isosrbide dinitrate 
Nitro electric industrial 
Frandol ® 
 
Tape ® 
1 day Matrix 
Treatment and 
prophylaxis of 
angina pectoris 
Clonidine 
Boehringer/Ingelneim 
Catapress® TTS 7 days   
Treatment of 
hypertension 
Estradiol 
Ciba-Giegy 
Estraderm ® 3 days Reservoir 
Relief from post 
menopausal 
symptoms 
Nicotine 
Alza Nicoderm ® 1 day Reservoir 
Aid in smoking 
cessation 
Ciba-Giegy Habitrol ®   Matrix 
 
 
Park-Davis Prostep ®   Matrix 
 
 
Fentanyl 
Jenssens 
Duragesic ® 5 days  Post operative 
analgesic 
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1.2.13 Evaluation of Transdermal Drug Delivery Device 
Table 1.2.8: Testing of transdermal drug delivery system 128,129 
TYPE OF TEST ON FINAL 
PRODUCT 
TESTS 
 
Chemical test 
• Content  
• Content uniformity 
• Purity 
• Residual Solvent 
 
Physical test • USP apparatus 5 (Paddle over disk) 
Release testing 
• USP apparatus 6 (Cylinder) 
• USP apparatus 7 (Reciprocating disk) 
• Peel property 
Test for adhesion 
• Tack property 
                  Thumbtack test 
                  Rolling ball tack test 
                  Quick stick test 
                  Probe tack test 
• Shear strength 
 
Cutaneous toxicity 
• Contact dermatitis 
• Growth of microorganisms 
• Cytotoxicity 
• Sensitization study 
Percutaneous absorption 
model 
• In vitro testing 
• In vivo testing 
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IN VITRO TESTING OF TRANSDERMAL DELIVERY SYSTEM  
 
Figure 1.2.12: In Vitro testing procedure 
 
  
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
Proper skin preparation and appropriate cell design gives good in vivo results. Skin 
preparation includes selection of proper skin. One can choose human skin or can also 
go for animal or artificial membrane like Nylon, Cellulose acetate etc. Skin separation 
includes the treatments needed for separation of required part of skin from other 
unwanted parts. Then separated skin we mount on the diffusion cell which can be one 
chambered (one donor compartment) or two chambered (two donor compartment). 
 
Selection of membrane for in vitro study of transdermal drug delivery system 
Various skin models used by various researchers are given in Figure 1.2.13. Though 
there is no rule regarding to selection of the skin model. But generally researchers 
starts with artificial membrane, then in vitro animal skin, then in vitro human skin 
(cadaver skin), then in vivo animal skin, then finally in vivo human skin. 
 
 
 
SELECTION  
OF SKIN 
SEPARATION 
•  Human 
•  Animal 
•  Artificial 
•  Heat 
•  Chemical 
•  Physical 
  
•  One chambered 
    (Vertical type) 
•  Two chambered 
          (Horizontal type) 
SKIN PREPARATION 
 
CELL DESIGN 
 
IN-VITRO TESTING 
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Figure 1.2.13: Selection of membrane. 
SKIN MODEL 
USED
IN VITRO IN VIVO ARTIFICIAL 
•Hairless mouse
•Hairless rat skin
•Guinea pig skin
•Fuzzy rat skin
•Human skin
•Furry rat
•Guinea pig
•Rabbit
•Dog
•Human
•Ion exchange 
membrane
•Nucleopore
membrane
•Silicone membrane
•Artificial lipid 
barrier
 
Franz diffusion cell 130,131 
It is one chambered (vertical) type cell. Most widely used for in-vitro testing of 
TDDS. Many modifications have been made in the Franz diffusion cell design 
according to the requirement. Here skin is mounted on the plate above O ring. 20-70 
ml phosphate buffer of pH 7.4 is filled in reservoir compartment. Transdermal patch 
is applied on upper layer of skin. Diffusion medium in reservoir is stirred at particular 
rpm. Sampling is done at particular interval from reservoir compartment i.e. specified 
volume of fluid is withdrawn and is replaced by equivalent amount of the same fluid. 
 
In vitro drug release profile modeling 
In-vitro drug release has been recognized as an important tool in drug development 
and as an important parameter in quality control. Under certain conditions, it can be 
used as a surrogate for the assessment of bio-equivalence or prediction of 
bioequivalence.132 
A good understanding of the release mechanism of the dosage form as well as the 
physical chemical properties of the drug will enable development of accurate 
dissolution tests.133 
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An appropriate drug release test is required to characterize the drug product and 
ensure batch-to-batch re-producibility and consistent pharmacological/biological 
activity and to evaluate scale up and post approval changes such as manufacturing site 
changes, component and composition changes. The release of drug from a sustained 
release formulation is controlled by various factors through different mechanisms 
such as diffusion, erosion or osmosis. Several mathematical models are proposed by 
many researchers to describe the drug release profiles from various systems.134,135 
In order to characterize the kinetics of drug release from dosage forms several model 
dependent methods are reported by various researchers.136,137 The model dependent 
methods all rely upon a curve fitting procedure. Different mathematical functions 
have been used to model the observed data. Both the linear and non-linear models are 
being used in practice for dissolution modeling. Linear models include Zero order, 
Higuchi, Hixson-Crowell, quadratic and Polynomials, where as the nonlinear models 
include First order, Weibull, Korsmeyer- Peppas, Logistic etc.138 There are several 
linear and non-linear kinetic models widely used to describe release mechanisms and 
to compare test and reference dissolution profiles in Table 1.2.9. 
Table 1.2.9: Drug release profile model equations 
Function Equation 
Zero-order kt=diss%  
First-order [ ]kte1100=diss%  -  
Hixson-Crowell 





















 −−=∫
3
6416.4
11100% ktdiss  
Higuchi 5.0kt=diss%  
Korsmeyer-Peppas nkt=diss%  
Weibull ( )



=
β
Td
t
ediss --1100%  
 
Note:   % diss = Percent dissolved at time t;  
  K = Dissolution rate constant 
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n    = Release component which is indicative of drug release mechanism;  
β      = Shape parameter Td, time at which 63.2% of the drug is dissolved. 
 
Zero order kinetics 132 
Drug dissolution from pharmaceutical dosage forms that do not disaggregate and 
release the drug slowly (assuming that area does not change and no equilibrium 
conditions are obtained) can be represented by the following equation:  
tKWW t 00   - =  
Where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is the 
amount of drug in the pharmaceutical dosage form at time t and K is proportionality 
constant. Dividing this equation by W0 and simplifying: 
tK=f 0t  
Where ft = 1- (wt/ w0) and ft represents the fraction of drug dissolved in time t and k0 
the apparent dissolution rate constant or zero order release constant. In this way, a 
graphic of the drug-dissolved fraction versus time will be linear if the previously 
established conditions were full filled.  
 
First order kinetics 132,139 
This type of model to analyze drug dissolution study was first proposed by Gibaldi 
and Feldman and later by Wagner. The relation expressing this model: 
303.2
tK+Q log=Q log 10t  
Where, Qt is the amount of drug released in time t, Q0 is initial amount of drug in the 
solution and K1 is the first order release rate constant. In this way a graphical 
relationship between ft   versus time to get the Zero order constant from the slope.  
 
Korsmeyer Peppas model 132,140 
Korsmeyer et al., developed a simple semi empirical model, relating exponentially the 
drug release to the elapsed time (t). 
n
k
t tK=
Q
Q
∞
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Where Qt is the amount of drug released in time t, Q0 is initial amount of drug in the 
solution; Kk is a constant incorporating structural and geometric characteristic of the 
drug dosage form and n is the release exponent, indicative of the drug release 
mechanism. 
 
Table 1.2.10: Release exponent of Korsmeyer Peppas model and its   
                       corresponding drug transport mechanism. 
Release exponent 
(n) 
Drug transport 
Mechanism 
Rate as a function 
of time 
0.5 Fickian diffusion t -0.5 
0.5<n<1.0 Anomalous transport t n-1 
1.0 Case-II transport Zero-order release 
Higher than 1.0 Super Case-II transport t n-1 
 
Higuchi Model 130,133 
The model purposed by the Higuchi 141 is described by following formula:  
2
1
HtK=Qt  
Where Qt is the amount of drug released at time t and KH is the Higuchi release rate. 
This is the most widely used model to describe drug release from pharmaceutical 
matrices. A linear relationship between square root of time and concentration 
indicates that the drug release follows strict Fickian diffusion. For purpose of data 
treatment, the above equation is usually reduced to:    
                                                             2
1
Kt=Q  
Therefore a plot of amount of drug released versus the square root of time should be 
linear if drug release from the matrix is diffusion controlled. Alternatively, the drug 
release rate is proportional to the reciprocal of the square root of time. An important 
advantage of the above equations is its simplicity.  
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Hixson- Crowell model 132,138 
Hixson and Crowell recognizing that the particle regular area is proportional to the 
cubic root of its volume derived an equation that can be described in the following 
manner: 
tKWW t 03
1
3
1
0  - =  
Where W is the initial amount of drug in the pharmaceutical dosage form, W is the 
remaining amount of drug in the pharmaceutical dosage form at time t and K is a 
constant incorporating the surface–volume relation.  
 
Weibull model 142 
A general empirical equation described by Weibull was adapted to the dissolution / 
release process from pharmaceutical dosage forms, the Weibull equation expresses 
the accumulated fraction of the drug, m, in solution at time, t, by: 
( )





 −−−= a
Ttm i
β
exp1  
In this equation, the scale parameter, a, defines the time scale of the process. The 
location parameter, Ti, represents the lag time before the onset of the dissolution or 
release process and in most cases will be zero. The shape parameter, β, characterizes 
the curve as either exponential (β=1) (Case 1), sigmoid, S-shaped, with upward 
curvature followed by a turning point (β>1) (Case 2), or parabolic, with a higher 
initial slope and after that consistent with the exponential (β <1) (Case 3). This 
equation may be rearranged into: 
 
( )[ ] ( ) aTitbm log-log*-1lnlog =  
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1.3 SKIN IRRITATION AND SKIN SENSITIZATION STUDIES 
 
1.3.1 Skin Irritation and Sensitization 
The concept of skin irritation or inflammation has a very long history, Egyptian 
scrolls, dated perhaps as early as 2650 BC, have several references to a word 
indicating inflammation that is associated with wounds. 
In 1889, Julius Cohnheim described inflammation as a series of changes to the 
affected area including redness, swelling, pain, warmth. Earlier  to 1985 it was 
thought that chemical irritation to the skin occurs  in phases like increased 
permeability and blood flow, infiltration of cells, leucocytosis etc. After 1985 Patrick 
et al., Agner and serup 1987 reported that irritation of chemical and resulting effects 
on the skin appeared to be related to the specific irritant applied. Further more, skin 
irritation appears to be produced by multiple mechanisms resulting invariable patterns 
of response.1, 2 
We can broadly classify skin sensitization irritation and inflammation in to following 
categories.3, 4 
 
1. Allergic Contact Dermatitis (Skin Sensitization) 
Definition and Description 5,6 
Allergic contact dermatitis or dermatitis venenta, is the result of an interaction 
between the complicated pathophysiological mechanisms of type-IV cell mediated 
immunity and environmental sensitizer (allergens).  
Acute contact dermatitis is characterized by papules and sharply demarcated 
erythema. Blisters are also produced following the release of cytotoxic compounds by 
white cells attracted to the affected site. 
The key element in the formation of sub chronic and chronic allergic dermatitis is due 
to recurrent exposure to the causative agent. 
 
2. Light induced cutaneous toxicity 4,7 
The wavelength of light found in UV-B   spectrum is generally considered the 
primary source of toxic changes in the skin. The specific wavelength responsible for a 
particular biological response is termed as “action spectrum” for that effect. In some 
cases, xenobiotics play a role in these effects while in others, the interaction of light 
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with the normal compound of the skin is responsible in either case; adverse reaction 
of the skin to light (UV or Visible) is termed as photo sensitization. 
 
2.1 Photo sensitization not related to xenobiotics 
The exposure of the unprotected skin to UV light (from sunlight or artificial sources) 
can result toxic responses. These includes short term, generally reversible effects such 
as sunburn (erythema) and tanning (enhanced pigment darkening) as well to as long 
term, generally irreversible effects such as premature skin ageing (actinic elastosis) 
and development of the skin cancer. 
2.2 Photo sensitisation related to xenobiotic exposure 
Xenobiotics localized within the skin can interact with light and produces adverse 
reaction in the skin in many ways. These include phototoxicity, photo allergy 
depigmentation, induction of endogenous photosensitizes and induction of 
photosensitive disease states.8 
 
3.  Cutaneous Carcinogenesis 9 
The skin is the most common site of cancer in humans. Both benign and malignant 
tumors may be derived from viable keratinocytes and melanocytes of the epidermis, 
and rarely from skin appendages, blood vessels, peripheral nerves and lymphoid 
tissue of the dermis. Histologically, basal cell and squamous cell carcinomas that 
develop from keratinocytes account for 60% and 30% for all the skin cancers 
respectively.  
 
4 Acne-like eruptions 4 
These reactions are initiated by the proliferation of the epithelium of sebaceous glands 
and formation of keratin cyst resulting in the development of a pustule filled with 
fatty compounds and other product of sebaceous origin. 
 
Evaluating chemicals for the adverse effect on the skin 
1 Sensitization testing in animals 
Sensitizations   test   is   done   to   evaluate   the   allergic   potential   of chemicals, to 
assess potential sensitization properties. Animals is treated with an intial or several 
doses of chemical (the induction phase) by intradermal or cutaneous application. 
Following an incubation or sensitization phases for approximately two weeks the 
Chapter – 1       Introduction 
 
 
Shital D. Faldu  Ph.D. Thesis 61 
animal is treated with second dose or series of doses of the same test chemical (the 
challenge phase).   Sensitization is evaluated by examining the skin reaction following 
the challenge phase compared with any skin reaction immediately following the 
induction phase. 
  
Intradermal Techniques  
Draize et, al.10 were the first to describe standardized irritation and sensitization tests. 
The Draize test is the simplest and most predictive tests to perform. However the test  
have several draw backs including high incidence of negatives with weak sensitizers11 
further more, the test; recommends a consistent induction concentration of 0.1% 
injected intradermally without regard to use pattern or exposure potential of the 
chemicals.12 
Freud’s complete adjuvant test13 is the test in which test substances is mixed with 
Freud’s complete adjuvant (FCA a mixture of heat killed Mycobacterium 
tuberculosis, paraffin oil and mannide monooleate) prior to intradermal injection for 
induction. The use of FCA increases the immunological response and aids in the 
detection of weak sensitizers. This test utilizes three injections of this mixture at 
different sites during induction phase. In the challenge phase the test substance is 
generally applied on epidermally (non-occluded) in range of non-irritating 
concentrations. This test is considered as sensitive as the optimization test and is of 
low cost to perform. The primary drawback of this test is the use of intradermal 
induction doses which actually bypasses the effect of stratum corneum and stratum 
corneum is highly important to limit the absorption of potential sensitizers. Further 
more the use of FCA may cause the sensitizing potential of the test chemical to be 
over-estimated.14 
 
Epicutaneous Techniques 
The open epicutaneous test utilizes an induction phase of repeated applications of an 
undiluted test substance (which may be a formulation of a final product for consumer 
exposure) over several weeks. The challenge phase separated in to initial and 
rechallange phases. Klecak et al (1977) found this test to be sensitive, highly 
predictive test.15 
The buckler test was designed to reproduce a human patch test in animals and 
therefore allows variation of conditions to optimize detection of moderate strong 
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sensitizers prior to testing in humans. This test utilizes induction and challenge phases 
of occluded epidermal doses of the test substances that may be allergic chemicals or 
final product formulations.16  
 
2 Irritation testing in animals 
The evaluation of compound for irritability in animals correlates well with the degree 
of skin response in humans. 
 
Single Application Irritation Testing 
The test described by Draize et al.10 or slight modification of this test is the most 
widely used for predicting the potential skin irritation of chemicals and chemical 
mixtures. In this test hair are clipped from the back of a rabbit and four distinct areas 
for the application of test substances are identified. Two of four areas were abraded 
by making four epidermal incisions in the appropriate areas. All four areas were 
covered by gauze that is held in place with adhesive tape and the test substance is 
applied to the appropriate area under the gauze. 
 
The entire trunk of the rabbit is wrapped in impervious cloth or plastic to hold the 
patches in place and decrease the evaporation of volatile test substances. The rabbits 
were generally remain wrapped for 24 hr after treatment and are evaluated for 
irritation at the time of unwrapping and 24 and 48 hr after being unwrapped. 
Generally four test substances are evaluated in a series of six rabbits. 
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Table-1.3.1: Division of various elements of irritation in to distinct categories of    
                       grading according to Draiz et al. 
Sr. No. Skin reaction Score 
1. Erythema and Escher Formation  
 Very slight erythema (barely perceptible) 1 
 Well defined erythema 2 
 Moderate to severe erythema 3 
 Severe erythema (beet redness) to slight Escher formation 4 
 Total possible erythema score 4 
2. Edema Formation  
 Very slight Edema (Barely perceptible) 1 
 Slight Edema edges of area well defined by definite raising) 2 
 Moderate edema (area raised approximately 1mm) 3 
 Severe edema (raised 1mm and extending beyond the area of exposure) 4 
 Total possible edema score 4 
 Total possible score for primary irritation 8 
 
 
Repetitive Application Irritation Testing 
The repetitive application over at least 7-14 days appears to be better able to predict 
the irritability of test substances than the single application. Additionally, the 
repetitive application test to assess irritability can be combined with an assessment for 
systemic toxicity by cutaneous route. This is highly relevant especially in the case of 
transdermal drug delivery. In  repetitive irritant testing usually, three or more groups 
of five to ten animals per sex are used with each group receiving a different dose of 
test substance daily for 2,3,4 or 13 weeks. An additional group of animals is handled 
similarly but treated with the vehicle or when no vehicle is used with water to serve as 
control group is removed from the back of the animal. The animal is then wrapped 
with an occlusive dressing and returned to its home cage for the period of 6 hr. The 
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wrapping is removed and the back is gently wiped. The animals are observed daily for 
the signs of cutaneous irritation. 
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1.4 CARDIOVASCULAR DISEASE 
Cardiovascular diseases are the class of diseases that involve the heart or blood 
vessels (arteries and veins). 
 Heart diseases which affect the heart in several different ways but they all 
cause the ultimate problem of disrupting the vital pumping action of the 
heart. e.g. Cardiac arrhythmias, Heart attack, Myocardial infraction, Valvular 
disorders, Coronary artery disease, Congenital heart disease; Heart muscle 
disease or Cardiomyopathy; Pericardial diseases. 
 Vascular disease or Blood vessel disease which affects the blood vessels and 
ultimately causes heart dysfunctioning. e.g. Hypertension, Hypotension, 
Atherosclerosis, Embolism etc. 
 
1.4.1 Cardiac arrhythmias1-4 
The rhythm of the heart is normally generated and regulated by pacemaker cells 
within the sinoatrial (SA) node, which is located within the wall of the right atrium.  
SA nodal pacemaker activity normally governs the rhythm of the atria and ventricles.  
Causes of Cardiac arrhythmias 
A frequent cause of arrhythmia is coronary artery disease because this condition 
results in myocardial ischemia or infarction.  When cardiac cells lack oxygen, they 
become depolarized, which lead to altered impulse formation and/or altered impulse 
conduction. The former concerns changes in rhythm that are caused by changes in the 
automaticity of pacemaker cells or by abnormal generation of action potentials at sites 
other than the SA node (termed ectopic foci).  Altered impulse conduction is usually 
associated with complete or partial block of electrical conduction within the heart.  
Altered impulse conduction commonly results in reentry, which can lead to 
tachyarrhythmia. Finally, many different types of drugs (including antiarrhythmic 
drugs) as well as electrolyte disturbances (primarily K+ and Ca++) can precipitate 
arrhythmias. 
Classification of Cardiac Arrhythmias 
Bradycardia denotes a decrease in heart rate. 
Tachycardia is the term denoting an increase in heart rate. 
Extrasystoles: these are premature beats that occurs before the next expected beats. 
This may be artrial, ventricular or nodal, depending on its site of origin. 
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Paroxymal Supraventricular Tachycardia: It is the condition in which the heart 
rate suddenly increases to 150-200 beats/min and 1:1 AV conduction is maintained. 
Atrial-flutter: It is a very rapid but regular beating of atria with a rate between 240-
400 per min. 
Atrial Fibrillation: It is a rapid, continuous chaotic and irregular beating of atria. It is 
of great danger. 
Ventricular Fibrillation: It is a irregular and chaotic ventricular arrhythmia with 
rapid rate and disorganized spread of impulses throughout the ventricular 
myocardium. It is Very Dangerous. 
Heart block: It is the term applied to a condition in which the nerve impulses are 
delayed or fail to get through from their source in the right atrium to the ventricles. It 
is obstruction of the impulse, in the heart thus suddenly, decreasing the heart rate and 
the pulse rate.   
Cardiac arrhythmias treatment 
When arrhythmias require treatment, they are treated with drugs that suppress the 
arrhythmia. These drugs are called antiarrhythmic drugs. There are many different 
types of antiarrhythmic drugs and many different mechanisms of action. Most of the 
drugs affect ion channels that are involved in the movement of sodium, calcium and 
potassium ions in and out of the cell. These drugs include mechanistic classes such as 
sodium-channel blockers, calcium-channel blockers and potassium-channel blockers. 
By altering the movement of these important ions, the electrical activity of the cardiac 
cells (both pacemaker and non-pacemaker cells) is altered, hopefully in a manner that 
suppresses arrhythmias.  
Classification of Antiarrhythmic drugs 
Class I: Na channel blockers (membrane-stabilizing drugs) block fast Na channels, 
slowing conduction in fast-channel tissues Class I drugs are subdivided based on the 
kinetics of the Na channel effects. e.g. Quinidine, Procainamide 
Class Ia drugs have a intermediate kinetic 
Class Ib drugs have fast kinetics 
Class Ic drugs have slow kinetics.  
Class II: Class II drugs are β-blockers, which affect predominantly slow-channel 
tissues (SA and AV nodes), where they decrease rate of automaticity, slow conduction 
velocity, and prolong refractoriness. Thus, heart rate is slowed. e.g. Propranolol 
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Class III: Class III drugs are primarily K channel blockers, which prolong action 
potential duration and refractoriness in slow- and fast-channel tissues. e.g. 
Amioderone, Sotalol 
Class IV: Class IV drugs are the nondihydropyridine Ca channel blockers, which 
depress Ca-dependent action potentials in slow channel tissues and thus decrease rate 
of automaticity, slow conduction velocity, and prolong refractoriness. Heart rate is 
slowed. e.g. Verapamil, Diltiazem. 
 
1.4.2 Hypertension5-8 
Hypertension or high blood pressure is a condition in which the blood pressure in the 
arteries is chronically elevated. With every heart beat, the heart pumps blood through 
the arteries to the rest of the body. Blood pressure is the force of blood that is pushing 
up against the walls of the blood vessels. If the pressure is too high, the heart has to 
work harder to pump, and this could lead to organ damage and several illnesses such 
as heart attack, stroke, heart failure, aneurysm, or renal failure. 
Classification of hypertension  
Hypertension may be classified as essential or secondary. Essential hypertension is 
the term for high blood pressure with unknown cause. It accounts for about 95% of 
cases. Secondary hypertension is the term for high blood pressure with a known direct 
cause, such as kidney disease, tumors, or other diseases. 
Causes of Hypertension 
Though the exact causes of hypertension are usually unknown, there are several 
factors that have been highly associated with the condition. These include Smoking, 
Obesity or being overweight, Diabetes, Sedentary lifestyle, Lack of physical activity, 
High levels of salt intake (sodium sensitivity), Insufficient calcium, potassium, and 
magnesium consumption, High levels of alcohol consumption, Stress, Aging, 
Medicines such as birth control pills, Genetics and a family history of hypertension, 
Chronic kidney disease, Adrenal and thyroid problems or tumors.  
Symptoms of Hypertension 
There is no guarantee that a person with hypertension will present any symptoms of 
the condition. Extremely high blood pressure may lead to some symptoms, however, 
and these include severe headaches, Fatigue or confusion, Dizziness, Nausea, 
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Problems with vision, Chest pains, Breathing problems, Irregular heartbeat, Blood in 
the urine.  
Treatment of Hypertension  
Medications most often prescribed for high blood pressure include the following:  
Water pills (diuretics) 
Diuretics are used very widely to control mildly high blood pressure, and are often 
used in combination with other medications. They increase sodium excretion and 
urine output and decrease blood volume. The sensitivity to the effect of other 
hormones in your body is decreased. e.g. Hydrochlorothiazide.  
Beta-blockers 
Beta-blockers reduce heart rate and decrease the force of heart contraction, thereby 
reducing the pressure generated by the heart. They are preferred for people who have 
associated coronary heart disease, angina, or history of a heart attack, since they also 
prevent recurrent heart attacks and sudden death. e.g. Carvedilol, metoprolol, atenolol.  
Side effects - Fatigue, depression, impotence, nightmares  
Calcium channel blockers 
Calcium channel blocking agents work by relaxing the muscle in the walls of the 
arteries.  
They also reduce the force of contraction of the heart. e.g. Nifedipine, diltiazem, 
verapamil, nicardipine, amlodipine, felodipine.  
Side effects - Ankle swelling, fatigue, headache, constipation, flushing  
Angiotensin-converting enzyme (ACE) inhibitors  
ACE inhibitors stop the production of a chemical called angiotensin II, a very potent 
chemical that causes blood vessels to contract, a cause of high blood pressure. 
Blockage of this chemical causes the blood vessels to relax. e.g. Captopril, enalapril, 
lisinopril. 
Angiotensin receptor blockers  
Angiotensin receptor blockers work on receptors in tissues all over the body to 
prevent uptake of angiotensin II, and therefore inhibit the vasoconstrictor effect of 
angiotensin II. e.g.  Losartan, valsartan.   
Alpha-blockers 
Alpha-blockers relax blood vessels by blocking messages from the nervous system 
that cause muscular contraction.  
Examples – Terazosin, doxazosin. 
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Blockers of central sympathetic (autonomic nervous) system 
These agents block messages out of the brain from the autonomic nervous system that 
contract blood vessels. The autonomic nervous system is the part of the nervous 
system that is automatic and controls heart rate, breathing rate, and other basic 
functions. The effect of these drugs is to relax blood vessels, thus lowering blood 
pressure. e.g. Clonidine.  
Direct vasodilators 
Direct vasodilators relax (dilate) the blood vessels to allow blood to flow under lower 
pressure. These medications are often given through an IV line in an emergency (that 
is, in malignant hypertension). e.g. Nitroprussidediazoxide. Oral medications are 
hydralazine and minoxidil. 
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1.5 INTRODUCTION TO DRUG 
 
1.5.1 Diltiazem HCI 1 
Diltiazem is a benzothiazepine calcium channel-blocking agent most similar to 
verapamil in its clinical effects. Diltiazem increases exercise capacity and improves 
multiple markers of myocardial ischemia, reduces heart rate, may improve cardiac 
output, improve myocardial perfusion, educes left ventricular work load and may 
prevent calcium induced perfusions injury that occurs after procedures such as 
angioplasty. 
 
A. Physiochemical profile 
Structure:   
 
 
Empirical formula:   C22H26N2O4S HCl 
Molecular weight:   450.98 
Chemical name:   1, 5-Benzothiazepin-4 (5H)-one, 3-(acetyloxy)- 
                                                -5- [2- (dimethylamino) ethyl]-2, 3-dihydro-2-          
                                                (4-methoxyphenyl)-, monohydrochloride                                   
Category:    Antianginal, Calcium Channel Blocker,  
                                                            Antihypertensive. 
Description:    White crystalline powder or small crystals,      
                                                            odorless and bitter taste. 
Melting point:   207.5-212°C 
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Solubility:   
Table 1.5.1: Solubility of Diltiazem hydrochloride in different solvent 
Solvent Solubility 
Water Freely soluble 
Formic acid Freely soluble 
Methanol Freely soluble 
Chloroform Freely soluble 
Absolute alcohol Sparingly soluble 
Ether Insoluble 
 
B. Pharmacology 2,3,4 
Mechanism of action  
Hypertension. Diltiazem produces its antihypertensive effect primarily by relaxation 
of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. 
The magnitude of blood pressure reduction is related to the degree of hypertension; 
thus hypertensive individuals experience an antihypertensive effect, whereas there is 
only a modest fall in blood pressure in normotensives.  
Angina. Diltiazem has been shown to produce increases in exercise tolerance, 
probably due to its ability to reduce myocardial oxygen demand. This is accomplished 
via reductions in heart rate and systemic blood pressure at submaximal and maximal 
workloads. Diltiazem has been shown to be a potent dilator of coronary arteries, both 
epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery 
spasms are inhibited by diltiazem.  
Dosage: Adult: 30-60 mg 3 times in day. 
 
C.  Pharmacokinetic 
Diltiazem is well absorbed from the gastrointestinal tract and is subject to an 
extensive first-pass effect, giving an absolute bioavailability (compared to intravenous 
administration) of about 40%. Diltiazem undergoes extensive metabolism in which 
only 2% to 4% of the unchanged drug appears in the urine. In vitro binding studies 
show Diltiazem is 70% to 80% bound to plasma proteins. The plasma elimination 
half-life following single or multiple drug administration is approximately 3.0 to 4.5 
hr. Desacetyl Diltiazem is also present in the plasma at levels of 10% to 20% of the 
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parent drug and is 25% to 50% as potent as a coronary vasodilator as Diltiazem. 
Minimum therapeutic plasma Diltiazem concentrations appear to be in the range of 50 
to 200ng/ml. 
 
Table 1.5.2: Pharmacokinetic data of Diltiazem hydrochloride 3 
Extend of absorption 80-90% 
Bioavailability 40-67% 
Onset of action 30-60 min 
Peak plasma level 2-3 hr 
Protein binding 70-80% 
Therapeutic serum level 50-200 ng/ml 
Metabolite Desacethyl diltiazem 
Excreted unchanged in urine 2-4% 
Half life elimination 3.5-6 hrs 
 
D. Indication 
Angina, Atrial fibrillation, Hypertension, Cardiomyopathy, Diabetic neuropathy 
 
E. Contraindications 
Diltiazem is contraindicated in patients with sick sinus syndrome except in the 
presence of a functioning ventricular pacemaker, second- or third-degree AV 
block except in the presence of a functioning ventricular pacemaker, hypotension 
(less than 90 mm Hg systolic), hypersensitivity to the drug, acute myocardial 
infarction and pulmonary congestion documented by x-ray on admission.  
 
F. Adverse effects 
AV block, Confusion, Constipation, Depression, Heat failure, Hypotension, 
Stevens-Johnson syndrome 
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G. Market products of Diltiazem hydrochloride 5,6 
Table.1.5.3 Different formulations of Diltiazem hydrochlorides 
Conventional Dosage form 
Brand Name Formulation Available Strength Company  
Angizem Tablet  30mg, 60mg Sun Pharma 
Dicard Tablet 30mg, 60mg Intas 
Diltime Tablet 30mg, 60mg, 90 mg Zydus Cadila 
Dilzem Tablet  30mg, 60mg, Torrent 
 
Modified Release Dosage forms 
Angizem cd Tablet 90mg, 120mg, 180mg Sun pharma 
Dilter CD Capsule 60mg, 90mg, 120mg Sun Pharma 
Diltime Tablet 120mg Zydus Cadila 
Dilzem Tablet 90mg Torrent 
 
Injectable dosage form 
Dilzem Injection 5mg/ml Torrent 
 
  
1.5.2 Atenolol 7,8,9 
Atenolol is a β-adrenolytic, cardioselective drug, having no intrinsic 
sympathomimetic activity. 
A.  Physicochemical profile 
          Structure 
 
 
 
 
 
 
 
Emperical formula    C14H22N2O3  
Chapter – 1       Introduction 
 
 
Shital D. Faldu  Ph.D. Thesis 75 
Molecular weight   266.3  
Chemical Name   (RS)-4-(2-hydroxy-3-          
                                                             isopropylaminopropoxy)phenylacetamide  
Category    Antihypertensive 
Description    Atenolol is a white and odorless powder. 
Melting Point                                     152-155oC 
Dissociation Constant (pKa)             9.6 @ 24oC 
Partition Co-efficient                        0.23 
Table 1.5.4: Solubility of atenolol in different solvents 
Solvent Solubility 
Water Sparingly Soluble 
Ethanol Soluble 
Methanol Soluble 
Ether Practically Insoluble 
 
B. Pharmacology 
Mechanism of action  
Atenolol is a beta-adrenaoreceptor antagonist, or a more commonly known as a beta 
blocker. Atenolol slows down the strength of the heart’s contractions and reduces its 
oxygen requirements and the volume of blood it has to pump. Hypertension (high 
blood pressure) may be treated with these drugs because of their ability to increase the 
diameter of the blood vessels thus allowing blood to flow under less pressure. Some 
of these medicines include a diuretic to help reduce blood pressure by increasing the 
body’s excretion of excess fluid. Beta blockers are also used to treat Myocardial 
infarction (heart attack) and Arrhythmias (rhythm disorders), angina (chest pains), and 
disorders arising from decreased circulation and vascular constriction, including 
migraine.  
Dosage   
Adult 50-100mg daily 
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C. Pharmacokinetic 
Bioavailability following oral administration is about 45%, but with individual 
variation this can triple or quadruple. Peak plasma concentrations occur 2-4 hours 
after oral administration and the duration of therapeutic effect is up to 24 hours. 
Plasma concentration increases comparatively with the patient’s age. If taken with 
food, the absorption is reduced by approximately 20%. Protein binding is 
approximately 3% and the volume of distribution is 0,7 l/kg. Atenolol has low lipid 
solubility. Hepatic metabolism is negligible and the drug is eliminated, almost always 
unchanged, through the kidneys. Only 10% of Atenolol is eliminated as metabolite, 
none of which have any pharmaceutical activity in man. Plasma half-life is 6-9 hours. 
In case of impaired renal function half-life is prolonged, but impaired hepatic function 
has no effect on half-life. 
 
D. Indication 
Antihypertensive,  Anti-Angina,  Anti-Arrhythmic,  Myocardial Infarctions,  Alcohol 
Withdrawal,  Anxiety States,  Migraine Prophylaxis,  Hyperthyroidism, Tremor  
 
E. Contraindications 
Atenolol is contraindicated in patient with Asthama, Congestive cardiac failure and 
Phaeochromocytoma. 
 
F. Adverse effect                                                                                                                  
The most serious adverse effects are heart failure, heart block, and bronchospasm. 
Other more minor side-effects include fatigue and coldness of extremities. It causes 
CNS effect of depression, hallucination, confusion. It causes nausea, vomiting, 
constipation and abdominal pain. It causes skin rash, pruritis, decreased tear 
production, blurred vision and soreness. 
 
G. Marketed product 
Aloten (Core), Altol ( Indoco ), Angitol ( Ind-Swift ), Antipress (Saga Labs ), Atcardil 
(Sun Pharma ), AteCard (Dabur), Atecor (Win-Medicare), Atelol (Themis Pharma), 
Aten (Kopran), Atenex (Recon), Atenova (Lupin), Atormin (PCI), Atpark (Parke 
Davis), Beta (Stadmed), Betacard (Torrent), Betanol (Unisearch), beten (Sigma Labs), 
Biduten (Croydon), BP-NOL (Elder), Catenol (Alidac), Eucard (Malladi Drugs), 
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Hipres (Cipla), Lakten-50 (Shalaks), Lonol (Khandelwal), Normolol (Pace, SOL), 
Pertenol (Karnataka Antibiotics), Telol (Max), Tenase (Jenburkt), Tenolol (IPCA), 
Tensicard (Troikaa), Tensimin (Unique).  
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1.6 INTRODUCTION TO POLYMERS 
1.6.1 Ethyl Vinyl Acetate Copolymer 1-5 
1. Synonyms 
Acetic acid, ethylene ester polymer with ethane, CoTran; ethylene vinyl acetate 
copolymer; EVA; EVA copolymer, EVM; poly(ethylene co-vinyl-acetate); 
VA/ethylene copolymer; vinyl acetate/ethylene copolymer 
2. Chemical properties 
Chemical name                                             Ethylene vinyl acetate copolymer  
CAS Registry Number                          (24937-78-8) 
Empirical formula and molecular weight (CH2CH2)x (CH2CH(CO2CH3))y 
Structural formula                                       Ethylene vinyl acetate copolymer is a     
                                                                        Random copolymer of ethylene and     
                                                                        Vinyl copolymer of ethylene and vinyl                    
                                                                         acetate 
Functional category                                      Membrane, Transdermal backing  
 
3. Physical properties  
Description 
Ethylene vinyl acetate is available as white waxy solid in pellet or powder form. 
Films are translucent. 
Density                                      0.92-0.94 gm/cm3                                          
Flash point                                260oC 
Melting point                            75-102oC depending on polymer ratios 
 
Table 1.6.1: Characteristics of different CoTran (3M Drug Delivery Systems)   
                     film grades 
Grade Vinyl acetate 
(%) 
Thickness 
(µm) 
Moisture vapour 
transmission rate (g/m2/24h) 
CoTran 9706 9 101.6 26.4 
CoTran 9715 19 76.2 64.8 
CoTran 9716 19 101.6 48.6 
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Stability and storage condition  
Ethylene vinyl acetate copolymers are stable under normal conditions and should be 
stored in a cool, dry place. Films of ethylene vinyl acetate copolymers should be 
stored at 0-30oC and less than 75% relative humidity. 
Incompatibilities  
Ethylene vinyl acetate is incompatible with strong oxidizing agents and bases. 
 
4. Application in Pharmaceutical Formulation or Technology 
Ethylene vinyl acetate copolymers are used as membranes and backings in laminated 
transdermal drug delivery system. They can also be incorporated as components in 
backings in transdermal systems. Ethylene vinyl acetate copolymers have been shown 
to be an effective matrix and membrane for the controlled delivery of atenolol1,2, 
triprolidine3,4 and furosemide.5 The system for the controlled release of atenolol can 
be further developed using ethylene vinyl acetate copolmers and plasticizers.1 
 
1.6.2 Polymethacrylates 6-9  
 
1. Synonyms 
Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit; Kollicoat MAE 30 D; Kollicoat 
MAE 30 DP; polymeric methacrylates. 
 
2. Chemical properties  
Structural Formula 
 
 
 
For Eudragit RL and Eudragit RS: 
R1 = H, CH3 
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R2 = CH3, C2H5 
R3 = CH3 
R4 = CH2CH2N(CH3)3 +Cl-  
Functional Category  
Film former; tablet binder; tablet diluent. 
 
Chemical Name and Cas Registry Number 
Table 1.6.2: Chemical name, Trade name, Company name and CAS registry  
Number of Polymethacrylate 
CHEMICAL NAME TRADE NAME 
COMPANY 
NAME 
CAS 
NUMBER 
Poly(ethyl acrylate, methyl methacrylate, 
trimethylammonioethyl methacrylate 
chloride)1 : 2 : 0.2 
ERL 100 
Röhm 
GmbH 
[33434- 
24-1] 
Poly(ethyl acrylate, methyl methacrylate, 
trimethylammonioethyl methacrylate 
chloride)1 : 2 : 0.1 
ERS 100 
Röhm 
GmbH 
[33434- 
24-1] 
 
3. Physical properties 
Alkali Value:                         23.9–32.3 for Eudragit RL 100 
Density (Bulk):                      0.390 g/cm3 
Density (Tapped):                 0.424 g/cm3 
Density (True):                      0.816–0.836 g/cm3 for Eudragit RL and RS PO 
Refractive Index:                   n20D = 1.38–1.385 for Eudragit RL and RS 
Viscosity (Dynamic):            ≤15 mPa  for Eudragit RL and RS 
Stability and Storage Conditions  
Dry powder polymer forms are stable at temperatures less than 30°C. Above this 
temperature, powders tend to form clumps, although this does not affect the quality of 
the substance and the clumps can readily be broken up. Dry powders are stable for at 
least 3 years if stored in a tightly closed container at less than 30°C. 
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Incompatibilities 
Incompatibilities occur with certain polymethacrylate dispersions depending upon the 
ionic and physical properties of the polymer and solvent. For example, coagulation 
may be caused by soluble electrolytes, pH changes, some organic solvents, and 
extremes of temperature. 
 
4. Application in pharmaceutical formulation or technology 
Polymethacrylates are primarily used in oral capsule and tablet formulations as film-
coating agents. Depending on the type of polymer used, films of different solubility 
characteristics can be produced. 
Eudragit RL, RS are used to form water-insoluble film coats for sustained-release 
products. Eudragit RL films are more permeable than those of Eudragit RS, and films 
of varying permeability can be obtained by mixing the two types together. 
 
1.6.3 Ethyl cellulose: 10-13  
 
1. Synonyms 
Aquacoat EDC; Aqualon; Ethocel; Surelease 
2. Chemical properties 
Non proprietary name:   
                        BP : Ethylcellulose 
                        PhEur : Ethylcellulosum 
                        USPNF : Ethylcellulose 
Chemical name:                                     Cellulose ethyl ether. 
Empirical formula:                                       C12H23O6(C12H22O5)nC12H23O5  
Functional category:          
Coating agent, flavoring fixative, tablet binder, tablet filler, viscosity increasing agent. 
Table1.6.3: Concentration of ethyl cellulose used 
Use Concentration (%) 
Microencapsulation 10-20 
Sustained release tablet coating 2-20 
Tablet coating 1-3 
Tablet granulation 1-3 
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3. Physical properties 
Description:  
Ethyl cellulose is a tasteless, free flowing, white to light tan-                                          
coloured powder. 
Density                                            0.4 g/cm3 
Specific gravity                              1.12-1.15g/cm3 
Glass transition temperature       129-133°C 
Solubility  
It is practically insoluble in glycerin, propylene glycol and water. EC that contains 
less than 46.5% ethoxyl groups if freely soluble in chloroform, methyl acetate, 
tetrahydrofuran. EC that contains not less than 46.5% ethoxyl groups if freely soluble 
in ethanol, ethyl acetate, methanol, and toluene. 
Moisture content 
Ethyl cellulose absorbs very little water from humid air or during immersion and that 
small amount evaporates readily. 
Stability and storage conditions  
Ethyl cellulose is stable, slightly hygroscopic material. It is chemically resistant to 
alkalis both dilute and concentrated, and to salt solutions, although it is more sensitive 
to acidic material than are cellulose esters.   
                            
Table 1.6.4: Different grades of ethyl cellulose 
Grade Viscosity (mPa s) Mean particle size (µm) 
Ethocel Std 4 Premium 3-5.5 204 
N-7 5.6-8 160 
Ethocel Std 7FP Premium 6-8 9 
Ethocel Std 7 Premium 6-8 210 
N-10 8-11 225 
Ethocel Std 10F Premium 9-11 5 
Ethocel Std 10P Premium 9-11 5 
N-14 12-16 212 
Ethocel Std 20P Premium 18-22 - 
N-22 18-24 243 
Ethocel Std 45P Premium 41-49 - 
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N-50 40-50 305 
N-100 80-105 - 
Ethocel Std 100FP Premium 90-110 194 
Ethocel Std 100P Premium 90-110 40 
 
1.6.4 Carbopol 93414-17 
Carbopol 934P is specially tailored for pharmaceutical industries. It can be useful for 
internal pharmaceutical dosage forms. Carbopol 934P is high purity grade and used 
for thickening, suspending and emulsifying. It is also useful in tablets for binding and 
sustained release formulations. 
1. Synonyms 
Carboxy polymethylene, carboxyvinyl polymer 
2. Chemical property 
Chemical name: carboxy polymethylene 
Chemical structure: 
    
Nonproprietary name:  
carbopol 940 L R, carbomer, carbomera 
Functional category: 
Bioadhesive, suspending agent, viscosity increasing agent, release modifying agent, 
tablet binder. 
 
3. Physical properties 
Description:  
A white, fluffy, acidic, hygroscopic powder with a slight characteristic odour. 
Typical properties: 
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carbopol is soluble in water, alcohol, and glycerin. Agents that can neutralize 
carbopol include sodium hydroxide, potassium hydroxide, sodium bicarbonate, borax, 
amino acids, polar organic amines. 
Specific gravity:                           1.41 
Density (bulk):                              5 g/cm3 
Density (tapped):                          1.4  g/cm3 
Viscosity (0.5%w/v):                    40-60 poise  
Acidity/ alkalinity:                       pH = 2.7-3.5 for a 0.5 % w/v aqueous dispersion,      
                                                       pH = 2.5-3.0 for a 1 %w/v aqueous dispersion. 
 
4. Applications of carbopol in pharmaceutical formulation or technology 
Carbopol are mainly used in liquid or semisolid pharmaceutical formulations as 
suspending or viscosity-increasing agents. Formulations include creams; gels, and 
ointments for use in ophthalmic, rectal, and topical preparations. carbomer grades, 
even with low residual benzene content, such as Carbopol 934P, are no longer 
included in the PhEur 2002. Carbopol having low residuals only of ethyl acetate, such 
as Carbopol 971P or 974P, may be used in oral preparations, in suspensions, tablets, 
or sustained release tablet formulations. In tablet formulations, Carbopols are used as 
dry or wet binders and as a rate controlling Excipients. In wet granulation processes, 
water or an alcohol-water blend is used as the granulating fluid. Anhydrous organic 
solvents have also been used, with the inclusion of a polymeric binder. The tackiness 
of the wet mass can be reduced with the addition of certain cationic species to the 
granulating fluid or, in the case of water, with talc in the formulation.  
Carbopol resins have also been investigated in the preparation of sustained release 
matrix beads, as enzyme inhibitors of intestinal proteases in peptide-containing 
dosage forms, as a bioadhesive for a cervical patch and for intranasally administered 
microspheres, and in magnetic granules for site-specific drug delivery to the 
esophagus. 
Carbopols are also employed as emulsifying agents in the preparation of oil-in-water 
emulsions for external use. For this purpose, the Carbopol is neutralized partly with 
sodium hydroxide and partly have been investigated as a viscosity increasing aid in 
the preparation of multiple emulsions 
. 
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1.6.5 Hydroxypropyl methyl cellulose18-21  
Hydroxypropyl methyl cellulose is mixed hydroxyl alkyl cellulose ether and may be 
regaded as thew propylene glycol ether of methyl cellulose. It is available in many 
grades of different viscosity range from 5 to 100000 cps. 
 
1. Chemical properties 
Chemical name and CAS registry number: cellulose, 2-hydroxypropyl methyl 
ether (9004-65-3) 
Nonproprietary name: BP: Hypromellose, JP: Hydroxypropyl methyl cellulose, 
PhEurr: Hypromellosum, USP: Hypromellose 
Chemical structure: 
    
Where, 
n is number of glucose units in cellulose molecule. 
R is CH3 or CH2CH (0H)CH 3 . 
Viscosity (2% aqueous solution) 
 HPMC K100 LV                  100 cps 
 HPMC A15 C                       2,000cps 
 HPMC K4M                         4,000 cps 
 HPMC K15M                       15,000 cps 
 HPMC K100M                     1, 00,000 cps      
Functional category 
oating agent, film former, rate-controlling polymer for sustained release, stabilizing 
agent, suspending agent, tablet binder, viscosity increasing agent. 
 
2. Physical properties 
    Description: Appearance: white or off-white powder, odorless, tasteless   
    Particle size: about 98.5% through 100 mesh; 100% through 80 meshes.  
   Carbonation temperature:         280-300°C  
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   Specific gravity:                           1.26-1.31  
   Temperature to change color:    190-200°C  
   Surface tension:                           42-56 dyne/cm (2% solution).  
   Acidity/alkalinity:                        pH 5.5-8.0 for a 1%w/w aqueous solution 
   Ash:                                               1.5-3% depending upon the grade 
   Density (bulk):                             0.341 g/cm3 
   Density (tapped):                         0.557 g/cm3 
   Density (true):                              1.326 g/cm3 
   Glass transition temperature:   170-180oC 
   
Moisture content 
Hypromellose absorbs moisture from the atmosphere, the amount of water absorbed 
depending upon the initial moisture content and the temperature and relative humidity 
of the surrounding air. 
Solubility 
It is soluble in cold water, forming a viscous colloidal solution; practically insoluble 
in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and 
dichloromethane, mixtures of methanol and dichloromethane and mixtures of water 
and alcohol. Certain grades of hypromellose are soluble in aqueous acetone solution, 
mixtures of dichloromethane and propan-2-ol and other organic solvents. 
Stability and storage condition 
Hypromellose powder is a stable material, although it is hygroscopic after drying. 
Solutions are stable at pH 3-11. Increasing temperature reduces the viscosity of 
solutions. Hypromellose undergoes a reversible sol-gel transformation upon heating 
and cooling, respectively. The gel point is 50-90oC. 
Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, 
hypromellose will not complex with metallic salts or ionic organics to form insoluble 
precipitates. 
Applications of hydroxypropyl methyl cellulose in pharmaceutical formulation 
or technology 
It is suspending, viscosity enhancing and film forming agent. HPMC is most widely 
used in hydrophilic matrix sustaining release tables and other type of controlled 
release pharmaceutical dosage forms, because of its characteristic namely non-toxic 
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nature, its capacity to incorporate active pharmaceutical, manufacture of tablet by 
direct compression without previous granulation as well as pH independent nature. 
 
1.6.6 Polyvinyl pyrolidone 22-27 
PVP (polyvinyl pyrrolidone, povidone, polyvidone) is a water-soluble polymer made 
from the monomer N-vinyl pyrrolidone: 
1. Synonyms 
Polvinylpolypyrrolidone; N-Vinylbutyrolactam polymer; poly[1-(2-oxo-1-
pyrrolidynyl)ethylene];  
2. Chemical properties 
Chemical name  
1-Ethenyl-2-pyrrolidoinone homopolymer (IUPAC); Poly[1-(2-oxo-1-
pyrrolidinyl)ethylene]; polyvidone; polyvinylpyrrolidone; PVP; 1-vinyl-2-
pyrrolidinone polymer 
CAS Registry Number                                   9003-39-8  
Empirical formula                                          (C6H9NO)n 
Structural formula  
                                                                                     
 
Molar mass                                                     2.500 - 2.5000.000 g·mol−1 
Functional category                                       Stabilizing agent, binding agent  
 
4. Physical properties  
Description      White to light yellow, hygroscopic, amorphous powder 
Density             1.2 g/cm³ 
Melting point   110 - 180 °C (glass temperature) 
 
Stability and storage condition  
Keep in a tightly closed container, stored in a cool, dry, ventilated area. Protect 
against physical damage. Isolate from incompatible substances. Containers of this 
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material may be hazardous when empty since they retain product residues (dust, 
solids); observe all warnings and precautions listed for the product.  
Incompatibilities:  
It is incompatible with strong oxidizing agent and strong reducing agents. 
 
4. Application in Pharmaceutical Formulation or Technology  
It is used as a binder in tablet formulations. PVP added to Iodine forms a complex in 
solution which is known under the trade name Betadine. PVP also used as coating 
agent for photo-quality ink-jet papers and transparencies, as well as in inks for inkjet 
printers. PVP is used in shampoos and toothpastes, in paints, and adhesives. It is also 
used in contact lens solutions and in steel-quenching solutions. PVP is used in hair 
sprays, hair gels, as a food additive, as a stabilizer, as a blocking agent during 
Western blot analysis. 
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Chapter 2      Literature reviews 
 
2.1 LITERATURE REVIEWS ON TRANSDERMAL DRUG DELIVERY     
      SYSTEM 
1Jamakandi and co-workers (2009)  used different polymeric grades of hydroxy 
propyl methyl cellulose (6cps, 15cps and K4M) for the development of transdermal 
drug delivery system of Nicorandil, an antiaginal drug. Matrix patch were evaluated 
for their physiochemical characterization followed by in vitro evaluation. Among the 
six different HPMC formulations, transdermal patch with 6 cps and 6 %w/v DMSO as 
permeability enhancer showed maximum release. 
  
Janardhanan Bagyalakshmi and co-workers (2008)2 developed membrane-
moderated transdermal systems of Ampicillin sodium and to evaluate them with 
respect to various in vitro and in vivo parameters. The membrane type transdermal 
systems were prepared using a drug with various antinucleant polymers like hydroxyl 
propyl methylcellulose (HPMC), Methyl cellulose (MC), Cellulose acetate phthalate, 
chitosan, sodium alginate (SA) and sodium carboxy methyl cellulose in an ethanol: 
pH 4.7 buffers by the solvent evaporation technique with HPMC as the rate 
controlling membrane for all the system. The release and permeation of the drug from 
the SA patch was found to be the maximum. The in vivo study of SA patch exhibited 
a peak plasma concentration of 126µg/mL at t  4 hours. max
 
Murthy T.E.G.K. and co-workers (2008)3 studied the influence of hydrophilic 
polymers on the permeability of Carvidiol from cellulose acetate films. The dried 
films were evaluated for appearance, thickness and drug release characteristic. In vitro 
permeation studies were carried out with Franz- diffusion cell. The drug release 
followed zero order kinetics and controlled by diffusion mechanism. 
 
Wahid and co-workers (2008)4 chemically modified chitosan using acetaldehyde 
and propionaldehyde to form Schiff”s bases. Drug free polymeric film of chitosan, 
chemically modified chitosan and chitosan/hydroxyl propyl methylcellulose blend 
were prepared and evaluated for various physiochemical characters. All the films 
were evaluated for bursting strength, swelling index, moisture uptake, thickness 
uniformity, drug content uniformity, tensile strength, percent elongation at break, 
flatness, water vapor transmission rate and in vitro drug permeation study. 
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5 Shaila Lewis and co–workers (2007) characterized plasma concentration time 
profiles for nicotine after single application of nicotine transdermal system to the 
upper fore arm of healthy smokers. A 12cm2 system was applied for 24h. Plasma 
nicotine concentration achieved a mean Cmax value of 14.5ng/ml. the result indicated 
that the system has potential usefulness in smoking cessation. The pharmacokinetic 
profile of marketed patch system was compared with the developed system. 
Significant difference was observed in the pharmacokinetic parameters. 
 
Shahi S. R. and co-workers (2007)6 studied the effect of various penetration 
enhancers such as Isopropyl Myristate (IPM), Dimethyl sulphoxide (DMSO), Benzyl 
alcohol, Menthol oil, oleic acid, Eucalyptus oil to increase the permeability of 
Ketorolac Tromethamine. The efficiency of the enhancers to improve the topical 
delivery of Ketorolac Tromethamine was sequenced in the order of DMSO> 
Eucalyptus > isopropyl myristate > menthol > oleic acid > benzyl alcohol.  
 
Vanja and co–workers (2006)7 computed solubility of methotrexate using Fedor 
method. Permeability studied was carried out using artificial membranes such as 
cellophane and dialysis membrane and biological membrane such as rat skin and egg 
shell membrane. Flux and permeability coefficient determination showed that dialysis 
membrane and egg shell membrane exhibited similar barrier properties as that of rat 
skin when compared with cellophane. 
 
Saxena and co-workers (2006)8 prepared Transdermal patches of metaclopramide 
hydrochloride using polyvinylalcohol and polyvinylpyrolidone. The physiochemical 
parameters like thickness, drug content, weight variation, moisture content, moisture 
uptake and drug penetration studies were evaluated for the patch. The in vitro drug 
penetration studies showed that burst release of the drug in initial hours and thereafter 
the drug was released slowly up to 12 hr. The stability studies indicated that all the 
patches maintained good physical appearance and drug content for 6 month at 40oC 
and 75% RH. 
 
9   Bharkatiya and co-workers (2006) prepared transdermal films of Nimesulide using 
four different polymers using solvent casting technique. Dibutylphthalate was used as 
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plasticizer. In vitro permeation profile of formulation containing drug reservoir with 
HPMC: PVP showed highest permeation. The release of drug from all formulations 
followed the diffusion controlled Higuchi model and zero order release kinetics 
 
Sadhna Gupta and co-workers (2005)10 formulated and evaluated metaprolol 
tartarate transdermal drug delivery system using Eudragit RL and Hydroxypropyl 
methylcellulose. This transdermal drug delivery system was characterized for their 
thickness, tensile strength and drug content. They were characterized for in vitro 
release kinetics and drug skin permeation studies. The system comprising of Eudragit 
RL: Hydroxypropylmethylcellulose in 40:60 ratio exhibited drug skin permeation 
87.5µg/h/cm2. The transdermal drug delivery system exhibited better and constant 
drug plasma profile for 24h as compared to oral administration. 
 
11Ramesh Panchangula and co–workers (2005)  developed transdermal reservoir 
patch of naloxone and evaluated for in vivo studies, stability studies and irritancy 
potential. Propylene glycol and oleic acid have been used as penetration enhancers 
and showed developed transdermal system of naloxone is efficacious, stable and safe 
upon single and multiple dose application. 
 
12Schurad B. and co-workers (2005)  investigated the transdermal in vitro 
permeation behavior of the Proterguride using hairless mouse skin as a model 
membrane. Drug in adhesive matrix formulations based on different types of pressure-
sensitive adhesives (Eudragit® E 100 and Gelva®7883 as acrylates, Oppanol® B 15 
SFN as polyisobutylene, and BioPSA® 7-4202 as silicone) with a drug load of 3% by 
weight were prepared.   It was found that Gelva®-based patches show good physical 
stability, good skin adhesion, and moderate flux values and, thus, can be evaluated as 
a basis for a suitable formulation for the transdermal administration of Proterguride.  
Kanikkannan N. and co-workers (2004)13 prepared monolithic drug-in-adhesive 
type transdermal patches of melatonin containing penetration enhancers such as fatty 
alcohols, fatty acids, and terpenes. The addition of enhancers in the patch increased 
the permeation of melatonin through hairless rat skin. The flux values of patches 
containing octanol, nonanoic acid, and myristic acid were higher than the control 
patch (no enhancer), but the differences were not statistically significant (P > 0.05). 
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Decanol, myristyl alcohol, and undecanoic acid at 5% concentrations showed 
significantly higher flux values through hairless rat skin (enhancement ratios 1.7, 1.5, 
and 1.6 for decanol, myristyl alcohol, and undecanoic acid, respectively) (P < 0.05). 
Menthol and limonene at 5% w/w showed maximum permeation of melatonin among 
all enhancers studied (enhancement ratios was 2.1 and 2.0 for menthol and limonene, 
respectively) (P < 0.001). 
Amir Mehdizadeh and co-workers (2004)14 designed to evaluate different matrix, 
drug-in-adhesive and reservoir formulation of Fentanyl transdermal patches. He has 
designed drug-in-adhesive patches by designing full factorial design. The results 
showed that the release kinetics obeyed the square root of time or Higuchi model, 
indicating the diffusion controlled release mechanism. It was found that the amount of 
fentanyl needed for each 10cm2 three days drug-in-adhesive should be 3.3mg. The 
respective amount for reservoir and matrix patches were 2.5 and 5mg. it was 
concluded that acrylic pressure sensitive adhesive showed the best adhesion and 
release properties. 
 
15Murthy S N and co-workers (2004)  prepared formulation containing 5mg/patch 
salbutamol sulfate(SS), providing an input rate of 100µg/h of  SS  and subjected for 
pharmacokinetic and pharmacodynamic evaluation in moderately asthmatic patients. 
A linear correlation was observed between cumulative amount of drug diffused in 
vitro and cumulative AUC of serum concentration time curve. A steady state serum 
concentration of 2.87 ± 0.1 ng/ml was attained after an initial lag period of 4.67 ± 
1.03 hr. 
Y. S. R. Krishnaiah  and co-workers (2004)16 investigated the effect of limonene on 
the in vitro permeation of nimodipine across the excised rat abdominal skin from a 
2% w/w hydroxypropyl methyl cellulose (HPMC) gel drug reservoir system. The 
HPMC gel formulations containing 1.5% w/w of nimodipine and selected 
concentrations of limonene (0% w/w to 8% w/w) were prepared, and subjected to in 
vitro permeation of the drug through excised rat abdominal epidermis.  The flux of 
nimodipine across rat epidermis was markedly increased by the addition of limonene 
to the HPMC gels. A maximum flux of nimodipine was observed (203 ± 0.6 μg/cm2 · 
h) with an enhancement ratio of about 5.7 when limonene was incorporated in HPMC 
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gel at a concentration of 4% w/w. The results suggest that limonene is useful for 
enhancing the skin permeability of nimodipine from transdermal therapeutic systems 
containing HPMC gel as a reservoir. 
17 Priyanka Arora and co-workers (2002) deigned  matrix type transdermal patches 
containing diclofenac diethylamine using different ratios of polyvinylpyrrolidone 
(PVP) and Eethylcellulose (EC) by solvent evaporation technique. All the prepared 
formulations were subjected to physical studies like moisture content, moisture uptake 
and flatness and in vitro release studies and in vivo skin permeation studies. In vitro 
permeation studies were performed across cadaver skin using a modified diffusion 
cell. They concluded that diclofenac diethylamine can be formulated into the 
transdermal matrices type patches to sustain its release characteristics and the polymer 
composition (PVP:EC, 1:2) was found to be the best choice for manufacturing 
transdemal patches of diclofenac diethylamine among the formulation studies. 
 
M. Aquil and co-workers (2002)18 developed matrix type transdermal drug delivery 
system of Pinacidil monohydrate by film casting technique or mercury substrate 
method and skin penetration studies using Keshary Chien diffusion cell on albino rat 
skin. The cumulative % of drug release in 48h was found to be highest (92.18%) from 
formulation Eudragit RL100: PVP K-30 (6:4). 
 
19Hong Zaho and co-workers (2002)  formulated matrix-type transdermal delivery 
systems of testosterone (TS) using three different pressure sensitive adhesives (PSA) 
The effect of PSA, skin permeation enhancers and solubilizers on the rat skin 
permeation rate of TS were systematically investigated. The highest skin permeation 
rate (4.14 µg/cm2/hr) was achieved when 2% TS was loaded in DuroTak® 87-2516 
together with 10% span 80 and 3% dodecylamine, the permeation enhancer. In vivo 
studied showed that the application of an experimental patch on rat abdominal skin 
resulted in a prompt and significantly higher plasma concentration of TS than that of a 
commercially product (Testoderm) designed to apply on scrotal skin.  
 
20 Michael H. and co–workers (2002) studied the release of permeation enhancers 
from transdermal drug delivery system of drug-in-adhesive type using known 
enhancers from eight types of adhesive polymers. They showed that, enhancers 
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released completely from the adhesive and the release rate depended on the types of 
adhesives. They also showed that acrylic adhesive and polyisobutylene adhesive 
showed slower drug release rate than silicon adhesive. 
 
21Kim J.H. and co-workers (2002)  investigated the effect of various pressure 
sensitive adhesives (PSA) on the percutaneous absorption of physostigmine across 
hairless mouse skin. Physostigmine showed the highest permeability from silicone 
adhesive matrix. Among, acrylic adhesive the permeability of physostigmine was the 
highest from grafted acrylic adhesive. This study also showed that several non-ionic 
surfactants, including PEG-20 evening primrose glycerides, enhanced the permeation 
of physostigmine across hairless mouse skin better than oleic acid. 
 
Verma, P. R. and co-workers (2000)22 developed matrix-dispersion-type transdermal 
drug delivery system of propranol using different ratios of mixed polymeric grades of 
Eudragit. In vivo evaluation was carried out on healthy human volunteers following a 
balanced incomplete block design (BIBD). In vitro dissolution rate constant k and 
pharmacokinetic parameters generated from plasma and urine were evaluated 
statistically. Statistically excellent correlation was found between percentages of drug 
absorbed from patch versus Cmax, AUC0-24, and AUC0- . A highly significant 
difference was observed when Cmax and AUC0- generated from plasma and urine 
data were compared, but when Ke, t e, ka, t1/2 1/2 were compared, the difference was not 
significant. Urinary excretion data are suggested as a simpler alternative to blood-
level data in studying the kinetics of absorption and deriving the absorption 
parameter.  
 
Varshney and co-workers (1999)23   used Arosol-OT (AOT), an ionic moiety of the 
surfactant docusate sodium, to enhance the permeation of nitroglycerine. The drug 
encapsulated in reservoirs with surfactant arranged in normal and reverse micelle 
pattern. They shown that 5% weight of AOT in water, arranged in normal micellar 
pattern, can increase the permeability of nitroglycerine 12.3 fold. 
 
Kusum Devi and co–workers (1998)24 developed and evaluated free films and 
transdermal patches of ketorolac tromethamine using polymers and pressure sensitive 
adhesives. PVP and PVA were used as polymer matrix materials and acrylic and 
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silicone based pressure sensitive adhesives were used as adhesive matrix materials. 
They observed that the permeation of drug with span 80 was more when compared to 
tween 80, oleic acid, propylene glycol as enhancers. 
  
Narasimha Murthy and co–workers (1996)25 carried out drug release studies from 
transdermal films of terbutaline sulphate using polymers such as hydroxypropyl 
methylcellulose and sodium carboxy methyl cellulose and reported that the 
hydroxypropyl methylcellulose films showed a greater rate of release compared to 
that of sodium carboxymethyl cellulose across all the barriers used. 
 
26 Mishra A and co–workers (1996) prepared transdermal formulations of 
testosterone designed for biphasic delivery, containing a blend of polymeric 
components polyvinyl alcohol and polyvinyl pyrrolidone in isopropyl alcohol. They 
reported that the film initially showed burst effect and then sustained release of 
testosterone. 
 
McDaid and co–workers (1996)27 prepared Amlodipine base from its besylate salt 
and various physiochemical properties relevant to transdermal delivery determined. 
Permeation of the drug from a range of hydrophilic and hydrophobic bases through 
hairless mouse skin was studied and the influence of the penetration enhancers in a 
sodium carboxymethyl cellulose 3% gel base was examined. The flux of drug could 
be further enhanced using variable percentage of ethanol in the donor phase. In vivo 
studied using rabbits were performed to assess the suitability of a reservoir type 
device. No adverse local effects in the animal model arising from the application of 
the transdermal device were observed. 
 
Jain G K and co–workers (1996)28 studied the effect of penetration enhancer (α- 
limonene) on poly vinyl alcohol and polyvinyl pyrrolidone films containing verapamil 
hydrochloride as drug. They reported that the drug permeation was enhanced by using 
α- limonene as permeation enhancer. 
 
29 Thacharodi D and co–workers (1995) studied different permeability of 
propranolol hydrochloride by controlled cross-linking with glutarldehyde to regulate 
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the drug release in the devices. Chitosan gel was used as the drug reservoir. The drug 
release profile through rabbit pinna skin showed that the drug delivery is completely 
controlled by the devices. The rate of drug released was found to be dependent on the 
type of membrane used. 
Lee Y. L. and co-workers (1994)30 developed transdermal delivery system for 
ketotifen. In vitro skin penetration results showed that ketotifen had optimal skin 
permeability at pH 7.5. In addition, ketotifen had higher rate of penetration through 
stripped skin. Ketotifen patch was fabricated in a stainless mold containing Eudragit 
S-100 and PEG 400. Other components, tween, span and fatty acids were also 
incorporated into the patch as penetration enhancers. For animal study, a patch with 
area of 30 cm2 was applied on the dorsal skin of rabbit. The plasma level, after 10 hrs 
administrations were reached 60 ng/ml and maintained a constant level. The results 
proposed that ketotifen was successfully absorbed through the skin from the applied 
patch. 
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2.2 LITERATURE REVIEW ON DRUGS 
 
2.2.1 Diltiazem HCl 
1Ekapol Limpongsa and co-workers (2008)  prepared the suitable polymeric films 
for the development of diltiazem hydrochloride transdermal drug delivery systems. 
Hydroxypropyl methylcellulose (HPMC) and ethylcellulose (EC) were used as 
hydrophilic and hydrophobic film formers, respectively. Effects of HPMC/EC ratios 
and plasticizers on mechanical properties of free films were studied. Effects of 
HPMC/EC ratios on moisture uptake, in vitro release and permeation through pig ear 
skin of diltiazem HCl films were evaluated. The film composed of 8:2 HPMC/EC, 
30% DBP and 10% IPM, IPP or Tween80 loaded with 25% diltiazem HCl should be 
selected for manufacturing transdermal patch by using a suitable adhesive layer and 
backing membrane. Further in vitro permeation and in vivo performance studies are 
required. 
 
Prashant M. Satturwar and co-workers (2008)2 conclude that Rosin in combination 
with PVP and with incorporation of Dibutyl phthalate (30% w/w) produces smooth 
flexible films with improved tensile strength and percentage elongation. The release 
rate of Diltiazem HCl from films and permeation across skin increases with increase 
in drug and PVP loading but is independent of film thickness. Patches containing 
Rosin: PVP (7:3) show promise for pharmacokinetic and pharmacodynamic 
performance evaluation in a suitable animal model.  
 
Gopal Krishna Murthy T E and co-workers (2008)3 prepared transdermal gels of 
Diltiazem hydrochloride using polymers like HPMC, NaCMC, MC, Carbopol, 
PEG6000 and  PVP. The correlation coefficient values revealed that the diffusion 
profile follows zero order kinetic and the mechanism of drug release was governed by 
Peppas model. The diffusion exponent of release profile has a value indicate case II 
transport diffusion. 
 
4Lakshmana Prabhu and co-workers (2008)  developed matrix dispersion type 
transdermal drug delivery system of Diltiazem hydrochloride using different ratios of 
rosin with Eudragit RL and PVP. The patch prepared by the combination of rosin and 
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PVP was not transparent one and shows an uneven distribution of PVP, which may be 
due to the hydrophilic nature of PVP. The effects of polymers on the technological 
properties, i.e. drug release, water vapor transmission rate, % moisture loss, % 
moisture absorption and thickness were investigated. The patch containing Rosin: 
ERL PM (6:4) showed a release of 2651 µg in 24 hr in order to improve the release 
various proportion of camphor was included in the formulations. The patch containing 
rosin: ERL PM (6:4) with 5 %w/v of camphor showed a sustained release of the drug 
extending over a period of 24 hr. Further skin permeation and skin irritation was 
carried out on rat skin and rabbit respectively. Therefore it can be concluded that the 
patch containing Rosin : ERL PM (6:4) with 5%w/v of camphor achieved the desired 
objectives of  transdermal drug delivery system, such as overcoming of first pass 
effect, extended release and reduced frequency of administration. 
 
T E Gopal Krishna Murthy and co–workers (2007)5 prepared and evaluated  
Eudragit RS 100 films  as rate controlling membrane for  transdermal drug delivery 
systems using Diltiazem HCl as a drug.. Acetone-methanol (8:2), chloroform-
methanol (8:2), dichloromethane-methanol (8:2) and ethyl acetate-methanol (8:2) 
were used as solvents in the preparation of films. Dibutyl phthalate at a concentration 
of 15% w/w of the polymer was used as a plasticizer. The dry films were evaluated 
for Physical appearance, Thickness uniformity, Folding endurance, Water Vapor 
Transmission, Drug diffusion and Permeability Coefficient. Both Water vapor 
transmission and Drug diffusion rate followed zero order kinetics. The mechanism of 
drug release was governed by peppas model. The diffusion exponent of release 
profiles (slope) has a value of n>1, which indicates non-analmous transport diffusion. 
Eudragit RS 100 films employed with ethyl acetate: methanol in 8:2 ratios as casting 
solvent yielded low area of patch with desired release rate for both drugs. 
 
6Swamy P V and co-workers (2004)  designed mucoadhesive bilayered buccal 
devices comprising a drug containing mucoadhesive layer and a drug free backing 
membrane. Films composed of mixture of drug Diltiazem hydrochloride, chitosan, 
hydroxypropylmethylcellulose and ethyl cellulose. Films were fabricated by solvent 
casting technique and were evaluated for in vitro drug release, bioadhesion strength, 
and tensile strength, folding endurance, thickness and drug content uniformity.  A 
combination of chitosan and hydroxypropyl methylcellulose (1:1) using propylene 
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glycol (50 % by weight of polymer) as a plasticizer gave promising result. 
 
7 Ritu Gupta and co-workers (2003) developed transdermal drug delivery system  of 
Diltiazem HCl employing different ratios of polymers like ethyl cellulose  and 
povidone and evaluated for the potential drug delivery using depilated freshly excised 
abdominal mouse skin. The cumulative amount of drug was found to be proportional 
to the square root of time, i.e. Higuchi kinetic. Film composed of povidone: EC (1:2) 
should be selected for the development of Diltiazem hydrochloride, using a suitable 
adhesive layer and backing membrane for potential therapeutic use. 
 
S K Jain and co-workers (2003)8 developed transdermal drug delivery system of 
Diltiazem to obtain a prolonged controlled drug delivery. Both the matrix diffusion 
controlled (MDC) and membrane permeation controlled (MPC) systems were 
developed. The matrix diffusion controlled systems used various combinations of 
hydrophilic and lipophillic polymers, whereas membrane permeation controlled 
systems were developed using the natural polymer chitosan. The MDC systems were 
prepared using the cast film method and the MPC systems by an adhesive sealing 
technique. Both the systems were characterized for in vitro and in vivo performance. 
The in vitro release studies showed that the release from the matrix diffusion 
controlled transdermal drug delivery systems follows a nonfickian pattern and that 
from the membrane permeation controlled transdermal drug delivery systems follow 
zero-order kinetics. The release from the matrix systems increased on increasing the 
hydrophilic polymer concentration, but the release from the membrane systems 
decrease on cross-linking of the rate controlling membrane and also on addition of 
citric acid to the chitosan drug reservoir gel. The in vivo studies of the selected 
systems showed that both systems are capable of achieving the effective plasma 
concentration for a prolonged period of time. The MPC system achieved effective 
plasma concentration a little more slowly than the MDC system, but it exhibited a 
more steady state plasma level for 24 hr. 
 
Rao and co-workers (1998)9  developed ethyl cellulose, polyvinyl pyrollidone (PVP) 
film containing Diltiazem HCl and Indomethacin. The influences of initial drug 
concentration, film composition and film thickness on the vitro drug release rate as 
well as drug permeation trough rat abdominal skin were studied. The in vitro skin 
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permeation profiles showed increased flux values with increased drug and PVP 
concentration in the film. They concluded that films composed of ethyl cellulose: 
PVP: Diltiazem (8:2:2) or indomethacin (8:2:3) with suitable adhesive layer and 
backing membrane could be developed for therapeutic purpose. The flux through rat 
skin was dependent on concentration of drug and PVP in matrix. 
 
10Tank H M and co-workers (1998)  prepared Verapamil free base and Diltiazem 
free base from corresponding salt forms and characterized prior to evaluate their in 
vitro diffusion kinetics from ethylene vinyl acetate- vinyl acetate 40% copolymer 
membrane. Base forms of original drug molecules exhibited enhanced transmembrane 
permeation as compared to corresponding salt form facilitating to deliver the drug in a 
controlled manner, across a convenient small surface area of delivery device. 
 
10 P Rama Rao and co-workers (1997) studied permeability of cellulose acetate(CA) 
free films casted from chloroform solution containing different plasticizer like Dibutyl 
phathalate(DBP), propylene glycol 600 (PEG 600) and propylene glycol (PG) with a 
view to developing a suitable rate controlling membrane for transdermal use. 
Permeability characteristics of free film were studied using the drug such as Diltiazem 
Hydrochloride and Indomethacin. The films plasticized with PEG600 showed higher 
permeability for both drug compared with other films.  
 
Nitsch and co-workers (1991) 12 studied in vitro transcutaneous uptake of Diltiazem 
HCl from reservoir type formulation (ointment). Each formulation was evaluated for 
release of Diltiazem across skin employing Franz diffusion all over 12 hour period. 
The release of Diltiazem across skin increased with increase in concentration of 
Diltiazem. 
 
2.2.2 Atenolol 
 
13  S S Agrawal and co-workers (2007) formulated matrix-type transdermal patches 
of Atenolol  and metoprolol tartrate using polyvinylpyrrolidione, cellulose acetate 
phthalate, hydroxypropylmethylcellulose phthalate and ethyl cellulose. The 
physiochemical evaluation of the polymer matrices was performed for suitability. In 
vitro permeation studied was performed using rat abdominal skin and result indicated 
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that maximum release was obtained at 48h and 85% of Atenolol and 44% metoprolol 
tartrate. The drug permeation studies across cadaver skin showed about 27% of 
reduction in the amount of drug release as that compared to rat abdominal skin.  
 
14Anroop B and co–workers (2005)  used prodrug approach to increase the 
permeability of Atenolol. They prepared Atenolol ester to increase its lipophillicity 
and permeation studied carried out in isolated porcine skin; promising result were 
obtained with caproate ester to increase lipophillicity of Atenolol with a view to 
enhance its permeation through lipophillic barrier of the skin. Atenolol caproate ester 
was found to be promising in improving its percutaneous absorption.  
15Cho C. W. and co-workers (2004)  have developed matrix transdermal film of 
Atenolol using ethyl vinyl acetate. The rate of drug release from EVA matrix 
increased with increasing temperature and drug loading dose. There was linear 
relationship between the flux of Atenolol and square root of loading dose. Among the 
plasticizer used, diethyl phthalate had the best enhancing effects on drug release. 
16S P Gupta and co–workers (2004)  developed polymer matrix system for 
transdermal delivery of Atenolol for its prolonged and controlled release systemic 
availability. To achieve the desired and controlled release rate, different combinations 
of Eudragit RL with polyvinyl pyrrolidone and polyethylene glycol 4000 were used in 
the preparations of polymeric matrix system. These preparations were evaluated for in 
vitro release and permeation of the drug across pig skin. The desired systems 
exhibited linear relationship between drug release (Q) versus time0.8(hr0.8). The 
product exhibiting required skin permeation 64 mcg/h/cm2 to achieve an effective 
plasma concentration was selected for the in vivo performance evaluation. The study 
revealed that the designed polymeric matrix transdermal drug delivery system of 
Atenolol could be successful with improved performance. 
Jin Kim and co-workers (2003)17 prepared EVA matrix system for transdermal 
delivery of Atenolol. The effects of drug concentration, temperature, and plasticizers 
on drug release were studied from the Atenolol-EVA matrix. The release rate of drug 
from the EVA matrix increased with increased temperature and drug loading doses. 
The flux of Atenolol versus the reciprocal of the loading dose yielded a straight line. 
The release of Atenolol from the EVA matrix follows a diffusion-controlled model, 
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where the quantity released per unit area is proportional to the square root of time. 
Among the plasticizers used such as alkyl citrates and phthalates, tributyl citrate 
(TBC) showed the best enhancing effects.  
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2.3 LITERATURE REVIEWS ON POLYMERS 
 
1Krishnaiah and co-workers (2009)  evaluated ethylene vinyl acetate (EVA) 
copolymer membranes with vinyl acetate content of 18% w/w (EVA1802) for 
transdermal delivery of ondansetron hydrochloride. The EVA1802 membranes 
containing selected concentrations (0, 5, 10 and 15 %w/w) of PEG6000 were 
prepared, and subjected to in vitro permeation studies from a nerodilol-based drug 
reservoir. Flux of ondansetron from EVA1802 membranes without PEG6000 was 
64.1 ± 0.6 μg/cm2·h, and with 10%w/w of PEG6000 (EVA1802-PEG6000-10) it 
increased to 194.9 ± 4.6 μg/cm2·h. The EVA1802-PEG6000-10 membrane was coated 
with an adhesive emulsion, applied to rat epidermis and subjected to in vitro 
permeation studies against controls. Flux of ondansetron from transdermal patch 
across rat epidermis was 111.7 ± 1.3 μg/cm2·h, which is about 1.3 times the required 
flux. It was concluded from the comparative pharmacokinetic study that TTS of 
ondansetron, prepared with EVA1802-PEG6000-10 membrane, provided average 
steady-state plasma concentration on par with multiple-dosed oral tablets, but with a 
low percent of peak-to-trough fluctuation. 
 
2R Sadashivivaih and co-workers (2008)  prepared matrix type transdermal drug 
delivery system of Haloperidol using different ratios of Ethyl cellulose(EC) and 
Polyvinyl Pyrrolidone(PVP) by solvent evaporation technique. In vitro studied was 
done using modified Franz diffusion cells through human cadaver skin utilizing 20% 
PEG-40 in normal saline. Higuchi and Peppas models wee used for optimizing the 
formulation. 
 
Gannu R. and co-workers (2007)3  developed and evaluated matrix type transdermal 
drug delivery systems (TDDS) of nitrendipine (NTDP). Ten formulations composed 
of Eudragit RL 100 and Hydroxypropyl methyl cellulose in the ratios of 5:0, 4:1, 3:2, 
2:3, 1:4 in formulations A1, A2, A3, A4, A5 and Eudragit RS 100 and Hydroxypropyl 
methyl cellulose in the same ratios in formulation B1, B2, B3, B4, B5 respectively 
were prepared. All formulations carried 6 % w/w of carvone as penetration enhancer 
and 15% w/w of propylene glycol as plasticizer in dichloromethane and methanol as 
solvent system. Formulations A4 (flux 23.51 μg/hr/cm2) and B5 (flux 22.98 
μg/hr/cm2) showed maximum skin permeation in the respective series. The flux 
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obtained with formulation A4 and B5 meets the required flux (19.10 μg/hr cm2).   
 
Shin S. C. and co-workers (2007)4 studied the effect of different types of penetration 
enhancers on the permeability of quinupramine through the rat skin. The relative 
bioavailability of quinupramine in the matrix containing polyoxyethylene-2-oleyl 
ether as an enhancer was approximately 2.81 times higher than the group without an 
enhancer. These results showed that the quinupramine-EVA matrix containing a 
permeation enhancer could be a good transdermal delivery system for providing 
sustained plasma concentrations. 
 
5 Ubaidulla U. and co-workers (2007) developed a matrix-type transdermal 
therapeutic system containing carvedilol with different ratios of hydrophilic and 
hydrophobic polymeric combinations by the solvent evaporation technique. In vitro 
permeation results followed Higuchi kinetics (r = 0.9953- 0.9979), and the mechanism 
of release was diffusion mediated. Based on physicochemical and in vitro skin 
permeation studies, patch formulation containing ethyl cellulose: 
polyvinylpyrrolidone (7.5:2.5) and Eudragit RL: Eudragit RS (8:2) were chosen for 
further in vivo studies. The bioavailability studies in rats indicated that the carvedilol 
transdermal patches provided steady-state plasma concentrations with minimal 
fluctuations and improved bioavailability of 71% and 62% in comparison with oral 
administration.  
 
6Gattani S G and co-workers (2007)  prepared monolithic matrix type transdermal 
film of Lovastatin using two different polymer combinations Ethyl cellulose (EC) 
with Polyvinyl Pyrrolidone (PVP) and Eudragit RL100 (ERL) with Eudragit RS100 
(ERS). All the formulation carried 10%w/w Lovastatin and 30%w/w Dibutyl 
Phthalate (DBP) as a plasticizer in chloroform as solvent system. On the basis of in 
vitro permeation studies formulation ERL: ERS, 4:1 having maxim rate of permeation 
and it was selected as optimized formulation. The correlation co-efficient obtained 
from Higuchi plot was found to be in the Range of 0.97-0.99 indicating the diffusion 
mechanism of drug release. 
 
7  Singh Y. T. and co-workers (2007) prepared transdermal patches of carvedilol 
using HPMC by the solvent evaporation technique. In this investigation, the 
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membranes of Eudragit RL100 and Eudragit RS100 were used to achieve controlled 
release of the drug. In vitro permeation studies were performed using hairless guinea 
pig skin and followed the super case II transport mechanism. The effects of non-ionic 
surfactants Tween 80 and Span 80 on drug permeation were studied. The non-ionic 
surfactants in the patches increased the permeation rate, Span 80 exhibiting better 
enhancement relative to Tween 80.  
 
T E Gopal Krishna Murthy and co-workers (2006)8 prepare rate controlling 
membrane of cellulose acetate and ethyl cellulose. The permeability characteristics 
were studied using propranolol hydrochloride as a drug. The dry films were evaluated 
for physical appearance, thickness, content uniformity, folding endurance, water 
vapor transmission, drug diffusion and permeability coefficient. The mechanism of 
drug release was governed by Peppas model. The diffusion exponent of release profile 
indicates non anomalous transport diffusion. 
 
Das M. K. and co-workers (2006)9 studied the effect of polymeric composition, drug 
content and plasticizer on the permeation of trazodone hydrochloride across the 
mouse epidermis for the development of transdermal therapeutic system. The 
polymers used were Eudragit RL100 and RS100. Triethylcitrate was used as 
plasticizer. The in vitro drug release increased with increasing amount of Eudragit 
RL100 in the film. It was observed that the maximum skin permeability was attained 
at a loading dose of 10% w/w in the film. The present study has demonstrated the 
potential of the fabricated pseudolatex transdermal films for sustained release of 
trazodone hydrochloride.  
 
Tanwar Y. C. and co-workers (2005)10  developed transdermal drug delivery 
systems of Salbutamol sulphate using Eudragit RL100 and PVP by solvent casting 
technique employing mercury as a substrate. Propylene glycol was used as a 
plasticizer. In vitro permeation profiles across the guinea-pig dorsal skin using K-C 
diffusion cell are reported. Incorporating PEG-400 and tween 60 into the films 
enhanced the permeation across guinea-pig skin. The permeation followed zero order 
kinetics and mechanism was found to be matrix diffusion 
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Mukherjee B. and co-workers (2005)11 developed a suitable matrix type transdermal 
drug delivery system (TDDS) of Dexamethasone using blends of two different 
polymeric combinations, Povidone (PVP) and Ethyl cellulose (EC) and Eudragit 
RL100 with PVP. The formulations of PVP: EC provided slower and more sustained 
release of drug than the PVP : Eudragit formulations during skin permeation studies. 
They conclude that PVP–EC polymers are better suited than PVP– Eudragit polymers 
for the development of TDDS of Dexamethasone. 
 
12Khatun M. and co-workers (2004)   prepared polymeric films of Naproxane using 
Eudragit RS100 by solvent casting method. Naproxen was incorporated in two 
different percent loading (8.3 % w/w and 20.8 % w/w of films). Effects of two 
plasticizers (PEG 1500 and PEG 4000) and two release modifiers (PVA and HPMC) 
on in vitro drug release from naproxen loaded Eudragit RS films were assessed. 
Inclusion of PEG in Eudragit RS films caused the drug to be released by diffusion 
(Fickian) kinetics whereas PVA and HPMC containing formulations released drug by 
diffusion mechanism coupled with erosion. 
 
13N Udpa and co-workers (2004)  prepared matrix type transdermal patches 
containing glibenclamide using different ratios of ethyl cellulose (EC), polyvinyl 
pyrolidione(PVP) and Eudragit RL100(ERL) and Eudragit RS100 (ERS) by solvent 
evaporation technique. All the prepared formulations were subjected to 
physiochemical studies like thickness, weight variation, drug content, moisture 
content, moisture uptake, flatness in vitro release and in vitro permeation study 
through mouse skin. Based on in vitro skin permeation study ERL: ERS (1:4) and EC: 
PVP (3:2) were selected for in vitro experiment. The pharmacokinetic evaluation 
showed that the patches could maintain steady state concentration of drug within the 
pharmacologically effective range for prolonged period of time. 
 
14V Kusumdevi and co-workers (2003)  prepared transdermal patches of Verapamil 
HCl using four different polymers Eudragit RL100, Eudragit RS100, HPMC 15cps 
and Ehyl cellulose of varying degree of hydrophilicity and hydrophobicity. The effect 
of the polymers on the technological properties i.e. drug release, WVTR, % Moisture 
absorption , % moisture loss , folding endurance and thickness was investigated,. 
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Different formulation were prepared in accordance with the 23 factorial design with 
ERL100 being the patent polymer substitution with ERS 100, HPMC and EC 
decreased all the above values in accordance with their decreasing degree of 
hydrophilicity. In vitro release studies showed zero order release of the drug from all 
the patches. Percutaneous absorption studies were carried out in rabbits. The 
pharmacokinetic parameters calculated and it was concluded that the patch containing 
ERL 100 and HPMC in the ratio 8:2 has achieved the objectives of transdermal drug 
delivery system. 
 
Paul W. S. and co-workers (2003)15  investigated the influence of storage conditions 
and types of plasticizers on the properties and stability of Ethyl cellulose and 
polymethacrylate films. The effects of different plasticizers on the morphology, 
transparency, mechanical property and water vapor permeability of the prepared films 
were studied. The film samples were exposed to storage conditions of 30 oC and 50 or 
75 %RH. The films prepared from aqueous Ethyl cellulose dispersions were relatively 
weaker and more brittle than acrylate films. Acrylate films did not show any 
significant change in mechanical property when stored at high humidity. They 
concluded that changes in mechanical property of Ethyl cellulose films on storage 
were mainly attributed to the loss of plasticizers during storage, causing further 
coalescence of Ethyl cellulose films and to a smaller extent, reduction in moisture 
content of the film. 
 
16V. Shankar and co-workers (2003)  prepared drug free polymeric films of ethyl 
cellulose using castor oil and glycerin at a concentration of 30%w/w and 40%w/w of 
dry polymer, as a plasticizer. The permeability characteristics of free film were 
studied using nifedipine as a drug in 4% HPMC gel. From in vitro in vivo study it was 
concluded that faster release was observed from Ethyl cellulose patch containing 
glycerol as plasticizer. 
 
Dandagi P. M. and co-workers (2003)17 prepared transdermal films of ketotifen 
fumarate using Eudragit L 100, Hydroxypropyl methyl cellulose and ethyl cellulose in 
combinations. Polyethylene glycol 400 was used as plasticizer. Permeation enhancers 
like Dimethyl sulfoxide and propylene glycol were used at different concentrations 
and in vitro drug release studies were carried out. They concluded that as the 
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concentration of permeation enhancers increased, the drug release increased. 
 
Aqil Mohamed and co–workers (2003)18 prepared and evaluated of monolithic 
matrix type transdermal drug delivery system of Metoprolol tartarate using different 
concentration ratios of Eudragit RL100 and Polyvinyl pyrrolidone K-30. They 
reported that, the release of drug from the matrix was controlled and the skin 
permeation rate followed zero order kinetics. 
 
19 Kulkarni R. and co-workers (2002) prepared and evaluated transdermal patch of 
Verapamil hydrochloride using Eudragit RS 100. They reported that films plasticized 
with polyethylene glycol showed higher permeability of verapamil hydrochloride as 
compared to Dibutyl phthalate. They also reported that permeability of drug decreased 
as the concentration of Dibutyl phthalate and polyethylene glycol increased. 
 
Panigrahi L and co-workers (2002)20 prepared pseudo-latex transdermal drug 
delivery system of Terbutaline sulphate using Eudragit RS 100. They reported that the 
drug release profiles from the patches followed apparent zero order patterns for a 
period of 12 hrs. 
 
 Kapoor and co-workers (2002)21  formulated sodium alginate patches containing 
nicotine and used  Ethyl cellulose or whatman filter paper as rate controlling 
membrane. Prepared patches were evaluated for thickness, drug content, content 
uniformity, weight variation, water uptake, stability and in vitro release characteristics 
using sigma membrane, excised rat skin and excised rabbit skin.  
 
Arabi H and co-workers (2002)22 studied the performance of a membrane controlled 
reservoir system (MCRS) for scopolamine hydrobromide (SH) using ethylene-vinyl 
acetate copolymer (EVA) and ethyl cellulose (EC) membranes. The results obtained 
showed that in the EVA membrane, the permeability of SH across membrane 
increased with the increase of vinyl acetate percentage in copolymer. Microscopic 
studies of EVA membrane surface showed that the size of surface porosity increases 
with the increase of vinyl acetate percentage in the co polymer. In the case of EC 
membrane, the results showed that the rate of release increases with the increase of 
porosity size of EC surface despite of having high molecular weight. 
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23Rao P. R. and co-workers (2000)  formulated polymeric films containing 
propranolol hydrochloride using different ratios of ethyl cellulose (EC) and poly 
vinylpyrrolidone (PVP) using mercury substrate method. The release rate propranolol 
hydrochloride increased linearly with increasing drug concentration and PVP fraction 
in the film, but was found to be independent of film thickness.  It was also observed 
that the release of drug from the films followed the diffusion-controlled model at low 
drug concentration. The in vitro skin permeation profiles displayed increased flux 
values with increase of initial drug concentration in the film, and also with the PVP 
content. From this study, it is concluded that the films composed of EC : PVP : Drug 
in 9:1:3, 8:2:2 and 8:2:3, should be selected for the development of transdermal drug 
delivery systems using a suitable adhesive layer and backing membrane for potential 
therapeutic applications.  
 
24Kulkarni Raghavendra and co–workers (2000)  prepared drug free polymeric 
films of polyvinyl pyrolidone (PVP), ethyl cellulose (EC), Eudragit RS 100 (ERS) 
and Ethylene vinyl acetate (EVA) using Verapamil HCl as model drug. The prepared 
films were evaluated for drug release study and they showed that, drug diffusion 
followed nearly zero order kinetics and it is in the order of PVP>EC>ERS>EVA.  
 
25 S Sridevi and co-workers (2000) developed acrylic based transdermal drug 
delivery system for Glibenclamide and evaluate its pharmaco-dynamic performance 
in male wistar rats. The drug embedded in a polymeric matrix of polymethyl 
methylacrylate and ethyl cellulose. Transdermal drug delivery system significantly 
sustained the hypoglycemic activity for 24 hr in normal rat when compared to oral 
administration where the effect declined after 8 hr. 
 
Ocak  and co–workers (1999)26 developed a membrane controlled transdermal 
system of Isosorbide dinitrate using carbomer gel as the drug reservoir and ethylene 
vinyl acetate copolymers and polyethylene membranes were used as rate controlling 
membrane. The release rate achieved using the polyethylene rate controller mimicked 
the commercial product and was closed to the target flux and was thought to bee 
promising for commercial development. 
 
Nagarajan M. and co–workers (1996)27 prepared gelatin films of Salbutamol 
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sulphate transdermal drug delivery system using ethyl cellulose film as rate 
controlling membrane. They reported that controlled release of Salbutamol sulphate 
was observed for a period of 12-24 hrs and the drug release was found to depend on 
the proportion of gelatin used in drug reservoir layer. They showed that drug release 
from gelatin films can be controlled using ethyl cellulose film as rate controlling 
membrane. 
 
28Balasubramanian Iyer and co–workers (1979)  studied the release  of suspended 
Trimcinolone acetonide from films of lanolin alcohol in combination with Ethyl 
cellulose and propylene glycol or cetyl alcohol followed the diffusion-controlled 
granular matrix model. The results suggested that the drug release follows a diffusion- 
controlled matrix model and a square root of time release profile. The release rate 
constants were proportional to drug concentration.   
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2.4 LITERATURE REVIEWS ON SKIN IRRITATION AND SENSITIZATION 
STUDIES 
 
Shin Irie and co-workers (2006)1 assessed the skin reaction of PHK-301p, a newly 
developed nicotine patch. They conducted a phase I study that consisted of 2 parts: a 
skin irritation test (48-h closed patch test) and a photosensitivity test (24-h closed 
patch test + Ultraviolet A irradiation). Twenty healthy men were treated with PHK-
301p and placebo. Both preparations were punched out to a circle of 6-mm diameter 
and were applied simultaneously to each participant. Skin irritation and 
photosensitivity were assessed by a physician who was kept unaware of the treatment. 
In the skin irritation test, moderate and mild erythemas were observed in each 
participant 72 h after application (24 h after removal) for PHK-301p. Mild erythema 
was observed in one participant 49 h after application (1 h after removal) for placebo. 
The skin irritation index, which was calculated based on the skin reactions of 
participants, was 7.5 for PHK-301p and 2.5 for placebo. In the photosensitivity test, 
one participant had mild erythema (±) approximately 25 and 72 h after application of 
PHK-301p. No solar urticaria was observed. From these results, it was concluded that 
PHK-301p is an acceptable product as a nicotine patch. 
 
J. Bircher and co-workers (2006)2 investigated adverse skin reaction for Nicotine 
transdermal therapeutic system (TTS). 14 volunteers (10 male, 4 female) with a 
History of former adverse skin reactions to this device were investigated. Skin tests 
for contact urticaria and patch tests for contact allergy were done with the individual 
components of the TTS. Irritant reactions due to occlusion were present in 9 subjects. 
The optimal test agent and concentration for elucidating the adverse skin reaction was 
on aqueous solution of 10% nicotine base. Nicotine should be added to the expanding 
list of transdermally delivered drugs which may elicit contact dermatitis. 
Janet  Tamada and co-workers (2004)3 examined whether pre application of 
corticosteroid preparations could reduce skin irritation from iontophoresis used by the 
GlucoWatch G2® Biographer (Cygnus, Inc., Redwood City, CA) in monitoring 
interstitial glucose levels frequently and automatically. Numerous corticosteroid 
preparations were screened to identify formulations that did not interfere with 
adhesion of the Biographer to the skin or glucose sensing. Kenalog and Cortizone-10 
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sprays were selected and, in a double-masked, randomized, controlled trial, were 
applied to the forearms of 66 subjects with diabetes and allowed to dry. Biographers 
were applied and worn for 15 h, and home blood glucose measurements were taken 
every 30 min to assess accuracy. Irritation was assessed periodically by trained 
observers and study subjects. Skin irritation was reduced by both corticosteroid 
sprays, with the fraction of subjects who experienced moderate irritation reduced by 
57% and 43% for the Kenalog and Cortizone-10. Pre application of these preparations 
did not affect the clinical utility of interstitial glucose readings. Pre application of 
Kenalog or Cortizone-10 Quick Shot sprays significantly reduced skin irritation due 
to iontophoresis, and did not interfere with glucose measurements.  
4Murthy N S and co-workers (1998)  developed transdermal films of terbutaline 
hydrochloride using hydroxypropyl methyl cellulose as monolithic matrix, for 
evaluation of pharmacokinetic and pharmacodynamic parameters. The skin irritation 
study revealed no signs of erythema or edema in rabbits. Transdermal drug 
formulation was more effective than oral dosage form as evident from the 
pharmacodynamic studies carried out on guinea pig, using histamine aerosol induced 
bronchospasm model. 
 
Wilson and co-workers (1998)5 determined whether topical pretreatment with 
triamcinolone acetonide 0.1% cream might be useful in reducing the incidence and/or 
severity of chronic skin irritation associated with the testosterone transdermal delivery 
(TTD) systems used to treat post-pubertal hypogonadism in males. Adult male 
volunteers wore three topical systems, which were applied to the upper back daily for 
6 weeks: (1) TTD with no pretreatment of application site; (2) TTD with pretreatment 
of application site using triamcinolone acetonide 0.1% cream; and (3) an inactive 
occlusive dressing (control). Skin reactions were graded on a scale from 0 to 4 (0 = 
none, 4 = severe) and were assessed daily by research personnel. At assessment 1, 
pretreatment with triamcinolone acetonide 0.1% cream (compared with no 
pretreatment) was associated more often with scores of 0 (no erythema), with 
comparable occurrences of mild skin irritation, and with fewer occurrences of 
moderate erythema. Results of this study suggested that in patients using TTD 
systems, the incidence and severity of skin irritation at application sites may be 
reduced through pretreatment with triamcinolone acetonide 0.1% cream. 
 
Shital D. Faldu  Ph.D. Thesis  119
Chapter 2      Literature reviews 
 
William P. Jordan and co-workers (1998)6 compared the skin irritation of an 
investigational testosterone transdermal system (System I) with that of a marketed 
testosterone transdermal system (System II) in healthy men. In Part 1 of the study, 
System I was applied 10 times over 14 days to the same skin site on the backs of 26 
healthy men. In Part 2, the skin irritation resulting from daily application of Systems I 
and II was assessed over 14 days in 17 men less than 65 years of age and 16 men 65 
years of age or older. At the end of Part 1 of the study, 65.4% of the subjects 
experienced no erythema, 15.4% of subjects had faint erythema, and 19.2% had 
moderately intense erythema immediately after System I removal. At the completion 
of Part 2, none of the System I application sites were assessed as having moderately 
intense erythema, whereas one third (33.3%) of System II application sites 
demonstrated moderately intense erythema. There were no differences in erythema 
rates between younger and older subjects with either transdermal system. During this 
study, repeated application of System I to the same skin site resulted in acceptable 
non cumulative irritation, suggesting that application-site rotation may not be 
necessary. A comparison of the two systems demonstrates that System I results in 
significantly less application-site irritation than does System II and that older men do 
not have a higher rate of skin reactions. 
William P. Jordan and co-workers (1997)7  compared topical irritation rates for 
scrotal (Testoderm Testosterone Transdermal System; ALZA Corporation, Palo Alto, 
CA) and nonscrotal (Androderm Testosterone Transdermal System; SmithKline 
Beecham Pharmaceuticals, Philadelphia, PA) products. This open-label, crossover 
studied randomized 60 healthy, adult males to 14 days each of two treatments: one 
40-cm2 scrotal system delivering approximately 4 mg testosterone over 24 hours, or 
two 37-cm2 nonscrotal systems worn on the back or upper outer arm, providing 
approximately 5 mg testosterone over 24 hours. Scrotal systems produced no 
confirmed contact allergy and less topical irritation than nonscrotal systems. The four 
subjects with contact allergy to nonscrotal systems used the scrotal system without a 
reaction, suggesting testosterone was not the allergen. 
 
Krishna and co–workers (1996)8 formulated a carboxy methylcellulose sodium 
based transdermal drug delivery system for propranolol and evaluated it for in vitro 
and in vivo performance. In vitro studies using excised hair free rat skin model 
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resulted in 66.54% permeation at the end of 24hr in a zero order permeation profile. 
Skin irritation studies in rats evaluated for flare and wheal with respect to a formalin 
control indicated that the drug containing patch invoked only a mild response over a 7 
day period. 
L. Speroff and co-workers (1996)9 determined  the efficacy and local tolerance of a 
new matrix transdermal drug-delivery system that delivers 0.02 mg of 17β-estradiol 
(E2) daily for 7 days for the relief of vasomotor symptoms. A total of 324 surgically 
or naturally menopausal women, all with prior hysterectomy and moderate to severe 
vasomotor symptoms participated in two independent, 12-week, randomized, double-
blind, placebo-controlled studies. After a 4-week, treatment-free period, each woman 
received a continuous regimen of either one E2 transdermal system, two E2 
transdermal systems, or placebo transdermal systems applied every week for 12 
weeks. To measure local tolerance, skin irritation was objectively and systematically 
evaluated under blue light after removal of the transdermal systems. Few clinically 
significant skin reactions occurred, and only nine (3%) of the subjects withdrew 
because of a skin effect. After initial increase, serum E2 concentrations remained 
stable throughout the study, achieving values of approximately 20 and 40 pg/mL 
above baseline for one and two E2 transdermal systems, respectively.  
Michael Robinson and co-workers (1991) developed10  transdermal patch for the 
antihistamine triprolidine (TP) might provide benefits in terms of increased efficacy 
and reduced sedative side effects. They developed a binary vehicle delivery system 
comprised of TP in 0.5% oleic acid (OA) in propylene glycol (PG). Rabbit skin 
irritation and Buehler guinea pig skin sensitization testing indicated that this 
TP/OA/PG formula had both skin irritation and ACS potential. In clinical tests, skin 
irritation was due mainly to the OA–PG vehicle, but was enhanced in the presence of 
high TP concentrations. They suggested that the TP/OA/PG formula had a very high 
ACS potential. Subsequent predictive clinical patch testing was conducted with a 
buffered aqueous TP formula which provided in vitro skin penetration of the drug 
equivalent to the TP/OA/PG formula. These clinical studies demonstrated that TP 
itself had no significant irritation potential but still induced ACS reactions in a high 
proportion of test subjects.  
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2.5 LITERATURE REVIEWS ON STUDY ON HUMAN SKIN 
 
R Sadashivaiah and co-workers (2008)1 prepared Matrix-type transdermal drug 
delivery systems of haloperidol lactate using different ratios of ethyl cellulose 
(EC):polyvinyl pyrrolidone (PVP) (3:2, 2:3, 4:1, 1:2, 2:1, and 1:4) by solvent-
evaporation technique. Physicochemical parameters were characterized, and 
dissolution studies of the formulated films were performed. In vitro permeation 
studies were done using modified Franz diffusion cells through human cadaver skin 
utilizing 20% PEG 400 in normal saline. Permeation studies illustrated that 4% 
hyaluronidase enzyme was a good enhancer. The prepared films were subjected to 
scanning electron microscopy (SEM) and fourier transform infrared spectroscopy 
(FT-IR) spectral analysis. Higuchi and Peppas models were used for optimizing the 
formulation. 
 
Petkar K. C. and co-workers (2007)2 studied permeability of Losartan potassium 
(LP) across human cadaver skin. They also studied the influence of capsaicin, sex and 
site of application on permeation characteristics and determined an appropriate animal 
model for human skin permeability. Optimized controlled formulation (without 
capsaicin) released 42.17% (±1.85) of LP in 12 hr whereas treatment formulation 
(with capsaicin 0.028 % w/v) released 48.94% (±1.71) of LP with significant 
difference on null hypothesis. Influence of sex showed statistically significant 
difference for permeation of LP through male and female rats (p<0.05). In-vitro 
permeation of LP across human skin was compared with the permeation across rat 
and mice skins. It was suggested that the membranes are good models for human skin 
permeability. In conclusion simple transdermal adhesive patches formulations 
incorporating high molecular weight of LP can deliver a dose in-vivo and proposed 
model skin membranes can be utilized for future pharmacokinetics and toxic kinetic 
studies as well as metabolism studies of LP. 
 
3Ana Melero and co-workers (2007)  studied the influence of propylene glyol(PG), 
ethanol and oleic acid (OA) on nortryptyline hydrochloride (NTH) penetration 
through human epidermis at different Ph (5.5 and 7.4). A pH value of 5.5 in the donor 
solution decreases significantly the permeability co-efficient with respect to a pH 
value of 7.4. The vehicle showed an increasing enhancement effect in the order: 
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polysorbate 80 > ethanol/PG/OA > PG > ethanol > ethanol/lactic acid > lactic acid at 
pH 5.5 while they reduced the permeation of NTH at pH 7.4.  
 
4 Panigrahi L. and co-workers (2005)  prepared a pseudolatex transdermal delivery 
of terbutalin sulphate and evaluate the effect of pH and organic ester penetration 
enhancers on permeation kinetics of terbutaline sulphate through mice abdominal and 
human cadaver skin. Increase in the permeation flux with increasing pH was 
observed.  The permeation profile and related kinetic parameters of terbutaline 
sulphate was determined in presence of three ester type permeation enhancers 
incorporated in the films, viz. methyl laureate, isopropyl lanolate and isopropyl 
myristate. The more pronounced enhancing effect was obtained with isopropyl 
myristate amongst the three, regarding permeation flux, permeability coefficient and 
diffusion coefficient. This was attributed to its solubility parameter being nearer to the 
solubility parameter of human skin, and probably due to its passage across the skin 
barrier through the lipid pathway.  
 
5Dimitrios A and co-workers (2004)   performed in vitro permeation of ondansetron 
through human cadaver epidermis. In vitro release studies were carried out using 
modified Franz diffusion cells and human epidermis, taken from cadaver skin by heat 
separation technique. To estimate the effect of the type and concentration of the 
penetration enhancers and the skin from different donors, an 32 asymmetrical factorial 
design was used. Formulations containing lauric acid and oleic acid as penetration 
enhancers, showed the largest Q values [amounts of ondansetron permeated per unit 
area of epidermal membrane (µg/cm2)] at 24, 48, and 72 hr, as well as steady state 
flux values, among all formulations tested. The other enhancers increased the flux in 
the following order: lauryl alcohol > glycerol monooleate > Azone® > cineole > oleyl 
alcohol > 1-methyl-2-pyrrolidinone. Moreover, the concentration of the penetration 
enhancer and the type of the skin were proved to significantly affect the permeation 
rate of ondansetron through human epidermis. From the results obtained, it was 
shown that the formulations containing lauric acid or oleic acid at 5% or 10% could 
increase sufficiently the permeation of ondansetron. Therefore, the transdermal 
administration of ondansetron seems feasible. 
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G.D. Gupta and co-workers (2004)6 prepared matrices of Repaglinide and evaluated 
for their physico-chemical characteristics: weight variation, thickness uniformity, 
tensile strength and percent elongation at break, drug content uniformity, in-vitro 
permeation study, interaction studies and stability studies. In-vitro permeation studied 
was carried out across human cadaver skins using a modified Keshery- Chien 
diffusion cell. Different models were applied to evaluate release mechanism and 
kinetics. Based on the best fit of permeation data to different mathematical models it 
was concluded that all the formulations followed zero order kinetics with matrix 
diffusion pattern.  The permeation rate was enhanced which was confirmed by skin 
flux, enhancement factor and permeability coefficient.  
 
Deepak Gondaliya and co-workers (2003)7 designed and evaluated unilaminate 
transdermal adhesive matrix system of bupropion base using Eudragit E. The in vitro 
release and epidermal flux through human cadaver skin were studied. The delivery 
rate of bupropion ranged from 10.5mg to 31.4mg/day/3.14cm2 and release of drug 
from the matrices obeyed zero order kinetics. Triethylcitrate and dibutylphtalate have 
no influence on the diffusion of bupropion through human cadaver skin. Succinic acid 
in the adhesive matrix retarded the diffusion while propylene glycol and myristic acid 
alone and combination enhanced the flux of bupropion. 
 
8 Pongjanyakul and co–workers (2003) fabricated nicotine transdermal patches using 
an acrylic adhesive emulsion to form a transparent matrix film. The in vitro release 
behavior and permeation of nicotine across abdominal human epidermis was studied 
using United States Pharmacopeias dissolution apparatus 5 (paddle over disk) and 
modified Franz-diffusion cell, respectively. The release of nicotine from transdermal 
patches showed a good linear co relation with the square root of time. This indicated a 
matrix diffusion controlled release mechanism. This study also showed that the 
transdermal system provides a good delivery system with more than 65% of the 
nicotine delivery being controlled by the device. 
9Sanjay K. Iain and co-workers (2003)  prepared transdermal drug delivery systems 
based on polymeric pseudolatex and matrix diffusion controlled systems for 
salbutamol and compared for in vitro skin permeation profile and in vivo 
performances. Poly (isobutylene) was used as release controlling polymer in both the 
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systems. In vitro skin permeation was studied using the human cadaver skin in franz 
diffusion cell. Permeation rate constants for matrix diffusion controlled system and 
pseudolatices were 10.625 and 13.750 mcg/hr/cm2 respectively. The prepared 
transdermal systems were tested on human volunteers having chronic reversible 
airways obstruction and compared with oral treatments (Asthaline).  
H M Tank and co-workers (1998)10 prepared verapmil free base from corresponding 
salt form and characterized prior to evaluate its in vitro diffusion kinetic from isolated 
epidermis of human cadaver skin. The flux of verpamil using donor phase from pure 
verapmil base and saturated alcoholic solution of base across isolated epidermis were 
88.2± 3.95 and 304.2 ± 14.15 mg/cm2 h 103 respectively. 
 
11Narasimha Murthy S and co-workers (1997)  prepared Terbutaline sulphate 
transdermal films using various cellulose like sodium carboxy methyl cellulose, 
cellulose acetate and ethyl cellulose. They studied the drug release from human 
cadaver skin and reported that, the films made from hydrophilic polymers showed a 
greater rate of release than that of hydrophobic polymers. 
 
12Murthy N S and co–workers (1997)  designed transdermal films of terbutalin 
sulphate as monolithic matrices using cellulose polymers like hydroxypropyl methyl 
cellulose (HPMC), sodium carboxymethyl cellulose (CMC), PEG 400 and 
propyleneglycol were used as enhancer in various ratios. In vitro diffusion studies 
were carried out across isolated stratum corneum of fresh human cadaver skin using a 
polycarbonate feeding bottle modified as a diffusion cell. The release of drug from 
formulation followed zero order kinetics. The transdermal permeability across human 
skin was enhanced with the increasing plasticizer concentration.  
 
13Bret Berner and co–workers (1989)  studied the skin permeation of nitroglycerine 
and ethanol as a function of the volume fraction of ethanol. An optimal concentration 
range of aqueous ethanol produces 5-10 fold increases in nitroglycerine flux across 
skin. For aqueous ethanol solution saturated with nitroglycerine with an ethanol 
volume fraction less than or equal to 0.7, the flux of nitroglycerine across is liner with 
the ethanol flux and is traced to a liner solubility relationship and a constant diffusion 
coefficient. 
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Pramod Sarpotdar and co-workers (1986)14 studied the effect of polyetylene glycol 
400 on the penetration of drugs through human cadaver skin. Polyethylene glycol 400 
was used in various concentrations in the donor and the receptor compartment. It was 
observed that polyethylene glycol 400 had significant effects on the penetration rates 
of compounds, both when used in the donor as well as in the receptor compartment. 
These effects were barrier specific and are related to the alteration of the skin 
structure and the mass flow of water. 
 
Chandrasekaran and co-workers (1977)15 developed a mathematical model for 
estimating the temporal pattern of scopolamine delivery from a transdermal 
therapeutic system through human skin in vivo. The model was useful in optimizing 
the design of the therapeutic system. The transdermal therapeutic system in 2.5 cm2 in 
area and the strength is specified by its temporal pattern of drug release, 200 µg 
promising dose, and 10µg/hr for 72 hr.  
 
16James Ostrenga and co–workers (1971)  investigated the penetration of two topical 
steroids, fluocinolone acetonide and fluocinonide, through human abdominal skin for 
various propylene glycol-water gels. The similarity between the in vivo and in vitro 
composition profiles for both steroids suggested that clinical efficacy can be predicted 
from in vitro data and from the physical properties of the steroids. The correlations 
indicated that the in vivo results were directly dependent upon penetrability. 
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3.1 PLAN OF WORK 
 
3.1.1 Objective of the study 
1. To screen the cardiovascular drugs which is able to penetrate the skin. 
2. To find out skin permeation flux for the cardiovascular drugs which is successful to  
    permeate skin. 
3. To perform drug additive interaction studies. 
4. To prepare matrix diffusional and membrane moderated transdermal drug delivery   
     system. 
5. To carry out permeability study of device through human live skin. 
6. To develop protocol for cutaneous toxicity studies and perform cutaneous toxicity  
     study for transdermal drug delivery system. 
7. To perform stability study of final selected formulation. 
. 
3.1.2 Selection of cardiovascular drugs suitable for transdermal drug delivery    
system 
After extensive literature survey and contemplating, we selected following drugs on 
the basis of prerequisite physio-chemical and pharmacokinetic properties for 
transdermal drug delivery system. These drugs are 
1. Diltiazem hydtrochloride 
2. Atenolol 
 
The pharmacokinetic data of these drugs is collected from best available sources and 
is presented in Table 3.1.1. These drugs have been selected on the basis of  
 · Shorter half-life 
 · Small dose  
 · Small molecular weight 
 · Moderate lipid solubility  
 · Extensive first pass metabolism 
 · Peak plasma level at nano gram level 
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Table 3.1.1: Pharmacokinetic data of drugs 
Pharmacokinetic data Diltiazem  Atenolol 
Extent of absorption 80-90 % 50% 
Bioavailability 40-67 % 45% 
Time for Peak plasma level 2-3 hr 2-4 hr 
Protein binding 70-80 % 6-16 % 
Therapeutic serum level 40-200 ng/ml 280 ng/ml 
Volume of distribution 1.9-4.3 liter/ kg 0.7 liter/ kg 
Half life of  elimination 3.5-6 hrs 6-7 hr 
 
All the above properties make these drugs as potential candidate to be formulated in 
to transdermal drug delivery system 
 
3.1.3 Study of design aspects and other biological consideration of transdermal 
patches. 
Apart from studying permeability studies of selected drugs other aspects like design, 
manufacturing and biological consideration are also important. We have listed these 
as follows: 
1. Drug additive interaction study 
2. Preparation of matrix and membrane moderated transdermal drug delivery 
system.  
3. Design proper diffusion cell for in vitro permeability study 
4. Permeability study through human live skin. 
5. Skin irritation tests for selected drugs and other additives used in transdermal 
patch 
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3.2 MATERIALS USED IN PRESENT INVESTIGATION 
 
Ingredients Suppliers 
Diltiazem Hydrochloride BP Sun Pharmaceutical Ind. Ltd., India 
Atenolol 
Eudragit RL 100 Signet Chemical Corporation, India 
Eudragit RS 100 
Ethyl cellulose 22 CPS USP/EP  
Ethylene Vinyl Acetate Copolymer 
(Vinyl Acetate 40%)   
Aldrich Chemicals, U.K. 
Polyvinyl Pyrrolidone Loba Chemical  Pvt. Ltd., Mumbai, India 
Triethanol amine 
Propylene glycol 
Hydroxy propyl methyl cellulose 400 
CPS, USP 2208 
Signet Chemical Corporation, India 
Carbopol 934 Corel Pharma Chem., Ahmedabad, India 
Ethanol Baroda Chemical Industries Ltd., 
Vadodara, India 
Silica Department of Pharmaceutical Science, 
Rajkot, India 
Sodium Chloride Finar Chemicals Ltd., Ahmedabad, India 
Acetone 
Dibutyl Phthalate E-Merck Specialities Pvt Ltd., Mumbai, 
India Hydrochloric acid 
Ammonia solution S D Fine Chem. Ltd., Mumbai, India 
Solvent ether I.P. Ranbaxy Fine Chemical Ltd., New Delhi, 
India Mercury 
Toluene 
Natural Rubber solution Beta Surgical Ltd., Rajkot, India 
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3.3 INSTRUMENTS USED IN PRESENT INVESTIGATION 
 
Instruments Suppliers 
Sartorius electronic balance Shimadzu, Kyoto, Japan 
(Model CP-224 S) 
Digital pH meter Systronic, Ahmedabad, India 
UV/VIS Double beam spectrophotometer 
2204 
Shimadzu, UV-1700, Kyoto, Japan 
Differential scanning calorimeter DSC – Shimadzu 60 with TDA trend line 
software, Shimadzu, Tokyo, Japan 
FTIR Spectrophotometer 8400 Shimadzu Corporation, Japan 
Magnetic Stirrer Remi equipment, Mumbai, India 
Mechanical water bath shaker NSW-133 
Centrifuger REMI R-23  
Micrometer (0.001mm) Mitutoyo, Japan 
Hot air oven Tempo Instrument Pvt Ltd., Mumbai, 
India 
Thermostatic water bath  Istrument manufacturing corp Pvt. Ltd., 
Ambala, India 
Remi equipment, Mumbai, India Speed regulator 
Stability chamber Thermo Lab., Mumbai, India 
Rabbit holder Self prepared 
 
 3.4 SOFTWARE USED IN PRESENT INVESTIGATION 
 
Instrument Supplier 
Diffusion profile calculator Self developed 
Microsoft office Microsoft Pvt. Ltd. 
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4. PREPARATION OF DILTIAZEM BASE FROM OFFICIAL    
    SALT FORM AND ITS CHARACTERIZATION  
 
4.1 AIM OF PRESENT INVESTIGATION 
The goal of present investigation was to design and evaluate transdermal drug 
delivery system of Diltiazem for the treatment of cardiovascular diseases. Extensive 
efforts have recently been focused on placing a drug delivery system in a particular 
region of body for maximizing drug availability and minimizing dose dependent side 
effects. Diltiazem hydrochloride (DTZ), a drug used in the treatment of angina 
pectoris has recently become very popular for treatment of old age hypertension.1, 2 
The drug is well absorbed form gastrointestinal tract, but its bioavailability is low due 
to extensive first pass metabolism.3
Diffusion of drug molecule across a membrane is influenced by a physicochemical 
nature of drug and membrane polymer. In general human skin is considered as 
hydrophobic and it is reported 4, 5  that the salt form of original drug molecule has poor 
permeability across skin as compared to its base form. Commonly used membranes 
for controlled release systems are hydrophobic in nature. Here an attempt is being 
made to test the scope of the above information to get enhanced release of base form 
of Diltiazem. The aim of present work is to prepare and characterize base forms of 
Diltiazem molecule from corresponding salt forms and evaluate their in vitro 
permeation kinetics. 
 
4.2 Experimental 
 
4.2.1 Preparation of Diltiazem free base from official salt form 
Diltiazem base was prepared from hydrochloric salt. 1 gm of Diltiazem hydrochloride 
was dissolved in 20 ml of distilled water. Strong ammonia solution was added and pH 
was adjusted upto 9.5. Diltiazem free base was precipitated out. The base was 
extracted and purified using solvent ether. Extraction process was carried out four 
times using 20 ml ether. Ethereal phase was collected and evaporated at 40oC.White 
amorphous powder of Diltiazem base was obtained. 
 
4.2.2 Characterization of Diltiazem free base 
The physiochemical properties of Diltiazem free base was determined using following 
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parameters. 
Determination of melting point 
Melting point of drug was determined by taking small amount of drug in a capillary 
tube closed at one end and placed in a melting point apparatus and the temperature at 
which drug melts was recorded. This was performed in triplicates and average value 
was noted. 
 
6,7,8,11Determination of partition co-efficient 
The partition co-efficient study was performed using n-octanol as oily phase and 
phosphate buffer, pH 7.4, as aqueous phase. The two phases were mixed in an equal 
quantity and were saturated with each other on a mechanical water bath shaker NSW-
133 at 32oC for 24 hr. The saturated phases were separated by centrifugation at 2000 
rpm on a REMI R-23 centrifuge. Standard plots of drug were prepared for both, the 
phosphate buffer and octanol. Equal volumes (10ml each) of the two phases were 
taken in conical flasks and, to each; 100mg of weighed amount of drug was added. 
The flasks were shaken at 32oC for 6h to achieve a complete partitioning at 100rpm. 
The two phases were separated by centrifugation at 1000 rpm for 5min and they were 
then analyzed for respective drug contents by UV/VIS spectroscopy method. The 
partition co- efficient of drug K o/w was calculated using the following formula: 
K = (Concentration in octanol/ Concentration in phosphate buffer pH 7.4)  o/w 
 
 
8 Solubility studies 
The solubility study  of Diltiazem base was performed in phosphate buffer solution, 
pH 7.4, in distilled water, methanol, chloroform, ether, alcohol (95%), acetone, 
toluene, glycerol, liquid paraffin, triethanol amine and  silicone oil separately by 
adding excess amounts of drug in each case and keeping the excess drug containing 
flasks on a water bath shaker NSW-133 for 24hr at 32oC.  
 
UV /VIS Spectroscopic Analysis 
UV spectrum of Diltiazem base was recorded on UV/VIS Spectrophotometer by 
scanning 5 μg/ml solution of Diltiazem base in 0.01N hydrochloric acid and scanned 
between 200-400nm using UV/VIS Spectophotometer.  
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Infrared (IR) Spectroscopic Analysis 
The Fourier Infrared (FTIR) spectrums of moisture free samples of Diltiazem base 
was recorded on IR spectrophotometer by potassium bromide (KBr) pellet method. 
The scanning range was 4000 – 400 cm-1 -1 and the resolution was 1 cm . 
 
Differential Scanning Calorimetry (DSC) Analysis  
DSC scans of the powered samples were recorded using DSC- Shimadzu 60 with 
TDA trend line software. Drug was weighed (7-10 mg) and heated at a scanning rate 
of 10oc/min under dry nitrogen flow (100 ml/min) between 50-350oc. Aluminium 
pans and lids were used for drug sample. Pure water and indium were used to 
calibrate the DSC temperature scale and enthalpy response.  
 
4.3 Result and discussion 
Diltiazem base prepared form official hydrochloric salt was white amorphous powder, 
which showed following characteristics.       
 
4.3.1 Melting point 
Melting point of Diltiazem base was determined by capillary tube method and it was 
found to be 102o C±1.4337 (average of three readings). This value is same as that of 
the literature citation. 9 
. 
104.3.2 Partition co-efficient
Octanol and in vitro study fluid (here phosphate buffer, pH 7.4) are considered to be 
the standard system to determine drug partition coefficient between skin and in vitro 
study fluid.10 The logarithamic value of partition coefficient (log P) value was 
experimentally found to be 2.198. The result’s obtained also indicate that the drug 
possess sufficient lipophillicity, which fulfills the requirements of formulating it into a 
transdermal patch. The biphasic nature of drug mimics the biphasic nature of skin, 
thus ensuring easy penetration through the skin. As per literature survey for successful 
transdermal drug delivery system partition coefficient should be in the range of 1 to 4.  
 
4.3.3 Solubility study  
Solubility of Diltiazem base was evaluated in different solvent. The results are 
mentioned in Table 4.3.1. 
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Table 4.3.1 Solubility of Diltiazem base in different solvents 
Solvent Solubility 
Phosphate buffer (pH 7.4) Insoluble 
Distilled water Insoluble 
Methanol Freely soluble 
Chloroform Freely soluble 
Ether Freely soluble 
Alcohol (95%), Freely soluble 
Acetone Freely soluble 
Toluene Freely soluble 
Glycerol Insoluble 
Liquid paraffin Soluble 
Triethanolamine Soluble 
Silicone oil Insoluble 
0.01N Hydrochloric acid Soluble 
 
An attempt was made at this point to learn whether the media phosphate buffer, pH 
7.4, was able to maintain sink condition in diffusion as well as in permeation studies. 
Here form solubility studied data it was found that solubility of drug was poor in 
phosphate buffer, pH 7.4. Therefore it becomes difficult to maintain sink condition 
during diffusion study. Diltiazem base was soluble in 0.01 N HCl and it was selected 
as a diffusion medium.9
 
4.3.4 UV/VIS Spectroscopic analysis  
The UV maxima of resultant solution were measured with Shimadzu, Japan UV/VIS 
Spectophotometer. The UV maxima of Diltiazem base in the solution was found to be 
236.0 nm, which was suitable for the preparation of standard curve and estimation of 
Diltiazem base from various formulations. Figure 4.3.1 shows the UV spectrograph of 
Diltiazem base in 0.01N HCl. 
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Figure 4.3.1: UV spectrograph of Diltiazem in 0.01N HCl 
 
 
 
4.3.5 Infrared (IR) Spectroscopic Analysis 
Diltiazem was subjected for FTIR spectroscopic analysis, to characterize drug. The 
FT-IR spectra obtained for pure drug is given in Figure 4.3.2. The characteristic peak 
of the pure drug and group was mentioned in Table 4.3.2.  FT-IR Spectra for base was 
compared with that given for FT-IR spectra of official salt form.13 Diagnostic peaks 
and finger print regions were identical. These characteristics peaks are useful in drug 
– excipients compatibility study. 
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Figure 4.3.2 FT-IR Spectra of pure drug (Diltiazem) 
 
12Table 4.3.2: FT-IR Spectral data of Diltiazem
Frequency (cm-1) Assignment 
3074.63 Aromatic C-H stretch 
2941.54 Aliphatic C-H stretch 
2821.95 O-CH  C-H stretch 3
1745.64 Acetate C = O stretch 
1676.20 Lactam C = O stretch 
o-substituted aromatic C-H  out-
of-plane deformation 
835.21 
p-substituted aromatic C-H  out-
of-plane deformation 
773.48 
 
4.3.6 Differential Scanning calorimetry (DSC) analysis 
Differential Scanning Calorimetry enables the quantitative detection of all processes 
in which energy is required or produced (endothermic or exothermic phase 
transformation). DSC curves obtained for pure drug is shown in figure 4.3.3. Pure 
powered Diltiazem showed a melting endotherm at 110.77 0C. 
DSC study is useful for further drug excipients interaction study to check suitability 
of polymers. 
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Figure 4.3.3: DSC thermogram of Diltiazem 
50.00 100.00 150.00 200.00 250.00 300.00
Temp [C]
-15.00
-10.00
-5.00
0.00
mW
DSC
110.77 C
Thermal Analysis Result
    
                                   
4.4 CONCLUSION 
In the present study, Diltiazem base was prepared from its official hydrochloride salt 
and characterized using different parameters. Melting point, Refractive index were 
determined to check purity of drug. From solubility study it was found that 0.01N HCl 
was able to maintain sink condition, so it was suitable as a diffusion medium. The 
results obtained from Partition co-efficient study revealed that the drug possessed 
sufficient lipophillicity, which fulfills the requirements of formulating it into a 
transdermal patch. Differential scanning calorimetry and Fourier transform infrared 
spectroscopy gave idea regarding chemical structure of pure drug. UV/VIS 
Spectroscopic data are useful for the preparation of standard curve and estimation of 
Diltiazem base released from various formulations. 
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5. PREPARATION AND CHARACTERIZATION OF  
    POLYMERIC MATRIX DIFFUSIONAL TRANSDERMAL        
    DRUG DELIVERY DEVICE OF DILTIAZEM   
 
AIM OF PRESENT INVESTIGATION 
Controlled release dosage forms have been extensively used to improve therapy with 
several important drugs. However, the development processes are faced with several 
difficulties. In an attempt to reduce the cost of drug development process and 
advantageously reap the benefits of patient regime, health care firms are now 
investing strategically in the development of new drug delivery system.1
Globally, cardiovascular diseases are the number one cause of death and are projected 
to remain so. An estimated 17.5 million people died from cardiovascular disease in 
2005, representing 30 % of all global deaths. Of these deaths, 7.6 million were due to 
heart attacks and 5.7 million due to stroke. About 80% of these deaths occurred in 
low- and middle-income countries. If current trends are allowed to continue, by 2015 
an estimated 20 million people will die from cardiovascular disease (mainly from 
heart attacks and strokes). 2
Diltiazem, a calcium channel blocker, has been shown to be safe and effective in the 
treatment of patients in atrial fibrillation and/or atrial flutter. It has a mean plasma 
half-life of 3.5 hrs and only 40-67% of the orally administered drug reaches the 
circulation due to hepatic metabolism. The model predicts that mean plasma 
Diltiazem concentration of 79, 172, and 294 ng/ml are required to produce a 20%, 
30%, and 40% reduction in heart rate, respectively.3 This concentration can be 
achieved by preparing matrix diffusion controlled transdermal drug delivery system. 
The transdermal controlled drug delivery is a newer approach to deliver drug in to 
systemic circulation at a predetermined rate. This system should duplicate continuous 
intravenous infusion, which not only bypasses hepatic ‘first pass’ elimination but also 
maintains a constant, prolonged and therapeutically effective drug level in the body. 
This is made possible by using intact skin as a port of drug administration to provide 
continuous delivery of drug in to systemic circulation. Following skin permeation, the 
drugs first reach the systemic circulation. The drug molecules are then transported to 
the target site, which could be relatively remote from the site of administration, to 
produce therapeutic action. 
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Matrix diffusion controlled release transdermal drug delivery systems are monolithic 
systems which are the simplest and least expensive means of controlling the release of 
an active agent. Here the active agent is physically blended with the polymer agent. 
The release rate is governed by Higuchi equation. Parameter influencing the release 
characteristics of monolithic devices can be classified as solute dependent factors like 
solubility, partition co-efficient and diffusion coefficient of drug in the polymer 
matrix. The solute independent parameters are system variables like geometry, 
tortuosity, pores, concentration, volume fraction and diffusion layer etc. in the present 
investigation solute related factors were considered to fabricate the devices using 
different polymer matrix. Polymer matrices employed were of non polar and 
hydrophobic nature. 
With perception to above objective, it is necessary to modify current solid dosage 
forms in to controlled transdermal drug delivery system. A first step in this process is 
to illustrate how formulation and process variables could give drug release through 
skin. The aim of present investigation is to formulate and optimize the Diltiazem 
matrix diffusion controlled transdermal drug delivery system. In the present 
investigation, the influence of various grades and concentration of polymers were 
studied. Study was carried out to formulate an elegant product exhibiting desired 
therapeutic performance, from a small and cute dosage form. 
In order to achieve this goal, following criteria were set 
? The dosage form should remain intact for a period of 24 hr. 
? Drug should be delivered in a controlled manner. 
? The size of dosage form should be small with a view to enhance convenience of 
patient as well as compliance to therapy. 
? Plasma concentration should be achieved within short period of time. 
 
5.1 ANALYTICAL METHOD FOR ESTIMATION OF DILTIAZEM BASE 
Diltiazem base can be estimated by various methods such as UV Spectroscopy, 
HPLC, HPTLC etc. In the present investigation Diltiazem was estimated by UV 
Spectrophotometry. 
 
5.1.1 Determination of λmax 
 A solution of Diltiazem was prepared in 0.01N HCl and UV spectrum was taken 
using Systronic 2201 UV/VIS double beam spectrophotometer. UV spectrum of 
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Diltiazem base was recorded by scanning 5 μg/ml solution of Diltiazem base in 0.01N 
Hydrochloric acid and scanned between 200-400 nm.       
 
5.1.2 Preparation of calibration curve  
The calibration curve of Diltazem base in 0.01N HCl was prepared by measuring the 
absorbance of the solution in the range of 4-20 μg/ml. the absorbance of the solution 
was measured at the wavelength 236.0nm. 
Dilitazem (50mg) was dissolved in 40ml 0.01N HCl and volume was made up to 
50ml using 0.01N HCl in 50 ml volumetric flask. This stock solution (1mg/ml) was 
further diluted with 0.01N HCl to obtained solution of 4 to 20μg/ml. Absorbance of 
each solution was measured at 236.0 nm using Shimadzu, Japan UV/VIS 
Spectrophotometer with 0.01N HCl as a reference standard. The standard curve was 
generated for entire range of 4 to 20 μg/ml. The experiment was performed in 
triplicate and based on average absorbance; the equation for the best line fit was 
generated.  
 
5.1.3 Result and discussion 
 
Determination of λmax 
The UV maxima of resultant solution were measured with Systronic UV- 2201 
UV/VIS Spectophotometer. Figure 4.3.1 shows the UV spectrograph of Diltiazem 
base in 0.01N HCl 
 
Calibration curve 
The calibration curve of Diltuiazem base in 0.01N HCl was prepared by measuring 
the absorbance of the solution in the range of 4-20 μg/ml. the absorbance of the 
solution measured at the wavelength 236.0 nm. The results of standard curve are 
shown in Table 5.1.1 and Figure 5.1.2 
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Table 5.1.1: Calibration curve of Diltiazem in 0.01N HCl at 236.0 nm 
Concentration Absorbance ( μg/ml ) 
0 0.000 (0.000) 
4 0.237 (0.004) 
8 0.450 (0.002) 
12 0.647 (0.001) 
16 0.849 (0.006) 
20 1.055 (0.005) 
Correlation coefficient = 0.9991 
Absorbance = 0.051 x concentration + 0.0257 
Values in parenthesis indicates standard deviation (n=3) 
 
 
 5.1.1: Calibration curve of Diltiazem in 0.01N HCl at 236.0nm 
y = 0.051x + 0.0257
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5.2 PREFORMULATION STUDIES 
 
The following pre formulation studies were performed for Diltiazem 
 
5.2.1 Infrared (IR) Spectroscopic analysis 4 
In the preparation of film formulation, drug and polymer may interact as they are in 
close contact with each other, which could lead to the instability of drug. Pre 
formulation studies regarding the drug-polymer interaction are therefore very critical 
in selecting appropriate polymers. FT-IR spectroscopy was employed to ascertain the 
compatibility between Diltiazem and the selected polymers. The individual drug and 
drug with excipients were scanned separately. 
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The Fourier Infrared (FTIR) spectrums of moisture free samples were recorded on IR 
spectrophotometer by potassium bromide (KBr) pellet method. The scanning range 
was 4000 400 cm-1 and the resolution was 1 cm-1. Pottasium bromide was mixed with 
drug and polymer and the spectra were taken. FT-IR spectrum of Diltiazem was 
compared with FR-IR spectra of Diltiazem with polymers. Disappearance of 
Diltiazem peaks or shifting of peak in any of the spectra was studied.  
 
5.2.2 Differential scanning calorimetry analysis 
Differntial scanning calorimetry enables the quantitative detection of all processes in 
which energy is required or produced (i.e., endothermic or exothermic phase 
transformation). DSC curves for pure drug. Diltiazem, Ethylene vinyl acetate 
copolymer (vinyl acetate 40%) and their composites were recorded using DSC- 
Shimadzu 60 with TDA trend line software. Drug and polymer was weighed (7-10 
mg) and heated at a scanning rate of 10oc/min under dry nitrogen flow (100 ml/min) 
between 50-350oC. Aluminum pans and lids were used for drug sample. Pure water 
and indium were used to calibrate the DSC temperature scale and enthalpy response.  
 
5-105.2.3 Drug permeability study using human live skin 
The permeation studies were performed in a Fite’s diffusion cell (cell capacity of 10 
ml, cross sectional area was 1.32 cm2). The drug permeation study was performed 
using human live skin. The skin was used after fulfilling all the ethical requirements. 
The skin was store at 4 to 5o C in saline solution until usage.  
The dermatomed skin (thickness 140 μm) was washed with soap solution, followed by 
washing with distilled water. Skin was further washed with distilled water until it 
showed zero absorbance at 236.0 nm. Skin (thickness 140 μm) was cut, measured and 
mounted between the donor and receptor compartment of the diffusion cell. The 
dermal side of skin was facing receptor compartment. The receptor compartment of 
the diffusion cell was filled with 200 ml of 0.01 N HCl. The donor compartment 
contained 1 ml solution of Diltiazem base in 0.01N HCl having concentration 6.38 
mg/ml. The Fite’s diffusion cell was kept in side the beaker containing receptor fluid. 
The temperature of diffusion medium was maintained at 37 ± 0.5oC by circulating 
water jacket. This whole assembly was kept on a magnetic stirrer and solution in the 
receiver compartment was constantly and continuously stirred during the whole 
experiment using magnetic bead. The diagrammatic representation of in vitro 
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diffusion study through human live skin is given in Figure 5.2.1.  
 
Figure 5.2.1:  Drug permeability study using Fite’s diffusion cell 
 
The samples were withdrawn (2 ml, each time) at different time interval and an equal 
amount of 0.01N HCl, was replaced each time. Absorbance of the sample was read 
spectrophotometrically at 236.0 nm taking 0.01N HCl solution, as a blank. The 
amount of drug permeated per square centimeter at each time interval was calculated 
and plotted against time. The regression analysis of steady state data was done and 
release rate was computed. The experiment was triplicated and mean result recorded. 
 
5.2.4 Improvement of skin permeability using enhancers 
The first transdermal drug delivery system was developed for scopolamine for motion 
sickness in 1981. In spite of the therapeutic success achieved in last 15 years by using 
transdermal drug delivery system, the numbers of transdermal drug delivery system 
available in the market are very few. This is mainly dew to limited permeation 
behavior of drug across skin. 
The limitation of transdermal drug delivery due to ionic characteristic of drugs and 
large molecular weight of drugs can be overcome to some extent by use of 
permeability enhancers. Sorption promoters or sorption enhancers are not drugs but 
they are molecules which reversibly alter the barrier nature of the stratum corneum. 
11,12,13,14 Sorption promoters allow the drugs to penetrate into skin and the drug 
permeate across skin more readily and thus increase systemic availability. 15,16  
Azone, propylene glycol and alcohol was evaluated for Diltiazem permeation 
enhancement activity across human live skin. A solution of Diltiazem base (6.38 
mg/ml) was prepared in 0.01N HCl and it was incorporated with enhancer to 10% 
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concentration level. The permeation study was carried out as described in section 
5.2.3. 
To improve the permeability of Diltiazem across human live skin, alcohol in 
gradually increasing concentration in donor phase was added and evaluated for 
influence on permeation kinetic of Diltiazem. 
 
5.2.5 Result and discussion 
FT-IR spectroscopic and Differential scanning calorimetric studied was carried out to 
assess any interaction between the drug and the excipients. Simultaneously 
permeability study of drug was carried out through live human skin and also assesses 
effect of permeability enhancers on permeability of drug through human live skin. 
 
Infrared (IR) Spectroscopic analysis 
The chemical interaction between the drug and the polymer often leads to identifiable 
changes in the Infrared (IR) profile of complexes. The FT-IR spectrum of pure 
Diltiazem was shown in figure 4.3.2. The FT-IR spectra of Diltiazem with EVA (VA 
40%)copolymer, Ethyl cellulose, Eudragit RL100, Eudragit RS 100 are shown in 
Figure 5.2.2. the presence or absence of characteristics peaks associated with specific 
structural groups of the drug molecule was noted. From the FTIR spectra it was 
revealed that no interaction occurred between Diltiazem and different polymers.    
 
Figure 5.2.2: IR specta of Diltiazem composites                                                   
 
 
                
 
 
 
Shital D. Faldu  Ph.D. Thesis                                                147
Chapter 5                                                             Matrix diffusional TDDS of Diltiazem 
             
 
 
 
 
 
 
 
            
 
 
 
Shital D. Faldu  Ph.D. Thesis                                                148
Chapter 5                                                             Matrix diffusional TDDS of Diltiazem 
             
Differential scanning calorimetric analysis 
Differntial scanning calorimetry enables the quantitative detection of all processes in 
which energy is required or produced, during phase transformation (i.e., endothermic 
or exothermic phase transformation). DSC curves for pure drug, Diltiazem is shown 
in Figure 4.3.3. DSC curve of EVA and Diltiazem composite are shown in Figure 
5.2.3. Pure powdered Diltiazem showed a melting endotherm at 110.770C  
temperature. DSC scan of EVA showed a broad endotherm due to the presence of 
residual moisture in polymers. DSC thermogram of Diltiazem base with EVA exhibits 
endothermic peaks at near to 111.07 0C temperature. This reveals the absence of any 
interaction occurring between drug and polymers.  
                                                         
Figure 5.2.3(a): DSC thermogram of EVA (VA 40%) copolymer 
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Figure 5.2.3(b): DSC thermogram of Diltiazem and its composites 
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Drug permeability study using human live skin 
In vitro permeation study is predictive of in vivo performance of a drug. Permeation 
studies were performed for saturated solution of Diltiazem base in 0.01N HCl across 
human live skin using 0.01N HCl as a diffusion medium in the receptor compartment 
of a modified diffusion cell at 37 ± 0.5 oC. The amount of drug permeated per square 
centimeter at each time interval was calculated and plotted against time (Figure 5.2.4).   
 
Figure 5.2.4: Permeation study of Diltiazem in 0.01N HCl through human live  
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The permeation of Diltiazem hydrochloride across isolated human skin has been 
reported 9.38 μg/cm2 hr and it was very poor.10 The conversion of salt from Diltiazem 
hydrochloride to base form, exhibited improved diffusivity across skin preparation. 
The flux of Diltiazem through human live skin was 23.84 μg/cm2 hr with time lag 1.5 
hr. The diffusion co-efficient was 2.178 x 10-5 2cm / hr, permeability was 3.51 x 10-3 
cm/hr and permeability co-efficient 33.38 X 10-2 μg/cm hr. The high intrinsic 
diffusion coefficient of lipophillic drug seems to have played role in improvement of 
skin flux. The results of permeation of pure drug across live human skin indicated that 
the base form of Diltiazem has quite good permeation characteristics.  
The magnitude of flux was just sufficient to meet pharmacokinetic requirement of 
steady state plasma concentration. The improvement in percutaneous permeation of 
Diltiazem base was due to its hydrophobic nature which partitions easily from 
solution to skin. The further improvement in flux was done using different skin 
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penetration enhancer, so as to have a small size of device meeting the requirement of 
steady state plasma concentration of drug. 
 
Improvement of permeability using enhancers 
The permeation behavior of drug across the skin is controlled by stratum corneum. It 
is composed largely of fatty material along with keratin and other bioorganic 
compounds. Usually hydrophobic drug penetrate more as compare to hydrophilic and 
ionic compounds. To design a convenient transdermal controlled delivery for patient, 
the size of drug delivery play an important role and usually small size of delivery 
device meeting pharmacokinetic requirement of drug, is preferred for better 
compliance to therapy by a patient. 
The skin flux of Diltiazem from hydrochloric acid solution was found to be 23.84 
μg/cm2 hr. To improve skin flux, three chemical enhancers propylene glycol, Azone 
and ethanol were evaluated. The permeation behavior of Diltiazem in presence of skin 
penetration enhancer is presented in Figure 5.2.5. 
The flux was improved and rank order of flux was propylene glycol < Azone < 
Alcohol. It was found to be 26.05, 30.01 and 34.95 μg/cm2 hr for propylene glycol, 
azone and ethyl alcohol respectively. Propylene glycol has a skin hydration property 
and by this way it improves the permeation of molecule. However it is hydrophilic as 
compare to azone and alcohol but Diltiazem is hydrophobic in nature so due to this 
reason the flux is less as compare to azone and alcohol. Azone is used to improve 
permeation of both types of drugs i.e. hydrophilic as well as hydrophobic. As such 
azone is water immiscible and soluble in organic solvent. Due to its hydrophobicity 
the flux is improved but it is less than that observed with alcohol. The permeation 
behavior of azone is still remaining to be explored, but it seems that it temporarily 
alters the keratin structure of stratum corneum, and this behavior seems to have 
improved the permeability of Diltiazem. 
 
Permeation of Diltiazem in presence of alcohol was greatly improved and the highest 
flux (34.95 μg/cm2 hr) was found with alcohol as compare to propylene glycol and 
azone at same concentration (10%) level. 
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 Figure 5.2.5: Permeation study of Diltiazem through human live skin   
                        using penetration  enhancers 
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Permeation of Diltiazem in presence of alcohol was substantially improved. To 
optimize the suitable concentration of alcohol in order to get desired permeation rate 
meeting pharmacokinetic requirement of steady state plasma concentration of drug. 
Alcohol in gradually increasing concentration was further evaluated for Diltiazem 
permeation enhancement activity across human live skin.  
 
Figure 5.2.6: Permeation study of Diltiazem in presence of ethanol through  
                       human live skin 
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Alcohol concentration in donor phase was maintained 10%, 20%, 25%, 40% and 
95.5% alcohol. The permeation profiles are shown in Figure 5.2.6. The Diltiazem 
flux was 34.95, 56.05, 65.58, 71.00 and 83.14 μg/cm2 hr for 10%, 20%, 25%, 40% 
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and 95.5% alcohol. Table 5.2.1 and Figure 5.2.7 present the relationship between 
concentration of alcohol in donor phase and solubility of Diltiazem in skin. 
 
Table 5.2.1: Permeation kinetic of Diltiazem with increasing concentration  
                     of alcohol 
Concentration 
of ethanol 
Skin flux Lag time Diffusion 
coefficient 
Permeability 
coefficient (μg/cm2 hr) (hr) 
 (% v/v) (cm2/hr) (μg/cm hr) 
10% 34.95 0.51 6.410x 10-5 0.4893 
20% 56.05 0.42 7.780 x 10-5 0.7847 
25% 65.58 0.33 9.890 x 10-5 0.9181 
40% 71.00 0.26 1.256 x 10-4 0.9940 
95.5% 83.14 0.20 1.633  x 10-4 1.1639 
 
 
Figure 5.2.7: Effect of ethanol concentration on skin flux of Diltiazem 
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Here after 25% Alcohol the improvement in Cs becomes steady. The possible 
explanation for the improvement in permeation of Diltiazem across skin is given 
below. The lipid content of stratum corneum as reported 29 was 44.5±1.17 %w/w.  
The principle barrier for skin penetration rests in stratum corneum. A random brick 
model for drug transport across stratum corneum is reported.29  Stratum corneum 
consists of protein rich thin plates (cells) separated from one another by thin layer 
intercellular lipids. Following parallel pathways for drug diffusing across stratum 
corneum have been proposed. 
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1. through the cell/intercellular in series 
2. through the lipid intercellular routes 
3. through the flattened protein cells. 
4. through the lipid intercellular route which is lipophillic 
It is reported that the lipid layers play a significant role in skin permeation for 
lipophillic drugs.29 The factor γ for lipophillic drug, γ = KD /Dp >>> 104L  indicating a 
high intrinsic diffusion coefficient across lipid layer (DL) as compared to intrinsic 
diffusion coefficient across protein rich layer (Dp) of sratum corneum K, was lipid-
protein partition coefficient. Diltiazem base is hydrophobic, freely soluble in lipid 
solvents. It is the lipophillic nature of this drug rendered the drug to travel freely (as 
compared to Dlitiazem hydrochloride) from the lipid layer. Alcohol being lipid 
solvent seems to have fluidized the lipid barrier of skin facilitating solution diffusion 
membrane mechanism in stratum corneum for Diltiazem penetration. 
Ethanol being a good solvent for Diltiazem base seems to have improved the 
thermodynamic activity of Diltiazem base. It is reported that higher the concentration 
of drug in cells of stratum corneum more will be the flux29. Alcohol improves the 
thermodynamic activity of Diltiazem in stratum corneum by maintaining high 
concentration in the stratum corneum. As concentration in donor phase increased the 
skin flux is also increased. The solubility of Diltiazem in stratum corneum (Cs) is 
improved and this improvement has lead to overall improvement in permeation 
behavior of Diltiazem across skin. At low alcohol concentration level permeation 
improvement from protenous phase seems to be responsible and at higher 
concentration level changes in fatty barrier seems to be responsible. At very high 
concentration i.e. above 40 to 95.5 %v/v dehydrating effect of alcohol seems to play 
role showing very small change in Cs and Cs becomes steady. 
From above explanation 25 %v/v alcohol in donor phase is just sufficient to have 
desired skin flux to meet pharmacokinetic requirement of steady state Diltiazem 
concentration in blood. The flux was 65.58 μg/cm2 hr so, 25 %v/v alcohol was 
selected for preparation of reservoir patch of Diltiazem.                            
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5.3 PREPARTION AND CHARACTERIZATION OF POLYMERIC MATRIX              
DIFFUSIONAL TRANSDERMAL  DRUG DELIVERY   DEVICES OF 
DILTIAZEM   
 
5.3.1 Preparation of polymeric matrix device 
Matrix – type transdermal patches containing Diltiazem were prepared using different 
ratios of drug to polymers (Table 5.3.1).The polymers were weighed in requisites 
ratios keeping the total polymer weight 800mg, and dissolved in a given solvent.  
Diethyl Phathalate (2% w/w of polymer composition), Di-n-butyl Phalate (30% w/w 
of polymer composition) and glycerin (40% w/w of polymer composition) were used 
as a plasticizer for EVA, ERL100, ERS100 and EC respectively. Diltiazem 
(533.33mg) was added and mixed using a mechanical stirrer. The uniform dispersion 
of polymeric solution of drug (10 ml) was poured on the mercury surface (73.86 cm2), 
and dried at room temperature. After 24h, the films were cut into a 3.14 cm2 area and 
backing membrane (biaxial oriented polyethylene film) was then glued. A glossy 
paper having a smooth surface was used as a release liner. The devices were stored in 
desiccators until used. 
 
Table 5.3.1: Composition of polymeric matrix diffusional patches of Diltiazem 
Formulation  Polymers Plasticizers Solvent 
code (%w/w of polymer composition) 
EVA (VA 40%) 
copolymer 
F1 DEP (2 %) Toluene 
F2 EC Glycerin (40 %) Chloroform 
F3 ERS100 DBP (30%) Chloroform 
ERL100: ERS100 
F4 DBP (30 %) Chloroform 
(1:4) 
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 Figure 5.3.1: Matrix diffusional transdermal patch of Diltiazem 
 
 
5.3.2 Physiochemical evaluation of polymeric matrix device 
Thickness 
The thickness of the laminate was assessed at six different points of the prepared 
medicated film using thickness gauge micrometer (0.001mm, Mitutoyo, Japan). For 
each formulation, three randomly selected laminated were used. 
 
Weight variation 
The weight variation for each batch was determined using Sartorius electronic balance 
(Model CP-224 S), Shimadzu, Japan. Six patch from each batch (3.14 cm2), were 
weighed individually and the average weight was calculated. 
 
Drug content 
The Diltiazem content of each prepared film was measured in triplicate and analyzed 
by UV-VIS spectrophotometer and expressed as the percentage of nominal lode. 
Patches (n=3) of specified area (3.14 cm2), were cut and weighed accurately. The 
pieces were taken into 100 ml volumetric flask and dissolved in respective solvent. 
The solution was filtered through whatman filter paper (Nyulge Nune, UK). This 
stock solution was diluted 100 times using respective solvent and the absorbance of 
the resulting solution was measured at specific wavelength. The content of Diltiazem 
was calculated at 281.5 nm for toluene and 259 nm for chloroform using calibration 
curve prepared using respective solvent system.17, 18
 
Flatness 
The flatness was measured manually for the prepared films. Longitudinal strips were 
cut out from each film, one from the center and two from either side. The length of 
each strip was measured and the variation in the length because of non uniformity in 
 
Shital D. Faldu  Ph.D. Thesis                                                156
Chapter 5                                                             Matrix diffusional TDDS of Diltiazem 
             
flatness was measured by determining percentage constriction, considering 0% 
constriction is equivalent to 100 % flatness.5 Flatness was determined using below 
given formula: 
 % Constriction = [(l1 – l2)/ l2] * 100 
Where,  
l1 = Initial length of each strip 
l2 = Final length of each strip 
The flatness for Diltiazem matrices was measured in triplicate and average reading 
was considered. 
 
Folding endurance 
The folding endurance was measured manually for the prepared films. The folding 
endurance of the films was determined by repeatedly folding a strip measuring 2x2 
cm size at same place till it break.19 The number of times the film could be folded at 
the same place without breaking gave the value of folding endurance. 
 
20Moisture content (Loss on drying) 
The inherent moisture presents in material may influence the stability of dosage 
forms, especially if it contains a drug that is sensitive to water. The absolute method is 
employed to determine the moisture content which gives a weight loss registered 
during process. 
 
Three patch from each batch (3.14 cm2), were weighed individually and the average 
weight was calculated. This weight was considered as an Initial weight. Then all the 
patches were kept in a desiccators containing activated Silica at normal room 
temperature for 24hr. The final weight was noted when there was no further change in 
the weight of individual patch. The percentage moisture absorption was calculated as 
a difference between initial and final weight with respect to final weight. 
% Moisture content = [(Initial weight – Final weight)/ Final weight]* 100  
 
 
Moisture absorption 21 
Moisture uptake also influences the stability of dosage form. Low moisture uptake 
protects the material from microbial contamination. So for transdermal drug delivery 
system it is necessary to determine % Moisture absorption of matrices. 
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Three patch from each batch (3.14 cm2), were weighed individually and the average 
weight was calculated. This weight was considered as an Initial weight. Then all the 
patches were kept in a desiccators containing 200 ml saturated solution of Sodium 
chloride (Relative humidity of 75%) at normal room temperature for 72h. The final 
weight was noted when there was no further change in the weight of individual patch. 
The percentage moisture absorption was calculated as a difference between final and 
initial weight with respect to initial weight. The % Moisture absorption was 
determined using below formula: 
% Moisture absorption = [(Final weight – Initial weight)/ Initial weight]* 100  
 
Water vapor transmission rate (%WVTR) 22,23 
For this study vials of equal diameters were used as transmission cells. These cells 
were washed thoroughly and dried in oven, about 1 gm of activated silica was taken in 
cells and the polymeric films measuring 3.14cm2 were fixed over the brim with the 
help of an adhesive. The cells were weighed accurately and initial weight was 
recorded, and then kept in a closed desiccators containing 200 ml saturated solution of 
potassium chloride. The cells were taken out and weighed after 6, 12, 24, 36, 48 and 
72 hr of storage. The amount and rate of water vapor transmitted was calculated by 
the difference in weight using below given formula: 
% Water vapor transmission rate = (Final weight- Initial weight)/ time * Area  
 
5.3.3 Result and discussion 
The present investigation deals with the development of Diltiazem base loaded 
polymeric matrix using different polymers. The preliminary screening was carried out 
for the selection of best polymer. 
A diffusion mediated matrix controlled transdermal drug delivery system for 
Diltiazem base was successfully prepared using different polymers using mercury 
subtract method and all matrices were evaluated using different physiochemical 
parameters. 
 
Thickness 
With the help of micrometer (0.001mm), Mitutoyo, Japan, the thickness of film was 
measured at six different points and the average thickness was noted. The thickness 
results are given in Table 5.3.2. The results indicate that there was no much difference 
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in the thickness with in the formulations. Thickness in the different formulations was 
in the range of 173.33 ± 1.443 μm to 85 ± 2.5 μm. Maximum thickness was found in 
formulation F1, while minimum found in formulation F4. These results revealed that 
thickness was found to increase as hydrophobic portion of polymer increases. The 
results of thickness also indicate uniform distribution of the drug and polymer over 
the mercury surface. The rank order of thickness of Diltiazem loaded polymeric 
matrices was   
EVA (40% vinyl acetate)> EC> ERS 100> ERL100:ERS100 (1:4) 
 
         Table 5.3.2: Results of thickness uniformity of F1 to F4 matrix formulations  
Average thickness (μm) Formulation 
code 
Sr. No. 
Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 172.5 175.0 172.5 173.33 ± 1.443 
2 F2 115.0 117.5 117.5 116.66 ± 1.443 
3 F3 150.0 152.5 150.0 150.83 ± 1.443 
4 F4 85.0 87.5 82.5 85.00 ±  2.500 
       *Standard deviation, n=3 
 
Weight variation 
Drug loaded films (3.14cm2) were weighed using Sartorius electronic balance (Model 
CP-224 S), Shimadzu, Japan and the results of weight variation are given in Table 
5.3.3. The weight of 3.14 cm2 film ranged from 50.30 ± 0.100 mg to 58 ± 0.500 mg. 
The weight of the patches was found to be uniform among different batches.  
 
        Table 5.3.3: Results of weight variations of F1 to F4 matrix formulations 
Average weight (mg) Sr. No. Formulation 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 53.0 53.1 52.9 53.00 ± 0.100 
2 F2 52.5 52.6 52.3 52.46 ± 0.152 
3 F3 58.0 57.5 58.5 58.00 ± 0.500 
4 F4 50.3 50.2 50.4 50.30 ± 0.100 
    *Standard deviation, n=3 
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In a weight variation test, the pharmacopoeial limit for the percentage deviation of all 
the films of less than mg is ± 10%. The average percentage deviation of all 
formulations was found to be within the limit, and hence all the formulation passed 
the test for weight variation as per official requirements. All the formulations showed 
acceptable pharmaco-technincal properties. From the results obtained, it was clear that 
there was proper distribution of Diltiazem in the film formulations. Hence it was 
concluded that drug was uniformly distributed in all the formulation, with acceptable 
deviation. 
 
Drug content 
Drug content of the matrices was carried out to ascertain that the loading of drug is 
uniform in the formulation. The results obtained are represented in Table 5.3.4. 
The films were found to contain 97.87% - 101.23% of the labeled amount of 
Diltiazem indicating uniformity of drug content. The average percentage deviation of 
all formulations was found to be within the limit, and hence all the formulation passed 
the test for content uniformity as per official requirements. All the formulations 
showed acceptable pharmaco-technincal properties. From the results obtained, it was 
clear that there was proper distribution of Diltiazem in the film formulations. Hence it 
was concluded that drug was uniformly distributed in all the formulation, with 
acceptable deviation. 
 
         Table 5.3.4: Results of % drug content of F1 to F4 matrix formulations 
Drug content (mg) Formulation 
code 
Sr. No. 
Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 98.57 96.52 98.53   97.87 ± 1.172 
2 F2 101.20 100.05 101.23 100.82 ± 0.672 
3 F3 97.80 98.90 99.02   98.57 ± 0.672 
4 F4 101.50 101.20 101.00 101.23 ± 0.251 
         *Standard deviation, n=3 
  
The drug content analyses of prepared formulation showed that the process employed 
to prepared patches was capable of giving uniform drug content, with minimum batch 
variability. 
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Flatness 
The flatness was measured manually for the prepared films. An ideal patch should be 
formulated in such a way that it possesses a smooth surface and it should not constrict 
with time. Flatness studies were performed to assess the same. The results of the 
flatness study showed that none of the formulations had the differences in the strip 
length before and after their cuts. It indicates 100% flatness observed in the 
formulated patches. Thus, no amount of constriction was observed in the film of any 
formulation and it indicates smooth flat surface of the patches and thus they could 
maintain a smooth surface when applied on to the skin. 
 
Folding endurance 
Folding endurance was determined manually for drug loaded polymeric matrices. The 
folding endurance of the films was determined by repeatedly folding a strip measuring 
2x2 cm size at same place till it break. The number of times the film could be folded 
at the same place without breaking gave the value of folding endurance. The results of 
folding endurance are given in Table 5.3.5. 
   
    Table 5.3.5: Results of folding endurance of F1 to F4 matrix formulations 
Folding endurance Sr. No. Formulation  
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 248 250 247 248.33 ± 1.527 
2 F2 245 244 247 245.33 ± 1.527 
3 F3 15 17 18   16.66 ± 1.527 
4 F4 19 17 18    18.00 ± 1.000 
     *Standard deviation, n=3 
 
Here formulation F1 and formulation F2 shows good folding endurance as compare to 
formulation F3 and F4.  
 
Moisture content (Loss on drying) 
The moisture content was determined by keeping the drug loaded polymeric matrix 
patches in desiccator containing activated silica for 24hr. The percentage moisture 
content was calculated from the weight differences relative to the final weight. The 
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results of the moisture content studies for different formulations are shown in Figure 
5.3.2.  
               Figure 5.3.2: % moisture content of F1 to F4 matrix formulations 
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                  * Standard deviation, n=3   
The moisture content in all the formulations was found to be low and ranged from 
0.681 ± 0.019 to 3.181 ± 0.024%. The result revealed that the moisture content was 
found to increase with increasing concentration of hydrophilic polymers. The small 
moisture content in the formulations helps them to remain stable and from being a 
completely dried and brittle film. The rank order of % moisture content of Diltiazem 
loaded polymeric matrices was   
EVA (40% vinyl acetate) < EC < ERS 100 < ERL100:ERS100 (1:4) 
 
Moisture absorption  
Moisture uptake also influences the stability of dosage form. Low moisture uptake 
protects the material from microbial contamination. So for transdermal drug delivery 
system it was necessary to determine % Moisture absorption of matrices. 
The results of the moisture content studies for different formulations are shown in 
Figure 5.3.3. 
The moisture absorption in all the formulations was found to be low and ranged from 
0.7584 ± 0.0276 to 3.2617 ± 0.05696%. The result revealed that the moisture 
absorption was found to increase with increasing concentration of hydrophilic 
polymers. The small moisture absorption in the formulations helps them to remain 
stable and protects the material from microbial contamination and bulkiness of the 
patches. The rank order of % moisture absorption for Diltiazem loaded matrices was 
 EVA (40% vinyl acetate) < EC < ERS 100 < ERL100:ERS100 (1:4) 
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    Figure 5.3.3: % Moisture absorption of F1 to F4 matrix formulations  
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Water vapor transmission rate (%WVTR) 
The water vapor transmission rates of different formulation were evaluated, the results 
are shown in Figure 5.3.4. Diltiazem films containing ERL100 showed higher % 
WVTR as compared to other polymers. This may be due to the hydrophilic nature of 
ERL 100. Formulation F1 and F2 showed less % WVTR as compared to F3 and F4. 
The rank order of % water vapor transmission rate for Diltiazem loaded polymeric 
matrices was EVA (40% vinyl acetate) < EC < ERS 100 < ERL100:ERS100 (1:4) 
 
         Figure 5.3.4: % water vapor transmission rate of F1 to F4 matrix                
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5.4 IN VITRO DIFFUSION STUDY OF MATRIX DIFFUSIONAL        
     TRANSDERMAL DRUG DELIVERY DEVICE OF DILTIAZEM 
The release rate determination is one of the most important study to be conducted for 
all controlled release delivery systems. The diffusion studies of patches are very 
crucial, because one needs to maintain the drug concentration on the surface of 
stratum corneum consistently and substantially greater than the drug concentration in 
the body to achieve a constant rate of drug permeation.24 
 
5.4.1 Experimental 
In vitro diffusion studies of D iltiazem from various transdermal patches was studied 
using modified Keshary-Chien diffusion cell (Figure 5.4.1). The diffusion cell 
consists of two parts; the upper parts i.e. The donor compartment and contains the 
active ingredients and the carrier adhesive/patch; the bottom part contains the receptor 
solution, the water jacket for temperature control, and the sampling port. 
 
The effective permeation area of the diffusion cell and receptor cell volume was 
3.14cm2 and 40 ml, respectively. The temperature was maintained at 37±0.5oC. The 
receptor compartment contained 40 ml of 0.01N HCl stirred by magnetic stirrer.  
 
Samples (2 ml) were withdrawn and replaced with the same volume of fresh receptor 
solution, through the sampling port of the diffusion cell at different time intervals. 
The absorbance of the withdrawn samples were measured using UV VIS 
spectrophotometer at 237.8 nm using 0.01N HCl as a blank. The experiments were 
done in triplicate. Amount of drug released per square centimeter of patch were 
plotted against function of square root of time for different formulations. The release 
rate Q/√T was determined by simple regression analysis of steady state data.       
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Figure 5.4.1: Modified Keshary-Chien diffusion cell 
 
 
Figure 5.4.2: Experimental setup 
 
 
 
5.4.2 Result and discussion 
Diffusion studies are important for ensuring the sustained release performance and the 
reproducibility of rate and duration of drug release. In vitro release profile is an 
important tool that predicts in advance how the drug will behave in vivo 25. The 
results of in vitro drug diffusion studies of transdermal patches are depicted in Table 
5.4.1 and Figure 5.4.3.  
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Table 5.4.1: In vitro diffusion profiles of Diltiazem from F1 to F4 formulations 
2Cumulative amount of drug release from device (μg/cm ) 
Formulation code 
Time 
(hr ½) 
F1 F2 F3 F4 
0.707 1105.51 ± 15.20 486.25 ± 5.39 180.16 ± 5.34 305.87 ± 6.32 
1.000 1499.85 ± 20.33 750.17 ± 10.34 339.65 ± 6.40  475.53 ± 8.44 
1.414 2099.63 ± 25.46 1164.70 ± 15.34 540.96 ± 7.35 845.80 ± 10.32 
1.732 2470.25 ± 26.59 1520.00 ± 18.45 688.56 ± 10.49 1050.56 ± 12.53 
2.000 2985.46 ± 32.46 1775.24 ± 20.58 830.25 ± 11.40 1295.23 ± 15.42 
2.236 3231.56 ± 30.29 1920.56 ± 22.59 940.56 ± 17.39 1475.47 ± 18.48 
2.449 3500.23 ± 45.38 2100.36 ± 25.79 1075.82 ± 19.84 1675.69 ± 19.32 
Q/√T 
1488.10 946.30 503.29 794.08 
(μg/cm2 √hr) 
Correlation 
coefficient 
0.9976 0.9959 0.9990 0.9987 
*Standard deviation, n=3 
The results of diffusion study of Diltiazem loaded polymeric matrix formulated using 
various polymers are presented in Table 5.4.1 and profiles are shown in Figure 5.4.2. 
The release rate Q/√T (μg/cm2 √hr) was determined by simple regression analysis of 
steady state data. The release of Diltiazem from all the matrices followed square root 
law. The rank order of release was 
EVA (40% vinyl acetate) >EC > ERL100:ERS100 (1:4) > ERS 100   
 
Figure 5.4.3: In vitro diffusion profiles of Diltiazem from F1 to F4 formulations 
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Formulation F1 EVA (VA 40%) copolymer exhibited maximum Q/√T release rate 
1488.10 μg/cm2√h while Formulation F3 exhibited minimum Q/√T release rate 
(503.29 μg/cm2 √h).  The physiochemical property of polymer plays important role in 
drug release characteristics, from the polymeric matrix. EVA (VA 40%) copolymer is 
more hydrophobic as compare to other polymers and enhanced permeation from the 
matrix. The solubility characteristic of Diltiazem base in EVA matrix seems to have 
played, the significant role in the release characteristics. The higher polymer 
solubility has played significant improvement in release of drug from EVA (VA 40%) 
copolymer matrix. EVA (VA 40%) copolymer matrix provides a good release for 
Diltiazem base. Based on physiochemical and in vitro release experiments, 
formulation F1 may be chosen for further in vitro permeability study through human 
live skin. 
 
In vitro release kinetic 
The release data was fitted into various mathematical models using software to know 
which mathematical model will best fit to obtained release profiles. The obtained R 
values for various models are given in Table 5.4.2. Here R is regression coefficient. 
 
Table 5.4.2.: Data of various parameters of model fitting of formulation F1 to F4               
Formulation Zero order 
equation 
First order  Higuchi’s 
code equation  equation 
F1 0.9774 0.9326 0.9960 
F2 0.9604 0.8915 0.9930 
F3 0.9907 0.9309 0.9984 
F4 0.9851 0.9074 0.9981 
 
The process of drug release in most controlled release devices including transdermal 
patches is governed by diffusion 26 and the polymer matrix has a strong influence on 
the diffusivity as the motion of a small molecule is restricted by the three –
dimensional network of polymers chain. The in vitro release profile could be best 
expressed by Higuchi’s equation for the permeation of drug from the matrix. 
In our experiment, the in vitro permeation profiles of all formulations could be best 
expressed by Higuchi’s equation (R2 = 0.9930 to 0.9984) for the permeation of drug 
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from a homogeneous- polymer matrix type delivery system that depends mostly on 
diffusion characteristics.27
 
5.5 TO OPTIMIZE DRUG LOADING IN MATRIX FOR ELEGANT    
       FORMULATION 
 
5.5.1 Experimental 
Drug loading (i.e. concentration) in matrix influences parameter of patch like folding 
endurance, thickness, weight variation, flatness, texture appearance, brittleness etc. 
EVA (VA 40%) copolymer was selected to device final matrix diffusional therapeutic 
system. Inclusion of Diltiazem in gradually increased concentration changes its above 
characteristics. The drug is compatible with polymer as seen in DSC profile.Higher 
concentration of drug can be loaded in matrix to achieve enhanced Q/√T release rate. 
Simultaneous changes that occur in the matrix are the texture, appearance, folding 
endurance etc which influences elegance of medicated laminate. A compromise is 
necessary between the loading of drug to have a maximum available Q/√T release rate 
and elegance of formulation.  Most of the investigations, employing diffusion study 
are directed towards determining flux, permeability coefficient and diffusion 
coefficient of drug across the polymeric vehicle components like membrane and 
matrices. Many unexplored points still exist whose study might prove profitable. For 
medicated laminates of monolithic characteristics, containing the dispersed drug, 
release rates are proportional to square root of concentration. Release of drug from 
laminated containing dissolved drug is expected to be linearly related to the initial 
concentration. This aspect of physical pharmaceutics has been less extensively 
studied. 
The release of drug from matrices is described by the well known Higuchi model. But 
when the drug has significant solubility in the polymer the release has been described 
by the following model equation. 28
 
Q = q/A = 2C (Dt/ π)1/2
 
Where, Q is the amount of drug (q) release to the sink at time t per unit area A of 
contact. D is diffusion coefficient of drug in the polymer and C is the initial 
concentration of drug in polymer mg/cm3. This equation showed the relationship 
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existing between the release rate Q/√T and C, the overall concentration of drug 
dissolved in polymer. The main purpose of present investigation was to test the scope 
and usefulness of above model in a series of Diltiazem loaded homogeneous EVA 
(VA 40% copolymer) matrices. 
 
Preparation of polymeric matrix device 
Matrix – type transdermal patches containing Diltiazem were prepared using different 
ratios of polymers and drugs (Table 5.5.1).The polymers were weighed in requisite 
ratios and dissolved in toluene. Diltiazem was added and mixed slowly with a 
mechanical stirrer. The uniform dispersion of polymeric solution of drug (10 ml) was 
poured on the mercury surface (73.86 cm2), and dried at room temperature. After 24h, 
the films were cut into a 3.14 cm2 area and backing membrane (biaxial oriented 
polyethylene film) was then glued. A glossy paper having a smooth surface was used 
as a release liner. They were kept in desiccators until used. 
 
Table 5.5.1: Composition of matrix diffusional transdermal patches of Diltiazem 
Formulation 
code 
Name of polymer  Ratio of 
drug/polymer 
Amount of drugs 
( mg) 
C1 EVA (VA 40%) copolymer 10:90 160.00 
C2 EVA (VA 40%) copolymer 20:80 200.00 
C3 EVA (VA 40%) copolymer 30:70 342.85 
C4 EVA (VA 40%) copolymer 40:60 533.33 
C5 EVA (VA 40%) copolymer 50:50 800.00 
 
Physiochemical evaluation of polymeric matrix device 
Prepared Diltiazem containing matrices were evaluated for various parameters like 
thickness , weight variation, drug content, flatness, folding endurance , moisture 
content, moisture absorption % WVTR etc, as per procedure given in the chapter 5, 
section 5.3.2. 
 
In vitro diffusion profile 
In vitro diffusion study of different matrices containing Diltiazem was carried out as 
per the procedure given in chapter 5, section 5.4.1. 
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Data Analysis 
Q, cumulative amount of Diltiazem released into infinite per unit surface area of 
device was plotted as a function of square root of time for each disc. Release rate 
Q/√T was computed for each disc from simple regression analysis of steady state data. 
The release data was fitted into various mathematical models using software to know 
which mathematical model will best fit to obtained release profiles. 
 
5.5.2 Result and Discussion 
The present investigation deals with the development of Diltiazem base polymeric 
matrices using different concentration of drug and polymer. This preliminary 
screening was carried out to for the selection of best matrices. A diffusion mediated 
matrix controlled transdermal drug delivery system for Diltiazem base was 
successfully prepared using different drug and polymers ratio using mercury subtract 
method and all matrices were evaluated using different physiochemical parameters. 
 
Thickness 
With the help of micrometer (0.001mm), Mitutoyo, Japan, the thickness of films was 
measured and the average thickness was noted. The thickness results were given in 
Table 5.5.2.  
The results indicate that there was no much difference in the thickness with in the 
formulations. Thickness in the different formulations was in the range of 216.66 ± 
2.88 μm to 87.5 ± 2.5 μm. Maximum thickness was found in formulation F6, while 
minimum found in formulation F1.  
These results revealed that thickness was found to increase as drug concentration 
increases. The thickness results also indicate uniform distribution of the drug and 
polymer over the mercury surface. The thickness of each film was determined and 
decrease in thickness of various transdermal drug delivery system were found to be of 
the order of  
C5 > C4 > C3 > C2 > C1 
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Table 5.5.2: Results of thickness uniformity of C1 to C5 matrix formulations 
Average thickness (μm) Sr. No. Formulation 
 Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 C1 85.0 90.0 87.5 87.50 ± 2.500 
2 C2 117.5 117.5 120.0 118.33 ± 1.443 
3 C3 145.0 150.0 147.5 147.50 ± 2.500 
4 C4 170.0 170.0 172.5 171.66 ± 1.443 
5 C5 215.0 215.0 220.0 216.66 ±  2.886 
      *Standard deviation, n=3 
 
Weight variation 
Drug loaded films (3.14cm2) were weighed using Sartorius electronic balance (Model 
CP-224 S), Shimadzu, Japan and the results of weight variation are given in Table 
5.5.3 The weight of 3.14 cm2 film ranged from 32.46 ± 0.152 mg to 53 ± 0.100 mg. 
The weight of the patches was found to be uniform among different batches.  
 
   Table 5.5.3: Results of weight variations of C1 to C5 matrix formulations  
Average weight (mg) Sr. No. Formulation  
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 C1 40.2 40.0 40.4 40.20 ± 0.200 
2 C2 44.5 44.6 44.4 44.50 ± 0.100 
3 C3 47.0 47.2 47.0 47.06 ± 0.115 
4 C4 53.0 52.0 51.5 52.16 ± 0.763 
5 C5 54.0 55.0 54.0 54.33 ± 0.577 
   *Standard deviation, n=3 
 
In a weight variation test, the pharmacopoeial limit for the percentage deviation of all 
the films of less than mg is ± 10%. The average percentage deviation of all 
formulations was found to be within the limit, and hence all the formulation passed 
the test for weight variation as per official requirements. All the formulations showed 
acceptable pharmaco-technincal properties. From the results obtained, it was clear that 
there was proper distribution of Diltiazem in the film formulations. Hence it was 
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concluded that drug was uniformly distributed in all the formulation, with small 
deviation. The results also showed that as the concentration of Diltiazem increases 
weight of matrices also increases. The weight of each film was determined and 
decrease in weight of various transdermal drug delivery system were found to of the 
order of C5 > C4 > C3 > C2 > C1 
 
Drug content 
Drug content of the matrices was carried out to ascertain that the drug is uniformly 
distributed in the formulation. The results obtained are represented in Table 5.5.4. 
 
   Table 5.5.4: Results of % Drug content of C1 to C5 matrix formulations 
Drug content (mg) Sr. No. Formulation  
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 C1 97.80 98.90 99.02 98.57 ± 0.672 
2 C2 101.50 101.20 101.00 101.23 ± 0.251 
3 C3 99.02 97.80 98.90 98.57 ± 0.672 
4 C4 98.57 96.52 98.53 97.87 ± 1.172 
5 C5 101.20 100.05 101.23 100.82 ± 0.672 
 
The films were found to contain 97.57%-101.23% of the labeled amount of Diltiazem 
indicating uniformity of drug content. The average percentage deviation of all 
formulations was found to be within the limit, and hence all the formulation passed 
the test for content uniformity as per official requirements. From the results obtained, 
it was clear that there was proper distribution of Diltiazem in the film formulations. 
Hence it was concluded that drug was uniformly distributed in all the formulation, 
with acceptable deviation. 
 
Flatness 
The flatness was measured manually for the prepared films. The results of the flatness 
study showed that none of the formulations had the differences in the strip length 
before and after their cuts. It indicates 100% flatness observed in the formulated 
patches. Thus, no amount of constriction was observed in the film of any formulation 
and it indicates smooth flat surface of the patches and thus they could maintain a 
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smooth surface when applied on to the skin. 
 
Folding endurance 
Folding endurance was determined manually for drug loaded polymeric matrices. The 
results of folding endurance are given in Table 5.5.5. 
  Table 5.5.5: Results of folding endurance of C1 to C5 film formulations 
Folding endurance Sr. No. Formulation 
 code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 C1 506 504 502 504.00 ± 2.000 
2 C2 446 445 448 446.33 ± 1.527 
3 C3 381 378 380 379.66 ± 1.527 
4 C4 248 246 250 248.00 ± 2.000 
5 C5 184 182 185 183.66 ± 1.527 
   *Standard deviation, n=3 
Here formulation C1 and formulation C2 showed good folding endurance as compare 
to formulation C4 and C5. As the concentration of drug increases  and polymer 
concentration decreases the folding endurance decreases and patch becomes more 
friable. 
 
Moisture content (Loss on drying) 
The moisture content was determined by keeping the drug matrices patches in 
dessicator containing activated silica for 24h. The percentage moisture content was 
calculated from the weight differences relative to the final weight. The results of the 
moisture content studies for different formulations are shown in Figure 5.5.1.  
Figure 5.5.1: Percentage moisture content of C1 to C5 matrix formulations  
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The moisture content in all the formulations was found to be low and ranged from 
0.556 ± 0.052 to 1.225 ± 0.013%. The result revealed that the moisture content was 
found to decrease with increasing concentration of Diltiazem base. The small 
moisture content in the formulations helps them to remain stable and from being a 
completely dried and becoming brittle and friable. The rank order of decrease 
moisture content of various transdermal drug delivery systems are given below.  
C1 > C2 > C3 > C4 > C5 
 
Moisture absorption  
The percentage moisture absorption was calculated as a difference between final and 
initial weight with respect to initial weight. The results of the moisture absorption 
studies for different formulations are shown in Figure 5.5.2.  
The moisture absorption in all the formulations was found to be low and ranged from 
0.6551 ± 0.0548 to 1.7361 ± 0.0453%. The result revealed that the moisture 
absorption was found to decrease with increasing concentration of hydrophobic 
Diltiazem base. The % Moisture absorption of each film was determined and decrease 
in % moisture absorption of various transdermal drug delivery system were found to 
of the order of  C1 > C2 > C3 > C4 > C5   
 
Figure 5.5.2: Percentage moisture absorption for C1 to C5 matrix formulations   
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Water vapor transmission rate (%WVTR) 
The water vapor transmission rates of different formulation were evaluated and the 
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results are shown in Figure 5.5.3.  
 
Figure 5.5.3: % WVTR of C1 to C5 matrix formulations 
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The % water vapor transmission rate of each film was determined and decreases % 
water vapor transmission rate of various transdermal drug delivery system were found 
to be in  the order of  C1 > C2 > C3 > C4 > C5. 
 
In vitro diffusion profile   
Diffusion studies are important for ensuring the sustained release performance and the 
reproducibility of rate and duration of drug release. In vitro release profile is an 
important tool that predicts in advance how the drug will behave in vivo 25. Diffusion 
studies for different formulations were performed using modified Keshary-Chien 
diffusion cell using 0.01N HCl as a diffusion medium at 37 ± 0.5 0C. Cumulative 
amount of Diltiazem released from the device into the diffusion medium was plotted 
against square root of time for each disc subjected under diffusion study. Release rates 
Q/√T were derived from simple regression analysis of steady state diffusion data. The 
results of in vitro drug diffusion study for transdermal patches are depicted in Table 
5.5.6 and Figure 5.5.4  
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Table 5.5.6: In vitro diffusion profiles of Diltiazem from EVA (VA 40%)   
                      copolymer polymeric matrices 
2Cumulative amount of drug release from device (μg/cm ) 
Formulation code 
Time 
(hr ½) 
C1 C2 C3 C4 C5 
0.707 155.40 ± 5.75 333.70 ± 10.44 497.60 ± 9.43 1105.51 ±  8.54 2900.60 ± 30.54 
1 250.10 ± 8.33 452.70 ± 11.53 743.49 ± 12.32 1499.85 ± 15.43 4007.65 ± 49.45 
1.414 367.50 ± 10.43 779.20 ±  15.33 1126.83 ± 14.53 2099.60 ± 20.43 5567.66 ± 59.23 
1.732 465.23 ± 15.34 1020.23 ± 20.54 1389.56 ± 18.30 2525.36 ± 25.32 6656.47 ± 78.34 
2 560.23 ± 20.43 1195.23 ± 21.43 1598.63 ± 25.32 2940.36 ±  26.32 7645.12 ± 85.34 
2.236 625.36 ± 22.54 1365.89 ± 22.75 1870.56 ± 26.30 3265.48 ± 30.53 8575.15 ± 99.23 
2.449 701.45 ± 25.66 1490.23 ± 31.43 2055.45 ± 30.35 3500.23 ± 40.43 9540.23 ± 99.34 
Q/√T 
μg/cm
310.95 690.61 891.44 1397.10 3749.10 2√hr 
Correlation 
coefficient 
0.9992 0.9966 0.9986 0.9993 0.9991 
 
 
Figure 5.5.4.: In vitro diffusion profiles of Diltiazem from EVA (VA 40%) 
copolymer polymeric matrices 
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         * Standard deviation, n=3 
Release rate Q/√T increased with increasing concentration of Diltiazem base in EVA 
(VA 40%) matrix. In our experiments, variable release profiles of Diltiazem from the 
different experimental patches composed of various proportion of drug and polymers 
were observed. Cumulative amount of drug diffused per square centimeter of patches, 
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into the diffusion medium when plotted against square root of time, showed linear 
relationship. Regression analysis was done to calculate Q/√T release rate. The rank 
order of release rate observed was  
C1 < C2 < C3 < C4 < C5 
 
2The formulation C5 exhibited the maximum Q/√T (3749.10 μg/cm h1/2) release rate, 
which were significantly different, compared to the lowest values in the formulation 
C1 (310.95 μg/cm2h1/2). Based on physiochemical characteristics and in vitro release 
experiments, formulation C4 may be chosen for further in vitro permeability study 
through human live skin. 
 
In vitro release kinetic 
The release data was fitted into various mathematical models using software to know 
which mathematical model will best fit to obtained release profiles. The obtained R 
values for various models are given in Table 5.5.7. Here R is regression coefficient.  
 
Table 5.5.7: Data of various parameters of model fitting of C1 to C5   
                     formulations  
Formulation Zero order equation First order equation Higuchi’s equation
C1 0.9897 0.9400 0.9987 
C2 0.9720 0.8904 0.9979 
C3 0.9877 0.9334 0.9979 
C4 0.9785 0.9308 0.9988 
C5 0.9904 0.9486 0.9985 
 
In our experiment, the in vitro permeation profiles of all formulations could be best 
expressed by Higuchi’s equation (R2 = 0.9979 to 0.9988) for the permeation of drug 
from a homogeneous- polymer matrix type delivery system that depends mostly on 
diffusion characteristics. 
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5.6 IN VITRO PERMEATION STUDY OF MATRIX DIFFUSIONAL   
     TRANSDERMAL DRUG DELIVERY DEVICE OF DILTIAZEM ACROSS    
     HUMAN LIVE SKIN 
 
5.6.1 Treatment and preparation of skin for permeation study 
Skin covers the entire external surface of the human body, representing the largest 
single organ. The integument acts as a protective barrier from environmental insults 
including trauma, radiation, harsh environmental conditions and infection.  
 
Human live skin was collected from unused portion of human male patients from 
private hospital with consent of plastic surgeon and patient, who have no problem 
regarding reactions to medicines or problems of breathing.  Healthy skin is taken from 
a place on patient’s body called the donor site. Common sites for the collection of 
skin graft include the upper anterior and lateral thighs.  Most people having a skin 
graft have a split-thickness skin graft.  If the entire thickness of the dermis is included, 
the appropriate term is full-thickness skin graft (FTSG). If less than the entire 
thickness of the dermis is included, this graft is referred to as a split-thickness skin 
graft (STSG). STSGs are categorized further as thin (0.005-0.012 in), intermediate 
(0.012-0.018 in), or thick (0.018-0.030 in), based on the thickness of the harvested 
graft. For study of controlled transdermal drug delivery system skin site is required.  
 
Regardless of technique, adequate anesthesia must be established because harvesting 
of skin grafts is a painful procedure. Lidocaine with epinephrine injected at the donor 
site may reduce blood loss and provide greater tissue turgor that assists in harvesting. 
Here surgery will probably be done while volunteers are under general anesthesia 
(unconscious and will not feel pain). In order to remove the thin and well preserved 
skin slices and stripes from the donor, surgeons use a special surgical instrument 
called a dermatome. This usually produces a split-thickness skin graft, which contains 
the skin with only a portion of the dermis.  
 
Dermatomes are typically air-powered or electric, although manually operated devices 
exist. Commonly used dermatomes include the Padgett and Zimmer, among others. 
All of these dermatomes harvest with a rapidly oscillating blade. The thickness is 
easily adjusted on the instrument. The width is typically adjusted in 1- to 2-inch 
 
Shital D. Faldu  Ph.D. Thesis                                                178
Chapter 5                                                             Matrix diffusional TDDS of Diltiazem 
             
increments by applying blade guards of different widths. 
A surgeon was familiar with the installation of the blade and depth settings and must 
check these before operating the device. Donor site was washed off with Betadine or 
other agent to prepare the donor site to allow the device to easily slide over the skin. 
Then skin was lubricated using mineral oil so dermatome allows easy gliding of the 
dermatome. The dermatome was held in the dominant hand of the operator at a 30-45° 
angle from the donor skin surface. With the non operating hand providing traction 
behind the dermatome, the assistant provides traction in front of the dermatome to 
help stretch and flatten the skin. The dermatome was runned when it engages the skin 
surface and then advanced in a smooth continuous motion over the skin with gentle 
downward pressure. After an appropriate length has been harvested, the dermatome is 
tilted away from the skin and lifted off of the skin to cut the distal edge of the graft 
and completed the harvesting. 
 
 The graft may then be gently washed of lubricant. The donor-site area is covered with 
a sterile dressing for 3 to 5 days. Collected skin graft was washed with saline to 
remove blood and other material and then kept in saline aseptically. This skin graft 
stored in a refrigerator at 4 - 5 C until further used.0
 
Figure 5.6.1: Dermatome 
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Figure 5.6.2: Dermatome blade guards 
 
Figure 5.6.3: Split-thickness skin graft 
 
Figure 5.6.4: Skin graft donor site 8 days after the skin was taken 
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5.6.2 In vitro permeation study through human live skin 
Permeation study was performed in a modified Keshary-Chien diffusion cell. The 
permeation study was performed using human live skin. The skin was used after 
fulfilling all the ethical requirements. Skin was kept at room temperature in saline and 
then washed with soap solution to remove adhering matter. A section of skin was cut 
having thickness 140µm and placed on the brim of diffusion cell in such a way that 
the dermal side of the skin was in the donor compartment and patch was affixed on 
the skin so that aluminum backing was upward. The receiver compartment was filled 
with 40 ml 0.01 N HCl. The transdermal patch containing Diltiazem: EVA (40:60) 
with backing membrane was firmly pressed on the human skin. To perfectly fix the 
release face of patch on the skin, the release face was covered with a very thin layer 
(10μm) of natural rubber solution. Once the adhesion to the skin surface was 
confirmed, flange of the diffusion cell mounted in such a way that the patch was 
situated precisely over the flange aperture. The whole assembly was kept on a 
magnetic stirrer and diffusion medium in the receiver compartment was constantly 
and continuously stirred using a magnetic bead. Samples (2 ml) were withdrawn and 
replaced with the same volume of fresh receptor solution, through the sampling port 
of the diffusion cell at different time intervals till 24 hrs. The absorbance of the 
withdrawn samples were measured using UV VIS spectrophotometer at 236.0 nm 
using 0.01N HCl as a blank. Cumulative amount of drug released per square 
centimeter of patch were plotted as function of time. The release rate was determined 
by simple regression analysis of steady state data. The experiments were triplicated 
and mean release rate was recorded. 
 
5.6.3 Results and discussion 
 
In vitro permeation study is predictive of in vivo performance of a drug. The result of 
in vitro skin permeation of Diltiazem from selected formulation C4 are shown in 
Figure 5.6.5  
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Figure 5.6.5: In vitro skin permeation profile of Diltiazem from Diltiazem:EVA  
                       (40:60) matrix patch through human live skin 
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                      * Standard deviation, n=3 
Various parameters of diffusion kinetics of Diltiazem released from device across 
human live skin are presented in Table 5.6.1.  The parameters listed in this table are 
useful for biopharmaceutics and pharmacokinetics of the matrix diffusional system 
evaluated.  
Table 5.6.1: Parameters of diffusion kinetics of Diltiazem from Diltiazem:EVA  
                     (VA 40%) co-polymer(40:60) matrix patch through human live skin 
Sr. No. Parameters Value 
1 Skin flux (Jss) 16.26  μg/ cm2 hr 
2 Time lag (tL) 1.63  hr 
3 Skin thickness (µm) 140 μm 
4 Diffusion coefficient 2.004 x 10-5 cm2/sec 
Solubility of drug in skin  
(Cs) 
5 11.36 mg/cm3
 
The time lag (tL) for devices is presented in Table 5.6.2. The average diffusion 
coefficient, D of Diltiazem was determined using D = h2/6 tL relationship, where Skin 
thickness h was 140 x 10-4 cm. The amount of Diltiazem retained by skin area used 
for permeation was calculated by dividing steady state flux with gradient of 
diffusivity and it was found to be 11.36 mg/cm3 of skin. The amount of Diltiazem 
retained in skin need to be incorporated in contact adhesive to serve as a prompt dose 
( priming dose) before steady state is established. The release of Diltiazem from 
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matrix diffusional system into infinite sink can be approximated by equation  
Release rate = Q/√T + He -Kt 
The first term on right hand side of the equation represents the time dependent 
delivery rate i.e Q vs. √T pattern. The second term represents the temporal pattern of 
drug release during priming dose period. 
Comparison of permeation kinetics: Patch without priming Dose: Patch with 
priming Dose 
The release rate (µg/hr) has linear relationship with area of release face of a 
transdermal rug delivery system. The final patch needs to be provided with adhesive 
system and priming dose.  To assess release kinetic of a complete patch, a patch of 
3.14 cm2 area was provided with a peripheral adhesive system (4 mm rim).from the 
data of solubility of drug in skin, a 0.216 % w/v Diltiazem in natural rubber solution 
was used as an adhesive system. This solution was uniformly layered in 4 mm rim 
surrounding 3.14 cm2 area of patch, to obtain 10 µm thick adhesive systems 
containing priming dose of 159 µg/cm2 area of delivery device. The device was firmly 
secured on human live skin and was subjected to diffusion experiment using 0.01 N 
HCl as diffusion medium. The release profile is shown in Table 5.6.2 and Figure 
5.6.6.  
 
Figure 5.6.6: In vitro skin permeation profile of Diltiazem from matrix patch 
through human live skin with priming dose and without priming dose 
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Table 5.6.2: Parameter of in vitro skin permeation kinetics of Diltiazem from 
matrix patch through human live skin with priming dose and without priming 
dose 
Cumulative amount of      
drug release (μg/cm
Cumulative amount of 
drug release (μg/cmParameters 2 2)          
Without priming dose  
) 
With priming dose 
Release rate 16.26 18.24 
(μg/cm2 hr) 
Correlation 
coefficient 
0.9985 0.9986 
1.03 hr Time lag (t ) 1.63 hr L
 
Computation of desired release rate (in vivo input) for target steady state plasma 
concentration of drug 
For Diltiazem t = 7 hrs, V1/2 d = 2.0 litres/Kg   and targetted steady state plasma 
concentration (Css) = 40 ng/ml and therefore the desired drug release can be 
calculated as follows. 
In vivo input = in vivo output 
 V                       = Css * d  *  K 70 e *
3                        = 40 ng/ml *  2x10 ml/kg  *  0.693/7 * 70 kg 
                       =  554.4 μg/hr 
Desired release rate = 554.4 μg/hr 
 
Computation of area of patch required for target steady state plasma 
concentration (Css) 
In vivo input = in vivo output = 554.4 μg/hr 
Jss(skin) x A = C  Vss * d  *  K 70  = 554.4 μg/hr e *
Area of patch = (554.4 μg/hr)/ Jss(skin)
                      = 554.4/18.24 cm2 
                                = 30.4 cm2 
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Formulation of final patch   
Final formulation was selected as 24 hour once a day device having area is 30.4 cm2.  
This formulation was provided with priming dose incorporated in natural rubber 
adhesive as follow.  
The amount of Diltiazem retained in skin need to be incorporated in contact adhesive 
to serve as prompt dose (priming dose). For preparation of final matrix diffusion drug 
delivery device containing peripheral adhesive system 0.216 % w/v Diltiazem in 
natural rubber solution is to be used as an adhesive system 0.62 ml of this solution 
was layered over 8.29 cm2 (4 mm) rim area of delivery device giving a 10µm thick 
layer, providing a priming dose of 159 µg/cm2 area of delivery device.                    
The release of Diltiazem from adhesive formulated for final device into infinite sink 
followed first order kinetics with rate constant 0.114 hr-1.  
 
5.7 STABILITY STUDY 
5.7.1. Stability study of matrix diffusional transdermal drug delivery device 
Stability is defined as the ability of particular drug or dosage form in a specific 
container to remain within its physical, chemical, therapeutic and toxicological 
specification. Drug decomposition or degradation occurs during stability, because of 
chemical alteration of the active ingredients or due to the product instability, lowering 
the concentration of the drug in the dosage form. The stability of pharmaceutical 
preparation should be evaluated by accelerated stability studies. The objective of 
accelerated stability studies is to predict the shelf life of a product by accelerating the 
rate of decomposition, preferably by increasing the temperature. Finally selected and 
optimized matrix diffusional transdermal drug delivery system of Diltiazem was 
subjected to stability study.  
The accelerated stability study was carried out according to ICH guideline by storing 
the samples at 25 0C / 60% RH, 30 0C/ 65% RH and 40 0C/ 75% RH for 90 days in a 
stability chamber (Thermo Lab., Mumbai, India). These samples were analyzed UV 
Spectrophotometerically and checked for changes in physical appearance and drug 
content at an interval of 15 days. 
 
5.7.2 Results and Discussion  
Formulation F4 was selected for stability study and observed for change in color, 
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appearance, flexibility and drug content. Temperature and humidity values selected 
were as per the ICH guidelines and the test was carried out in a stability chamber. The 
stability study was carried out at 25 0 0C / 60% RH, 30 C/ 65% RH and 40 0C/ 75% 
RH for 90 days. Diffusion study was carried out and it was observed that formulation 
stored at 40 0C exhibited higher Q/√T release rate as compared to those stored at 25 
0 0C and 30 C. The release rate at 30 0C was altered but it was in order. The product 
stored at 25 0C exhibited no change in release rate. 
Drug degradation study was carried out as per ICH guideline at above mentioned 
physical condition of temperature and humidity. Periodic samples were subjected to 
drug content analysis. The % retained in device was worked out and from the plot of 
log % retained versus time degradation rate constant was computed for 25 0C, 30 0C 
and 40 0C temperatures. The degradation was higher at an elevated temperature. The 
first order rate constant of degradation for room temperature was 1.105 x 10-3 -1 week . 
The self life calculated was 95 week.  
Results of stability study indicated a good stability for laminate (matrix) containing 
drug delivery device. The results of stability study indicated that the products should 
not be stored at an elevated temperature and also should not be refrigerated as at 
lower temperature transdermal patches lost overall flexibility and turned rigid loosing 
elegancy. The product should be stored at room temperature. 
5.8 SKIN IRRITATION AND SKIN SENSITIZATION STUDY  
 
5.8.1 Experimental 
 
Selection criteria for indication for skin irritation  
Skin irritation and skin sensitization though are different types of physiological 
responses yet they have several common indications. Skin sensitization is systematic 
response and skin irritation is primarily is local response.A protocol was devised for 
evaluation of skin irritation and/or sensitization in such a manner that the signs at the 
sight of application would be assessed in common for the both and further, to 
distinguish sensitization from irritation; additional observation has been made. The 
assessment of signs and selected criteria was such that it itself indicated differences in 
irritation and sensitization. 
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The signs and selected criteria as indication for skin irritation and sensitization are as 
follows: 
1. Erythema                                                                                            Score 
• No redness or barely perceptible                                                     0 
• Slight redness, spotty or diffuse                                                      1 
• Moderate uniform redness, well defined erythema                         2 
• Intense redness (moderate to severe erythema)                               3 
• Severe erythema (fiery red)                                                             4 
 
2. Scaling                                                                                                  Score 
• Absent totally                                                                                   0 
• Fine                                                                                                  1 
• Moderate                                                                                          2 
• Severe with large flakes                                                                   3 
 
3. Fissures                                                                   Score 
•  No fissure seen                                                                                 0 
•  Fine cracks                                                                                       1 
•  Single or multiple boarder fissures                                                  2 
•  Fine cracks with hemorrhage or exudation                                      3    
 
4. Oedema formation                                                                               Score 
•  Oedema absent totally                                                                        0 
•  Very slightly oedema (barely perceptible)                                         1   
•  Slight oedema( edges of area well defined by definite raising)         2  
•  Moderate oedema (area raised approx 1 mm)                                    3  
•  Severe oedema ( area raised more than 1 mm and extending            4 
          beyond the area of exposure) 
 
5. Ecchymosis (Hemorrhage in to skin or bruising)                              Score 
• Absent                                                                                                   0 
• Very slight hemorrhage mainly aggravated by shaving                       1   
• Clear sign of hemorrhage                                                                      2 
• Spreaded hemorrhage and clearly perceptible bruising                        3 
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• Severe bruising  and  hemorrhage                                                     4 
 
6. Necrosis (Areas of dead skin)                                                              Score 
• Absent                                                                                                0 
• Little exudates but no part of dead skin seen                                     1 
• Exudates and clear regions containing layers /flaked                        2   
         dead skin 
 
Study plan 
The study plan for evaluating skin sensitization and irritation was made using 
common where critical assessment indicated whether chemical sensitizing or irritating 
or safe. The sensitization included induction period following a short sensitization 
period giving allergic reaction at the application site; this has been discussed under 
literature review. Once this sensitivity was established, the subsequent exposure to the 
chemical will lead to higher response both locally (at the site of application) and 
systematically due to secondary immune reaction (hypersensitivity). A 28 days 
protocol had been made which is divided in to the following phases. 
 
1. Pre-exposure period                           (2 days) 
2. Induction phase                                  (5 days) 
3. Rest                                                    (12 days) 
4. Challenge phase                                 (till 28 days) 
 
The protocol is presented in Table 5.8.1 
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Table 5.8.1: A typical protocol of irritation and sensitization study. 
 
SR. 
NO. 
Name And 
Concentration 
SENSITIZATION / IRRITATION TESTING 
PRE-EXPOSURE 
PERIOD 
INDUCTION PHASE REST CHALLENGE PHASE 
  Φ = 30M Φ = 30M Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 After 12 Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 
D1 D2 D3 D4 D5 D6 D7 Days D19 D20 D21 D22 D28 
1 Erythema 
                          
                          
Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  
2 Scaling 
                          
                          
Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  
3 Fissures 
                          
                          
Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  
4 
Oedama 
formation 
                          
                          
Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  
5 Ecchymosis 
                          
                          
Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  
6 Necrosis 
                          
                          
Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  Avg  
Total of all score              
Total average per 
animal 
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Figure 5.8.1(a): Cutaneous toxicity studies on albino white rabbits 
Figure 5.8.2(b):  Demonstration of patch application during cutaneous toxicity   
                            study 
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  Shaved site for patch application  
 
 
Figure 5.8.2: Various scores of erythema 
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Application time was specified for each day and observations were taken at specified 
days score of each sign was entered in the respective cells of the table. 
 
Selection of animal species 
New Zealand white rabbit were selected due to following reasons. 
1. Availability of large surface area of skin compared to guinea pig and mouse. 
2. Ease in hair removal at the back 
3. It was observed that the rabbits were less interested to remove the patches 
applied on to them comparing to rats. 
4. Comparative ease in handling the species than the rat and the guinea pig. 
5. Albino rabbit is species of choice in the skin irritation testing. 31,32 
 
Methodology involved in cutaneous toxicity study 
Cutaneous toxicity comprised critical steps involving skills like invasion free shaving, 
selecting a site which is comfortable and beyond the reach of the limbs of animal and 
time management on account of large numbers of samples to be investigated with six 
parameters for almost a month. 
 
1. Shaving and selection of site of drug application 
According to protocol one set of animal contained, four New Zealand white rabbits. 
The back of six rabbits was shaved with fresh Gillete® 7 O’ Clock super platinum 
blade is quite satisfactory non-invasive technique. Finally, four rabbits having best 
shaved sites were selected out of six, to carry out study. This was done to omit any 
chance of interference of invasion and irritation signs. 
 
2. Toxicity application patch 
Normal saline was used for the preparation of control patch. A 0.5 ml sample of the 
control article was then applied to site by introduction under a double gauze layer to 
an area of skin approximately 2.0 cm2. The concentration of NaCl was 0.9 %w/v in 
distilled water. This was applied to the skin surface (shaved) and made adhered with 
the help of medical adhesive tape (entirely covered) from 3 M company product 
named “3 M Micropore”. Then animals were returned to their cages. After 24 hr 
exposure, the article was removed. The test sites were wiped with tap water to remove 
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any remaining test article residue. 
 
The final Diltiazem matrix patch (2.2 cm2) was supported with aluminum foil. This 
was applied to the skin surface (shaved) and made adhered with the help of “3 M 
Micropore”- medical adhesive tap (3M, Corporation, U.K.). 
 
5.8.2 Results and discussion 
The sensitization included induction period following a short sensitization period 
giving allergic reaction at the application site.  Once this sensitivity was established, 
the subsequent exposure to the chemical would lead to higher responses both locally 
(at the site of application) and systematically due to secondary immune reaction 
(hypersensitivity). 
 
Sensitization testing 
The protocol gave provisions for refractory period as induction phase, secondary a 
exposure as challenge phase. Following observations would indicate the agent as a 
sensitizer. 
1. If score of respective sign has increased during the days when the patch is not 
applied. 
2. Any exaggerated response during challenge phase. 
3. Any systemic response in terms of decreased activity, fever tremor or any 
other unusual symptoms. (giving indication of systemic reactions which is 
characteristics of sensitivity) 
 
Irritation testing 
The same protocol employed for sensitization studies performed irritation evaluation. 
The limitation was of assessing sensitization testing first, because if chemical or agent 
was recognized as sensitizer and then separate study for irritation assignment was 
needed. In such case, separate study is not recommended since the chemical would be 
discarded earlier if it was found to be sensitizer. Hence forth, the question was of 
assessing the agent whether a local irritant after establishing it non-sensitizing. 
Therefore, one common protocol can judge whether a non-sensitizing agent was 
producing irritation or not following observations would indicate the agent as an 
irritant 
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1. If the score of each sign decreased slightly or not increases during zero 
application days, but the same increases with repeated application. 
2. Elevated scores showed decrease in rest phase. 
3. Scores started decreasing after 1st day of induction phase. 
4. Scores elevated at day 19, but decreased till day 28. 
 
Control patch (Normal saline) 
Normal saline is not irritant or sensitizing in nature. However, the study for normal 
saline was incorporated so that any response due to animal variation or irritation due 
to shaving (non-chemical method) should be investigated. Table 5.8.2 shows 28 days 
study of irritation and sensitization for normal saline. Except scaling no other scores 
for signs of irritation were zero.  At the end of 28 days score for each sign was zero 
except necrosis and oedema formation. Therefore, protocol indicated control as a safe 
(non-sensitizing and non-irritating) which (n-saline) otherwise is also safe. Inversely 
this was also proved that our protocol was systematic and designed in proper manner. 
This result was useful during study of other drugs. Score 1 for any individual sign for 
individual animal was not irritating and its symptoms have been explained earlier in 
experimental section. Though for scaling, score 1 (fine) for individual animal has not 
come in study of control, otherwise also it has been considering irritating.  
Table 5.8.3: The average score for each sign after day 20 and day 28 during  
                      irritation and sensitization study of normal saline  
Average score at 
day 20 
Average score at 
day 28 Sr. No. Sign 
1 Erythema 0.5 0.0 
2 Scaling 0.0 0.0 
3 Fissures 0.5 0.0 
4 Oedema formation 1.0 0.5 
5 Ecchymosis 0.0 0.0 
6 Necrosis 0.5 0.25 
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Table 5.8.2: Skin irritation and sensitization study using 0.9 % NaCl as a control 
 
 
 
 
 
SR.  
Name And 
Concentration 
SENSITIZATION / IRRITATION TESTING 
PRE-EXPOSURE 
PERIOD 
INDUCTION PHASE REST CHALLENGE PHASE 
  
Φ = 30M Φ = 30M Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 After 12 Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 
D1 D2 D3 D4 D5 D6 D7 Days D19 D20 D21 D22 D28 
1 Erythema 
0 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 
0 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0 Avg 0.5 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0 Avg 0 
2 Scaling 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 
3 Fissures 
0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg 0 Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg 0 Avg 0 
4 
Oedama 
formation 
0 0 0 0 0 0 1 0 1 0 1 0 1 0 1 0 0 0 1 1 1 1 1 0 1 0 
0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 1 1 1 0 1 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg 0 Avg 1 Avg .75 Avg .5 Avg .25 
5 Ecchymosis 
1 0 1 1 1 0 1 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
1 0 1 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0.5 Avg 1 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 
6 Necrosis 
0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 0 0 1 0 1 0 1 0 1 
0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 0 0 1 0 1 0 1 0 0 
Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg .5 Avg .25 
Total of all score 2 4 2 9 9 6 6 2 0 9 8 4 2 
Total average per 
animal 
0.5 1 0.5 2.25 2.25 1.5 1.5 0.5 0 2.25 2 1 0.5 
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Study of Diltiazem matrix patch  
The results of skin irritation and skin sensitization study for Diltiazem matrix patch is 
presented in Table 5.8.4. Following inferences has been drawn from irritation and 
sensitization studies of Diltiazem matrix diffusional transdermal drug delivery system. 
From Table 5.8.5, it was clear that the Diltiazem was non irritating since the 
maximum score for each sign for given concentration of drug was not more than 1, 
though the number of animals giving score 1 for the various sign was increased. 
However, score 1 is not considered under irritating category therefore Diltiazem patch 
was considered as safe. Though it does not show average score more than 1 at day 20 
but this indication solely cannot be taken as a sign of non-irritating. The reason for 
this was that individual animal show score more than 1, but the average was less than 
1 (which means that some animals showed score 0, out of four animals). 
Diltiazem is non- sensitizing in nature. The reason for this was reduction in various 
scores even after repeated application. All the tables’ indication and total score 
irritating scores were reduced from day 20 to day 28. Therefore, the primary and 
secondary sensitization was absent. 
Table 5.8.5: The average score for each sign after day 20 and day 28 during        
                     irritation and  sensitization study of Diltiazem matrix patch 
Average score at 
day 20 
Average score at 
day 28 Sr. No. Sign 
1 Erythema 0.75 0.25 
2 Scaling 0.5 0.25 
3 Fissures 0.5 0.25 
4 Oedema formation 0.5 0.0 
5 Ecchymosis 0.25 0.0 
6 Necrosis 0.5 0.25 
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Table 5.8.4: Skin irritation and sensitization study of Diltiazem matrix patch 
 
 
 
 
 
SR. 
NO.  
Name And 
Concentration 
SENSITIZATION / IRRITATION TESTING 
PRE-EXPOSURE 
PERIOD 
INDUCTION PHASE REST CHALLENGE PHASE 
  
Φ = 30M Φ = 30M Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 After 12 Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 
D1 D2 D3 D4 D5 D6 D7 Days D19 D20 D21 D22 D28 
1 Erythema 
0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 0 0 0 1 1 1 1 1 1 1 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 
Avg 0 Avg 0 Avg .25 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg 0 Avg .75 Avg .75 Avg 0.5 Avg 0.5 
2 Scaling 
0 0 0 1 1 1 1 1 1 1 1 0 1 0 1 0 1 0 1 1 1 1 1 1 0 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 
Avg 0 Avg .25 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg .25 Avg .25 Avg 0.5 Avg .75 Avg .75 Avg .25 
3 Fissures 
0 0 0 0 0 0 1 0 1 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 
Avg 0 Avg 0 Avg 0 Avg .25 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 
4 
Oedama 
formation 
1 0 1 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 
1 0 1 0 1 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg .25 Avg 0 
5 Ecchymosis 
1 0 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
1 0 1 0 1 1 1 1 1 1 1 0 1 0 1 0 1 0 1 0 1 1 1 1 0 0 
Avg 0.5 Avg .75 Avg 1 Avg 1 Avg 1 Avg .75 Avg .75 Avg .25 Avg .25 Avg .25 Avg 0.5 Avg 0.5 Avg 0 
6 Necrosis 
1 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 
0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 
Avg .25 Avg .25 Avg 0.5 Avg .25 Avg .25 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 
Total of all score 5 7 11 12 13 10 8 4 2 12 14 12 5 
Total average per 
animal 
1.25 1.75 2.75 3 3.25 2.5 2 1 0.5 3 3.5 3 1.25 
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Table 5.8.6: Maximum sensitization and irritation score of various signs at last  
                      day for Diltiazem matrix patch   
Sr. No. Sign Score N 
1 1 1 Erythema 
1 1 2 Scaling 
10 1 3 Fissures 
0 4 4 Oedema formation 
0 4 5 Ecchymosis 
1 1 6 Necrosis 
 
5.9 CONCLUSION 
 
EVA (VA 40%) copolymer matrix modulated transdermal drug delivery system of 
Diltiazem has been prepared successfully. Among different polymers evaluated EVA 
(VA 40%) copolymer gave a medicated matrix, which was stable, non irritant and non 
sensitizing to skin and was safe. It also complied with official and non official 
pharmaco-technical specification. The matrix device evaluated for Diltiazem release 
in vitro into infinite sink and across human live skin, enabled to provide adequated 
rate of Diltiazem, meeting requisite pharmacokinetic requirement of steady state 
plasma concentration for 24 hours, giving once a day drug delivery system. 
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6. PREPARATION AND CHARACTERIZATION OF MEMBRANE       
    MODERATED RESERVOIR TYPE TRANSDERMAL DRUG DELIVERY   
     DEVICE OF DILTIAZEM                    
 
AIM OF PRESENT INVESTIGATION 
Polymers have officially entered the field of pharmacy for design of novel drug 
delivery systems. Polymers are the key ingredients in drug delivery systems where 
they are mainly used to deliver the drug in predetermined fashions and in controlled 
manner. They are used either as carriers of medicament i.e. matrix or as a barrier to 
moving drug molecules i.e. membrane. In either case the rate of release from dosage 
form can be controlled and in this aspect the delivery systems differs from the 
conventional dosage forms. 
For conventional administration the size of the dosage form is usually influenced by 
the dose of the drug while in case of novel, sustained and controlled drug delivery 
systems size of the dosage form and hence the elegancy of dosage form is influenced 
by the pharmacokinetic aspect i.e., steady state blood concentration or target 
concentration desired which in turn will be influenced by the amount of drug 
delivered per unit area per unit of time by the drug delivery system. The drug flux 
from a delivery device will depend on the physicochemical characteristics of rate 
controlling polymer as well as drug molecule and its formulation also. 
It is fact that as the size of any dosage forms when increases beyond certain limit; the 
convenience of therapy is reduced. For membrane or matrix moderated novel drug 
delivery system intended for percutaneous administration of drug an elegant and cute 
formulation is preferable. The most commonly used membranes for controlled release 
systems are nonporous, homogeneous, polymeric films. Diffusion of a drug molecule 
from a membrane moderated delivery device is governed by steady state Fick’s law 
equation. 
Jss = D K Cd / h 
Where, Jss is a steady state flux (μg/cm2.h), K is drug partition coefficient, D is 
diffusion coefficient cm2/hr, Cd is concentration difference on either side of 
membrane which is usually donor phase concentration mg/ml, h is thickness of 
membrane in cm.  So far membrane remaining saturated with drug, a constant amount 
of drug will diffuse across a unit surface area of membrane. There is linear 
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relationship between magnitude of drug flux and area of drug delivery device. For 
many purposes a constant release rate is desirable for extended period of time. The 
transdermal entry of a drug into systemic circulation at desired rate can be achieved 
by using a suitable rate controlling membrane and drug reservoir.1 The permeability 
of drug through polymeric free films was dependent on characteristics of the polymer 
2, 3, casting solvent 4 and plasticizer used.5
Here an attempt is being made to evaluate the diffusion characteristics of base forms 
of originally official salts form, across various rate controlling polymeric membrane. 
The aim was to determine flux and permeation rate of Diltiazem base across various 
polymeric rate controlling membranes with a target to receive a membrane exhibiting 
promising rate, so that a dosage form releasing requisite amount of drug from a small 
surface area can be formulated to have elegant and acceptable dosage form. 
 
6.1 Preparation of polymeric rate controlling membrane using different 
polymers 
6.1.1 Preparation of polymeric rate controlling membrane 
Polymeric membranes were prepared by solution casting technique on a substrate. 
Glass substrate was used where the components of membrane facilitated easy lifting 
of the membrane. In the cases where difficulty of lifting the membrane arose, mercury 
pool technique was used to cast the film. The composition along with different 
conditions employed is listed in a Table 6.1.1. 
 
Table 6.1.1: Composition of rate controlling membrane 
Polymer Solvent Plasticizer % w/w of 
plasticizer 
Substrate Temperature 
(0C)   
EVA 
(VA 40%) 
copolymer 
Toluene DEP 2.00 Glass 85 
EC Chloroform DEP 2.00 Glass 85 
PVAC Benzene DEP 5.00 Mercury 90 
ERS 100 Chloroform DEP 15.00 Mercury 60 
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Specified weight of membrane polymer and additives were dissolved in respective 
solvents (10ml) by heating the mixture at controlled temperature until a clear solution 
was formed. The solution cooled to room temperature. The solution was poured in 
leveled glass Petri dish (Glass substrate) or on the pool of mercury contained in 
leveled glass Petri dish (Mercury pool substrate). The solvent was allowed to 
evaporate overnight. The membrane were carefully lifted and dried at room 
temperature at least for 24 hours. The membranes were stored in air tight container 
until used. 
 
6.1.2 Physiochemical evaluation of polymeric rate controlling membrane 
Physical appearance 
All prepared membrane was evaluated for its physical appearance like color, texture, 
distribution of polymers and uniformity. 
 
Thickness 
The thicknesses of the membrane were assessed using micrometer (0.001mm, 
Mitutoyo, Japan). Thickness at five different places was measured and average 
thickness was recorded. 
 
Density 
Density was determined by accurately weighing a piece of 2 x 2 cm. the volume of 
pieces was calculated using its thickness and density was calculated as  
Density = Mass of membrane / volume of membrane 
 
Water sorption characteristics 
Accurately weighed piece of membrane was kept and equilibrated in distilled water 
for 24 hrs and percentage of water sorbed was found out from weight difference after 
24 hr.  
 
6.1.3 Results and discussion 
The present investigation deals with the development of polymeric membrane using 
different plasticizer and solvent. This preliminary screening was carried out to for the 
selection of best polymeric membrane. It was possible to cast the membrane of 
different polymers. The physical parameters were evaluated as follows. 
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Physical appearance 
The physical characteristics of each membrane was evaluated visually and noted. The 
results are given in Table 6.1.2. From results obtained it was found that as compare to 
other polymeric membrane, the membrane containing EVA is more elastic and 
flexible. 
Table 6.1.2: Physical characteristics of plain membrane 
Polymer Appearance Texture Distribution of 
polymers 
EVA (VA 40%)  
Opaque Flexible, Elastic Uniform 
copolymer 
EC Transparent Flexible Uniform 
PVAC Transparent Flexible Uniform 
ERS 100 Transparent Flexible Uniform 
 
Thickness 
With the help of micrometer (0.001mm), Mitutoyo, Japan, the thickness of films was 
measured at three different points and the average thickness was noted. The results of 
thickness are given in Table 6.1.3. The results indicate that there was no much 
difference in the thickness with in the membrane. Thickness in the different 
membrane was in the range of 61.66 ± 2.88 μm to 34.16 ± 1.433 μm. Maximum 
thickness was found in ERS100, while minimum found in EVA.  
 
Table 6.1.3: Results of thickness of polymeric rate controlling membrane 
Average thickness (μm)   
Sr. No. Polymers 
Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 EVA (VA40%) 
copolymer 
35.0 32.5 35.0 34.16 ± 1.433 
2 EC 45.0 42.5 47.5 45.00 ± 2.500 
3 PVAC 50.0 52.5 50.0 50.83 ± 1.433 
4 ERS 100 60.0 60.0 65.0 61.66 ± 2.886 
         *Standard deviation, n=3 
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Density and water sorption 
The density and water sorption characteristics of each membrane were determined. 
The results are given in Table 6.1.4. The results indicate that there was no much 
difference in the density with in the membrane. Density of the different membrane 
were in the range of 1.1002 to 0.9260 mg/ml. water sorption characteristics was found 
almost zero for all the polymers. Results indicates that the membrane were 
hydrophobic. 
Table 6.1.4: Physical characteristics of membrane 
Sr. No. Name of Polymer Density Water sorption 
(wt/24hr)  (mg/ml) 
1 EVA (VA 40%) copolymer 1.0220 NIL 
2 EC 0.9260 NIL 
3 PVAC 1.0660 NIL 
4 ERS 100 1.1002 NIL 
 
6.2 In vitro permeability study of Diltiazem through different polymeric   
      membranes 
6.2.1 Experimental 
The permeation studies were performed in a Fite’s diffusion cell (cell capacity of 10 
ml, cross sectional are 1.32 cm2). 
The permeation studies were performed using polymeric membrane. A section of 
membrane was cut, measured and placed on the Fite’s diffusion cell. A saturated drug 
solution (1 ml solution of Diltiazem base in ethanol having concentration 300 mg/ml) 
was kept in the donor compartment. The receiver compartment was filled with 200 ml 
of 0.01N HCl. The Fite’s diffusion cell was kept in side the beaker containing 
receptor compartment. The temperature of diffusion cell was maintained at 37 ± 0.5 
oC by circulating water jacket. This whole assembly was kept on a magnetic stirrer 
and solution in the receiver compartment was constantly and continuously stirred 
during the whole experiment using magnetic bead.  
The samples were withdrawn (2 ml, each time) at different time interval and an equal 
amount of 0.01N HCl was replaced each time. Absorbance of the samples was read 
spectrophotometrically at 236.0 nm taking 0.01N HCl solution, as a blank. The 
cumulative amount of drug permeated per square centimeter at each time interval was 
 
Shital D. Faldu  Ph.D. Thesis   206
Chapter 6                                                      Membrane moderated TDDS of Diltiazem   
 
calculated and plotted against time. The release rate µg/cm2 hr was determined by 
simple regression analysis of steady state data. 
 
6.2.2 Results and Discussion 
Drug permeability studies are important for ensuring the sustained release 
performance and the reproducibility of rate and duration of drug release. In vitro 
release profile is an important tool that predicts in advance how the drug will behave 
in reservoir type transdermal drug delivery system. Drug permeability studies for 
different polymeric membranes were performed in a modified Fite’s diffusion cell 
using 0.01N HCl, as a diffusion media at 37 ± 0.5 oC. The results of in vitro drug 
diffusion studies from polymeric membrane are depicted in Figure 6.2.1. The release 
flux “Jss” was determined from the regression analysis of steady state data. 
 
Table 6.2.1: Parameters of permeation kinetic of Diltiazem across polymeric  
                      membrane 
EVA (VA 40%) 
copolymer 
Parameter EC PVAC ERS 100 
Flux 
1633.40 1099.8 836.34 581.29 
(μg/cm2 hr) 
Correlation 
coefficient 
0.9969 0.9958 0.9946 0.9910 
Permeability 
coefficient 5.579 4.949 4.251 3.584 
(µg/cm hr) 
 
All the membrane was sufficiently hydrophobic and Diltiazem base was also 
hydrophobic exhibited permeation across all the membrane. Membrane thickness 
independent permeation rate is an important tool to rate the membranes for 
permeation study. However, the permeation coefficient for EVA (VA 40%) 
copolymer was the highest; this is due to good partitioning of Diltiazem base from 
EVA (VA 40%) copolymer than other polymer used to prepare membrane. EVA (VA 
40%) copolymer was selected as rate controlling membrane, to device reservoir type 
transdermal drug delivery system. This membrane was further characterized for 
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various diffusion parameters. 
 
 Figure 6.2.1: Release profiles of Diltiazem through various polymeric membrane 
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6.3 Effect of thickness of membrane on release profile 
6.3.1 Experimental 
The release of drug from membrane is described by the well known steady state 
Fick’s law equation. 
                                            Jss = D K Cd / h 
Where, Jss is a steady state flux (μg/cm2.h), K is drug partition coefficient, D is 
diffusion coefficient cm2/hr, Cd is concentration difference on either side of 
membrane which is usually donor phase concentration mg/ml, h is thickness of 
membrane in cm.  So far membrane remaining saturated with drug, a constant amount 
of drug will diffuses across a unit surface area of membrane. There is linear 
relationship between magnitude of drug flux and area of drug delivery device. 
Thickness of membrane is an important parameter to formulate a robust device. A 
very thin membrane should give a product prone to rupture by minor mechanical 
injury to patch. Thickness influence release characteristics of drug and for to select a 
membrane giving substantial flux, still giving  a robust formulation the diffusion 
study of EVA (VA 40%) copolymer rate controlling membrane of different thickness 
was carried out using Fite’s diffusion cell. The Diltiazem release flux was computed 
by regression analysis of steady state data.  
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The main purpose of present investigation was to prepare EVA (VA 40%) copolymer 
rate controlling membrane of different thickness and to evaluate diffusion 
characteristics of Diltiazem using these membranes. 
Preparation of EVA (VA 40%) copolymer membrane                                          
Rate controlling polymeric membranes of EVA (VA 40%) copolymer were prepared 
as per method described in Chapter 6.1.1. To prepare polymeric membrane having 
different thickness, different quantity of polymeric solution was casted over mercury 
pool. 
Drug permeability study through polymeric membrane 
The permeation studies were performed in a Fite’s diffusion cell, as per the procedure 
described in chapter 6.2.1. The cumulative amount of drug permeated per square 
centimeter at each time interval was calculated and plotted against time. The release 
rate μg/cm2 hr was determined by simple regression analysis of steady state data. 
 
6.3.2 Results and Discussion 
Drug permeability studies for different polymeric membranes were performed in a  
Fite’s diffusion cell using 0.01N HCl, as a diffusion media at 37 ± 0.5 oC. The results 
of in vitro drug diffusion studies from polymeric membrane are depicted in Table 
6.3.1 and Figure 6.3.1. 
 
Table 6.3.1: Release flux of Diltiazem from different thickness EVA (VA 40%)  
                     copolymer membrane  
Sr. No. Thickness Flux 
 (µm)  (μg/cm2h) 
1 30 1378.12 
2 50 996.25 
3 60 901.27 
4 65 801.95 
5 70 763.87 
6 80 539.84 
7 100 277.68 
8 105 264.18 
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EVA (VA 40%) copolymer membrane having thickness 30 μm exhibited maximum 
flux for Diltiazem. The flux of Diltiazem, across membrane covering reservoir with 
saturated solution of Diltiazem, followed near to zero order release, exhibiting a high 
release rate. Substantial high flux of Dilitazem was due to “Burst effect phenomena” 
was due to high diffusivity or solubility of drug in polymer, the drug molecules 
appearing fast at the receptor side of barrier membrane.  
Usually for an ideal membrane, for a permeant passing through it, a linear relationship 
without intercept on either axis is expected, when release rate is plotted as function of 
thickness. The negative intercept on X-axis indicates burst effect phenomena, 
showing high diffusivity of drug in the membrane.  
Figure 6.3.1: Correlation between thickness of polymeric membrane and release   
                       rate 
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Various parameters of kinetics of Diltiazem released from polymeric membrane are 
presented in Table 6.3.2. The parameters listed in this table are useful for 
biopharmaceutical aspect of the membrane moderated system evaluated. The most 
commonly used membrane for controlled release systems are nonporous, 
homogeneous polymeric films. Diffusion of a drug molecule from a membrane 
moderate delivery device is governed by steady state Fick’s law  
Jss = D. K. Cd/ h 
 
Where, Jss is steady state flux μg/cm2 hr, K is drug partition co-efficient, D is 
diffusion coefficient cm2/hr and Cd is concentration difference on either side of 
membrane which is usually donor phase concentration mg/ml, h is thickness of 
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polymeric membrane in cm. so far membrane remaining saturated with drug, a 
constant amount of drug will diffuse across an unit surface area of membrane. 
 
Table 6.3.2: Various parameters of kinetics of Diltiazem released from polymeric 
                      membrane 
Thickness Flux Membrane 
permeability  
Permeability 
coefficient  (μm x 10-4)  (μg/cm2h) 
-3 P = (Jss/Cd) x 10 P’ = Jss x h 
(cm/hr) (µg/cm hr) 
30 1300.12 4.3337 3.9003 
50 996.25 3.3208 4.9812 
60 901.27 3.0000 5.4076 
65 801.95 2.6730 5.2126 
70 763.87 2.5460 5.3470 
80 539.84 1.7990 4.3187 
100 277.68 0.9256 2.7768 
105 264.18 0.8206 2.5484 
 
Membrane permeability P (cm/hr) and membrane thickness independent permeation 
rate P’ (mg/cm.hr) were calculated using below equation 
 
P = Jss/Cd 
 
P’ = Jss. h 
A linear relationship was observed between release flux and membrane permeability. 
The correlation coefficient was 0.9958. As thickness increased the release rate 
decreased. The thickness independent permeation rates remained in order and limit.  
At thickness higher than 100 µm and above the permeation rate decreases as thickness 
goes on increasing above certain level, the barrier properties seems to be turning to 
matrix characteristics showing enhanced path length for moving drug molecule to 
partition into diffusion medium. Due to this permeation rate seems to be decreasing.  
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Figure 6.3.2: Correlation between membrane permeability and release rate         
                       through polymeric membrane 
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6.4 Formulation and optimization of reservoir device of Diltiazem 
Here an attempt is being made to evaluate the diffusion characteristics of base forms 
of originally official salts forms, across EVA (VA 40%) copolymer hydrophobic 
membrane. The aim was to determine flux and permeation rates of Diltiazem base 
through polymeric membrane and to formulate and optimize the Diltiazem membrane 
moderated reservoir type controlled transdermal drug delivery system of Diltiazem.  
 
6.4.1 Experimental 
Component of Device 
The following components were used to fabricate the controlled drug delivery system 
Preparation of Diltiazem base 
Diltiazem free base was prepared as per method describe in chapter 3. 
Backing membrane 
Polyethylene coated aluminum foil was used as protective backing. 
Drug reservoir 
Low density polyethylene sheet 0.220 mm to 0.400 mm thick was drilled to a circular 
hole of desired size and glued on to the polyethylene coated aluminum foil, forming a 
reservoir well. The drug formulation was filled in the reservoir.  
EVA (VA 40%) copolymer rate controlling membrane  
The method of preparation is described in chapter 6.1.1. 4% w/v solution of EVA 
(VA 40 %) copolymer containing Dibutyl phalate (2% w/w of polymer weight) was 
used as a plasticizer. The films were cut into a 3.14 cm2 area and covered with glossy 
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paper having a smooth surface. The film was kept in desiccators until used. 
Adhesive system 
Natural rubber solution prepared by masticating natural rubber with fixatives, 
tackifiers, preservatives in volatile solvents (hexane) was received readymade and 
was used as an adhesive. 
Peel off release liner 
Silicon sheet was used as peel off protective liner. 
Fabrication of reservoir device 
Membrane moderated reservoir type device was fabricate to evaluate the permeation 
kinetic of Diltiazem base. Low density PVC valley was taken as a reservoir. 0.3 ml 
Alcoholic solution of Diltiazem base having concentration 300 mg/ml was filled in 
the reservoir. The reservoir was covered with EVA membrane having thickness 30μm 
using adhesive. Reservoir patch was covered with liner and placed in desiccators until 
used. 
 
Drug content analysis of reservoir patch 
The plain patch without Diltiazem and a medicated patch were used for drug content 
analysis. The reservoir patch was taken into 100 ml volumetric flask and dissolved in 
10 ml toluene. The solution was filtered through whatman filter paper (Nyulge Nune, 
UK). This stock solution was diluted 100 times using toluene. The amount of drug 
present was determined UV-VIS spectrophotometerically at 281.5 nm. The blank 
solution was prepared using reservoir patch free from drug. 
 
6.4.2 Results and discussion  
A membrane moderated transdermal controlled drug delivery system for Diltiazem 
base was successfully prepared using EVA (VA 40%) copolymer and reservoir patch 
was evaluated by drug content analysis. 
 
Drug content 
Drug content of the reservoir patch was carried out to ascertain that the drug is 
properly added in the formulation. The prepared reservoir patch found to contain 
95.34 ± 0.345 of the labeled amount of Diltiazem. The average percentage deviation 
of formulation was found to be with in the limit, and hence the formulation passed the 
test for content uniformity as per official requirements. The drug content analysis of 
 
Shital D. Faldu  Ph.D. Thesis   213
Chapter 6                                                      Membrane moderated TDDS of Diltiazem   
 
prepared formulation showed that the process employed to prepared patches was 
capable of giving uniform drug content, with minimum batch variability. 
 
6.5 In vitro diffusion study of reservoir device containing Diltiazem 
6.5.1 Experimental 
Modified Keshary-Chien diffusion cell was used for diffusion study. Device was 
clamped on the brim of the cell. Membrane was kept facing the diffusion medium. 
Diffusion medium was stirred with bar type magnetic stirrer and maintained at 37 ± 
0.5oC. The effective permeation area of the diffusion cell and receptor cell volume 
was 3.14 cm2   and 40 ml, respectively. The receptor compartment contained 40 ml of 
0.01N HCl.  Periodic samples (2 ml) were withdrawn and replaced with the same 
volume of fresh receptor solution, through the sampling port of the diffusion cell at 
different time intervals for 6 hr. The absorbance of the withdrawn samples were 
measured using UV VIS spectrophotometer at 236.0 nm using 0.01N HCl as a blank. 
The experiments were done in triplicate. Cumulative amount of drug released per 
square centimeter of patch were plotted against function of time. The release rate was 
determined by simple regression analysis of steady state data.  
 
6.5.2 Result and discussion 
Diffusion studies are important for ensuring the sustained release performance and the 
reproducibility of rate and duration of drug release. The results of in vitro drug 
diffusion profile for transdermal patch is depicted in Figure 6.5.1. 
 
Figure 6.5.1: In vitro diffusion profiles of Diltiazem from reservoir device  
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Cumulative amount of drug diffused per square centimeter of patches, into the in vitro 
fluid when plotted against time, showed near to zero order release. The release flux 
(1397.50 μg/cm2 hr) was calculated from the regression analysis of steady state data. 
The correlation coefficient was 0.9929 and exhibited zero order kinetic.  
 
6.6 In vitro human live skin permeation study of Reservoir device of Diltiazem 
6.6.1 Experimental 
Here an attempt is being made to evaluate the diffusion characteristics of base forms 
of the drug molecule, across human live skin. The aim was to determine flux and 
permeation rate of Diltiazem base through human live skin. In general human skin is 
considered hydrophobic. The survey of permeability of hydrophobic molecule 
indicates that majority of lipophillic drug crosses the skin barrier at a faster rate. The 
objective was to test scope of this information so as to get cute and elegant drug 
delivery system. 
 
Treatment and preparation of skin for permeation study 
Human live skin was received from six healthy human male patients of an age 25 to 
30 years. The skin was treated and stored as per method mentioned in Chapter 3. 
  
In vitro permeation study through human live skin    
The permeation study was performed in a modified Keshary-Chien diffusion cell. The 
permeation study was performed using human live skin. The skin was used after 
fulfilling all the ethical requirements. Skin was kept at room temperature in saline and 
then washed with soap solution followed by washing with distilled water. A section of 
skin was cut and clamped on the brim of diffusion cell in such a way that the dermal 
side of the skin was facing the receiver compartment. The receiver compartment was 
filled with 40 ml 0.01 N HCl. The transdermal patch containing Diltiazem was firmly 
pressed onto the center of human skin. Once the adhesion to the skin surface had been 
confirmed, flange of the diffusion cell mounted in such a way that the patch was 
situated precisely over the flange aperture. The whole assembly was kept on a 
magnetic stirrer and solution in the receiver compartment was constantly and 
continuously stirred using a magnetic bead. Samples (2 ml) were withdrawn and 
replaced with the same volume of fresh receptor solution, through the sampling port 
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of the diffusion cell at different time intervals till 24 hrs. The absorbance of the 
withdrawn samples were measured using UV VIS spectrophotometer at 236.0 nm 
using 0.01N HCl as a blank. The experiments were done in triplicate. Amount of drug 
released per square centimeter of patch were plotted against function of time. The 
release rate was determined by simple regression analysis of steady state data. 
6.6.2 Results and discussion 
In vitro permeation studied is predictive of in vivo performance of transdermal drug 
delivery system. The results of in vitro skin permeation of Dltiazem from reservoir 
device across human live skin are shown in Figure 6.6.1  
 
Figure 6.6.1: In vitro skin permeation profile of Diltiazem from reservoir device 
                      through human live skin 
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                 * Standard deviation, n=3 
Various parameters of diffusion kinetics of Diltiazem released from device across 
isolated skin are presented in Table 6.6.1. The parameters listed in Table 6.6.1 are 
useful for biopharmaceutics and pharmacokinetics of reservoir device evaluated. 
2Reservior device containing Diltiazem provided 40.77 ± 0.9584 μg/ cm  hr skin flux. 
The time lag (tL) for devices is presented in Table 6.6.1. The average diffusion 
coefficient, D of Diltiazem was determined using D = h2/6 tL relationship, where skin 
thickness h was 140 x 10-4 cm. The amount of Diltiazem retained by skin area used 
for permeation was calculated by dividing steady state flux with gradient of 
diffusivity and it was found to be 17.298 mg/cm3 of skin. 
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Table 6.6.1: Parameters of diffusion kinetic of Diltiazem from reservoir device  
                      through human live skin 
Sr. No. Parameters Value 
240.77 μg/ cm  hr 1 Skin flux (Jss) 
0.908  hr 2 Time lag (tL) 
140 μm 3 Skin thickness (µm) 
4 Diffusion coefficient 3.2996 x 10-5 cm2/sec 
317.298 mg/cm5 Solubility of drug in skin (Cs) 
 
The amount of Diltiazem retained in skin  need to be incorporated in contact adhesive 
to serve as a prompt dose ( priming dose) before steady state is established. The 
release of Diltiazem from reservoir system into infinite sink can be estimated by 
equation. 
Release rate = Jss (in sink) + He -Kt 
The first term on right hand side of the equation represents the steady state delivery 
rate i.e. Q Vs T pattern. The second term represents the temporal pattern of drug 
release during priming dose period. 
Comparison of permeation kinetic: Patch without priming Dose: Patch with  
priming Dose 
The release rate (µg/hr) has linear relationship with area of release face of a 
transdermal drug delivery system. The final patch needs to be provided with adhesive 
system and priming dose. The quantity of Diltiazem to be loaded in adhesive as 
priming dose was derived from separate diffusion experiment, on trial and error basis, 
where EVA (VA 40%) copolymer rate controlling membrane was layered with 0.075 
ml adhesive solution contains 2.19 mg/ml Diltiazem over 1cm2 area (gives a smear of 
approximate 10μm thick) and was affixed over human skin and subjected to in vitro 
diffusion study. The steady state release rate of Diltiazem was 29.78 μg/cm2 hr with 
diffusion coefficient of 2.41x10-5 2 cm /hr, for skin thickness of 140 μm. Amount of 
Diltiazem absorbed per cm3 of skin was approximated by dividing steady state flux 
with gradient of diffusivity, which was found to be 17.298 mg per cm3 of skin. 
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To assess release kinetic of a complete patch, a patch of 3.14 cm2 area of delivery 
device was covered with adhesive system. From the data of solubility of drug in skin, 
0.323 % w/v Diltiazem in rubber solution was used as an adhesive system. 0.236 ml 
of this solution was uniformly layered over 3.14 cm2 area of patch, to obtain 10 µm 
thick adhesive systems containing priming dose of 242 µg/cm2 area of delivery 
device. The device was firmly secured on skin of human live skin and was subjected 
to diffusion study using 0.01 N HCl as diffusion medium.  
Figure 6.6.2: In vitro skin permeation profile of Diltiazem from reservoir patch 
through human live skin with priming dose and without priming dose 
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Table 6.6.2: Parameters of in vitro permeation kinetics of Diltiazem from 
reservoir device through human live skin with priming dose and without priming 
dose 
Cumulative amount of 
drug release (μg/cm
Cumulative amount of 
drug release (μg/cm2 2) 
Without priming dose 
) 
With priming dose 
Parameters 
Release rate 40.77 43.95 
(μg/cm2 hr) 
Correlation 
coefficient 
0.9953 0.9921 
0.908  hr 0.463 hr Time lag (t ) L
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Computation of area of patch required for target steady state plasma 
concentration of Diltiazem 
As mentioned in section 5.6.3 desired release rate of Diltiazem was 554.4 μg/ hr. 
In vivo input = in vivo output = 554.4 μg/hr 
Jss(skin) x A =  C  Vss * d  *  Ke * 70 = 554.4 μg/hr 
Area of patch = (554.4 μg/hr)/ Jss(skin)  = 12.61 cm2 
 
Formulation of final reservoir type transdermal drug delivery system of 
Diltiazem meeting targeted steady state plasma concentration 
The effective area for desired steady state release of Diltiazem computed is 12.61 
cm2. An adhesive system covering the membrane is to be provided. Priming dose 
needs to be included in the adhesive layer. 
The adhesive solution (readymade received- Beta Surgical, Rajkot) was prepared 
using natural rubber masticated with fixative, tackifiers, preservatives and solvent 
hexane. 
For preparation of final patch 0.323 % w/v Diltiazem base in natural rubber solution 
is to be used as an adhesive system. 0.95 ml of this solution is to be uniformly layered 
over release face of device to obtained 10 μm thick adhesive system containing 242 
mg Diltiazem/cm2 of delivery device as a priming dose.  
The release phase is to be provided with a protective liner. The device to be packed in 
brown paper covering and to be stored at 20 to 25 0C. 
 
6.7 Modification in formulation (Gel in reservoir) 
Incorporation of Diltiazem base in reservoir formulation of a device containing EVA 
(VA 40%) copolymer as a rate controlling membrane material would provide an 
elegant , efficient and economic membrane moderated transdermal controlled drug 
delivery which would be convenient for patient but here attempt was carried out to 
incorporate drug in carbopol gel, to facilitate easy fabrication. As enclosing of 
semisolid is preferred to solution in the reservoir so far processing is concerned.6   
Here an attempt is being made to evaluate the diffusion characteristics of Diltiazem 
base, from a gel formulation across EVA (VA 40%) copolymer hydrophobic 
membrane. The aim was to formulate a gel containing Diltiazem base. The medicated 
gel is to be evaluated for permeation kinetics through EVA (VA 40%) copolymer 
membrane (30 μm) containing reservoir system. Further permeation study was carried 
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out using human live skin. 
 
6.7.1 Experimental 
6.7.1.1 Component of Device 
The following components were used to fabricate the membrane moderated reservoir 
type controlled drug delivery system of Diltiazem base. 
Backing membrane 
Polyethylene coated aluminum foil was used as protective backing. 
Drug reservoir 
A low density flexible polymer sheet of 2 to 5 mm thick was drilled to a circular hole 
of 2 cm diameter and it was affixed on polyethylene coated aluminum foil to form a 
reservoir well. The drug formulation was filled in the reservoir.  
EVA rate controlling membrane 
EVA (VA 40%) copolymer membrane (30 μm) was used as a rate controlling 
membrane. 
Preparation of transdermal gel7
Diltiazem base was dissolved in alcohol and this solution was mixed with propylene 
glycol and distilled water. Required weight of carbopol was dispersed in aqueous 
phase and soaked overnight. The dispersion was then mixed with triethanolamine to 
neutralize carbopol. The gel formed was stirred with bar type stirrer at slow speed to 
get homogeneous gel. The pH of gel was 6.9.1.  Compositions of gel formulation are 
given in Table 6.7.1. 
Table 6.7.1: Composition of Diltiazem gel 
Amount of  ingredients  Ingredients 
F1 F2 F3 
Diltiazem base 0.5 gm 0.5 gm 0.5 gm 
Carbopol 0.1 gm 0.1 gm 0.1 gm 
Ethanol  3.0 ml 4.0 ml 5.0 ml 
Propylene glycol 2.0 ml 1.0 ml 0.5 ml 
Triethanolamine 0.35 ml 0.35 ml 0.35 ml 
Distilled Water  Up to 10 gm Up to 10 gm Up to 10 gm 
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Adhesive system 
Natural rubber solution prepared by masticating natural rubber with fixatives, 
tackifiers, preservatives in volatile solvents (hexane) was received readymade and 
was used as an adhesive. 
Peel off release liner 
Silicon sheet was used as peel off protective liner. 
 
6.7.1.2 Fabrication of reservoir device containing gel 
Membrane moderated reservoir type device were fabricate to evaluated the 
permeation kinetic of Diltiazem base where the reservoir well was filled with 1.5 gm 
of Diltiazem gel.  The reservoir was covered with EVA (VA 40%) copolymer 
membrane having thickness 30μm. The reservoir filled with donor phase gel 
contained 75mg of Diltiazem base. A 10μm thick adhesive layer was provided on 
release face. The patch was covered with silicone liner, packed in brown paper and 
stored at room temperature in desiccators until used. 
 
6.7.1.3 Physiochemical evaluation of reservoir patch containing gel 
Drug content 
The Diltiazem content of prepared reservoir patch was measured in triplicate and 
analyzed by UV-VIS spectrophotometer at 236nm. Patches (n=3) of specified area 
(3.14 cm2), were taken into 100 ml volumetric flask and dissolved in 10 ml methanol. 
Membrane was removed and washed with methanol. The solution was filtered 
through whatman filter paper (Nyulge Nune, UK). This stock solution was diluted 100 
times using methanol. The absorbance of the resulting solution was measured at about 
236nm using corresponding blank solution. The blank solution was prepared using 
reservoir patch free from drug. 
 
6.7.1.4 In vitro diffusion study of reservoir device containing Diltiazem gel 
Modified Keshary-Chien diffusion cell was used for diffusion study. Silicone liner 
was peeled off and the device was clamped on the brim of the cell. Membrane was 
kept in such a way that it was facing the diffusion medium. Diffusion medium 0.01N 
HCl was stirred with bar type magnetic stirrer and maintained at 37 ± 0.5oC. The 
effective permeation area was 3.14cm2. Periodic samples (2 ml) were withdrawn and 
replaced with the same volume of fresh receptor solution. The absorbance of the 
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withdrawn samples were measured using UV VIS spectrophotometer at 236.0nm 
using 0.01N HCl as a blank. The experiments were done in triplicate. Cumulative 
amount of drug released per square centimeter of patch were plotted against function 
of time for formulation. The release rate was determined by simple regression 
analysis of steady state data. 
 
6.7.1.5 In vitro human live skin permeation study of Reservoir device of    
            Diltiazem gel 
Diffusion study of Diltiazem from selected reservoir device across human live skin 
was performed using modified Keshary-Chien diffusion cell. A section of skin was 
cut and placed on the brim of diffusion cell in such a way that the dermal side of the 
skin faced donor compartment. The patch of Diltiazem was affixed on the skin in such 
a way that backing membrane was facing upward. Diffusion study was carried as 
mentioned in section 6.6.1. 
The experiments were done in triplicate. Amount of drug released per square 
centimeter of patch were plotted against function of time. The release rate was 
determined by simple regression analysis of steady state data. 
6.7.2 Result and discussion 
A membrane moderated reservoir type transdermal controlled drug delivery system 
for Diltiazem base was successfully prepared using carbopol gel and patch was 
evaluated for drug content. 
 
Drug content 
Drug content of the reservoir patch was carried out to ascertain that the drug is 
uniformly distributed in the formulation. The prepared film formulations (3.14cm2) 
were dissolved in 10 ml toluene in a 100 ml volumetric flask and the volume was 
adjusted up to 100 ml using toluene. The amount of drug present was determined by 
measuring the absorbance spectrophotometrically at 281.5 nm using toluene as a 
blank. The results obtained are represented in Table 6.7.2. 
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Table 6.7.2: Results of % Drug content of F1 to F3 reservoir patch contains  
                     Diltiazem gel 
Drug content (mg) Sr. No. Formulation 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 99.02 97.80 98.90 98.57 ± 0.672 
2 F2 98.57 96.52 98.53 97.87 ± 1.172 
3 F3 101.20 100.05 101.23 100.82 ± 0.672 
     *Standard deviation, n=3 
 
The patches were found to contain 97.87% - 100.82% of the labeled amount of 
Diltiazem indicating uniformity of drug content. The average percentage deviation of 
all formulations was found to be with in the limit, and hence all the formulation 
passed the test for content uniformity as per official requirements. The drug content 
analyses of prepared formulation showed that the process employed to prepare 
patches was capable of giving uniform drug content, with minimum batch variability. 
 
In vitro drug diffusion study of reservoir device containing gel 
Diffusion study for membrane moderated reservoir type transdermal controlled drug 
delivery system was performed in a modified Keshary-Chien diffusion cell using 
0.01N HCl, as a diffusion medium at 37 ± 0.5 0C. The results of in vitro drug 
diffusion studies from transdermal patches are depicted in Figure 6.7.1. 
Figure 6.7.1: In vitro diffusion profiles of Diltiazem from reservoir containing     
                       Diltiazem gel 
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Shital D. Faldu  Ph.D. Thesis   223
Chapter 6                                                      Membrane moderated TDDS of Diltiazem   
 
Table 6.7.3: Parameters of in vitro permeation kinetic of Diltiazem from  
                     Reservior device containing Diltiazem gel 
Parameters F1 F2 F3 
Flux 779.36 883.46 1003.6 
Correlation 
coefficient 
0.9984 0.9955 0.9993 
         
A device containing reservoir filled with a gel containing Diltiazem was covered with 
EVA membrane of 30μm thickness. In vitro diffusion study of Diltiazem released into 
infinite sink was carried out using the modified Keshary-Chien diffusion cell. Release 
of drug from the devices was diffusion under membrane controlled. The rank order of 
release of flux was F1< F2 < F3. 
 
The release flux was calculated from the regression analysis of steady state data.  
Formulation F1 exhibited minimum release rate (779.36 μg/cm2  h) while Formulation 
F3 exhibited maximum release rate (1003.6 μg/cm2 h). Based on in vitro release 
experiments, formulation F3 was chosen for further in vitro permeability study 
through human live skin. 
 
In vitro human live skin permeation study of selected Reservoir device of 
Diltiazem containing Diltiazem gel 
Device F3 exhibited maximum in vitro release flux and it was selected for fabrication 
of final device. Diffusion study of Diltiazem from selected reservoir device across 
human live skin was performed using modified Keshary-Chien diffusion cell. The 
experiments were done in triplicate. Amount of drug released per square centimeter of 
patch were plotted against function of time. The release rate was determined by 
simple regression analysis of steady state data. The results of in vitro skin permeation 
of Dltiazem from reservoir device are shown in figure 6.7.2. 
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  Figure 6.7.2: In vitro skin permeation profile of Diltiazem from reservoir device          
                         containing gel through  human live skin 
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              *Standard deviation, n=3 
 
Various parameters of diffusion kinetics of Diltiazem released from device across 
human live skin are presented in Table 6.7.4.   
Table 6.7.4: Parameters of diffusion kinetics of Diltiazem from reservoir device  
                     containing  gel through  human live skin 
 
Sr. No. Parameters Value 
222.209 μg/ cm  hr 1 Skin flux (Jss) 
1.3237  hr 2 Time lag (tL) 
140 μm 3 Skin thickness (µm) 
4 Diffusion coefficient 2.4496 x 10-5 cm2/sec 
12.5877 mg/cm35 Solubility of drug in skin  (Cs) 
 
The time lag (tL) for devices is presented in Table 6.7.4. The average diffusion 
coefficient, D of Diltiazem was determined using D = h2/6 tL relationship, where skin 
thickness h was 140 x 10-4 cm. The amount of Diltiazem retained by skin area used 
for permeation was calculated by dividing steady state flux with gradient of 
diffusivity and it was found to be 12.5877 mg/cm3 of skin. 
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Comparison of permeation kinetics: Patch without priming Dose: Patch with 
priming Dose 
The release rate (µg/hr) has linear relationship with area of release face of a 
transdermal rug delivery system. The final patch needs to be provided with adhesive 
system and priming dose. The quantity of Diltiazem to be loaded in adhesive as 
priming dose was derived from separate diffusion experiment, on trial and error basis 
where EVA (VA 40%) copolymer rate controlling membrane was layered with 0.075 
ml adhesive solution contains 1.52 mg/ml Diltiazem over 1cm2  area (gives a smear of 
approximate 10μm thick) and was affixed over an human skin skin and subjected to in 
vitro diffusion study. The steady state release rate of Diltiazem was 20.80 μg/cm2 hr 
with diffusion coefficient of 1.68 x 10-5 cm2/hr, for an skin thickness of 140 μm. 
Amount of Diltiazem sorbed per cm3 of skin was approximated by dividing steady 
state flux with gradient of diffusivity, which was found to be 12.380 mg/cm3 of skin. 
To assess release kinetic of a complete patch, a patch of 3.14 cm2 area was provided 
with adhesive system. From the data of solubility of drug in skin, 0.23 % w/v 
Diltiazem in rubber solution was used as an adhesive system. This solution was 
uniformly layered in 4 mm rim surrounding 3.14 cm2 area of patch, to obtain 10 µm 
thick adhesive systems containing priming dose of 173 µg/cm2 area of delivery 
device. The device was firmly secured on skin of human live skin and was subjected 
to diffusion experiment using 0.01 N HCl as diffusion medium. The release profile is 
shown in Figure 6.7.3. 
 
Figure 6.7.3: In vitro skin permeation profile of Diltiazem from Reservior patch    
                      containing gel through human live skin with priming dose and  
                      without priming dose 
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Table 6.7.5: Parameters of in vitro permeation kinetics of Diltiazem from 
reservoir device containing gel through human live skin with priming dose and 
without priming dose 
  Parameters Cumulative amount of 
drug release 
(μg/cm
Cumulative amount of 
drug release 
2/hr) (μg/cm2/hr) 
Without priming dose With priming dose 
Release rate 
22.209 23.78 
 (μg/cm2 hr) 
Correlation 
coefficient 
0.9979 0.9965 
Time lag (t ) 1.3237 hr 0.735 hr L
 
Computation of area of patch required for target steady state plasma 
concentration (Css) of Diltiazem 
As per mentioned in section 5.4.3 desired release rate for target steady state plasma 
concentration of Diltiazem is 554.4 μg/ hr 
Area of patch = (554.4 μg/hr)/ Jss(skin)
                      = 554.4/23.78 cm2 
                                = 23.31 cm2 
Formulation of final reservoir type transdermal drug delivery system containing 
Diltiazem gel meeting targeted steady state plasma concentration  
The effective area for steady state release of Diltiazem was 23.31cm2. Adhesive 
system is to cover the release phase. The adhesive solution is to be prepared using 
natural rubber masticated with fixative, tackifiers and preservatives dissolved in n-
hexane.  
For preparation of final reservoir type transdermal drug delivery device of Diltiazem 
containing release phase covering adhesive, 0.231 %w/v solution of Diltiazem in 
rubber solution is to be used. This solution is to be layered over 23.31 cm2 area of 
delivery device giving a 10µm thick layer, providing a priming dose of 173 µg/cm2 
area of delivery device.  
The release face of the device is to be provided with a protective silicone liner. The 
device is to be packed in a brown paper covering and stored at 20 to 25 0C 
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6.8 STABILITY STUDY 
 
6.8.1 Stability study of reservoir device containing Diltiazem  
Membrane moderated reservoir device containing Diltiazem in form of solution and 
gel was subjected to accelerated thermal stability study. The accelerated stability 
studies were carried out according to ICH guideline by storing the samples at 25 0C / 
60% RH, 30 0 0C/ 65% RH and 40 C/ 75% RH for 90 days in a stability chamber 
(Thermo Lab., Mumbai, India). These samples were analyzed by UV 
Spectrophotometer method and checked for changes in physical appearance and drug 
content at an interval of 15 days. 
 
6.8.2 Results and Discussion 
Reservoir device containing alcoholic solution of Diltiazem and Diltiazem in carbopol 
gel was selected for stability study and observed for change in color, appearance, 
flexibility and drug content. Temperature and humidity values selected were as per 
the ICH guidelines and the test was carried out in a stability chamber. The stability 
studied was carried out at 25 0 0C / 60% RH, 30 C/ 65% RH and 40 0C/ 75% RH for 90 
days.  
In case of reservoir device contains ethanolic solution of Diltiazem, it was observed 
that formulation stored at 400C  there is drastic change in physical characteristic of 
product. Crystals of drug was observed in the reservoir stored at higher temperature. 
The release rate for product stored at 30 0C was also changed. The content of reservoir 
exhibited change in color from colourless to slight yellowish brown. However the 
product stored at 25 0C exhibited a little change in the flux, but the flux was in order. 
There was no change in color and appearance for the product stored at room 
temperature. The first order rate constant of degradation for room temperature was 
1.981 x 10-3. The self life calculated was 53 week. The results of stability study 
indicated that the products should be stored at a temperature not exceeding 25 0C. 
Diffusion study of reservoir patch containing carbopol gel was carried out and it was 
observed that formulation stored at 400C, exhibited burst effect phenomena. The 
release pattern and drug flux was altered. Due to decrease in viscosity of gel at an 
elevated temperature the content of reservoir turned quite soft. The drug flux for the 
product stored at room temperature was in order. There was no change in appearance, 
color for the product stored at room temperature. The first order rate constant of 
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-3degradation for room temperature was 1.721 x 10 . The self life calculated was 61 
week. Results of stability study indicates that product should be stored at temperature 
not exceeding 25 0C.  
 
6.9 SKIN IRRITATION AND SKIN SENSITIZATION STUDY 
6.9.1 Experimental 
Skin irritation and skin sensitization though are different types of physiological 
responses yet they have several common indications. Skin sensitization is systematic 
response and skin irritation is primarily is local response. 
A protocol was devised for evaluation of skin irritation and/or sensitization in such a 
manner that the signs at the sight of application would be assessed in common for the 
both and further, to distinguish sensitization from irritation. The skin irritation and 
skin sensitization study was carried out as per procedure mentioned in chapter 5.8.1. 
The final Diltiazem reservoir patch containing solution (1.0 cm2) and reservoir patch 
containing Diltiazem gel (1.5 cm2) was supported with aluminum foil. This was 
applied to the skin surface (shaved) and made adhered with the help of “3 M 
Micropore”- medical adhesive tap (3M, corporation, U.K.) 
 
6.9.2 Results and discussion 
The sensitization included induction period following a short sensitization period 
giving allergic reaction at the application site.  Once this sensitivity was established, 
the subsequent exposure to the chemical would lead to higher responses both locally 
(at the site of application) and systematically due to secondary immune reaction 
(hypersensitivity). 
 
Study of reservoir patch containing Diltiazem solution 
The results of skin irritation and skin sensitization study for Diltiazem reservoir patch 
containing alcohol are presented in Table 6.9.1. Following inferences has been drawn 
from irritation and sensitization studies of Diltiazem reservoir transdermal drug 
delivery system. 
 
From Table 6.9.2, it is clear that the Diltiazem is non irritating since the maximum 
score for each sign for given concentration of drug was not more than 1, though the 
number of animals giving score 1 for the various sign was increased. However, score 
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1 is not considered under irritating category therefore Diltiazem reservoir patch was 
considered as safe. Though it does not show average score more than 1 at day 20 but 
this indication solely cannot be taken as a sign of non-irritating. The reason for this 
was that individual animal show score more than 1, but the average was less than 1 
(which means that some animals showed score 0, out of four animals). 
 
Diltiazem is non- sensitizing in nature. The reason for this was reduction in various 
scores even after repeated application. Results shows that total irritating scores were 
reduced from day 20 to day 28. Therefore, the primary and secondary sensitization 
was absent.  
 
Table 6.9.2: The average score for each sign after day 20 and day 28 during  
irritation and  sensitization study of reservoir patch containing Diltaizem 
solution 
Average score at 
day 20 
Average score at 
day 28 
Sr. No. Sign 
1 Erythema 0.5 0.25 
2 Scaling 0.0 0.0 
3 Fissures 0.25 0.0 
4 Oedema formation 0.5 0.0 
5 Ecchymosis 0.0 0.0 
6 Necrosis 0.25 0.0 
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Table 6.9.1: Skin irritation and sensitization study of reservoir patch containing Diltiazem solution 
 
 
 
 
 
SR.  
Name And 
Concentration 
SENSITIZATION / IRRITATION TESTING 
PRE-EXPOSURE 
PERIOD 
INDUCTION PHASE REST CHALLENGE PHASE 
  
Φ = 30M Φ = 30M Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 After 12 Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 
D1 D2 D3 D4 D5 D6 D7 Days D19 D20 D21 D22 D28 
1 Erythema 
1 0 1 0 1 0 1 0 1 1 1 1 1 1 0 0 0 0 1 1 1 1 1 1 0 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg .25 Avg .25 Avg .25 Avg .25 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 
2 Scaling 
0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 
3 Fissures 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 
Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg 0 
4 
Oedama 
formation 
0 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 0 0 1 1 1 0 1 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg .25 Avg 0 Avg 0 Avg 0.5 Avg .25 Avg .25 Avg 0 
5 Ecchymosis 
1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg .25 Avg .25 Avg 0 Avg .25 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 
6 Necrosis 
0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 1 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg 0 
Total of all score 2 2 1 4 5 5 4 0 0 6 5 5 1 
Total average per 
animal 
0.5 0.5 0.25 1 1.25 1.25 1 0 0 1.5 1.25 1.25 0.25 
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day for reservoir patch containing Diltiazem solution   
Sr. No. Sign Score N 
1 1 1 Erythema 
0 4 2 Scaling 
0 4 3 Fissures 
0 4 4 Oedema formation 
0 4 5 Ecchymosis 
0 4 6 Necrosis 
 
Study of reservior patch containing Diltiazem gel 
The results of skin irritation and skin sensitization study for reservoir patch containing 
Diltiazem gel are presented in Table 6.9.4. Following inferences has been drawn from 
irritation and sensitization studies of reservoir containing Diltiazem gel. 
 
Table 6.9.5: The average score for each sign after day 20 and day 28 during  
 irritation and sensitization study of reservoir patch containing Diltiazem gel 
Average score at 
day 20 
Average score at 
day 28 
Sr. No. Sign 
1 Erythema 0.75 0.25 
2 Scaling 0.25 0.25 
3 Fissures 0.0 0.0 
4 Oedema formation 0.5 0.5 
5 Ecchymosis 0.25 0.0 
6 Necrosis 0.25 0.25 
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Table 6.9.4: Skin irritation and sensitization study of reservoir patch containing Diltiazem gel 
 
 
  
 
 
SR.  
Name And 
Concentration 
SENSITIZATION / IRRITATION TESTING 
PRE-EXPOSURE 
PERIOD 
INDUCTION PHASE REST CHALLENGE PHASE 
  
Φ = 30M Φ = 30M Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 After 12 Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 
D1 D2 D3 D4 D5 D6 D7 Days D19 D20 D21 D22 D28 
1 
Erythema 
1 0 1 0 1 0 1 1 1 1 1 1 1 0 1 0 1 0 1 1 1 1 1 1 1 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 
Avg .25 Avg .25 Avg .25 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg .25 Avg .75 Avg .75 Avg 0.5 Avg .25 
2 
Scaling 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg 0.25 
3 
Fissures 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 
4 Oedama 
formation 
1 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg .25 Avg .25 Avg .25 Avg .25 Avg .25 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 
5 
Ecchymosis 
1 0 1 0 1 0 1 0 1 0 1 0 1 0 0 0 0 0 1 0 1 0 1 0 0 0 
1 0 1 0 1 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg 0 
6 
Necrosis 
0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 1 0 0 1 1 1 1 0 1 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg 0 Avg 0 Avg .25 Avg .25 Avg 0.5 Avg .25 Avg .25 
Total of all score 4 4 4 6 6 5 3 1 2 8 9 7 5 
Total average per 
animal 
1 1 1 1.5 1.5 1.25 0.75 0.25 0.5 2 2.25 1.75 1.25 
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score for each sign for given concentration of drug was not more than 1, though the 
number of animals giving score 1 for the various sign was increased. However, score 
1 is not considered under irritating category therefore Diltiazem patch is considered as 
safe. Results shows that total irritating scores were reduced from day 20 to day 28. 
Therefore, the primary and secondary sensitization was absent. 
Table 6.9.6: Maximum sensitization and irritation score of various signs at last 
day for reservoir patch containing Diltiazem gel   
Sr. No. Sign Score N 
1 1 1 Erythema 
1 1 2 Scaling 
0 4 3 Fissures 
1 2 4 Oedema formation 
0 4 5 Ecchymosis 
1 1 6 Necrosis 
 
6.10 CONCLUSION 
EVA (VA 40%) Copolymer membrane moderated transdermal drug delivery system 
of Diltiazem was successfully prepared. Among different polymers used to prepared 
rate controlling membrane, EVA (VA 40%) copolymer, 30 μm thick membrane 
provided promising Diltiazem flux. Two different formulations of Diltiazem (I) 
alcoholic solution (II) Diltiazem gel were used to design two membrane moderated 
devices. On evaluation devices were found to be stable, non-irritant, non-sensitizing 
and safe. Devices complied to official and non-official pharmacokinetic 
specifications. The in vitro evaluation for drug release from device (I) and (II) across 
human live skin provided 43.95 and 23.78 μg/cm2hr, Diltiazem flux respectively. The 
fluxes were adequate to meet pharmacokinetic requirements of steady state plasma 
concentration of Diltiazem for 24 hrs from 12.61 cm2 reservoir device containing 
alohoolic solution of Diltiazem and 23.31 cm2 reservoir device containing gel, giving 
once a day drug delivery system of Diltiazem.  
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7 PREPARATION AND CHARACTERIZATION OF ADHESIVE    
   MATRIX DIFFUSIONAL TRANSDERMAL DRUG DELIVERY  
   DEVICE OF 
               
DILTIAZEM                          
AIM OF PRESENT INVESTIGATION  
The adhesive matrix diffusional system tends itself to simple and easy processing of 
delivery device. The  matrix (laminate, disc) being static in nature offers less 
problems of drug and formulation stability and results in robust product with near to 
no problems of handling and administration to patients.1 Laminated form of delivery 
device offers easy transfer of technique from laboratory operations to a large scale 
manufacturing. As preparation of sheets, laminates etc from polymer beads is the 
major activity of plastic industry. Screw extrusion or injection molding can facilitate 
the formation of drug laminates from the polymer beads mixed with additives and 
active agents. For the preparation of adhesive drug matrix diffusion controlled 
transdermal device laminates are prepared using drug loaded adhesive and this layer is 
covered by protective liner and fixed on backing membrane, followed by punching of 
laminates in desired size.2
This type of transdermal drug delivery system can be easily prepared on large scale as 
a continuous manufacturing process as compare to polymeric matrix diffusion 
controlled transdermal drug delivery device and membrane moderate reservoir type 
controlled transdermal drug delivery device.3   
Adhesive matrix diffusion controlled release transdermal drug deliver systems are 
monolithic systems which are the simplest and least expensive means of controlling 
the release of an active agent. Here the active agent is physically blended with the 
adhesive agent. The release rate is governed by Higuchi equation. The release in such 
system is proportional to square root of time and release is available until 
approximately 60 % of the drug is released. Thereafter release is related exponentially 
to time, exhibiting first order release.4
Parameter influencing the release characteristics of monolithic devices can be 
classified as solute dependent factors like solubility, partition co-efficient and 
diffusion coefficient of drug in the matrix. The solute independent parameters are 
system variables like geometry, tortuosity, pores, concentration, volume fraction and 
diffusion layer etc. In the present investigation solute related factors were considered 
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to fabricate the devices using adhesive.5  
With perception to above objective, it is necessary to modify current solid dosage 
forms in to controlled transdermal drug delivery system. A first step in this process is 
to illustrate how formulation and process variables could give drug release through 
skin. The aim of present investigation is to formulate and optimize the Diltiazem 
adhesive matrix diffusion controlled transdermal drug delivery system.  
 
7.1 Formulation and evaluation of adhesive drug matrix device of Diltiazem 
7.1.1 Experimental 
Preparation of adhesive matrix device of Diltiazem6
The transdermal therapeutic system comprised a backing membrane, an adhesive 
layer containing drug and a release liner. Adhesive matrix – type transdermal patches 
containing Diltiazem were prepared using different ratios of drug to adhesive (Table 
7.1.1). Diltiazem was accurately weighed and dissolved in very small quantity of 
alcohol. This solution was mixed with natural rubber adhesive (Readymade received – 
Beta surgical, Rajkot).  The uniform dispersion of drug and adhesive was spreaded on 
a drug impermeable polyethylene coated aluminum foil (5 x 3.5 cm2) with the help of 
TLC kit spreader to form a thin drug adhesive layer and dried at room temperature. 
After 24h, the films were cut into a 1.13 cm2 area and covered with glossy paper 
which is used as a protective liner. Dosage forms were kept in desiccators until further 
used. 
Table 7.1.1: Composition of prepared adhesive matrix films 
Formulation code Adhesive Diltiazem 
(mg/cm2) (mg/cm2) 
F1 10 4 
F2 10 6 
F3 10 8 
F4 10 10 
   
Physiochemical evaluation of adhesive matrix device 
 
Thickness 
The thickness of the patches was assessed at six different points using thickness gauge 
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micrometer (0.001mm, Mitutoyo, Japan).  
 
Weight variation 
The weight variation for patch was determined using Sartorius electronic balance 
(Model CP-224 S), Shimadzu, Japan. Six patch from single batch (1.13 cm2), were 
weighed individually and the average weight was calculated. 
 
Drug content 
The Diltiazem content of drug adhesive matrix was estimated in triplicate and 
analyzed by UV-VIS spectrophotometer at 236.0 nm. Patches (n=3) of specified area 
(1.13 cm2), were cut and weighed accurately. The pieces were extracted using 10ml 
0.01 N HCl in a 100 ml volumetric flask. It was shaken thoroughly and solution was 
transferred to a 100 ml volumetric flask. Similar procedure was repeated twice and 
collected fractions were mixed and filtered using whatman filter paper (Nyulge Nune, 
UK). This solution was diluted 100 times using 0.01 N HCl and UV absorbance of the 
resulting solution was measured at 236.0 nm using 0.01 N HCl as a blank. 
 
Moisture content (Loss on drying)  
The inherent moisture presents in material may influence the stability of dosage 
forms, especially if it contains a drug that is sensitive to water. The absolute method is 
employed to determine the moisture content which gives a weight loss registered 
during storage. 
Three patch from each batch (1.13 cm2), were weighed individually and the average 
weight was calculated. This weight was considered as an Initial weight. Then all the 
patches were kept in a desiccators containing activated Silica at normal room 
temperature for 24 hr.  Then, the final weight was noted when there was no further 
change in the weight of individual patch. The percentage moisture absorption was 
calculated as a difference between initial and final weight with respect to final weight. 
% Moisture content = [(Initial weight – Final weight)/ Final weight] * 100  
 
Moisture absorption  
Moisture uptake influences the stability of dosage form. Low moisture uptake protects 
the material from microbial contamination. So for transdermal drug delivery system it 
was necessary to determine % Moisture absorption by matrices. 
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Three patch from each batch (1.13 cm2), were weighed individually and the average 
weight was calculated. This weight was considered as an Initial weight. Then all the 
patches were kept in a desiccators containing 200 ml saturated solution of Sodium 
chloride (Relative humidity of 75%) at room temperature for 72h. The final weight 
was noted when there was no further change in the weight of individual patch. The 
percentage moisture absorption was calculated as a difference between final and 
initial weight with respect to initial weight. The % Moisture absorption was 
determined using below formula: 
% Moisture absorption = [(Final weight – Initial weight)/ Initial weight] * 100  
 
7.1.2 Results and discussion  
The present investigation deals with the development of Diltiazem base adhesive 
matrix using different concentration of drug and adhesive. A diffusion mediated 
matrix controlled transdermal drug delivery system for Diltiazem base was 
successfully prepared using adhesive and it was evaluated using different 
physiochemical parameters. 
 
Thickness 
The results of thickness measurements are given in Table 7.1.2. The results indicate 
that there was no much difference in the thickness within the formulations. Thickness 
difference among formulations ranged from 110 ± 0.00 μm to 83.33 ± 1.443 μm. The 
results also indicated uniform distribution of the adhesive. The results indicated that 
as the concentration of Diltiazem increased thickness also increased. 
 
Table 7.1.2: Results of thickness uniformity of F1 to F4 adhesive matrix  
                     formulations  
Average thickness (μm) Sr. No. Formulation  
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 85.0 82.5 82.5 83.333 ± 1.443 
2 F2 85.0 82.5 85.0 84.166 ± 1.443 
3 F3 90.0 95.0 92.5 92.500 ± 2.500 
4 F4 110.0 110.0 110.0 110.00 ±  0.000 
  *Standard deviation, n=3 
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Weight variation 
Drug loaded films (1.13 cm2) were weighed using Sartorius electronic balance (Model 
CP-224 S), Shimadzu, Japan and the results of weight variation are given in Table 
7.1.3.  
 
Table 7.1.3: Weight variations of F1 to F4 adhesive matrix formulations 
Average weight (mg) Sr. No. Formulation  
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 12.34 12.56 12.43 12.44 ± 0.1106 
2 F2 14.08 14.20 14.34 14.20 ± 0.1301 
3 F3 15.84 15.50 15.00 15.44 ± 0.4225 
4 F4 17.30 17.69 17.60 17.53 ± 0.2042 
     *Standard deviation, n=3 
The average percentage deviation of all formulations was found to be within the limit, 
and hence all the formulation passed the test for weight variation as per official 
requirements. All formulations showed acceptable pharmaco-technincal properties.  
 
Drug content 
Drug content of the drug adhesive matrix patch was carried out to ascertain that the 
drug loading is proper in the formulation. The prepared adhesive matrix patches (1.13 
cm2) were extracted using 0.01 N HCl. The amount of drug present was determined 
by measuring the absorbance spectrophotometrically at 236.0 nm using 0.01 N HCl as 
a blank. The results are represented in Table 7.1.4. 
 
Table 7.1.4: Results of % Drug content of F1 to F4 adhesive matrix formulations 
Drug content (mg) Sr. No. Formulation 
 Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 101.50 101.20 101.00 101.23 ± 0.251 
2 F2 98.57 96.52 98.53 97.87 ± 1.172 
3 F3 101.20 100.05 101.23 100.82 ± 0.672 
4 F4 97.80 98.90 99.02 98.57 ± 0.672 
      *Standard deviation, n=3 
 
Shital D. Faldu  Ph.D. Thesis                                             
 
240 
 
Chapter 7                                             Adhesive matrix diffusional TDDS of Diltiazem 
 
The medicated adhesive matrices were found to contain 97.87 %-101.23 % of the 
labeled amount of Diltiazem indicating uniformity of drug content. The average 
percentage deviation of all formulations was found to be within the limit, and hence 
all the formulation passed the test for content uniformity as per official requirements. 
All the formulations showed acceptable pharmaco-technincal properties. From the 
results obtained, it was clear that there was proper distribution of Diltiazem in the 
adhesive matrix formulations. Hence it was concluded that drug was uniformly 
distributed in all the formulations. 
The drug content analyses of prepared formulation showed that the process employed 
to prepared patches was capable of giving uniform drug content, with minimum batch 
variability. 
 
Moisture content (Loss on drying) 
The moisture content was determined by keeping the patches in desiccators 
containing activated silica for 24h. The percentage moisture content was calculated 
from the weight differences relative to the final weight. The results of the moisture 
content studies for different formulations are shown in Figure 7.1.1. 
                    
 Figure 7.1.1: Percentage moisture content from Diltiazem containing different                            
                        adhesive matrix device 
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                     * Standard deviation, n=3 
 
The moisture content in all the formulations was found to be low and ranged from 
1.049 ± 0.054 to 2.225 ± 0.013%. The % Moisture content of each device was 
determined and rank order of moisture content of various transdermal drug delivery 
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system were  F1 > F2 > F3 > F4. 
The result revealed that the moisture was present in the formulation due to presence of 
adhesive material but small moisture content in the formulations helps device to 
maintain its texture, flexibility etc. 
 
Moisture absorption  
The percentage moisture absorption was calculated as a difference between final and 
initial weight with respect to initial weight. The results of the moisture absorption 
studies for different Diltiazem adhesive matrix formulations are shown in Figure 
7.1.2. 
 
 Figure 7.1.2: Percentage moisture absorption from Diltiazem containing         
                        different adhesive matrix device 
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                   * Standard deviation, n=3  
 
The moisture absorption in all the formulations was found to be low and ranged from 
0.9203 ± 0.0570 to 2.7361 ± 0.0453%. The result revealed that the moisture 
absorption was found to decrease with increasing concentration of hydrophobic 
Diltiazem base. The % Moisture absorption of each film was determined and rank 
order of moisture absorption of formulations was F1 > F2 > F3 > F4. 
 
7.2 In vitro drug diffusion study of adhesive matrix diffusional transdermal drug  
      delivery device of Diltiazem 
7.2.1 Experimental 
In vitro diffusion study of Diltiazem from adhesive matrix transdermal patch was 
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carried out using modified Keshary-Chien diffusion cell. The transdermal therapeutic 
system with 3.14 cm2 of surface area was placed on the brim of diffusion cell facing 
receptor compartment. The receptor compartment contained 40 ml of 0.01N HCl as a 
diffusion medium. The diffusion medium was stirred with bar type magnetic stirrer. 
The temperature was maintained at 37 ± 0.5oC. Samples (2 ml) were withdrawn and 
replaced with the same volume of fresh receptor solution, through the sampling port 
of the diffusion cell at different time intervals till 6 hrs. The absorbance of the 
withdrawn samples were measured UV VIS spectrophotometrically at 236.0 nm using 
0.01N HCl as a blank. The experiments were done in triplicate. Amount of drug 
released per square centimeter of patch were plotted against function of square root of 
time for different formulations. The release rate Q/√T was determined by simple 
regression analysis of steady state data. 
 
7.2.2 Result and discussion 
Diffusion study is important for ensuring the sustained release performance and the 
reproducibility of rate and duration of drug release. The results of in vitro diffusion 
studies are depicted in Table 7.2.1 and Figure 7.2.1. 
 
Table7.2.1: Parameters of in vitro permeation kinetic of Diltiazem from      
                    adhesive matrix patch 
Formulation code 
Parameters 
F1 F2 F3 F4 
Q/√T 
(μg/cm
897.13 1012.50 1308.3 1556.70 2√hr)
Correlation 
coefficient 
0.9975 0.9980 0.9928 0.9981 
  
Release of Diltiazem from the drug loaded adhesive matrix followed square root law. 
The release rate Q/√T was computed by regression analysis of steady state data and it 
was the slope of the linear relationship obtained between cumulative amounts of 
Diltiazem released versus square root of time. 
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Figure 7.2.1: In vitro diffusion profiles of Diltiazem from drug adhesive matrix   
                      patch 
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               * Standard deviation, n=3 
Release rate Q/√T increased with increasing concentration of Diltiazem base in 
adhesive matrix. In our experiments, variable release profiles of Diltiazem from the 
different experimental patches composed of different proportion of drug and adhesive 
were observed. The rank order of release rate observed was F1 < F2 < F3 < F4.  
The formulations F4 exhibited the maximum Q/√T (1556.70 μg/cm2h1/2) release rate, 
which was significantly different, compared to the lowest value in the formulation F1 
(897.13μg/cm2h1/2). Based on in vitro release experiments, formulation F4 was 
chosen for further in vitro permeability study through human live skin. 
 
In vitro release kinetic 
In vitro diffusion study of Diltiazem released into infinite sink was carried out using 
the modified Keshary-Chien diffusion cell. The release data were fitted into various 
mathematical models using software to know which mathematical model will best fit 
to obtained release profiles. The obtained R values for various models are given in 
Table 7.2.2. Here R is regression coefficient. 
Table 7.2.2.: Data of various parameters of model fitting in formulations 
Formulation Zero order 
equation 
First order 
equation 
Higuchi’s 
equation 
F1 0.9888 0.9505 0.9993 
F2 0.9736 0.9218 0.9970 
F3 0.9529 0.8948 0.9896 
F4 0.9903 0.9570 0.9975 
 
Shital D. Faldu  Ph.D. Thesis                                             
 
244 
 
Chapter 7                                             Adhesive matrix diffusional TDDS of Diltiazem 
 
In our experiment, the in vitro permeation profile of adhesive matrix patch could be 
best expressed by Higuchi’s equation for the permeation of drug from an adhesive 
matrix device. 
 
7.3 In vitro human live skin permeation study of drug adhesive matrix device of     
      Diltiazem 
 
7.3.1 Experimental 
The permeation study was performed in a modified Keshary-Chien diffusion cell. The 
experiment was performed as mention in section 5.6.2. The experiments were done in 
triplicate. Amount of drug released per square centimeter of patch were plotted 
against function of time for adhesive matrix formulation. The release rate was 
determined by simple regression analysis of steady state data. 
 
7.3.2 Results and discussion 
The result of in vitro skin permeation of Diltiazem from adhesive matrix formulation 
is shown in figure 7.3.1 and Table 7.3.1.  
 
 Figure 7.3.1: In vitro skin permeation profile of Diltiazem from drug adhesive    
                        matrix patch through human live skin 
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Parameters of diffusion kinetics of Diltiazem released, from device across human live 
skin are presented in Table 7.3.1.  
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Table 7.3.1: Parameters of diffusion kinetic of Diltiazem from drug adhesive 
                        matrix patch through human live skin 
Sr. No. Parameters Value 
2 1 Skin flux (Jss) 19.64 μg/ cm hr 
2 Time lag (t ) 1.47 hr L
3 Human live skin thickness 
(µm) 
140 μm 
4 Diffusion coefficient 2.222 x 10-5 cm2/sec 
35 Solubility of drug in skin  
(Cs) 
12.37 mg/cm
 
Adhesive matrix device containing Diltiazem provided 19.64 μg/ cm2 hr skin flux. 
The time lag (tL) for devices is presented in Table 7.3.2. The diffusion coefficient, D 
of Diltiazem was determined using D = h2/6 tL relationship, where skin thickness h 
was 140 x 10-4 cm. The amount of Diltiazem retained by skin area used for 
permeation was calculated by dividing flux with gradient of diffusivity and it was 
found to be 12.37 mg/cm3 of skin. 
Computation of area of patch required for target steady state plasma 
concentration (Css) 
As mentioned in section 5.4.3, desired input rate through skin for target steady state 
plasma concentration of Diltiazem is 554.4 μg/ hr 
Area of patch = (554.4 μg/hr)/ Jss(skin)
                      = 554.4/19.64cm2 
                                = 28.22 cm2 
 
Formulation of final patch 
Final formulation was selected as 24 hour once a day device having area is 28.22 cm2. 
For the preparation of final adhesive matrix diffusion drug delivery device, 0.58 ml of 
natural adhesive solution was layered over 4 mm rim of delivery device giving 10 µm 
thick layers. This layer assists the perfect adhesion of device on the skin. 
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7.4 STABILITY STUDY 
 
7.4.1. Stability study of adhesive matrix diffusional transdermal drug delivery   
          device 
The objective of accelerated stability studies is to predict the shelf life of a product by 
accelerating the rate of decomposition, preferably by increasing the temperature. The 
optimized formulation of Diltiazem adhesive matrix patch was selected for the 
stability study.  
The accelerated stability study were carried out according to ICH guideline by storing 
the samples at 25 0C / 60 % RH, 30 0 0C/ 65 % RH and 40 C/ 75 % RH for 90 days in a 
stability chamber (Thermo Lab., Mumbai, India). These samples were analyzed by 
UV Spectrophotometer method and checked for changes in physical appearance and 
drug content at an interval of 15 days. 
7.4.2 Results and Discussion  
Final formulation selected was subjected to stability study and observed for change in 
color, appearance, flexibility and drug content. Temperature and humidity values 
selected were as per the ICH guidelines and the test was carried out in a stability 
chamber. The stability study was carried out at 25 0C / 60 % RH, 30 0C/ 65 % RH and 
40 0C/ 75 % RH for 90 days. Diffusion study was carried out and it was observed that 
formulation stored at 40 0C exhibited higher Q/√T release rate as compared to those 
stored at 25 0 0C and 30 C. The initial release of drug was higher at an elevated 
temperature due to decreased viscosity of adhesive matrix. Release rate at 30 0C was 
altered but it was in order. The product stored at 25 0C exhibited no change in release 
rate. The degradation was higher at an elevated temperature. The first order rate 
constant of degradation for room temperature was 1.329 x 10-3 -1 week . The self life 
calculated was 79 week.  
 
Results of stability study indicated a good stability for adhesive matrix loaded drug 
delivery device. The results of stability study indicated that the products should be 
stored at a temperature not exceeding 40 0C and also should not be refrigerated as at 
lower temperature it lost overall flexibility and turned rigid loosing elegancy. The 
product should be stored at room temperature. 
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7.5 SKIN IRRITATION AND SKIN SENSITIZATION STUDY 
7.5.1 Experimental 
Skin irritation and skin sensitization though are different types of physiological 
responses yet they have several common indications. Skin sensitization is systematic 
response and skin irritation is primarily is local response. A protocol was devised for 
evaluation of skin irritation and/or sensitization in such a manner that the signs at the 
sight of application would be assessed in common for the both and further, to 
distinguish sensitization from irritation. The skin irritation and skin sensitization study 
was carried out as per procedure mentioned in chapter 5.8.1. 
The final Diltiazem adhesive matrix patch (2.0 cm2) was supported with aluminum 
foil. This was applied to the skin surface (shaved) and made adhered with the help of 
“3 M Micropore”- medicated adhesive tap (3M Corporation, U.K.). 
7.5.2 Results and discussion  
The results of skin irritation and skin sensitization study for Diltiazem adhesive 
matrix patch is presented in Table 7.5.1. From this table total average score at day 20 
and total average score at day 28 were obtained respectively.  
 
From Table 7.5.2, it was clear that the Diltiazem adhesive matrix patch was non- 
irritating, since the maximum score for each sign did not exceed than 1.  Further 
Table 7.5.3 shows that average score at day 20 and day 28 was not exceeding more 
than 1 for any sign. Average score not exceeding more than 1 at any day for any sign 
was clearly indicative for non-irritation nature of the agent. 
 
Diltiazem is non-sensitizing in nature. The reason for this was reduction in scores 
even after repeated applications. All the tables show that maximum individual scores, 
average scores, total irritation scores were reduced at day 28th in comparison to all 
these scores at day 20th. Reduction in scores even after repeated application of test 
patch indicated absence of primary and secondary sensitization reaction. 
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Table 7.5.1: Skin irritation and sensitization study of Diltiazem adhesive matrix patch 
  
 
 
 
 
SR.  
Name And 
Concentration 
SENSITIZATION / IRRITATION TESTING 
PRE-EXPOSURE 
PERIOD 
INDUCTION PHASE REST CHALLENGE PHASE 
  
Φ = 30M Φ = 30M Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 After 12 Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 
D1 D2 D3 D4 D5 D6 D7 Days D19 D20 D21 D22 D28 
1 Erythema 
0 0 0 0 0 0 1 1 1 1 0 1 0 1 0 0 0 0 1 1 1 1 1 1 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg 0 Avg 0 Avg .75 Avg 0.5 Avg 0.5 Avg 0 
2 Scaling 
0 0 0 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg .25 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg .25 
3 Fissures 
0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 1 0 0 1 1 1 1 1 1 1 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg 0 Avg .75 Avg .75 Avg .75 Avg 0.5 
4 
Oedama 
formation 
1 0 0 1 0 1 1 1 1 0 0 1 0 1 0 1 0 0 1 2 0 2 0 2 0 1 
0 0 0 0 0 1 1 1 1 1 0 1 0 1 0 0 0 0 1 1 1 1 0 1 0 1 
Avg .25 Avg .25 Avg 0.5 Avg 1 Avg .75 Avg 0.5 Avg 0.5 Avg .25 Avg 0 Avg 1.25 Avg 1.25 Avg .75 Avg 0.5 
5 Ecchymosis 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 2 2 2 2 2 2 1 1 
0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 2 2 1 1 1 1 1 1 
Avg 0.5 Avg 0.5 Avg 0.5 Avg 1 Avg 1 Avg 1 Avg 0.5 Avg 0 Avg 0 Avg 2 Avg 1.5 Avg 1.5 Avg 1 
6 Necrosis 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1 2 1 1 0 0 
0 0 0 0 1 0 1 1 1 1 1 1 0 1 0 1 0 1 1 1 1 1 0 1 0 0 
Avg 0 Avg 0 Avg .25 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg .25 Avg 1.25 Avg 1.25 Avg .75 Avg 0 
Total of all score 3 4 7 16 15 13 10 3 1 24 20 17 9 
Total average per 
animal 
0.75 1 1.75 4 3.75 3.25 2.5 0.75 0.25 6 5 4.25 2.25 
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Table 7.5.2: The average score for each sign after day 20 and day 28 during     
skin  irritation and  sensitization study of Diltiazem adhesive matrix patch 
Average score at 
day 20 
Average score at 
day 28 
Sr. No. Sign 
1 Erythema 0.75 0.0 
2 Scaling 0.0 0.25 
3 Fissures 0.75 0.5 
4 Oedema formation 1.25 0.5 
5 Ecchymosis 2.0 1.0 
6 Necrosis 1.25 0.0 
 
Table 7.5.3: Maximum sensitization and irritation score of various signs at last 
day for Diltiazem adhesive matrix patch 
Sr. No. Sign Score N 
1 Erythema 0 4 
2 Scaling 1 1 
3 Fissures 1 2 
4 Oedema formation 1 2 
5 Ecchymosis 1 4 
6 Necrosis 0 4 
 
7.6 CONCLUSION 
An adhesive matrix diffusional transdermal controlled drug delivery device of 
Diltiazem was successfully prepared. The processing was non complicated, very 
simple and economic still meeting requirements of systemic administration of drug. 
Diltiazem loaded natural rubber based adhesive matrix were prepared and devices 
were fabricated containing varied drug loading. Device containing 10 mg/cm2  of  
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Diltiazem was found to meet the biopharmaceutical and pharmacokinetic requirement 
for the therapeutic use of device. On evaluation the device was found to be stable, 
non-irritant, non-sensitizing and safe. It complied with official and non- official 
pharmacotechnical specifications. In vitro evaluation for Diltiazem release from 
device across human live skin provided zero order release rate 19.64 μg/ cm2 hr. The 
flux was adequate to meet pharmacokinetic requirement of steady state plasma 
concentration for 24 hours, giving once a day drug delivery system of Diltiazem.   
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8 PREPARATIONS AND CHARACTERIZATION OF         
   POLYMERIC MATRIX DIFFUSIONAL TRANSDERMAL   
   DRUG DELIVERY DEVICE OF ATENOLOL 
 
AIM OF PRESENT INVESTIGATION 
The age-old theory that imparted the status of “dead, impermeable barrier devoid of 
biological activity” to skin had already been challenged by the development of 
pioneering transdermal products1, but a less than impressive commercial growth in 
this sector had raised some doubts about the feasibility of this route as an efficient 
device of drug delivery. The journey of transdermal research had commenced with a 
lots of enthusiasm, as it heralded the promise of noninvasive cutaneous application. 
The projected advantages were publicized so much that the target consumers were 
prepared to accept the product even if they were costlier alternatives to the 
conventional therapy. This acceptability factor had encouraged researchers and 
industries alike to take up challenging project in this particular area. For the last two 
decades, it remained an area of vital research interest, and data was generated for 
almost every available drugs.2
Transdermal dosage forms, though a costly alternative to the conventional 
formulations, are becoming popular because of some unique advantages. Controlled 
zero order absorption, simple administration mode and the option of easy removal in 
case of adverse manifestations make them particularly desirable in cardiovascular 
therapy. Nitroglycerine and Isosorbide dinitrate, the two antiischaemic drugs; and the 
Clonidine, an antihypertensive molecule, are being extensively used in the 
transdermal form. Studies that compared with the established dosage forms had 
shown that though patches were costlier than conventional prescription products they 
reduced the occurrence of hospitalization and diagnostic cost.  Currently numbers of 
antihypertensive drugs are under investigation for transdermal administration.  
Antihypertensive is group of cardiovascular agents that had generated excitement 
amongst the transdermal scientists, specifically the β-adrenergic receptor antagonist. 
These drugs have a multiple utilities and are administered in hypertension, ischaemic 
heart disease including certain types of arrhythmias. Since antihypertensive suffer 
from the disadvantages of extensive first pass metabolism and variable bioavailability, 
they were considered ideal transdermal candidate.3
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Atenolol, a β-adrenergic receptor antagonist, has been shown to be safe and effective 
in the treatment of patients with hypertension. It has a mean plasma half-life of 6 hrs 
and only 45% of the orally administered drug reaches the circulation due to hepatic 
metabolism. A model reported predicts that mean plasma Atenolol concentration of 
43, 99 and 175 ng/ml are required to produce a 20%, 30%, and 40% reduction in 
blood pressure respectively. 4 This concentration can be achieved by preparing matrix 
diffusion controlled transdermal drug delivery system. Atenolol, a hydrophilic drug, 
with a relatively high effective concentration was less investigated compare to other 
β- blockers. Limited data available on the permeation studies shows that permeation 
increases in presence of chemical enhancers.5
Matrix diffusion controlled release transdermal drug deliver systems are monolithic 
systems which are the simplest and least expensive means of controlling the release of 
an active agent. Here the active agent is physically blended with the polymer agent. 
The release rate is governed by Higuchi equation. Parameter influencing the release 
characteristics of monolithic devices can be classified as solute dependent factors like 
solubility, partition co-efficient and diffusion coefficient of drug in the polymer 
matrix. The solute independent parameters are systems variables like geometry, 
tortuosity, pores, concentration, volume fraction and diffusion layer etc. in the present 
investigation solute related factors were considered to fabricate the devices using 
different polymer matrix. Polymer matrices employed were of non polar and 
hydrophobic nature. 
With perception to above objective, it is necessary to modify current solid dosage 
forms in to controlled transdermal drug delivery system. A first step in this process is 
to illustrate how formulation and process variables could give drug release through 
skin. The aim of present investigation is to formulate and optimize the Atenolol 
matrix diffusion controlled transdermal drug delivery system. In the present 
investigation, the influence of various grades and concentration of polymers were 
studied. Study was carried out to formulate an elegant product exhibiting desired 
therapeutic performance, from a small and cute dosage form. 
In order to achieve this goal, following criteria were set 
? The dosage form should remain intact for a period of 24hr. 
? Drug is delivered in a controlled manner. 
? The size of dosage form should be small with a view to enhance convenience of 
patient as well as compliance to therapy. 
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? Plasma concentration should achieve within short period of time. 
 
8.1 ANALYTICAL METHOD FOR ESTIMATION OF ATENOLOL 
Atenolol can be estimated by various methods such as UV Spectroscopy, HPLC,  
HPTLC etc. In the present investigation Atenolol was estimated by UV 
Spectrophotometry. 
 
8.1.1 Determination of λmax 
 A solution of Atenolol was prepared in 0.01N HCl and UV spectrum was taken using 
Shimadzu UV/VIS double beam spectrophotometer. UV spectrum of was recorded by 
scanning 5 μg/ml solution of Atenolol in 0.01N Hydrochloric acid and scanned 
between 200-400 nm.       
 
8.1.2 Preparation of calibration curve  
The calibration curve of Atenolol in 0.01N HCl was prepared by measuring the 
absorbance of the solution in the range of 20-100 μg/ml. the absorbance of the 
solution was measured at 273.5 nm. 
Atenolol (100mg) was dissolved in 40ml 0.01N HCl and volume was made up to 
100ml using 0.01N HCl in 50 ml volumetric flask. This stock solution (1mg/ml) was 
further diluted with 0.01N HCl to obtained solution of 20 to 100 μg/ml. Absorbance 
of each solution was measured at 273.5 nm using Shimadzu UV/VIS 
Spectrophotometer with 0.01N HCl as a reference standard. The standard curve was 
generated for entire range of 20 to 100 μg/ml. The experiment was performed in 
triplicate and based on average absorbance; the equation for the best line fit was 
generated.  
 
8.1.3 Result and discussion 
 
Determination of λmax 
The UV maxima of resultant solution were measured with Shimadzu UV- 2201 
UV/VIS Spectophotometer. Figure 8.1.1 shows the UV spectrograph of Atenolol in 
0.01N HCl.  
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Figure 8.1.1: UV spectrograph of Atenolol in 0.01N HCl 
 
 
 
Calibration curve 
The calibration curve of Atenolol in 0.01N HCl was prepared by measuring the 
absorbance of the solution in the range of 20-100 μg/ml. the absorbance of the 
solution measured at the wavelength 273.5 nm. The results of standard curve are 
shown in Table 8.1.1 and Figure 8.1.2 
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Table 8.1.1: Calibration curve of Atenolol in 0.01N HCl at 273.5nm 
Concentration Absorbance 
( μg/ml ) 
0 0.000 (0.000) 
20 0.101 (0.005)  
40 0.184 (0.002) 
60  0.275 (0.001) 
80 0.365 (0.006) 
100 0.445 (0.007) 
Correlation coefficient = 0.9992 
Absorbance = 0.0044 x concentration + 0.0063 
Values in parenthesis indicates standard deviation (n=3) 
 
Figure 8.1.2: Calibration curve of Atenolol in 0.01N HCl at 273.5nm 
y = 0.0044x + 0.0063
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8.2 PREFORMULATION STUDIES 
The physiochemical properties of Atenolol were determined using following 
parameters. 
 
8.2.1 Determination of melting point 
Melting point of drug was determined using capillary tube closed at one end and 
placed in a melting point apparatus and the temperature at which drug melts was 
recorded. This was performed in triplicates and average value was noted. 
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8.2.2 Solubility studies  
The solubility studies were performed in phosphate buffer solution, pH 7.4, in 
distilled water, methanol, chloroform, ether, alcohol (95%), acetone, acetic acid, 
Isopropanol, Dioxane, acetonitril and ethyl acetate separately by adding excess 
amounts of drug in each case and keeping the excess drug containing flasks on a 
water bath shaker NSW-133 for 24hr at 32oC.  
 
8.2.3 Infrared (IR) Spectroscopic analysis 
In the preparation of film formulation, drug and polymer may interact as they are in 
close contact with each other, which could lead to the instability of drug. Pre 
formulation studies regarding the drug-polymer interaction are therefore very critical 
in selecting appropriate polymers. FT-IR spectroscopy was employed to ascertain the 
compatibility between Atenolol and the selected polymers. The individual drug and 
drug with excipients were scanned separately. 
The Fourier Infrared (FTIR) spectrums of moisture free samples were recorded on IR 
spectrophotometer by potassium bromide (KBr) pellet method. The scanning range 
was 4000 to 400 cm-1 and the resolution was 1 cm-1.Pottasium bromide was mixed 
with drug and polymer and the spectra were taken. FT-IR spectrum of Atenolol was 
compared with FR-IR spectra of Atenolol with polymers. Disappearance of Atenolol 
peaks or shifting of peak in any of the spectra was studied.  
 
8.2.4 Differential scanning calorimetry analysis 
Differntial scanning calorimetry enables the quantitative detection of all processes in 
which energy is required or produced during transformation of state(i.e., endothermic 
or exothermic phase transformation). DSC curves for pure drug Atenolol, Eudragit 
RL100 and Eudragit RS100 mixture and their composites were recorded using DSC- 
Shimadzu 60 with TDA trend line software. Drug and polymer was weighed (7-10 
mg) and heated at a scanning rate of 10oC min under dry nitrogen flow (100 ml/min) 
between 50-350oc. Aluminum pans and lids were used for drug sample. Pure water 
and indium were used to calibrate the DSC temperature scale and enthalpy response.  
 
8.2.5 Result and discussion 
Melting point 
Melting point of Atenolol was found to be 154 ± 2.5 oC (average of three readings). 
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This value is same as that of the literature citation. 
 
Solubility study  
Solubility of Atenolol was evaluated in different solvent. The results are mentioned in 
Table 8.2.1. 
       Table 8.2.1 Solubility of Atenolol in different solvents 
Solvent Solubility 
Methnol Soluble 
Acetic acid Soluble 
Dimethyl sulfoxide Soluble 
Methanol:Acetone (3:7) Soluble 
Ethanol (96%) Sparingly soluble 
Water Slightly soluble 
Isopropanol Slightly soluble 
Acetone Very Slightly soluble 
 Dioxane Very Slightly soluble 
Acetonitril Insoluble 
 Ethyl acetate Insoluble 
 Chloroform Insoluble 
 
Infrared (IR) Spectroscopic analysis 
FT-IR spectroscopic studied was carried out to assess any interaction between the 
drug and the excipients. The chemical interaction between the drug and the polymer 
often leads to identifiable changes in the Infrared (IR) profile of complexes. The FT-
IR spectrum of pure Atenolol is shown in figure 8.2.1(a). The FT-IR spectra of 
atenolol with Ethylene vinyl acetate copolymer (Vinyl acetate 40%), Ethyl cellulose, 
Eudragit RL100, Eudragit RS 100 are shown in Figure 8.2.1(b), the presence or 
absence of characteristics peaks associated with specific structural groups of the drug 
molecule was noted. From the FTIR spectra it was revealed that no interaction 
occurred between Atenolol and different polymers.    
 
 
 
 
Shital D. Faldu  Ph.D. Thesis  
 
258 
Chapter 8      Matrix diffusional TDDS of Atenolol   
 
Figure 8.2.1(a): FT-IR Spectra of pure drug (Atenolol) 
 
 
Table 8.2.2: FT-IR Spectral data of Atenolol 6
Frequency (cm-1) Assignment 
3346.61 -CO-NH- 
3153.72 -CO-NH- 
2964.69 C-H stretching (alkane) 
1643.41 C=O stretching (amide) 
1516.10 -N-C=O, amide 
1417.73 H2N-CO- 
1377.22 C-O stretching (alcohols) 
1244.13 Arylether 
1178.55 i-pr 
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Figure 8.2.1(b):  IR specta of Atenolol composites 
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Differential scanning calorimetric analysis 
Differential scanning calorimetry enables the quantitative detection of all processes in 
which energy is required or produced during transformation of state (i.e., endothermic 
or exothermic phase transformation). DSC curves for pure drug Atenolol was shown 
in figure 8.2.2(a). DSC curve of ERS 100, ERL 100 and Atenolol composite are 
shown in Figure8.2.2 (c). Pure powdered Atenolol showed a melting endotherm at 
158.95 oC temperature. DSC scan of ERL100 and ERS100 showed a broad endotherm 
due to the presence of residual moisture in polymers. 
 
DSC thermogram of Atenolol with ERL100 and ERS100 exhibits endothermic peaks 
at near to 161.80 oC temperature. Results reveal absence of any interaction occurring 
between drug and polymers.  
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          Figure 8.2.2(a): DSC thermogram of Atenolol 
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Figure 8.2.2(b): DSC thermogram of ERL100 and ERS 100 
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Figure 8.2.2 (c): DSC thermogram of Atenolol composite 
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Shital D. Faldu  Ph.D. Thesis  
 
262 
Chapter 8      Matrix diffusional TDDS of Atenolol   
 
8.3 PREPARTION AND CHARACTERIZATION OF POLYMERIC MATRIX   
      DIFFUSIONAL TRANSDERMAL DRUG DELIVERY  DEVICE OF  
      ATENOLOL 
 
8.3.1 Preparation of polymeric matrix device 
 
Matrix – type transdermal patches containing Atenolol were prepared using different 
polymers (Table 8.3.1).The polymers were weighed in requisites ratios keeping the 
total polymer weight 800 mg, and dissolved in a given solvent. Di-n-butyl Phalate 
(30% w/w of polymer composition) were used as a plasticizer. Atenolol (533.33mg) 
was added and mixed using a mechanical stirrer. The uniform dispersion of polymeric 
solution of drug (10 ml) was poured on the mercury pool. Solvent was evaporated at 
room temperature, and matrices were carefully lifted. Laminates were punched out to 
have a 3.14 cm2 area. Laminates were affixed on polyethylene coated aluminum foil 
backing.  The release face of medicated laminate was covered with peelable silicone 
liner. The devices were stored in desiccators, at room temperature until further used.7
 
Table 8.3.1: Composition of prepared films 
Formulation 
code 
Plasticizers (30% w/w of 
Polymers Solvent 
polymer composition) 
2ml acetic acid  
EVA (VA 40%) 
copolymer 
F1 ----------- and 10 ml 
toluene 
F2 ERS100 DBP Methanol 
F3 ERL100: ERS100(1:1) DBP Methanol 
F4 EC:PVP (2:3) DBP Methanol 
F5 ERL 100:HPMC (2:3) DBP Methanol 
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Figure 8.3.1: Matrix diffusional transdermal patch of Atenolol 
 
 
8.3.2 Physiochemical evaluation of polymeric matrix device  
Prepared Atenolol containing matrices were evaluated for various parameters like 
thickness , weight variation, drug content, flatness, folding endurance , moisture 
content, moisture absorption,  % WVTR etc, as per procedure given in the chapter 5, 
section 5.3.2. 
 
8.3.3 Result and discussion 
The present investigation deals with the development of Atenolol loaded polymeric 
matrix using different polymers. The preliminary screening was carried out for the 
selection of best polymer. A diffusion mediated matrix controlled transdermal drug 
delivery system for Atenolol was successfully prepared using different polymers 
using mercury subtract method and all matrices were evaluated using different 
physiochemical parameters. 
 
Thickness 
With the help of micrometer (0.001mm), Mitutoyo, Japan, the thickness of film was 
measured at six different points and the average thickness was noted. The results of 
thickness measurements are given in Table 8.3.2. The results indicate that there was 
no much difference in the thickness with in the formulations. Thickness in the 
different formulations was in the range of 182.5 ± 2.5 μm to 85.0 ± 2.5 μm. 
Maximum thickness was found in formulation F1, while minimum found in 
formulation F4. These results revealed that thickness was found to increase as 
hydrophobic portion of polymer increases. The results of thickness measurements also 
indicate uniform distribution of the drug and polymer over the mercury surface. The 
rank order of thickness of Atenolol loaded polymeric matrices was EVA (40% VA) 
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copolymer > ERS 100 > ERL100:ERS100 (1:1)> EC: PVP (2:3) >ERL 100: 
HPMC (2:3) 
 
Table 8.3.2: Results of thickness uniformity of F1 to F5 film formulations  
Average thickness (μm) Sr. 
No. 
Formulation 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 180.0 185.0 182.5 182.50  ± 2.500 
2 F2 165.0 165.0 162.5 164.16 ± 1.443 
3 F3 122.5 125.0 120.0 122.50 ± 2.500 
4 F4 115.0 112.5 115.0 112.50±  1.443 
5 F5 85.0 87.5 82.5 85.00 ± 2.500 
*Standard deviation, n=3 
 
Weight variation 
Drug loaded films (3.14cm2) were weighed using Sartorius electronic balance (Model 
CP-224 S), Shimadzu, Japan and the results of weight variation are given in Table 
8.3.3. The weight of 3.14 cm2 film ranged from 50.30 ± 0.100 mg to 58 ± 0.500 mg. 
The weight of the patches was found to be uniform among different batches.  
 
 Table 8.3.3: Results of weight variations of F1 to F5 film formulations 
Average weight (mg) Formulation 
Sr. No. 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 52.4 52.5 52.1 52.33 ± 0.208 
2 F2 55.3 55.8 55.6 55.56 ± 0.251 
3 F3 58.3 58.7 58.5 58.50 ± 0.200 
4 F4 50.6 50.1 50.9 50.53 ± 0.404 
5 F5 53.5 53.1 53.7 53.43 ± 0.305 
*Standard deviation, n=3 
 
In a weight variation test, the pharmacopoeial limit for the percentage deviation of all 
the films of less than mg is ± 10%. The average percentage deviation of all 
formulations was found to be within the limit, and hence all the formulation passed 
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the test for weight variation as per official requirements. All the formulations showed 
acceptable pharmaco-technincal properties. From the results obtained, it was clear that 
there was proper distribution of Atenolol in the film formulations. Hence it was 
concluded that drug was uniformly distributed in all the formulation, with small 
deviation. 
 
Flatness 
The flatness was measured manually for the prepared films. An ideal patch should be 
formulated in such a way that it possesses a smooth surface and it should not constrict 
with time. Flatness studies were performed to assess the same. The results of the 
flatness study showed that none of the formulations had the differences in the strip 
length before and after their cuts. It indicates 100% flatness observed in the 
formulated patches. Thus, no amount of constriction was observed in the film of any 
formulation and it indicates smooth flat surface of the patches and thus they could 
maintain a smooth surface when applied on to the skin. 
 
Folding endurance 
Folding endurance was determined manually for drug loaded polymeric matrices. The 
folding endurance of the films was determined by repeatedly folding a strip measuring 
2x2 cm size at same place till it break. The number of times the film could be folded 
at the same place without breaking gave the value of folding endurance. The results of 
folding endurance are given in Table 8.3.4. 
 
   Table 8.3.4: Results of folding endurance of F1 to F5 film formulations 
Folding endurance Formulation 
Sr. No. 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 248 250 247 248.33 ± 1.527 
2 F2 108 110 112 110.00 ± 2.000 
3 F3 55 50 57 54.00 ± 1.000 
4 F4 19 17 18 18.00 ± 1.000 
5 F5 35 38 45 39.33 ± 5.131 
 *Standard deviation, n=3 
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Here formulation F1, F2 and F3 shows good folding endurance as compare to 
formulation F4 and F5. 
 
Moisture content (Loss on drying) 
The moisture content was determined by keeping the drug loaded polymeric matrices 
patches in dessicator containing activated silica for 24h. The percentage moisture 
content was calculated from the weight differences relative to the final weight. The 
results of the moisture content studies for different formulations are shown in Figure 
8.3.2.  
 
Figure 8.3.2: % moisture content in drug loaded polymeric matrices of Atenolol 
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The moisture content in all the formulations was found to be low and ranged from 
0.571 ± 0.013 to 4.103 ± 0.210 %. The result revealed that the moisture content was 
found to increase with increasing concentration of hydrophilic polymers. The small 
moisture content in the formulations helps them to maintain texture.  
The rank order of % moisture content of Atenolol loaded polymeric matrices was   
EVA (VA 40%) copolymer < ERS 100 < ERL100:ERS100 (1:1) < EC: PVP 
(2:3)>ERL 100: HPMC (2:3) 
 
Moisture absorption  
% Moisture absorption was determined by keeping the drug matrices in a desiccators 
containing 200 ml saturated solution of Sodium chloride (Relative humidity of 75%) 
at normal room temperature for 72hr. The final weight was noted when there was no 
further change in the weight of individual patch. The percentage moisture absorption 
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was calculated as a difference between final and initial weight with respect to initial 
weight. The results of the moisture content studies for different formulations are 
shown in Figure 8.3.3.  
 
Figure 8.3.3: % Moisture absorption in polymeric matrices of Atenolol 
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                  * Standard deviation, n=3 
 
The moisture absorption in all the formulations was found to be low and ranged from 
0.7400 ± 0.0360 to 5.8734 ± 0.1706. The results revealed that the moisture absorption 
was found to increase with increasing concentration of hydrophilic polymers. The 
rank order of % moisture absorption for Atenolol loaded matrices was  
EVA (VA 40%) copolymer < ERS 100 < ERL100:ERS100 (1:1) < EC: PVP (2:3) 
<ERL100: HPMC (2:3) 
 
Water vapor transmission rate (%WVTR) 
The water vapor transmission rates of different formulation were evaluated, the results 
are shown in Figure 8.3.5. Atenolol films containing ERL100: HPMC showed higher 
% WVTR as compared to other polymers. This may be due to the hydrophilic nature 
of ERL 100 and HPMC. Formulation F1 and F2 showed less % WVTR as compared 
to F4 and F5. The rank order of % water vapor transmission rate for Atenolol loaded 
polymeric matrices was 
 EVA (VA 40%)copolymer < ERS 100 < ERL100:ERS100 (1:1) < EC: PVP (2:3) 
<ERL100: HPMC (2:3) 
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Figure 8.3.5: % water vapor transmission rate from drug loaded polymeric  
                      matrices of Atenolol 
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8.4 IN VITRO DIFFUSION STUDY OF ATENOLOL LOADED MATRIX  
      DIFFUSIONAL FILMS 
The release rate determination is one of the most important studies to be conducted 
for all controlled release delivery systems. The diffusion study of patches is very 
crucial, because one needs to maintain the drug concentration on the surface of 
stratum corneum consistently and substantially greater than the drug concentration in 
the body to achieve a constant rate of drug permeation.  
 
8.4.1 Experimental 
An in vitro diffusion study of Atenolol from various polymeric matrices was studied 
using modified Keshary-Chien diffusion cell.8 The effective permeation area of the 
diffusion cell and receptor cell volume was 3.14cm2 and 40 ml, respectively. The 
temperature was maintained at 37 ±0.5oC. The receptor compartment contained 40 ml 
of 0.01N HCl stirred by magnetic stirrer.  
Samples (2 ml) were withdrawn and replaced with the same volume of fresh receptor 
solution, through the sampling port of the diffusion cell at different time intervals. 
The absorbance of the withdrawn samples were measured using UV VIS 
spectrophotometer at 237.5 nm using 0.01N HCl as a blank. The experiments were 
done in triplicate. Amount of drug released per square centimeter of patch were 
plotted against function of square root of time for different formulations. The release 
rate Q/√T was determined by simple regression analysis of steady state data.      
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8.4.2 Result and discussion 
Diffusion studies are important for ensuring the sustained release performance and the 
reproducibility of rate and duration of drug release. In vitro release profile is an 
important tool that predicts in advance, the extent of concentration builds up in vivo. 
The results of in vitro drug diffusion studies from transdermal patches are depicted in 
Table 8.4.1 and Figure 8.4.1.  
 
Figure 8.4.1: In vitro diffusion release profiles of Atenolol from different matrix   
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Table 8.4.1: In vitro diffusion profiles of Atenolol from different polymer matrix 
2Cumulative amount of drug release from device (μg/cm ) 
Formulation code 
Time 
(hr ½) 
F1 F2 F3 F4 F5 
0.707 473.34 ± 25.67 726.48 ± 29.40 1060.46 ± 35.78 1120.23 ± 39.56 1210.39 ± 42.56 
1 571.56 ± 25.46 990.49 ± 35.78 1370.89 ± 55.39 1459.23 ± 55.29 1678.34 ± 60.43 
1.414 731.22 ± 31.56 1320.40 ± 51.34 1870.45 ± 60.99 1953.34 ± 61.64 2169.90 ± 71.34 
1.732 890.56 ± 35.67 1570.30 ± 55.78 2241.36 ± 71.64 2321.90 ± 71.56 2541.20 ± 80.43 
2 1025.89± 40.79 1810.37 ± 59.88 2564.90 ± 79.45 2659.86 ± 79.40 2958.68 ± 100.50 
2.236 1136.30± 64.99 1950.34 ± 64.99 2863.94 ± 90.57 3045.75 ± 80.38 3245.46 ± 106.34 
2.449 1200.13 ± 51.34 2160.80 ± 70.01 3090.34 ± 101.45 3320.00 ± 48.67 3458.95 ± 78.46 
Q/√T 
434.45 810.72 1220.90 1265.00 1337.80 
(μg/cm2 √hr) 
0.9958 0.9989 0.9917 0.9963 0.9936 R 
 
 
Shital D. Faldu  Ph.D. Thesis  
 
270 
Chapter 8      Matrix diffusional TDDS of Atenolol   
 
The results of diffusion study of Atenolol released from polymeric matrix, formulated 
using various polymers are presented in Table 8.4.1 and profiles are shown in Figure 
8.4.1. The release rate Q/√T (μg/cm2 √hr) was determined by simple regression 
analysis of steady state data. The release of Atenolol from all the matrices followed 
square root law. The rank order of release was EVA (VA 40%)copolymer < ERS 
100 < ERL100:ERS100 (1:1) < EC: PVP (2:3) < ERL100: HPMC (2:3) 
 
The in vitro permeation experiment indicated that when the hydrophilic polymer 
concentration increased, the amount of drug permeation increased. As described by 
Rao and Diwan,9 initial rapid dissolution of the hydrophilic polymers occurs when the 
patch is in contact with the hydrated skin, resulting in the accumulation of high 
amount of drug on the skin surface and thus leading to the saturation of the skin with 
drug molecule at all the time.6 
 
Formulation F1 EVA (VA 40%) copolymer exhibited minimum Q/√T release rate 
(434.45 μg/cm2√h) while Formulation F5 exhibited maximum Q/√T release rate 
(1337.80 μg/cm2 √h). The physiochemical property of polymer plays important role 
in drug release characteristics, from the polymeric matrix. EVA (VA 40%) copolymer 
is more hydrophobic as compare to other polymers and exhibited reduced permeation 
from the matrix. It was observed that as the concentration of hydrophilic polymer 
increased in the formulation the rate of diffusion increased subsequently. “Burst 
effect” was observed in the formulation F4 and F5 and this may be due to sufficient 
solubility of drug in the polymer. 
 
In vitro release kinetic 
The release data was fitted into various mathematical models using software to know 
which mathematical model will best fit to obtained release profiles. The obtained R 
values for various models are given in Table 8.4.2.  
The process of drug release in most controlled release devices including transdermal 
patches is governed by diffusion and the polymer matrix has a strong influence on the 
diffusivity as the motion of a small molecule is restricted by the three-dimensional 
network of polymers chain. The in vitro release profile could be best expressed by 
Higuchi’s equation for the permeation of drug from the matrix. 
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Table 8.4.2.: Data of various parameters of model fitting of formulations 
Zero order 
equation 
First order 
equation 
Higuchi’s 
equation 
Formulation 
F1 0.9804 0.9470 0.9962 
F2 0.9836 0.9440 0.9985 
F3 0.9836 0.9404 0.9998 
F4 0.9935 0.9606 0.9968 
F5 0.9835 0.9503 0.9977 
 
The importance of polymer dissolution on drug release from matrices has been known 
for ensuring the controlled release performance and the reproducibility of rate and 
duration of drug release. Initial “burst release” was observed in patches F4 and F5. 
This may be because of the much higher % of hydrophilic polymer. This hydrophilic 
components allow faster release of drug exhibiting small “time lag” to establish a 
concentration profile in the patches resulting in a “burst effect” in diffusion 
studies.10,11 When burst release as well as higher release rate was considered, 
formulation F4 and F5 may be avoided from the preparation of a physiochemically 
stable and controlled release patch type formulation. Formulation F1 and F2 gave the 
slowest release. Thus it can be reasonably be suggested that the formulation F3 is best 
suited for further in vitro permeability study through human live skin.12,13
 
8.5 TO OPTIMIZE FORMULATION USING BLENDS OF POLYMERS 
8.5.1 Experimental 
Different blend of polymer in matrix influences parameter of patch like folding 
endurance, thickness, weight variation, flatness, texture appearance, brittleness etc. 
ERL100 and ERS100 were selected to device final matrix diffusional therapeutic 
system. The drug is compatible with polymer as seen in DSC profile. A matrix 
laminate with different concentration of polymer was prepared with an aim to achieve 
improved Q/√T release rate. As the composition of laminate varies, it changes the 
texture, appearance, folding endurance etc which influences elegance of medicated 
laminate. A compromise is necessary between the loading of drug to have a maximum 
available Q/√T release rate and elegance of formulation.  
In this study, various matrix type transdermal patches containing Atenolol of variable 
combination of ERL100 and ERS 100 were prepared. It was desired to design a 
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polymer matrix that allows one to control the release of Atenolol via the most 
appropriate choice of polymeric blend of ERL 100 and ERS 100 among the 
formulation studied, using the different diffusion pathway of the individual polymeric 
composition to produce the desired overall prolong drug release. 
 
Preparation of matrix moderated Transdermal drug delivery device of Atenolol 
Matrix – type transdermal patches containing Atenolol were prepared using different 
ratios of polymer (Table 8.5.1).The polymer were weighed in requisite ratios and 
dissolved in 10 ml mixture of acetone: methanol (7:3). Atenolol (15 mg/cm2) and 
plasticizer Di-butyl phalate (30 %w/w of polymer weight) was added and mixed 
slowly with a mechanical stirrer. The uniform dispersion of polymeric solution of 
drug (10 ml) was poured on the mercury surface (73.86 cm2), and solvent evaporated 
at room temperature. The dried film was carefully lifted. Films were punched out to 
have 3.14 cm2 areas. Films were affixed on polyethylene coated aluminum foil as 
backing membrane. It was covered with peelable silicone liner and stored in 
desiccators at room temperature until further used. 
 
Table 8.5.1: Composition of various formulations of Atenolol 
Formulation 
code 
Polymeric blend Amount of drugs
Ratio of polymer 
(10%w/v) ( mg/cm2) 
C1 ERL 100 : ERS 100 1:4 15 
C2 ERL 100 : ERS 100 2:3 15 
C3 ERL 100 : ERS 100 1:1 15 
C4 ERL 100 : ERS 100 3:2 15 
C5 ERL 100 : ERS 100 4:1 15 
 
Physiochemical evaluation of polymeric matrix device 
Prepared Atenolol containing matrices were evaluated for various parameters like 
thickness, weight variation, drug content, flatness, folding endurance, moisture 
content, moisture absorption,  % WVTR etc, as per procedure given in the chapter 8, 
section 8.3.2. 
 
In vitro diffusion profile 
In vitro diffusion study of different matrices containing Atenolol was carried out as 
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per the procedure given in chapter 8, section 8.4.1. 
 
Data Analysis 
Cumulative amount of Atenolol released into infinite sink, per unit surface area of 
device was plotted as a function of square root of time for each disc. Release rate 
Q/√T was computed for each disc from simple regression analysis of steady state data. 
The release data was fitted into various mathematical models using software to know 
which mathematical model will best fit to obtained release profiles. 
 
8.5.2 Result and Discussion 
The present investigation deals with the development of Atenolol polymeric matrix 
using different concentration of polymer. This preliminary screening was carried out 
for the selection of best matrix. A diffusion mediated matrix moderated transdermal 
controlled drug delivery system for Atenolol was successfully prepared using 
different polymer ratio using mercury subtract method and all matrices were 
evaluated using different physiochemical parameters. 
 
Thickness 
With the help of micrometer (0.001mm), Mitutoyo, Japan, the thickness of films was 
measured and the average thickness was noted. The results of thickness measurements 
are given in Table 8.5.2.  
 
Table 8.5.2: Results of thickness uniformity of C1 to C5 film formulations 
Average thickness (μm) Formulation 
Sr. No. 
code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 C1 465 460 462.5 462.5 ± 2.500 
2 C2 470 470.5 472.5 471.0 ± 1.322 
3 C3 480 487.5 482.5 483.33 ± 3.810 
4 C4 510 510 510.5 510.16 ± 0.288 
5 C5 525 530 527.5 527.50 ±  2.500 
      *Standard deviation, n=3 
 
The results indicate that there was no much difference in the thickness within the 
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formulations. Thickness in the different formulations was in the range of 462.5 ± 
2.500 μm to 527.50 ± 2.500 μm. Maximum thickness was found in formulation C5, 
while minimum found in formulation C1. These results revealed that thickness was 
found to increase as hydrophilic portion of polymer increased. The results of 
thickness measurement also indicated uniform distribution of the drug and polymer 
over the mercury surface.  
 
Weight variation 
Drug loaded films (3.14cm2) were weighed using Sartorius electronic balance (Model 
CP-224 S), Shimadzu, Japan and the results of weight variation are given in Table 
8.5.3.  The weight of 3.14 cm2 film ranged from 0.187 ± 0.002 gm  to 0.215 ± 
0.01gm. The weight of the patches was found to be uniform among different batches.  
 
Table 8.5.3: Results of weight variations of C1 to C5 film formulations 
Average weight (mg) Formulation 
Sr. No. 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 C1 0.225 0.215 0.205 0.215 ± 0.01 
2 C2 0.190 0.185 0.195 0.190 ± 0.005 
3 C3 0.189 0.185 0.188 0.187 ± 0.002 
4 C4 0.194 0.193 0.208 0.198 ± 0.008 
5 C5 0.209 0.207 0.210 0.208 ± 0.001 
   *Standard deviation, n=3 
In a weight variation test, the pharmacopoeial limit for the percentage deviation of all 
the films of less than mg is ± 10%. The average percentage deviation of all 
formulations was found to be within the limit, and hence all the formulation passed 
the test for weight variation as per official requirements. All the formulations showed 
acceptable pharmaco-technincal properties. From the results obtained, it was clear that 
there was proper distribution of Atenolol in the film formulations. Hence it was 
concluded that drug was uniformly distributed in all the formulation.  
 
Drug content 
Drug content of the matrices was carried out to ascertain that the requisite amount of 
drug is loaded in the formulation. The prepared film formulations (3.14cm2) were 
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dissolved in 10 ml mixture of Acetone: Methanol (7:3) in a 100 ml volumetric flask 
and the volume was adjusted up to 100 ml using Acetone: Methanol (7:3). The 
amount of drug present was determined by measuring the absorbance 
spectrophotometrically at 282.0 nm using mixture of Acetone: Methanol (7:3) as a 
blank. The results obtained are presented in Table 8.5.4. 
 
Table 8.5.4: Results of % Drug content of C1 to C5 film formulations 
Drug content (mg) Formulation 
Sr. No. 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 C1 99.45 98.40 98.63 98.82 ± 0.551 
2 C2 101.45 100.60 100.32 100.79 ± 0.588 
3 C3 100.35 102.37 99.60 100.77  ± 1.432 
4 C4 97.46 98.70 98.50 98.22  ± 0.665 
5 C5 99.90 102.38 101.36 101.21 ± 1.246 
   *Standard deviation, n=3 
 
The films were found to contain 98.22% - 101.21 % of the labeled amount of 
Atenolol indicating uniformity of drug content. The average percentage deviation of 
all formulations was found to be within the limit, and hence all the formulation passed 
the test for content uniformity as per official requirements.  
 
Flatness 
The flatness was measured manually for the prepared films. The results of the flatness 
study showed that none of the formulations had the differences in the strip length 
before and after their cuts. It indicates 100% flatness observed in the formulated 
patches. Thus, no amount of constriction was observed in the film of any formulation 
and it indicates smooth flat surface of the patches and thus they could maintain a 
smooth surface when applied on to the skin. 
 
Folding endurance 
Folding endurance was determined manually for drug loaded polymeric matrices. The 
folding endurance of the films was determined by repeatedly folding a strip measuring 
2x2 cm size at same place till it break. The number of times the film could be folded 
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at the same place without breaking gave the value of folding endurance. The results of 
folding endurance are given in Table 8.5.5. 
 
Table 8.5.5: Results of folding endurance of C1 to C5 film formulations 
Folding endurance Formulation 
Sr. No. 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 C1 20 25 22 22.33 ± 2.516 
2 C2 20 24 23 22.33 ± 2.081 
3 C3 19 18 20 19.00 ± 1.000 
4 C4 17 18 18 17.66 ± 0.577 
5 C5 20 22 23 21.66 ± 1.527 
   *Standard deviation, n=3 
Here formulation C1 and formulation C2 showed good folding endurance as compare 
to formulation C3 and C4.  
 
Moisture content (Loss on drying) 
The moisture content was determined by keeping the drug matrices patches in 
desiccator’s containing activated silica for 24hr. The percentage moisture content was 
calculated from the weight differences relative to the final weight. The results of the 
moisture content studies for different formulations are shown in Figure 8.5.1.  
 
Figure 8.5.1: % moisture content of C1 to C5 film formulations containing   
                      Atenolol 
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The moisture content in all the formulations was found to be low and ranged from 
0.8023 ± 0.0525 to 4.6970 ± 0.1006 %. The result revealed that the moisture content 
was found to decrease with increasing concentration of hydrophilic polymer ERL 100.  
 
Moisture absorption  
The percentage moisture absorption was calculated as a difference between final and 
initial weight with respect to initial weight. The results of the moisture absorption 
study for different formulations are shown in Figure 8.5.2.  
 
Figure 8.5.2: % Moisture Absorption of C1 to C5 film formulations  
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The moisture absorption in all the formulations was found to be low and ranged from 
3.049 ± 0.0669 to 7.833 ± 0.0550 %. The result revealed that the moisture absorption 
was found to increases with increasing concentration of hydrophilic portion of 
polymer. Rank order of moisture absorption for the formulation was C5 > C4 > C3 > 
C2 > C1. 
   
Water vapor transmission rate (%WVTR) 
The water vapor transmission rates of different formulation were evaluated and the 
results are shown in Figure 8.5.3. The % water vapor transmission rate of each film 
was determined and rank order of water vapor transmission for Atenolol containing 
matrices was C1 > C2 > C3 > C4 > C5. The water vapor transmission influences the 
permeation of the drug from the barriers. 
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Figure 8.5.3: Results of % WVTR of C1 to C5 film formulations 
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In vitro diffusion profile   
Diffusion studies for different formulations were performed in a modified Keshary-
Chien diffusion cell using 0.01N HCl, as a diffusion medium at 37 ± 0.50C. 
Experiments were triplicated. Cumulative amount of Atenolol released from the 
device into receptor fluid was plotted as a function of square root of time for each 
medicated disc subjected under diffusion study. Release rates Q/√T were derived from 
simple regression analysis of steady state diffusion data. The results of in vitro drug 
diffusion study for transdermal patches are depicted in Table 8.5.6 and Figure 8.5.4  
 
Figure 8.5.4.: In vitro diffusion profiles of Atenolol from blend of polymer            
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Table 8.5.6: In vitro diffusion profiles of Atenolol from blend of polymer  
                     matrices 
2Cumulative amount of drug release from device (μg/cm ) 
                   
Release rate Q/√T increased with increasing concentration of Atenolol in ERL100: 
ERS100 matrix. In our experiments, variable release profiles of Atenolol from the 
different experimental patches, composed of various blend of polymers were 
observed. Cumulative amount of drug diffused per square centimeter of patches, when 
plotted against square root of time, showed linear graphic of the data obtained from 
different formulations. The rank order of Q/√T release rate for formulation was C1 < 
C2 < C3 < C4 < C5. The formulations C5 exhibited the greatest (1309.1μg/cm2h) 
release values, which were significantly different, compared to the lowest values in 
the formulation C1 (909.56 μg/cm2 h). Based on physiochemical data and in vitro 
release experiments, formulation C5 was chosen for further in vitro permeability 
study through human live skin. 
 
In vitro release kinetic 
The release data was fitted into various mathematical models using software to know 
which mathematical model will best fit to obtained release profiles. The obtained R 
values for various models are given in Table 8.5.7. 
 
 
Formulation code 
Time 
(hr ½) 
C1 C2 C3 C4 C5 
0.707 731.22 ± 29.47 884.20 ± 35.39 1060.46 ± 39.67 1141.34 ± 45.32 1180.11 ± 50.29 
1 990.49 ± 35.34 1121.24 ± 41.56 1370.89 ± 45.37 1492.39 ± 42.56 1631.15 ± 62.56 
1.414 1350.92 ± 41.23 1543.98 ± 46.89 1870.45 ± 52.34 2035.30 ± 28.46 2232.24 ± 72.42 
1.732 1579.46 ± 55.45 1833.50 ± 55.67 2241.36 ± 58.39 2531.59 ± 65.34 2604.56 ± 78.56 
2 1920.59 ± 67.89 2142.30 ± 60.93 2564.90 ± 70.30 2842.50 ± 69.80 2901.32 ± 67.38 
2.236 2064.68 ± 69.50 2371.10 ± 71.45 2863.94 ± 35.67 3051.49 ± 75.29 3160.45 ± 97.40 
2.449 2353.90 ± 71.85 2664.20 ± 78.56 3090.34 ± 89.40 3301.11 ± 90.40 3581.54 ± 105.37 
Q/√T 
(μg/cm
909.56 1014.1 1220.9 1258.5 1309.1 2√hr) 
Correlation 
coefficient 
0.9949 0.9969 0.9917 0.9962 0.9940 
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    Table 8.5.7.: Data of various parameters of model fitting of formulations   
                          Containing Atenolol 
Zero order 
equation 
First order 
equation 
Higuchi’s 
equation 
Formulation 
C1 0.9896 0.9564 0.9922 
C2 0.9917 0.9533 0.9973 
C3 0.9836 0.9404 0.9998 
C4 0.9618 0.9113 0.9934 
C5 0.9809 0.9386 0.9937 
 
In our experiment, the in vitro permeation profiles of all formulations could be best 
expressed by Higuchi’s equation (R2 = 0.9922 to 0.9998) for the permeation of drug 
from a polymeric matrix. 
 
8.6 In vitro permeation study of matrix diffusional transdermal drug delivery    
    device of Atenolol across human live skin 
 
8.6.1 Treatment and preparation of skin for permeation study 
Human live skin was collected from unused portion of human male patients from 
private hospital with consent of plastic surgeon and patient, who have no problem 
regarding reactions to medicines or problems of breathing. The skin graft was 
collected, treated and stored as mentioned in section 5.6.1. 
8.6.2 In vitro permeation study through human live skin 
Diffusion study of Atenolol from selected matrix device across human live skin was 
performed using modified Keshary-Chien diffusion cell. A section of skin was cut and 
placed on the brim of diffusion cell in such a way that the dermal side of the skin 
faced donor compartment. The patch of Atenolol was affixed on the skin in such a 
way that backing membrane was facing upward. Diffusion study was carried as 
mentioned in section 6.6.1. The experiments were done in triplicate. Amount of drug 
released per square centimeter of patch were plotted against function of time. The 
release rate was determined by simple regression analysis of steady state data. 
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8.6.3 Result and discussion 
In vitro permeation studied is predictive of in vivo performance of a drug. The results 
of in vitro skin permeation of Atenolol from formulation C5 are shown in figure 8.6.1  
 
Figure 8.6.1: In vitro skin permeation profile of Atenolol from matrix patch  
                       through human live skin 
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Various parameters of diffusion kinetics of Diltiazem released from device across 
excised human live skin are presented in Table 8.6.1.  The parameters listed in this 
table are useful for biopharmaceutical and pharmacokinetic of the matrix diffusional 
system evaluated.  
Table 8.6.1: Parameters of diffusion kinetic of Atenolol from Atenolol matrix   
                     diffusion controlled  transdermal drug delivery system 
Sr. No. Parameters Value 
2 68.73 μg/cm hr 1 Skin flux Jss 
1.06 hr 2 Time lag (tL) 
140 μm 3 Skin thickness (µm) 
4 Diffusion coefficient 3.081 x 10-5 cm2/sec 
Solubility of drug in skin  
(Cs) 
331.230 mg/cm5 
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From the time lag (tL) for device the average diffusion coefficient, D of Atenolol was 
determined using D = h2/6 tL relationship where thickness of human skin was 140 x 
10-4 cm. The amount of Atenolol retained by skin area used for permeation was 
computed by dividing skin flux with gradient of diffusivity. 
Cs = Jss/ (D/h) 
The value of Cs for device is presented in Table 8.6.1. The amount of Atenolol 
retained in skin need to be incorporated in contact adhesive to serve to saturate the 
skin area with permeate before steady state is established. The amount of permeate so 
incorporated in the adhesive system of device serves as priming dose.                     
The release of Atenolol from matrix diffusional system into infinite sink can be 
approximated by equation. 
                                       Release rate = Q/√T + He –Kt 
The first term on right hand side of the equation represents the time dependent 
delivery rate. The second term represents the temporal pattern of drug release during 
priming dose period.  
 
Comparison of permeation kinetics: Patch without priming Dose: Patch with 
priming Dose 
The release rate (µg/hr) has linear relationship with area of release face of a 
transdermal drug delivery system. The final patch needs to be provided with adhesive 
system and priming dose.  To assess release kinetic of a complete patch, a patch of 
3.14 cm2 area was provided with a peripheral adhesive system (4 mm rim). From the 
data of solubility of drug in skin, a 0.583 % w/v Atenolol in natural rubber solution 
was used as an adhesive system. This solution was uniformly layered in 4 mm rim 
surrounding 3.14 cm2 area of patch, to obtain 10 µm thick adhesive systems 
containing priming dose of 437 µg/cm2 area of delivery device. The device was firmly 
secured on skin of human live skin and was subjected to diffusion experiment using 
0.01 N HCl as diffusion medium. The release profile is shown in Table 8.6.2 and 
Figure 8.6.2.  
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Figure 8.6.2: In vitro skin permeation profile of Atenolol from matrix patch 
through human live skin with priming dose and without priming dose 
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Table 8.6.2: Parameters of in vitro skin permeation kinetic of Atenolol from 
matrix patch through human live skin with priming dose and without priming 
dose 
Parameters Cumulative amount of 
drug release (μg/cm
Cumulative amount of 
drug release (μg/cm2 2) 
Without priming dose 
) 
With priming dose 
Release rate 70.84 68.73 
(μg/cm2 hr) 
Correlation 
coefficient 
0.9983 0.9954 
0.86 hr Time lag (t ) 1.06 hr L
 
Computation of desired release rate (in vivo input) for target steady state plasma 
concentration of Atenolol 
For Atenolol t = 6 hrs, V1/2 d = 0.7 liters /Kg   and targeted steady state plasma 
concentration (Css) = 120 ng/ml the desired drug release can be calculated as follows. 
In vivo input = in vivo output 
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                       = C  Vss * d  *  K 70 e *
3                        = 120 ng/ml *  0.7x10 ml/kg  *  0.693/6 * 70 kg 
                      = 679.14 μg/hr 
 
In vivo input = in vivo output = 679.14 μg/hr 
 
Desired release rate = 679.14 μg/hr 
 
Computation of area of patch required for target steady state plasma 
concentration (Css) 
 
In vivo input = in vivo output = 679.14 μg/hr 
 
Jss(skin) x A = C  Vss * d  *  K 70  = 679.14 μg/hr e *
 
Area of patch = (679.14 μg/hr)/ Jss(skin)
                      = 679.14/ 70.84 cm2 
2                                 = 9.68 cm
 
Formulation of final patch 
As per British J. clinical  Pharm.14 steady state plasma concentration built up after 
administration of 25mg, 50mg and 100 mg Atenolol orally in human volunteers are 
recommended to develop peak plasma concentration of 126 ng/ml, 219 ng/ml and 390 
ng/ml respectively to control varied dose dependent physiological cardiac complains. 
Transdermal controlled drug delivery system is recommended as an alternative safe 
therapy with better compliance to therapy by the patient to reduced frequency of 
administration leading to better disease management. Following three patches of 
different configuration are formulated as an alternative to above oral administration, 
to meet requirement of desired steady state plasma concentration for varied cardiac 
conditions. Table 8.6.3 shows the composition of the formulations. 
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Table 8.6.3: composition of final Atenolol matrix moderated transdermal devices 
Components Patch 1 Patch 2 Patch 3 
Oral dose of Atenolol 25 mg 50 mg 100 mg 
Css, mean steady state plasma 
concentration (ng/ml) 
126 219 390 
Area of transdermal patch 
(cm
9.7 16 30 2) 
Predicted steady state plasma 
concentration 
120 200 375 
Steady state flux, Jss, through 
human live skin (μg/cm
70.84 70.84 70.84 2 hr) 
Priming dose in adhesive 
system (μg/cm
437 437 437 2) 
Protective liner Silicon sheet Silicon sheet Silicon sheet 
 
Area of transdermal drug delivery device is directly related to mean steady state 
plasma concentration that builds up after administration of device. The above 
formulations are 24 hour (once a day) devices. The specific size matrix formulation 
having area 9.7, 16 and 30 cm2 are affixed over polyethylene coated aluminum foil 
backing.  The formulations are to be provided with priming dose incorporated in 
natural rubber adhesive as follow. The amount of Atenolol retained in skin need to be 
incorporated in contact adhesive to serve as prompt dose. For preparation of above 
devices containing peripheral adhesive system a 0.583 % w/v Atenolol in natural 
rubber adhesive solution is to be layered surrounding 4 mm rim of the delivery 
device, providing 437 µg Atenolol per cm2 area of the adhesive system giving a 10 
µm thick adhesive layer. The finally fabricated devices are to be provided with 
silicone sheet as a protective liner and to be stored at room temperature. 
 
8.7 STABILITY STUDY 
8.7.1. Stability study of matrix diffusion controlled device 
The stability of pharmaceutical preparation should be evaluated by accelerated 
stability studies. The objective of accelerated stability studies is to predict the shelf 
life of a product by accelerating the rate of decomposition, preferably by increasing 
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the temperature. The optimized formulation of Atenolol matrix patch was subjected 
for the stability study.  
The accelerated stability study was carried out according to ICH guideline by storing 
the samples at 25 0C / 60% RH, 30 0C/ 65% RH and 40 0C/ 75% RH for 90 days in a 
stability chamber (Thermo Lab., Mumbai, India). These samples were analyzed by 
UV Spectrophotometer method and checked for changes in physical appearance and 
drug content at an interval of 15 days. 
5.7.2 Results and Discussion  
Final formulation was subjected to stability study and observed for change in color, 
appearance, flexibility and drug content. Temperature and humidity values selected 
were as per the ICH guidelines. 
 Diffusion study was carried out and it was observed that formulation stored at 40 0C 
exhibited higher Q/√T release rate as compared to those stored at 25 0C and 30 0C. 
The release rate at 30 0C was altered but it was in order. The product stored at 25 0C 
exhibited no change in release rate. 
Drug degradation study was carried out as per ICH guideline at above mentioned 
physical condition of temperature and humidity. Periodic samples were subjected to 
drug content analysis. The % retained in device was worked out and from the plot of 
log % retained versus time degradation rate constant was computed for 25 0C, 30 0C 
and 40 0C temperatures. 
The degradation was higher at an elevated temperature. The first order rate constant of 
degradation for room temperature was 1.280 x 10-3 -1 week . The self life calculated 
was 82 week. Results of stability study indicated storage of product at room 
temperature. 
8.8 SKIN IRRITATION AND SKIN SENSITIZATION STUDY 
8.8.1 Experimental 
Skin irritation and skin sensitization though are different types of physiological 
responses yet they have several common indications. Skin sensitization is systematic 
response and skin irritation is primarily is local response. A protocol was devised for 
evaluation of skin irritation and/or sensitization in such a manner that the signs at the 
sight of application would be assessed in common for the both and further, to 
distinguish sensitization from irritation. The skin irritation and skin sensitization study 
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was carried out as per mentioned in chapter 5.8.1. 
The final Atenolol matrix patch (2.25 cm2) was supported with aluminum foil. This 
was applied to the skin surface (shaved) and made adhered with the help of “3 M 
Micropore” – medicated adhesive tap (3 M Corporation, U.K.). 
8.8.2 Results and discussion    
The results of skin irritation and skin sensitization study for Atenolol matrix patch are 
presented in Table 8.8.1. From this table total average score at day 20 and total 
average score at day 28 were obtained. From  the average score it was clear that the 
Atenolol matrix patch was non- irritating, since the maximum score for each sign did 
not exceed than 1 except in one case i.e. score 2, for necrosis in one animal but this 
score was reduced to 1 at 28th day. This indicates that it had happened due to bruising 
during shaving. Therefore these scores can be ignored. Further Table 8.8.3 shows that 
average score at day 20 and day 28 was not exceeding more than 1 for any sign. 
Average score not exceeding more than 1 at any day for any sign was clearly 
indicative for non-irritation nature of the formulation. 
Atenolol is non-sensitizing in nature. The reason for this was reduction in scores even 
after repeated applications. All the tables show that maximum individual scores, 
average scores, total irritation scores were reduced at day 28th in comparison to all 
these scores at day 20th. Reduction in scores even after repeated application of test 
patch indicated absence of primary and secondary sensitization reaction. 
Table 8.8.2: The average score for each sign after day 20 and day 28 during  
                     irritation and  sensitization study of Atenolol matrix patch 
Average score at 
day 20 
Average score 
at day 28 
Sr. No. Sign 
1 Erythema 1.0 0.25 
2 Scaling 0.5 0.25 
3 Fissures 0.25 0.0 
4 Oedema formation 0.75 0.0 
5 Ecchymosis 0.25 0.25 
6 Necrosis 0.5 0.25 
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SR. 
NO.  
Name And 
Concentration 
SENSITIZATION / IRRITATION TESTING 
PRE-EXPOSURE 
PERIOD 
INDUCTION PHASE REST CHALLENGE PHASE 
  
Φ = 30M Φ = 30M Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 After 12 Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 
D1 D2 D3 D4 D5 D6 D7 Days D19 D20 D21 D22 D28 
1 Erythema 
0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 0 1 0 
0 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0 
Avg 0 Avg 0 Avg .25 Avg .75 Avg .25 Avg .25 Avg .25 Avg 0 Avg 0 Avg 1 Avg 0.5 Avg .25 Avg .25 
2 Scaling 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 1 1 1 0 1 0 1 0 1 1 0 0 0 1 1 1 1 0 1 0 1 
Avg 0 Avg 0 Avg .25 Avg 0.5 Avg .25 Avg .25 Avg .25 Avg .25 Avg 0 Avg 0.5 Avg 0.5 Avg .25 Avg .25 
3 Fissures 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg .25 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg .25 Avg 0 Avg 0 Avg 0 
4 
Oedama 
formation 
0 0 0 0 0 0 1 1 1 0 1 0 0 0 0 0 0 1 1 1 0 1 0 1 0 0 
0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 1 0 1 0 1 0 0 
Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg 0 Avg .25 Avg .75 Avg 0.5 Avg 0.5 Avg 0 
5 Ecchymosis 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg .25 
6 Necrosis 
0 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 0 0 1 1 1 1 0 1 0 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg .25 Avg .25 Avg .25 Avg .25 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg .25 Avg .25 
Total of all score 0 0 2 9 5 5 4 1 1 13 9 6 4 
Total average per 
animal 
0 0 0.5 2.25 1.25 1.25 1 0.25 0.25 3.25 2.25 1.5 1 
Chapter 8      Matrix diffusional TDDS of Atenolol   
 
Table 8.8.3: Maximum sensitization and irritation score of various signs at last      
                     day for Atenolol matrix patch 
Sr. No. Sign Score N 
1 1 1 Erythema 
1 1 2 Scaling 
0 4 3 Fissures 
0 4 4 Oedema formation 
1 1 5 Ecchymosis 
1 1 6 Necrosis 
 
8.9 CONCLUSION 
ERL100:ERS100 matrix moderated transdermal drug delivery system of Atenolol has 
been prepared successfully. Among different polymers evaluated ERL100:ERS100 in 
ratio of 1:1 containing 15 mg/cm2 of Atenolol provided a medicated matrix, which 
was stable, non-irritant and non-sensitizing to skin and was safe. It complied with 
official and non-official pharmacotechnical specification. The matrix  device 
evaluated for Atenolol release in vitro into infinite sink and across human live skin, 
enabled to provide adequate rate of Atenolol, meeting requisite pharmacokinetic 
requirement of steady state plasma concentration for 24 hours, giving once a day drug 
delivery system. Alternative to three oral conventional doses (25mg, 50mg and 
100mg) devices were provided by fabricating 9.7 cm2, 16 cm2 and 30 cm2 matrix 
diffusional controlled transdermal drug delivery system of Atenolol respectively, as 
once a day drug delivery systems. 
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9 PREPARATION AND CHARACTERIZATION OF ADHESIVE  
   MATRIX DIFFUSIONAL TRANSDERMAL DRUG DELIVERY  
   DEVICE OF ATENOLOL          
 
AIM OF PRESENT INVESTIGATION  
The adhesive matrix diffusional system tends itself to simple and easy processing of 
delivery device. The  matrix (laminate, disc) being static in nature offers less 
problems of drug and formulation stability and results in robust product with near to 
no problems of handling and administration to patients. Laminated form of delivery 
device offers easy transfer of technique from laboratory operations to a large scale 
manufacturing. As preparation of sheets, laminates etc from polymer beads is the 
major activity of plastic industry. Screw extrusion or injection molding can facilitate 
the formation of drug laminates from the polymer beads mixed with additives and 
active agents. For the preparation of adhesive drug matrix diffusion controlled 
transdermal device laminates are prepared using drug loaded adhesive and this layer is 
covered by protective liner and fixed on backing membrane, followed by punching of 
laminates in desired size.1
This type of transdermal drug delivery system can be easily prepared on large scale as 
a continuous manufacturing process as compare to polymeric matrix diffusion 
controlled transdermal drug delivery device and membrane moderate reservoir type 
controlled transdermal drug delivery device.   
Adhesive matrix diffusion controlled release transdermal drug deliver systems are 
monolithic systems which are the simplest and least expensive means of controlling 
the release of an active agent. Here the active agent is physically blended with the 
adhesive agent.2 The release rate is governed by Higuchi equation.3 The release in 
such system is proportional to square root of time and release is available until 
approximately 60% of the loaded drug is released from the matrix.4 Thereafter release 
is related exponentially to time, exhibiting first order release. 
Parameter influencing the release characteristics of monolithic devices can be 
classified as solute dependent factors like solubility, partition co-efficient and 
diffusion coefficient of drug in the matrix. The solute independent parameters are 
system variables like geometry, tortuosity, pores, concentration, volume fraction and 
diffusion layer etc. In the present investigation solute related factors were considered 
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to fabricate the devices using adhesive. With perception to above objective, it is 
necessary to modify current solid dosage forms in to transdermal controlled drug 
delivery system. A first step in this process is to illustrate how formulation and 
process variables could give drug release through skin. The aim of present 
investigation is to formulate and optimize the adhesive matrix diffusion controlled 
transdermal drug delivery system of Atenolol.  
 
9.1 Formulation and evaluation of adhesive drug matrix device of Atenolol 
9.1.1 Experimental 
Preparation of adhesive matrix device of Atenolol 
The transdermal therapeutic system comprised a backing membrane, an adhesive 
layer containing drug and a release liner. Adhesive matrix – type transdermal patches 
containing Atenolol were prepared using different ratios of drug to adhesive (Table 
9.1.1). Atenolol was accurately weighed and dissolved in very small quantity of 
alcohol. This solution was mixed with natural rubber adhesive (Readymade received – 
Beta surgical, Rajkot).  The uniform dispersion of drug and adhesive was spreaded on 
a drug impermeable polyethylene coated aluminum foil (5x3.5 cm2) with the help of 
TLC kit spreader to form a thin medicated adhesive layer and dried at room 
temperature. After 24h, the films were cut into a 3.14 cm2 area and covered with 
pellabel silicone protective liner. Dosage forms were kept in desiccators until further 
used. 
 
Table 9.1.1: Composition of prepared adhesive matrix films of Atenolol 
Atenolol Formulation 
code 
Adhesive 
(mg/cm2) (mg/cm2) 
F1 15 5 
F2 15 10 
F3 15 15 
                                     
Physiochemical evaluation of adhesive matrix device 
Prepared Atenolol containing adhesive matrices were evaluated for various 
parameters like thickness , weight variation, drug content, moisture content, moisture 
absorption etc, as per procedure given in the chapter 7, section 7.1.1. 
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9.1.2 Results and discussion  
The present investigation deals with the development of Atenolol adhesive matrix 
using different concentration of drug and adhesive. A diffusion mediated matrix 
controlled transdermal drug delivery system for Atenolol was successfully prepared 
using adhesive and it was evaluated using different physiochemical parameters. 
 
Thickness 
With the help of micrometer (0.001mm), Mitutoyo, Japan, the thickness of drug 
adhesive matrix was measured and the average thickness was noted. The results of 
thickness measurements are given in Table 9.1.2. The results indicate that there was 
no much difference in the thickness with in the formulations. Thickness in the 
different formulations was in the range of 122.5 ± 2.5 μm to 141.6 ± 2.886 μm. The 
results indicated uniform distribution of the adhesive.  
 
Table 9.1.2: Thickness uniformity of F1 to F3 adhesive matrix Atenolol   
                     formulations  
Average thickness (μm) Formulation 
code 
Sr. No. 
Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 120.0 122.5 125.0 122.5  ± 2.500 
2 F2 130.0 135.0 132.5 132.5  ± 2.500 
3 F3 145.0 140.0 140.0 141.6  ± 2.886 
    *Standard deviation, n=3 
 
Weight variation 
Drug loaded films (3.14 cm2) were weighed using Sartorius electronic balance (Model 
CP-224 S), Shimadzu, Japan and the results of weight variation are given in Table 
9.1.3.  
In a weight variation test, the pharmacopoeial limit for the percentage deviation of all 
the films of less than mg is ± 10%. The average percentage deviation of all 
formulations was found to be within the limit, and hence all the formulation passed 
the test for weight variation as per official requirements. All the formulations showed 
acceptable pharmaco-technincal properties.  
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Table 9.1.3: Weight variations of F1 to F3 adhesive matrix Formulations of    
                      Atenolol  
Average weight (mg) Formulation
Sr. No. 
Code Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 45.23 46.53 45.89 45.88 ± 0.650 
2 F2 60.00 58.96 60.13 59.69 ± 0.641 
3 F3 75.20 74.63 76.43 75.42 ± 0.919 
       *Standard deviation, n=3 
 
Drug content 
Drug content of the drug adhesive matrix patch was carried out to ascertain that the 
drug is properly added in the formulation. The results of drug content analysis are 
represented in Table 9.1.4. 
 
Table 9.1.4: % Drug content of F1 to F3 adhesive matrix formulations of     
                    Atenolol 
Drug content (mg) Formulation 
code 
Sr. No. 
Trial 1 Trial 2 Trial 3 Mean ± S.D.* 
1 F1 99.46 98.46 98.42 98.78  ± 0.589 
2 F2 97.23 96.23 96.13 96.56  ± 0.587 
3 F3 96.89 95.45 95.74 96.02  ± 0.761 
       *Standard deviation, n=3 
 
The films were found to contain 96.02 % - 98.78 % of the labeled amount of Atenolol 
indicating uniformity of drug content. The average percentage deviation of all 
formulations was found to be within the limit, and hence all the formulation passed 
the test for content uniformity as per official requirements. All the formulations 
showed acceptable pharmaco-technincal properties. From the results obtained, it was 
clear that there was proper distribution of Atenolol in the film formulations. Hence it 
was concluded that drug was uniformly distributed in all the formulation. 
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Moisture content (Loss on drying) 
The results of the moisture content study for different formulations are shown in 
Figure 9.1.1. The moisture content in all the formulations was found to be low. The 
result revealed that the moisture content was found to increases with increasing 
concentration of Atenolol. The % Moisture content of each device was determined, 
the rank order of moisture absorption was F1 < F2< F3.  
The result revealed that the moisture was present in the formulation due to presence of 
adhesive material.  Small moisture content in the formulations helps to maintain the 
texture of the formulation also prevents the dosage form being brittle. 
 
Figure 9.1.1: % moisture content from containing different adhesive matrix     
                       device of Atenolol 
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                      * Standard deviation, n=3 
 
Moisture absorption  
The percentage moisture absorption was calculated as a difference between final and 
initial weight with respect to initial weight. The results of the moisture absorption 
studies for different Atenolol adhesive matrix formulations are shown in Figure 9.1.2.  
The result revealed that the moisture absorption was found to increase with increasing 
concentration of Atenolol. The % Moisture absorption of each film was determined, 
the rank order of moisture absorption was F3 > F2 > F1.  
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Figure 9.1.2: % moisture absorption from Atenolol containing different adhesive     
                       matrix device 
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                  * Standard deviation, n=3                            
 
9.2 In vitro drug diffusion study of adhesive matrix diffusional controlled     
      transdermal drug delivery device of Atenolol 
   
9.2.1 Experimental 
In vitro diffusion study of Atenolol from adhesive matrix moderated transdermal 
patch was carried out using modified Keshary-Chien diffusion cell as per procedure 
given in the chapter 7,  section 7.2.1. The experiments were done in triplicate. 
Amount of drug released per square centimeter of patch were plotted against function 
of square root of time for different formulations. The release rate Q/√T was 
determined by simple regression analysis of steady state data. 
 
9.2.2 Result and discussion 
Diffusion study is important for ensuring the sustained release performance and the 
reproducibility of rate and duration of drug release.5,6 The results of in vitro drug 
diffusion studies from transdermal patches are depicted in Figure 9.2.1. 
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Figure 9.2.1: In vitro diffusion profiles of Atenolol released from drug adhesive 
matrix patch 
0
1000
2000
3000
4000
0 0.5 1 1.5 2 2.
Time (hr1/2)
C
um
ul
at
iv
e 
am
ou
nt
 o
f A
te
no
lo
l 
re
le
as
ed
 (m
cg
/c
m
5
)
F1 F2 F3
 
               * Standard deviation, n=3 
 
Release of Atenolol from the drug loaded adhesive matrix followed square root law. 
The release rate Q/√T was determined by simple regression analysis of steady state 
data.  
Release rate Q/√T increased with increasing concentration of Atenolol in adhesive 
matrix. In our experiments, variable release profiles of Atenolol from the different 
experimental patches composed of different proportion of drug and adhesive were 
observed. The rank order of release rate observed was F1 < F2 < F3.  
The formulations F3 exhibited the maximum Q/√T (1469.90μg/cm2√h) release rate, 
which was significantly different, compared to the lowest value in the formulation F1 
(512.65 μg/cm2√h). The formulation F2 exhibited 995.25 μg/cm2√h release rate. 
Based on in vitro release experiments, formulation F3 was chosen for further in vitro 
permeability study through human live skin. 
 
In vitro release kinetic 
In vitro diffusion study of Atenolol released into infinite sink was carried out using 
the modified Keshary-Chien diffusion cell. Release of drug from the corresponding 
devices was diffusion under membrane controlled. The release data was fitted into 
various mathematical models using software to know which mathematical model will 
best fit to obtained release profiles. The obtained R values for various models are 
given in Table 9.2.1.  
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Table 9.2.1.: Data of various parameters of model fitting for Atenolol adhesive  
                       matrix formulations  
Formulation Zero order equation First order equation Higuchi’s equation
F1 0.9785 0.9250 0.9987 
F2 0.9850 0.9377 0.9969 
F3 0.9698 0.9195 0.9959 
 
The in vitro release profile could be best expressed by Highuchi’s equation for the 
permeation of drug from the matrix.  
 
9.3 In vitro human live skin permeation study of adhesive drug matrix device of  
      Atenolol 
9.3.1 Experimental 
The permeation study was performed in a modified Keshary-Chien diffusion cell. The 
experiment was performed as mention in section 5.6.2. The experiments were done in 
triplicate. Amount of drug released per square centimeter of patch were plotted 
against function of time for adhesive matrix formulation. The release rate was 
determined by simple regression analysis of steady state data. 
9.3.2 Results and discussion  
Permeation study was performed for drug adhesive matrix patch across human live 
skin using 0.01 N HCl, as a diffusion medium. The result of in vitro skin permeation 
of Atenolol from adhesive matrix formulation is shown in Figure 9.3.1  
Figure 9.3.1: In vitro skin permeation profile of Atenolol from drug adhesive    
                       matrix patch through human live skin 
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Shital D. Faldu  Ph.D. Thesis                                             
 
 299
Chapter 9                                             Adhesive matrix diffusional TDDS of Atenolol 
 
Various parameters of diffusion kinetics of Atenolol released from device across 
human live skin are presented in Table 9.3.1.  
 
Table 9.3.1: Parameters of diffusion kinetics of Atenolol from drug adhesive 
                     matrix patch through human live skin 
Sr. No. Parameters Value 
2 1 Skin flux (Jss) 79.83 μg/ cm hr 
2 Time lag (t ) 0.82 hr L
3 Human live skin thickness (µm) 140 μm 
4 Diffusion coefficient 2.845 x 10-5 cm2/sec 
35 Solubility of drug in skin  (Cs) 39.35 mg/cm
 
Adhesive matrix device containing Diltiazem provided 79.83 μg/ cm2 hr skin flux. 
The time lag (tL) for devices is presented in Table 9.3.2. The diffusion coefficient, D 
of Diltiazem was determined using D = h2/6 tL relationship, where skin thickness h 
was 140 x 10-4 cm. The amount of Diltiazem retained by skin area used for 
permeation was calculated by dividing flux with gradient of diffusivity and it was 
found to be 39.35 mg/cm3 of skin. 
Computation of area of patch required for target steady state plasma 
concentration (Css) 
As mentioned in section 8.6.3, desired input rate through skin for target steady state 
plasma concentration of Atenolol is 679.14 μg/ hr 
Area of patch = (679.14 μg/hr)/ Jss(skin)
                      = 679.14/79.83cm2 
                                = 8.5 cm2 
 
Formulation of final patch 
As per British  J. of  clinical  Pharm.7 steady state plasma concentration built up after 
administration of 25mg, 50mg and 100 mg Atenolol orally in human volunteers are 
recommended to develop peak plasma concentration of 126 ng/ml, 219 ng/ml and 390 
ng/ml respectively to control varied dose dependent physiological cardiac complains 
in the human. Transdermal controlled drug delivery system compared to conventional 
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administration is recommended as a safe alternative with  better compliance to 
therapy by the patient, with reduced frequency of administration, leading to better 
disease management. Following three patches of different configuration were 
formulated as an alternative to above oral administration, to meet requirement of 
desired steady state plasma concentration for varied cardiac condition. Table 9.3.3 
shows the parameters of the formulations. 
 
Table 9.3.2: Parameters of final Atenolol adhesive matrix transdermal device 
Components Patch 1 Patch 2 Patch 3 
Oral dose of Atenolol 25 mg 50 mg 100 mg 
Css, mean steady state plasma 
concentration (ng/ml) 
126 219 390 
Area of transdermal 
patch(cm
8.5 14.2 26.6 2) 
Predicted steady state plasma 
concentration 
120 200 375 
Steady state flux, Jss, through 
human live skin (μg/cm
79.83 79.83 79.83 2 hr) 
Protective liner Silicon sheet Silicon sheet Silicon sheet 
 
The above formulations are 24 hour (once a day) devices. The drug loaded adhesive 
matrix was layered on specific dimension of polyethylene coated aluminum foil 
backing.   For the preparation of final adhesive matrix diffusion controlled drug 
delivery device peripheral plain adhesive was used for good adherence of device on 
the skin. The release face was covered with peelable protective liner. 
9.4 STABILITY STUDY 
9.4.1. Stability study of adhesive matrix diffusional transdermal drug delivery   
          device      
The objective of accelerated stability studies is to predict the shelf life of a product by 
accelerating the rate of decomposition, preferably by increasing the temperature. The 
optimized formulation of Atenolol adhesive matrix patch was subjected for the 
stability study. The accelerated stability study was carried out according to ICH 
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0guideline by storing the samples at 25 C / 60 % RH, 30 0C/ 65 % RH and 40 0C/ 75 
% RH for 90 days in a stability chamber (Thermo Lab., Mumbai, India). These 
samples were analyzed by UV Spectrophotometer method. Dosage forms were 
evaluated for changes in physical appearance and drug content at an interval of 15 
days. 
9.4.2 Results and Discussion      
Final formulation was subjected for stability study and observed for change in color, 
appearance, flexibility and drug content. Temperature and humidity values selected 
were as per the ICH guidelines and the test was carried out in a stability chamber. The 
stability study was carried out at 25 0C / 60 % RH, 30 0C/ 65 % RH and 40 0C/ 75 % 
RH for 90 days. 
Diffusion study was carried out and it was observed that formulation stored at 40 0C 
exhibited higher Q/√T release rate as compared to those stored at 25 0C and 30 0C. 
The initial release of drug was higher due to decreased viscosity at an elevated 
temperature. Release rate at 30 0C was altered but it was in order. The product stored 
at 25 0C exhibited no change in release rate. The degradation was higher at an 
elevated temperature. The first order rate constant of degradation for room 
temperature was 1.4 x 10-3 -1 week . The self life calculated was 75 week.  
9.5 SKIN IRRIITATION AND SKIN SENSITIZATION STUDY 
9.5.1 Experimental 
Skin irritation and skin sensitization though are different types of physiological 
responses yet they have several common indications. Skin sensitization is systematic 
response and skin irritation is primarily is local response. 
A protocol was devised for evaluation of skin irritation and/or sensitization in such a 
manner that the signs at the sight of application would be assessed in common for the 
both and further, to distinguish sensitization from irritation. The skin irritation and 
skin sensitization study was carried out as per mentioned in chapter 5.8.1. 
The final Atenolol adhesive matrix patch (2.0 cm2) was supported with aluminum foil. 
This was applied to the skin surface (shaved) and made adhered with the help of  “3 
M Micropore” – medical adhesive tap (3 M, Corporation, U.K.). 
 9.5.2 Results and discussion    
The results of skin irritation and skin sensitization study for Atenolol adhesive matrix 
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patch is presented in Table 9.5.1. From this table total average score at day 20 and 
total average score at day 28 were obtained respectively.  
 
From Table 9.5.2, it was clear that the Atenolol adhesive matrix patch was non- 
irritating, since the maximum score for each sign did not exceed than 1.  Further 
Table 9.5.3 shows that average score at day 20 and day 28 was not exceeding more 
than 1 for any sign. Average score not exceeding more than 1 at any day for any sign 
was clearly indicative for non-irritation nature of the agent. 
 
Atenolol is non-sensitizing in nature. The reason for this was reduction in scores even 
after repeated applications. All the tables show that maximum individual scores, 
average scores, total irritation scores were reduced at day 28th in comparison to all 
these scores at day 20th. Reduction in scores even after repeated application of test 
patch indicated absence of primary and secondary sensitization reaction. 
Table 9.5.2: The average score for each sign after day 20 and day 28 during skin 
 irritation and  sensitization study of Atenolol adhesive matrix patch 
Average score at 
day 20 
Average score 
at day 28 
Sr. No. Sign 
1 Erythema 0.75 0.0 
2 Scaling 0.0 0.25 
3 Fissures 0.75 0.5 
4 Oedema formation 1.25 0.5 
5 Ecchymosis 2.0 1.0 
6 Necrosis 1.25 0.0 
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Table 9.5.1: Skin irritation and sensitization study of Atenolol adhesive matrix patch 
  
 
 
 
 
SR.  
Name And 
Concentration 
SENSITIZATION / IRRITATION TESTING 
PRE-EXPOSURE 
PERIOD 
INDUCTION PHASE REST CHALLENGE PHASE 
  
Φ = 30M Φ = 30M Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 After 12 Φ=24H Φ=0 Φ=0 Φ=0 Φ=0 
D1 D2 D3 D4 D5 D6 D7 Days D19 D20 D21 D22 D28 
1 Erythema 
0 0 0 0 0 0 1 1 1 1 0 1 0 1 0 0 0 0 1 1 1 1 1 1 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg 0 Avg 0 Avg .75 Avg 0.5 Avg 0.5 Avg 0 
2 Scaling 
0 0 0 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Avg 0 Avg .25 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0 Avg 0 Avg 0 Avg 0 Avg 0 Avg .25 
3 Fissures 
0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 1 0 0 1 1 1 1 1 1 1 1 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 
Avg 0 Avg 0 Avg 0 Avg 0.5 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg 0 Avg .75 Avg .75 Avg .75 Avg 0.5 
4 
Oedama 
formation 
1 0 0 1 0 1 1 1 1 0 0 1 0 1 0 1 0 0 1 2 0 2 0 2 0 1 
0 0 0 0 0 1 1 1 1 1 0 1 0 1 0 0 0 0 1 1 1 1 0 1 0 1 
Avg .25 Avg .25 Avg 0.5 Avg 1 Avg .75 Avg 0.5 Avg 0.5 Avg .25 Avg 0 Avg 1.25 Avg 1.25 Avg .75 Avg 0.5 
5 Ecchymosis 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 2 2 2 2 2 2 1 1 
0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 0 2 2 1 1 1 1 1 1 
Avg 0.5 Avg 0.5 Avg 0.5 Avg 1 Avg 1 Avg 1 Avg 0.5 Avg 0 Avg 0 Avg 2 Avg 1.5 Avg 1.5 Avg 1 
6 Necrosis 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1 2 1 1 0 0 
0 0 0 0 1 0 1 1 1 1 1 1 0 1 0 1 0 1 1 1 1 1 0 1 0 0 
Avg 0 Avg 0 Avg .25 Avg 0.5 Avg 0.5 Avg 0.5 Avg .25 Avg .25 Avg .25 Avg 1.25 Avg 1.25 Avg .75 Avg 0 
Total of all score 3 4 7 16 15 13 10 3 1 24 20 17 9 
Total average per 
animal 
0.75 1 1.75 4 3.75 3.25 2.5 0.75 0.25 6 5 4.25 2.25 
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Table 9.5.3: Maximum sensitization and irritation score of various signs at last 
day for Atenolol adhesive matrix patch 
Sr. No. Sign Score N 
0 4 1 Erythema 
1 1 2 Scaling 
1 2 3 Fissures 
1 2 4 Oedema formation 
1 4 5 Ecchymosis 
0 4 6 Necrosis 
 
9.6 CONCLUSION 
An adhesive matrix diffusional transdermal controlled drug delivery device of 
Atenolol was successfully prepared. The processing was non-complicated, very 
simple and economic, still meeting requirements of systemic administration of drug. 
Atenolol loaded natural rubber based adhesive matrix were prepared and devices were 
fabricated containing varied drug loading. Device containing 15mg/cm2 of Atenolol 
was found to meet the biopharmaceutical and pharmacokinetic requirement for the 
therapeutic use of device. On evaluation, the device was found to be stable, non- 
irritant, non-sensitizing and safe. It complied with official and non- official pharmaco-
technical specifications. In vitro evaluation for Atenolol release from device across 
human live skin provided zero order release rate 79.83 μg/cm2 hr. The flux was 
adequate to meet pharmacokinetic requirement of steady state plasma concentration 
for 24 hours, giving once a day drug delivery system of Atenolol.  Alternatives to 
three oral conventional doses (25mg, 50mg and 100mg) devices were provided, by 
fabricating 8.5cm2, 14.2cm2 and 26.6cm2 adhesive matrix diffusional transdermal drug 
delivery system of Atenolol, respectively as once a day drug delivery system. 
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10. SUMMARY 
 
Administration of drugs in conventional manner is not free from toxicity and G.I. tract 
related problems. Also hepatic metabolism reduces bioavailability of drug and to 
initiate and sustained therapeutic action higher doses of drug is needed. Only I/V 
dreeps can solve the above problem, however continuous presence of needle in the 
circulatory portal is inconvenient to patient. Ultimately patient compliance is reduced, 
and management of disease suffers. T.D.D.S is an answer and also a safe and 
convenient alternative to I/V dreeps. It obviates hepatic metabolism also, the 
problems concerned with G.I. tract route are absent. Processing of T.D.D.S is also 
simple as compared to parentral and solid dosage forms. 
 
10.1 Preparation of Diltiazem base from official salt form and its   
       characterization 
? Hydrophobic drug penetrate more as compared to ionics and hydrophilic drug 
and with this information Diltiazem base was prepared from its official salt 
form and it was characterized prior to incorporate into drug delivery device  
? In the present study, Diltiazem base was prepared from its official 
hydrochloride salt and characterized using different parameters. Melting point, 
Refractive index was determined to check the purity of drug.  
? From solubility study it was found that 0.01N HCl was suitable to maintain 
sink condition so, it was selected as a diffusion medium. 
?  The results obtained from Partition co-efficient study revealed that the drug 
possessed sufficient lipophillicity, which fulfills the requirements of 
formulating it into a transdermal patch.  
? Differential scanning calorimetry and Fourier transform infrared spectroscopy 
gave idea regarding chemical structure of pure drug.  
? UV/VIS Spectroscopic data are useful for the preparation of standard curve 
and estimation of Diltiazem base from various formulations. 
 
10.2 Preparation and characterization of polymeric matrix diffusional    
        transdermal drug delivery device of Diltiazem 
?  Present investigation was aimed to formulate a robust, stable and simple 
matrix diffusional transdermal drug delivery system of Diltiazem. 
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?  Different matrix forming polymers like EVA (VA 40 %) copolymer, Ethyl 
cellulose, ERS 100 and ERL 100 were employed to form medicated matrices. 
Casting on glass substrate as well as mercury substrate can give medicated 
matrices.  
?  Matrix laminates were characterized for its physical characteristics like 
thickness, weight variation, drug content, % moisture absorption, % moisture 
loss and % water vapor transmission rate etc. 
?  Drug polymer interaction study was done with differential scanning 
calorimetry and FTIR and it was observed that there was no interaction 
occurring between drug and polymer. 
?  Diltiazem containing medicated matrices of polymer EVA (VA 40 %) 
copolymer, EC, ERS 100 and ERL 100: ERS 100 (1:1) was subjected to 
diffusion study using modified Kesharay- Chien’s diffusion cell. EVA (VA 
40%) copolymer exhibited maximum Q/√T release rate. The diffusion kinetic 
from all the polymers obeyed square root law and Higuchi model was best fit 
for all the medicated matrices. 
? Selected medicated matrices were further subjected to diffusion study to get 
desired Q/√T release rate, by incorporating gradually increasing concentration 
of Diltiazem. EVA (VA 40 %) copolymer: Diltiazem in 40:60 ratio exhibited 
maximum (desired) release rate. Also laminates complied with desired 
physical characteristics of drug distribution, elegance, thickness, content 
uniformity of drug etc. 
? Marix diffusional T.D.D.S of Diltiazem was fabricated using polyethylene 
coated aluminum foil as backing membrane, Diltiazem loaded EVA (VA 
40%) copolymer laminate as drug supplying layer, a adhesive system to keep 
the dosage form remaining attached throughout the duration of administration 
to the patient. A peelable silicone liner was used to protect device. 
? Matrix diffusional T.D.D.S. of Diltiazem (3.14 cm2) was evaluated for 
diffusion characteristic using human live skin (thickness – 140 μm). The 
release followed zero order kinetic, after a time lag. The skin flux was 18.24 
μg/cm2 hr. 
? Using pharmacokinetic data of Diltiazem, Cmax, t1/2, ke, CL total a targeted 
steady state plasma concentration that can be build up from the delivery device 
was computed. From the computation data, it was planned out too finally 
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fabricate once a day matrix diffusional Transdermal drug delivery device of 
Diltiazem. It was found that 30.4 cm2 delivery device could meet the 
requirement of steady state plasma concentration for 24 hr.  
? The delivery device was subjected to accelerated stability study as per ICH 
guideline. Results of stability study suggested a self life of 95 week for the 
device stored at room temperature. 
? The dosage form can be used as once a day transdermal drug delivery device 
of Diltiazem, for cardiac problems. 
 
10.3 Preparation and characterization of membrane moderated Reservoir type  
        transdermal drug delivery device of Diltiazem 
? Polymeric membranes were prepared using solution casting method. 
? Membranes were prepared using EVA (VA 40%) copolymer, Ethyl cellulose, 
Polyvinyl acetate, ERS 100 as a polymer. 
? Membranes were characterized physiochemically for appearance, 
transparency, thickness, density and water sorption etc. 
? Membranes were evaluated for Diltiazem permeability. EVA (VA 40%) 
copolymer membrane exhibited maximum flux compared to other membrane. 
Therefore it was selected as rate controlling membrane to device reservoir 
type transdermal drug delivery system of Diltiazem. 
? EVA (VA 40%) copolymer membrane of different thickness were prepared 
and evaluated for Diltiazem permeation kinetic with a view to optimize and 
select requisite thickness of membrane for devicing final drug delivery device. 
30 μm thick EVA (VA 40%) copolymer rate controlling membrane gave 
Diltiazem flux of 1378.12 μg/cm2 hr and it was selected to device final patch. 
? A reservoir patch (3.14 cm2 areas) was fabricated using selected membrane 
containing alcoholic solution of Diltiazem and evaluated for permeation 
kinetics using human live skin. The skin flux of Diltiazem 40.77 μg/cm2 hr 
was quite promising to device a cute and elegant reservoir type device. 
? The priming dose of Diltiazem was worked out from the data of diffusion 
kinetic of Diltiazem from device across human live skin. Incorporation of 
priming dose in release face covering adhesive system gave skin flux, 43.95  
μg/cm2 hr of Diltiazem. 
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? From the pharmacokinetic data of Diltiazem the requisite area required to 
fabricate final reservoir device was computed. 12.61 cm2 size of reservoir 
device was sufficient to meet targeted steady state Diltiazem concentration for 
24 hr. 
? Accelerated stability study as per ICH guideline indicated self life of 53 weeks 
for the product stored at room temperature. 
? Results of skin irritation and skin sensitization study on rabbit showed that 
patch was non irritating and free from skin irritation effects. 
? A patch was deviced using Diltiazm gel filled in the Reservoir compartment of 
(3.14 cm2) patch and evaluated for diffusion study using human live skin. Skin 
flux of Diltiazem was found to be 22.209 μg/cm2 hr. 
? The priming dose of Diltiazem was computed using parameters of diffusion 
kinetics of Diltiazem released from device across human live skin. 
Incorporation of priming dose in release face covering adhesive system gave 
skin flux of 23.78 μg/cm2 hr of Diltiazem. 
? Area of final reservoir device containing Diltiazem gel was computed from 
pharmacokinetic data of Diltiazem. A 23.31 cm2  reservoir type transdermal 
drug delivery device containing Diltiazem gel was sufficient to meet targeted 
steady state Diltiazem concentration for 24 hr. 
? Accelerated stability study as per ICH guideline indicated self life of 61 weeks 
for product stored at room temperature. 
? Results of skin irritation and skin sensitization study on rabbit showed that the 
patch was non-irritating and free from skin sensitization and was safe for use. 
 
10.4 Preparation and characterization of adhesive matrix diffusional      
        transdermal drug delivery device of Diltiazem 
The processing of Reservoir patch is complicated as compared to matrix type devices. 
Further among matrix devices, the processing of medicated film is little more 
complicated as compared to simple layering of a medicated mass on a backing 
surface. The very simple process for product still meets the requirement of systemic 
administration of drug; inspires one to prepare such devices. Attempt was made to 
formulate adhesive matrix type transdermal drug delivery system of Diltiazem. 
? Natural rubber base adhesive was received ready made ( Beta surgical, Rajkot) 
? Drug loaded matrices of different concentration were prepared using TLC kit. 
 
Shital D. Faldu  Ph.D. Thesis  310
Chapter 10  Summary   
 
? Adhesive matrix type devices were evaluated for physiochemical test like 
thickness, weight variation, drug content, % moisture content and % moisture 
absorption etc. 
? In vitro diffusion study of all the formulation followed square root law and 
Higuchi equation could be best fit for the drug release from the devices. 
Formulation F4 exhibited maximum Q/√T release rate, which was 1556.70 
μg/cm2 hr. 
? In vitro human live skin permeation kinetic showed zero order release rate 19 
64 μg/cm2 hr. 
? From the pharmacokinetic data and results of human live skin diffusion study, 
requisite area required to fabricate final device was worked out. A 28.22 cm2 
size Diltiazem loaded adhesive matrix device was found to meet targeted 
steady state Diltiazem concentration for 24 hours. 
? Accelerated stability study as per ICH guideline indicated self life of 79 weeks 
for the product stored at room temperature. 
? Results of skin irritation and skin sensitization study on rabbit showed that 
patch was non irritant, free from skin sensitization and safe for use. 
 
10.5 Preparation and characterization of polymeric matrix diffusional 
        transdermal drug delivery device of Atenolol 
The aim of present investigation is to formulate and optimize the Atenolol matrix 
diffusion controlled transdermal drug delivery system. In the present investigation, the 
influence of various grades and concentration of polymers were studied. Study was 
carried out to formulate an elegant product exhibiting desired therapeutic 
performance, from a small and cute dosage form. 
? Different matrix forming polymers like EVA (VA 40 %) copolymer, Ethyl 
cellulose, Polyvinly pyrolidone, HPMC, ERS 100 and ERL 100 were 
employed to form medicated matrices. Casting on glass substrate as well as 
mercury substrate can give medicated matrices.  
?  Matrix laminates were characterized for its physical characteristics like 
thickness, weight variation, drug content, % moisture absorption, % moisture 
loss and % water vapor transmission rate etc. 
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?  Drug polymer interaction study was done with differential scanning 
calorimetry FTIR and it was observed that there was no interaction occurring 
between drug and polymer. 
? Atenolol containing medicated matrices of polymer EVA (VA 40 %) 
copolymer, EC: PVP, ERS 100, ERL100: ERS100 (1:1) and ERL 100: HPMC 
were subjected to diffusion study using modified Kesharay- Chien’s diffusion 
cell. EVA (VA 40%) copolymer exhibited maximum Q/√T release rate. The 
diffusion kinetic from all the polymers obeyed square root law and Higuchi 
model was best fit for all the medicated matrices. 
? ERL100 and ERS100 were selected to device final matrix diffusional 
therapeutic system. In this study various matrix type transdermal patches 
containing Atenolol of variable combination of ERL100 and ERS100 were 
prepared. Also laminates complied with desired physical characteristics of 
drug distribution, elegance, thickness, content uniformity of drug etc. 
? Marix diffusional T.D.D.S of Atenolol was fabricated using polyethylene 
coated aluminum foil as backing membrane, laminate as drug supplying layer, 
an adhesive system to keep the dosage form remaining attached throughout the 
duration of administration to the patient. A peelable silicone liner was used to 
cover the laminate to protect it. 
? Matrix diffusional T.D.D.S. of Atenolol (3.14 cm2) was evaluated for 
diffusion characteristic using human live skin (thickness – 140 μm). The 
release followed zero order kinetic, after a time lag. The skin flux was 70.84 
μg/cm2 hr. 
? Using pharmacokinetic data of Atenolol, Cmax, t , k1/2 e, CL total a targeted 
steady state plasma concentration that can be built up from the delivery device 
was computed. As per British J. Clinical Pharma., three different oral 
conventional doses of Atenolol are recommended (25 mg, 50 mg, and 100 mg) 
for different cardiac complaints in human beings. Three polymeric matrix 
moderated transdermal drug delivery devices of Atenolol of different sizes i.e. 
9.7 cm2, 16 cm2 and 30 cm2 were fabricated to serve as once a day devices, as 
an alternative to above mentioned three conventional doses. 
?  The delivery device was subjected to accelerated stability study as per ICH 
guideline. Results of stability study suggested a self life of 82 week for the 
device stored at room temperature. 
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? Skin sensitization and skin irritation study was carried out and it was found 
that the dosage form was nonirritating and safe for use. 
? The device can be used as once a day transdermal drug delivery device of 
Atenolol, for cardiac problems. 
 
10.6 Preparation and characterization of adhesive matrix diffusional           
        transdermal drug delivery device of Atenolol 
The processing of Reservoir patch is complicated as compared to matrix type devices. 
Further among matrix devices, the processing of medicated film is little more 
complicated as compared to simple layering of a medicated mass on a backing 
surface. The very simple process for product still meets the requirement of systemic 
administration of drug; inspire one to prepare such devices. Attempt was made to 
formulate adhesive matrix type transdermal drug delivery system of Atenolol. 
? Natural rubber base adhesive was received ready made ( Beta surgical, Rajkot) 
? Drug loaded matrices of different concentration were prepared using TLC kit. 
? Adhesive matrix type devices were evaluated for physiochemical test like 
thickness, weight variation, drug content, % moisture content and % moisture 
absorption etc. 
? In vitro diffusion study of all the formulation followed square root law and 
Higuchi equation could be best fit for the drug release from the devices. 
Formulation F3 exhibited maximum Q/√T release rate, which was 1469.9 
μg/cm2 hr. 
? In vitro human live skin permeation kinetic showed zero order release rate 
79.83 μg/cm2 hr. 
? Using pharmacokinetic data of Atenolol Cmax, t1/2, ke, CL total a targeted 
steady state plasma concentration that can be build up from the delivery device 
was computed. As per British J of Clinical Pharma., three different oral 
conventional doses of Atenolol are recommended (25 mg, 50 mg, and 100 mg) 
for different cardiac complaints in human beings. Three polymeric matrix 
moderated transdermal drug delivery devices of Atenolol of different sizes i.e. 
8.5 cm2, 14.2 cm2 and 26.6 cm2 were fabricated to serve as once a day devices, 
as an alternative to above mentioned three conventional doses. 
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?  The delivery device was subjected to accelerated stability study as per ICH 
guideline. Results of stability study suggested a self life of 75 week for the 
device stored at room temperature. 
? Skin sensitization and skin irritation study was carried out and it was found 
that the dosage form was nonirritating and safe for use. 
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Formulation, Characterization and evaluation of  
transdermal patches of Diltiazem 
S. D. Faldu*, Dr. H. M. Tank, D. H. Parekh, R. B. Parmar 
* S. J. Thakkar pharmacy college, Avadh Road, Munjaka, Kalawad Road, 
Rajkot, Gujarat, India. 
Abstract: 
Dilitiazem free base was prepared from corresponding official salt & characterized 
prior to incorporation in various polymeric matrix diffusional transdermal therapeutic 
system. 
 Medicated matrices were prepared using different polymers like ethylene vinyl 
acetate (VA 40%) copolymer, Ethyl cellulose, Eudragit RS 100, Eudragit RL 100 : 
Eudragit RS 100 (1 : 4), were used as polymers. Solution casting on mercury substrate 
technique was used to prepare medicated film. The films were investigated for water 
vapour transmission rate, % Moisture loss, % Moisture absorption, folding endurance 
and thickness. 
 Transdermal therapeutic systems were fabricated using 120 – 140 μm thick 
medicated film laminated on polyethylene sheet, which in turn was laminated over 
polyethylene coated aluminum foil backing. Adhesive system was peripheral & 
devices were covered with peelable protective liner. 
 Therapeutic systems were evaluated using modified version of keshary – chien 
type diffusion cell, where 0.01M HCl was used as diffusion medium. Diltiazem 
released from the device was estimated using UV-visible spectrophotometer at 237.8 
nm. The release of diltiazem from all the patches was diffusion controlled & followed 
linear Q versus √T relationship. In vitro release rates of Diltiazem for EVA (VA 
40%), Ethyl cellulose, Eudragit RS 100, Eudragit RL 100: Eudragit RS 100 (1: 4), 
patches were 1488.10, 946.30, 503.29 & 794.08 μg/cm2/√h respectively EVA (VA 
40%) copolymer: Diltiazem (60: 40) therapeutic system exhibited maximum release 
rate. The Diltiazem flux from EVA (40%) copolymer system across dermatomed  
human live skin (thickness-140 μm) was investigated. The Epidermal flux was 16.26 
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μg / cm2 / hr & was maintained for 24 hours. 
 Prediction of in vivo performance using a reported model indicated a small 
size of therapeutic system to be sufficient to meet the pharmacokinetic requirement of 
steady state plasma concentration of diltiazem. 
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